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Several inflammatory lung disorders are characterised by airway neutrophilia
and release of cytotoxic neutrophil products. In particular, human neutrophil elastase
(HNE) is found in airway secretions from patients with emphysema, acute
respiratory distress syndrome, cystic fibrosis and pneumonia. Inhibition of HNE is
therefore a desirable therapeutic goal. Elafin is produced in the human lung and is a
cationic, low molecular weight inhibitor of HNE. The hypothesis driving this work
was that genetic augmentation of elafin may protect the lung against acute
inflammatory injury. A replication-deficient adenovirus encoding human elafin
cDNA under the control of the powerful murine cytomegalovirus promoter (Ad-
elafin) was used to produce elafin augmentation in view of the natural tropism of
adenovirus for respiratory epithelium.
Ad-elafin significantly protected pulmonary epithelial cells against the effects
of both HNE and whole activated human neutrophils in vitro. These findings were
extended by studying the effect of Ad-elafin on pulmonary neutrophilia induced by
lipopolysaccharide (LPS) in mice. Intratracheal (IT) Ad-elafin, administered in doses
low enough to obviate overt vector-induced inflammation, significantly augmented
LPS-mediated neutrophilia. In addition, LPS significantly up-regulated elafin
secretion from Ad-elafin transfected murine airways and from Ad-elafin transfected
human pulmonary epithelial cells.
The demonstration of a cytoprotective effect for a low molecular weight,
cationic elastase inhibitor capable of augmenting neutrophil recruitment during
inflammation suggested a potential antimicrobial function for elafin. Elafin was
shown to have significant antimicrobial activity against the respiratory pathogens
Pseudomonas aeruginosa and Staphylococcus aureus. On the basis of these
observations, the hypothesis that elafin may be protective against inflammatory
injury was tested in vivo. Low dose IT Ad-elafin (3xl07 plaque forming units) was
associated with a significant reduction in acute lung injury induced by Pseudomonas
aeruginosa in mice.
These findings suggest that augmentation of endogenous host defence
molecules can protect the lung against acute inflammatory injury. They further
suggest that adenoviral constructs containing selective promoters may allow
inflammation-specific expression of transgene using low doses of vector.
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Lung tissue may be damaged during episodes of pulmonary inflammation.
Tissue injury implies that endogenous local defence mechanisms have been
subverted, and that potentially destructive moieties such as human neutrophil
elastase (HNE) function relatively unopposed. The work described in this thesis was
stimulated by two fundamental questions. Firstly, can augmentation of host defence
molecules such as elafin (an endogenous pulmonary inhibitor of HNE) protect lung
tissue against the injurious effects of inflammation? Secondly, can augmentation of
elafin be efficiently achieved using transfer of the elafin gene to those cells
specifically susceptible to inflammatory injury?
Against this background, the following sections will outline the importance
of the neutrophil in inflammatory processes. The ability of molecules derived from
neutrophils to damage host tissue will be discussed, with emphasis on the importance
of HNE. Endogenous inhibitors of HNE will be described, with particular reference
to the function of elafin. Strategies available to augment host defence molecules in
the lung will focus on gene transfer techniques, and in particular the use of
recombinant adenoviral vectors.
1.2. ACUTE INFLAMMATION
Acute inflammation describes the sequence of programmed events occuring
in living tissues exposed to noxious stimuli. In simple terms, the early stages of acute
inflammation are characterised by vasodilatation, exudation of protein-rich fluid into
tissue spaces, and the extravasation of circulating leukocytes, predominantly in the
form of neutrophils (Figure 1). The noxious stimulus (eg invading bacteria) provokes
host cells into the generation of a complex array of inflammatory and anti¬
inflammatory mediators, with the aim of eradicating the source of inflammation
whilst restoring tissue viability. Acute inflammation is thought to have evolved to
counter the effects of pathogenic microbes (reviewed by Weissman, 1992), and in
this context the inflammatory process serves to isolate the offending micro-organism
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Figure 1. The histological features of acute pulmonary inflammation.
This section is from a patient with severe bacterial pneumonia. Alveoli are packed with
proteinaceous exudate and extravasated neutrophils.
The section was stained with haematoxylin and eosin (original magnification x 200).
This slide was kindly provided by Dr Donald Salter, Department of Pathology,
University of Edinburgh.
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and to recruit circulating neutrophils which recognise, ingest and destroy bacteria.
Removal of the noxious stimulus usually results in resolution of acute inflammation
without detriment to the host, and the process can thus be regarded as a highly
evolved and conserved mechanism of tissue protection.
However, under particular circumstances acute inflammation can proceed to
significant tissue injury. This may result through persistence of the noxious stimulus,
and/or through the toxic effects of inflammatory mediators released by the host. As
will be discussed in section 1.3.2., several potent cytotoxic agents are produced by
neutrophils, and these may be released extracellularly under specific conditions. In
this setting, it is notable that a highly developed network of "defence molecules" are
elaborated by tissues in order to preserve integrity. A fine but complex dividing line
therefore appears to exist between acute inflammation representing a beneficial
adaptive response, and becoming an injurious maladaptive principle. Although a
multitude of host factors may influence the outcome of acute inflammation, the
central host defence cell involved is the neutrophil. A schematic representation of
acute inflammation, with particular reference to the role of neutrophils, is shown in
Figure 2.
It should be stressed from the outset that while "allergic inflammation"
(which probably evolved in response to helminthic infestation and in which the
eosinophil plays an important part (Gleich et al., 1992)) is of central importance to
selected human diseases, the allergic response is not considered further in this thesis.
1.3. THE NEUTROPHIL
1.3.1. Origin and basic morphology.
The neutrophil is produced in bone marrow and is of myeloid lineage
(reviewed by Murphy, 1976). A small proportion of the bone marrow pool of
neutrophils is released into the circulation during health, such that a healthy human
adult will have between 2xl09 and 7.5x109 circulating neutrophils per litre of blood.
The circulating neutrophil is thought to have a short half-life of only a few hours
(Athens et al., 1961). The capacity for bone marrow to produce neutrophils is huge
however, and the number of circulating neutrophils rises dramatically and acutely in
response to inflammatory stimuli (Fliedner et al., 1964).
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The circulating neutrophil is a highly differentiated cell, approximately 10-15
fxm in diameter, characterised by the presence of a multilobed nucleus (reviewed by
Murphy, 1976). The cytoplasm contains numerous granules, the predominant species
being azurophilic (or primary) and specific (or secondary) granules, though less well
characterised granules also exist.
1.3.2. The physiological function of neutrophils.
The neutrophil is thought to exist primarily to eradicate bacteria. This
function was elucidated over one hundred years ago, and is beautifully described in
the works of Metchnikoff (1887, 1905) and his colleague Gengou (1901). The
principal functions of the neutrophil can be conveniently identified in the stages of
the cell's passage from the circulation to the location of pathogenic bacteria. The
neutrophil must "sense" an inflammatory stimulus in the microcirculation of a given
tissue, migrate from the vascular space to the bacterial focus, then engulf and destroy
bacteria. Failure of these mechanisms, as manifest in rare hereditary disorders,
results in a propensity to recurrent infection (reviewed by Malech and Nauseef,
1997). Finally the neutrophil must be cleared from the site of inflammation without
release of intracellular toxins. This sequence of events is summarised in Figure 2 and
described in more detail below. Further information on the function of neutrophils
can be obtained from a number of excellent review articles and monographs
(Metchnikoff, 1905; Murphy, 1976; Lehrer et al., 1988; Haslett et al., 1989; Weiss,
1989; Windsor et al., 1993; Rossi and Hellewell, 1994; Albert, 1995; Shanley et al.,
1995; Malech and Nauseef, 1997). In the context of the experimental work which
follows it is worth noting that neutrophilic inflammation can be induced in tissues by
local administration of lipopolysaccharide (LPS) (Hudson et al., 1977; Cybulsky et
al., 1988), a product of Gram-negative bacteria important in the pathogenesis of
septic shock (Morrison and Ryan, 1987). Indeed LPS is used specifically in order to
effect pulmonary neutrophilia in Chapter 4. The biology of LPS and its role in
initiating inflammation is outlined in Figure 3.
Circulating neutrophils are capable of forming reversible adhesive contacts
with endothelial cells in post-capillary venules. These contacts are mediated by the
interaction between a family of molecules known as selectins, and cell-surface
carbohydrate ligands (Bevilacqua and Nelson, 1993). Expression of the ligands
involved in mediating contact appears to be up-regulated by local inflammatory
stimuli. Thus, L-selectin is constitutively produced by neutrophils and binds to
5
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Figure 3. LPS biology.
Bacterial LPS consists of a polysaccharide region (itself consisting of an O-specific
chain, an outer core and an inner core) covalently bound to a lipid A region which
attaches LPS to the bacterial cell wall (reviewed by Malhotra and Bird, 1997). LPS
may engage a number of specific receptors on monocytes and macrophages including
CD14, p2 leukocyte integrins, and Toll-like receptor 4 (reviewed by Ingalls et ah,
1999). In the case of CD 14 free LPS (represented here by grey ovals) is bound by a
circulating protein called LPS-binding protein. This process initiates a conformational
change increasing the binding capacity of LPS for CD 14 (1). In contrast, free LPS has
relatively low affinity for the receptor (2). Ligation of LPS with CD 14 activates
macrophages (3). Reference to Figure 2 shows that LPS can therefore effectively
substitue for bacteria in models of neutrophilic pulmonary inflammation.
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ligands on activated endothelial cells (Jutila et al., 1989); E-selectin production by
endothelial cells is induced by inflammatory cytokines (Bevilacqua et ah, 1987); and
P-selectin is stored in endothelial cells and mobilised in response to endothelial
stimulation (Bonfanti et ah, 1989). It therefore appears that the degree of endothelial
activation can be detected by circulating neutrophils, the selectins mediating
"rolling" of neutrophils along endothelial surfaces in a way that permits further
determination of the neutrophil's fate.
Under appropriate conditions, "rolling" neutrophils may be committed to firm
adhesion as a consequence of the interaction between ^-integrins on neutrophils and
ligands on activated endothelial cells, principal among which is ICAM-1 (Luscinskas
et ah, 1991). Three species of (32-integrin have been identified on neutrophils,
namely CD1 la/CD18, CD1 lb/CD18 and CD1 lc/CD18 (reviewed by Shanley et ah,
1995). Of these, CD1 lb/CD 18 surface expression can be up-regulated upon
activation of neutrophils by signals such as C5a, leukotriene (LT)B4, and fMLP
(Hughes et ah, 1992). Furthermore, neutrophil activation appears to induce
conformational change in neutrophil (F-integrins, favouring firm adhesion to ICAM-
1 (Kuijpers et ah, 1992). The importance of interactions between (32-integrins and
ICAM-1 is emphasised by the marked reduction in neutrophil migration upon
blockade of these molecules (Arfors et al, 1987; Furie et al, 1991; Issekutz and
Issekutz, 1992). The complexity and redundancy in inflammatory mechanisms can
be appreciated however by the observation that CD11/CD18-independent neutrophil
migration can occur (Issekutz et ah, 1995).
The establishment of firm neutrophil-endothelial cell ligation results in
migration of neutrophils through endothelial cell gap junctions in response to
chemotactic gradients. A central role for early inflammatory cytokines in regulating
neutrophil migration is invoked by the function of IL-1 in up-regulating both the
expression of adhesion molecules and chemokines from endothelial cells
(Luscinskas et ah, 1991; Bittleman and Casale, 1995) The process of neutrophil
extravasation in response to chemokines has received a great deal of attention, and is
of specific relevance to work presented in Chapter 4. Before considering the
mechanisms involved in greater detail however, it is worth considering that the
neutrophil's journey from the endovascular compartment to the alveolus involves
negotiation of not only endothelial gap junctions but extracellular matrix, alveolar
epithelial cells, and epithelial lining fluid. Therefore, extrapolation of data from in
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vitro studies assessing any one of these potential barriers should be interpreted with
some caution.
Molecules with chemotactic activity for neutrophils (reviewed by Adams and
Lloyd, 1997) can be derived from bacteria (eg fMLP), from complement (eg C5a) or
from host cells (eg IL-8, growth-related oncogene a, epithelial-derived neutrophil
attractant 78, granulocyte chemotactic protein-2, platelet activating factor (PAF),
LTB4). Interestingly, migration across epithelial barriers appears to occur
preferentially in the basal-to-apical (ie physiological) direction (Parkos et ah, 1991;
Liu et ah, 1996), and is dependent upon the nature of the chemotactic stimulus
(Casale et ah, 1992). Transepithelial migration also appears to be critically
dependent on the origin of the epithelium, alveolar epithelium being more permissive
than bronchial epithelium (Carolan and Casale, 1996). In keeping with the situation
in endothelial cells, transepithelial migration appears to be largely (but not entirely)
CD1 lb/CD 18 dependent (Parkos et ah, 1991). While the binding requirements for
neutrophil migration are becoming clearer, considerable debate surrounds the issue
of whether neutrophil transmigration is dependent upon cell-surface expression of
proteolytic activity. This issue will be returned to in greater detail (particularly with
respect to expression of HNE) in Chapter 4. In brief, the role of a number of
neutrophil-derived enzymes has been examined in the context of migration across
cellular barriers and matrix, but clear evidence supporting any single mechanism is
currently lacking.
A further cautionary point in interpreting existing literature on neutrophil
migration is that not all of the concepts described above may be applicable in the
lung. For example, shear forces in the low pressure pulmonary arterial system differ
from those in the systemic circulation, and pulmonary neutrophil extravasation has
been shown to occur preferentially from capillaries rather than post-capillary venules
(Downey et ah, 1993). Furthermore, it should be noted that blockade of (32-integrins
or depletion of L-selectin does not abolish pulmonary neutrophil migration
(Mulligan et ah, 1993a; Hogg and Doerschuk, 1995). Finally, it should be noted that
the predominant cell type used in studies to elucidate mechanisms of neutrophil
migration has been the human umbilical vein endothelial cell (HUVEC), with very
little data pertaining to endothelial cells from the pulmonary vascular bed.
Once an extravasated neutrophil has reached the source of inflammation, it is
required to locate and engulf pathogenic bacteria. This process of phagocytosis
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commences as bacteria become bound to the neutrophil surface, when pseudopods
extend around the bacteria effectively enclosing them within a "phagosome" which is
itself enclosed within the neutrophil (reviewed by Murphy, 1976). Phagocytosis is
considerably enhanced if the bacteria are opsonised with complement factors (eg
C3b), or by IgG, the Fc portion of which is recognised by Fc receptors on the
neutrophil surface (reviewed by Wright, 1992).
Critically, the specific and azurophil granules of the neutrophil rapidly fuse
with internalised phagosomes, to produce membrane bound structures named
phagolysosomes. Azurophil and specific granules each contain an impressive arsenal
of bactericidal (and potentially cytotoxic) moieties (Table 1). In this way toxic
antimicrobial products are brought into close proximity with bacteria, but remain
isolated from the neutrophil's cytoplasm by means of a distinct membrane (Murphy,
1976). The means by which neutrophils destroy bacteria can be broadly divided into
oxidative and non-oxidative mechanisms.
Oxidative mechanisms are characterised by the ability of stimulated
neutrophils to increase oxygen uptake rapidly in tandem with activation of the
NADPH oxidase enzyme (reviewed by Weiss, 1989). This enzyme catalyses the
conversion of oxygen and NADPH to free oxygen radicals in the form of superoxide
anion. Superoxide anion undergoes a dismutation reaction leading to the generation
of hydrogen peroxide. In the presence of a second neutrophil granule enzyme,
myeloperoxidase (MPO), hydrogen peroxide reacts with chloride ions to generate
significant quantities of hypochlorous acid. Hypochlorous acid is a potent
bactericidal agent. This sequence of reactions rapidly consumes NADPH, which in
turn activates oxidation of glucose via the hexose monophosphate shunt (reviewed
by Lehrer et al., 1988). As such the process of oxygen radical generation is energy
intensive, and has been labelled the "respiratory burst".
In recent years, interest has increasingly been focused on non-oxidative
mechanisms of bacterial killing. Several antimicrobial peptides reside in neutrophil
granules (Table 1), some of which are discussed briefly here to illustrate the diversity
of microbicidal activity of these cells (antimicrobial peptides are discussed in more
detail in the relevant sections of Chapters 3, 5 and 6). Thus lysozyme is thought to
exert antimicrobial activity by hydrolysis of a recurring linkage between N-
acetylglucosamine and N-acetylmuramic acid residues in bacterial cell walls
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activity principally by chelating the iron essential for bacterial viability (Oram and
Reiter, 1968). Proteins found exclusively in azurophilic granules include
bactericidal/permeability-increasing protein (BPI), a cationic peptide which disrupts
membrane permeability in Gram-negative bacteria (Weiss et ah, 1978), and
cathepsin G which has activity against fungi as well as Gram-positive and Gram-
negative bacteria (Lehrer et ah, 1975; Shafer et ah, 1986). However most attention in
recent years has focused on the family of neutrophil defensins, small cationic
peptides with an impressively broad spectrum of antimicrobial activity
encompassing Gram-positive and Gram-negative bacteria, fungi and viruses (Ganz et
ah, 1985; reviewed by Lehrer et ah, 1988). The study of the defensins has stimulated
a hunt for further microbicidal peptides in neutrophils, and it seems likely that
several more will be identified in the future.
Whilst considering the antimicrobial function of neutrophil peptides it is
worth making brief mention of HNE, which is central to the work described in this
thesis. Section 1.4.1. will describe HNE as a potent serine protease found in
azurophil granules. In this setting it seems strange, at first glance, that a critical
antimicrobial function for HNE was not identified early in the study of neutrophil
biology. In fact, a body of evidence did gradually emerge to suggest an antimicrobial
function for HNE, either as a direct effect (Thorne et ah, 1976) or indirectly through
the proteolytic activation of bactericidal molecules such as cathelicidins (Shi and
Ganz, 1998; Cole et ah, 2001). However perhaps the most persuasive argument for
an antimicrobial function was provided by data describing an increased susceptibility
of elastase "knock-out" mice to Gram-negative bacterial sepsis (Belaaouaj et ah,
1998).
The efficiency with which neutrophils access target tissues and destroy
bacteria is epitomised by acute Streptococcal pneumonia, in which affected alveoli
are packed full with neutrophils and fibrinous inflammatory debris (see Figure 1). It
is salient to recall that even before the advent of penicillin a significant proportion of
patients with Streptococcal pneumonia survived without significant pulmonary
sequelae, thus testifying to the neutrophil's incredible proficiency (for a description
of the features of pneumonia in the pre-antibiotic era see Heath and Kay, 1980). The
histological features of pneumonia do however serve as a reminder that neutrophils
must be efficiently cleared from the site of inflammation without release of toxic
contents. This is achieved through the process of apoptosis, a highly regulated
sequence of events in which ageing neutrophils are recognised and phagocytosed by
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resident macrophages without extracellular release of toxic neutrophil products
(Savill et ah, 1989).
1.3.3. Neutrophil-mediated lung injury, and the specific role ofHNE.
Acute inflammation may resolve without residual tissue injury or
dysfunction. However there is no doubt that acute inflammatory processes may
alternatively damage tissues and lead to important pathological sequelae. This
variability in outcome implies that acute inflammation may, under certain
circumstances, be inappropriately or excessively stimulated and/or that endogenous
defence mechanisms are deficient in the tissues of certain individuals. Against this
background there are several reasons to implicate the neutrophil as a potential
effector of tissue injury. Certainly neutrophils contain a myriad of potentially
cytotoxic chemicals (Table 1), prominent tissue neutrophilia is associated with acute
inflammatory tissue injury (reviewed by Malech and Gallin, 1987), and neutrophil
influx is associated with inflammatory stimuli such as cigarette smoking
(Hunninghake and Crystal, 1983). However the neutrophilia associated with acute
tissue injury is not sufficient to establish a causative role for neutrophils, leading to
the question of whether the neutrophil is specifically capable of effecting tissue
injury? Certainly activated neutrophils may damage microvascular and pulmonary
vascular endothelial cells (Smedley et al., 1986; Worthen et al., 1987; Westlin and
Gimbrone, 1993), as well as pulmonary epithelial cells (Ayars et al., 1984).
Furthermore, in established models of acute lung injury, neutrophil depletion has
been shown to obviate tissue damage (Heflin and Brigham, 1981; Worthen et al.,
1987).
Support for the concept that excessive neutrophil activation may be important
in human lung injury is generally provided by reference to adult respiratory distress
syndrome (ARDS) (reviewed by Windsor et al., 1983; Simon and Ward, 1992;
Donnelly and Haslett, 1992). ARDS is characterised by an overwhelming and
catastrophic neutrophil influx into alveoli, often in response to an extra-pulmonary
stimulus such as pancreatitis, abdominal sepsis, or burns. The characteristic
pulmonary neutrophilia is associated with significant degradation of the alveolar-
capillary membrane, resulting in flooding of alveoli with proteinaceous exudate.
Further evidence for the role of neutrophils in acute inflammatory lung injury
in humans is provided by the detection of active, cytotoxic neutrophil products in
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airway secretions from patients with proven lung injury. It is highly likely that
several of the toxins identified in Table 1 contribute to the pathophysiology of
inflammatory lung conditions. However it is intriguing that one particular molecule,
HNE, has been consistently implicated in the pathogenesis of lung disorders
characterised by neutrophilia (reviewed by McElvaney and Crystal, 1997a). This has
made HNE a potentially attractive target in attempts to ameliorate pulmonary injury.
The following section (1.4.) will discuss HNE in detail, and will also briefly describe
two further neutrophil serine proteases implicated in lung injury, namely proteinase 3
and cathepsin G.
Before doing so it is worth attempting to place the information provided so
far in the appropriate context. Thus while the neutrophil plays an important part in
acute inflammatory lung injury and HNE appears to be a central mediator of
neutrophil-mediated damage, it must not be inferred that total ablation of neutrophils
(or HNE) is a desirable therapeutic aim in inflammation. Indeed, the potentially
devastating infective consequences of neutropenia are only too apparent clinically
(Lekstrom-Himes and Gallin, 2000), and elastase deficiency is similarly associated
with a propensity to Gram-negative sepsis (Belaaouaj et ah, 1998). The central
paradox of acute inflammation - whether (and under which conditions) the
neutrophil is beneficial or deleterious - therefore remains enormously relevant.
Furthermore, it must not be inferred that HNE is the single-most important
mediator of inflammation. Figure 2 (itself simplified) testifies to the complexity and
inherent redundancy in inflammatory mechanisms. It has therefore been argued that
targeting of any single inflammatory mediator is unlikely to result in therapeutic
benefit in inflammatory disorders. Nevertheless, it seems intuitively worthwhile to
target important early mediators of inflammation (eg TNF-a or IL-1) and/or late
effectors of damage such as HNE. Against this complex background it is important
to realise that clinical trials attempting to neutralise IL-1 or TNF-a have had mixed
outcomes, with generally favourable results in rheumatoid arthritis (reviewed by
O'Dell, 1999; Yiang et al., 2000) and disappointingly poor results in sepsis (Fisher et
ah, 1996; Abraham et ah, 1998; Vincent et ah, 1999).
Finally, it is sobering to consider that severe inflammatory tissue injury may
be effected in the relative absence of neutrophils and their products. For example
acute lung injury is well described among neutropenic patients (Ognibene et ah,
1986). Furthermore, although the neutrophil is the dominant cell type in sections and
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lavage samples from patients with acute pulmonary injury, an important role for the
alveolar macrophage has been suggested (Mass et al., 1972; Johnson and Ward,
1982; Sibille and Reynolds, 1990). While the experimental work in this thesis
necessarily concentrates on the role of neutrophil products in effecting lung
inflammation, it should be appreciated that alveolar macrophages may indeed
contribute to lung injury, a point that will be stressed intermittently in later chapters.
1.4. SERINE PROTEASES DERIVED FROM NEUTROPHIL GRANULES
l .4.1. Neutrophil elastase.
The association between neutrophils and proteolytic activity appears to have
been first described by Friedrich Midler (reviewed by Opie, 1922). However the
enzyme now recognised as elastase was probably first partially characterised by Opie
(1905), and named leucoprotease.
The single gene encoding HNE is a 4 kb gene on chromosome 19 (Zimmer et
al., 1992). The 267 amino acid product is inactive but a small N-terminus fragment is
cleaved by cathepsin C to yield the mature, proteolytically active protein (220 amino
acids) (Sinha et al., 1987; McGuire et al., 1993). The molecule is glycosylated, has a
molecular mass of 29 kDa, and is a basic molecule with a high arginine content
(Bode et al., 1989). HNE is produced in undifferentiated myeloid precursors, and
mRNA is not found in mature neutrophils (Fouret et al., 1989). HNE is stored in
active form in azurophil granules, and it has been estimated that the concentration in
each human neutrophil may approximate to 50p.M (McElvaney and Crystal, 1997a).
HNE is a serine protease, the catalytic site being formed by three residues
(histidine, aspartate and serine). The spatial arrangement of the catalytic site allows
the serine residue to act as a nucleophile which can attack the carbonyl atom of
selected peptide bonds, and particularly those formed by valine or alanine residues
(Bode et al., 1989). The natural inhibitors of HNE are described in detail in the
following section, but it is worth noting at this stage that four such inhibitors have
been identified in the lung, in the form of ai-protease inhibitor (cci-PI), CC2-
macroglobulin (0C2-M), secretory leukocyte protease inhibitor (SLPI) and elafin.
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The binding characteristics of HNE predict for the molecule's wide substrate
specificity (Table 2). With particular reference to tissue injury and inflammation, it is
apparent that HNE can degrade components of extracellular matrix, several
molecules of importance to acute and chronic inflammation, and some of its own
natural inhibitors. As described in section 1.3.2. HNE is capable of destroying
bacteria via direct (Belaaouaj et al., 2000) and indirect mechanisms (Shi and Ganz,
1998), and it seems most likely that HNE evolved to perform an intracellular
antimicrobial function.
The potential for extracellular HNE to damage lung tissue is suggested by the
molecule's abundance in neutrophils, its broad substrate specificity, and the presence
of active HNE in pulmonary secretions from patients with a variety of inflammatory
disorders. Evidence for a role in mediating human disease was provided in classic
papers describing a propensity for premature emphysema among patients deficient in
ai-PI, the major circulating inhibitor of HNE (Laurell and Eriksson, 1963; Eriksson,
1964). The protease-antiprotease theory of emphysema arose from these
observations. The theory contends that an excess of anti-elastases bathes the lung in
health, but that during inflammation excessive or unopposed release of HNE may
overwhelm prevailing levels of anti-elastase, leading to proteolytic destruction of
tissue. Supportive evidence includes the significant negative correlation between
total sputum elastase and the forced expiratory volume in one second (FEVi) in
chronic obstructive pulmonary disease (COPD) (Fujita et al., 1990; Vignola et al.,
1998). The protease-antiprotease theory is controversial in some respects, and in
particular because some patients with emphysema have normal anti-elastase activity
in bronchoalveolar lavage fluid (BALF). Nonetheless the theory stimulated
considerable interest in the association between HNE and pulmonary injury. Indeed
active HNE has been described in airway secretions from patients with emphysema
and chronic bronchitis (Fujita et al., 1990; Vignola et al., 1998), ARDS (Lee et al.,
1981; Suter et al., 1992), cystic fibrosis (CF) (Goldstein and Doring, 1986; Suter et
al., 1986; Birrer et al., 1994; Nunley et al., 1999), non-CF bronchiectasis (Stockley et
al., 1984a), pneumonia (Boutten et al., 1996), bronchopulmonary dysplasia (Merritt
et al, 1983), asthma (Vignola et al., 1998), and cryptogenic fibrosing alveolitis
(Schaaf et al., 2000). Increased levels of HNE have also been described in serum
from patients with established ARDS (Donnelly et al., 1995). Importantly,
immunohistochemical studies have shown that HNE is detectable in the extracellular
space in association with cleaved elastin in human bronchopneumonia (Watanabe et
al., 1990).
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Cellular functions influenced by HNE
Increased secretion of mucus from serous cells
Impairment of ciliary function
Cytotoxicity against pulmonary epithelial cells
Table 2. HNE substrates, and the influence of HNE on respiratory cell function.
The lists described are not exhaustive. They are designed to illustrate the broad
substrate specificity and cellular effects of HNE.
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Supportive evidence for an effect of HNE in producing lung injury has also
come from animal models. In particular, (intratracheal) IT instillation of HNE
produces emphysema in dogs (Janoff et al., 1977), extracellular elastase has been
shown to colocalise with alveolar structures in hamsters (Rudolphus et al., 1992),
and neutrophil-mediated pulmonary injury has been prevented by administration of
specific inhibitors of HNE (Rudolphus et al., 1993).
Against this background, inhibition of extracellular HNE seems a worthwhile
therapeutic goal, and forms a major objective of the work described in this thesis.
1.4.2. Proteinase3.
Proteinase 3 shares certain characteristics with HNE in that the genes for
each molecule are situated close together on chromosome 19, both are neutral serine
proteases, and both are produced in myeloid precursors then stored in an active form
in azurophil granules (Kao et al., 1988; Rao et al., 1991; Sturrock et al., 1992).
However while proteinase 3 is capable of degrading a variety of extracellular matrix
proteins, its range of substrate specificity is less than that of HNE (Rao et al, 1991;
reviewed by McElvaney and Crystal, 1997a). Furthermore, neutrophils are thought
to contain less proteinase 3 than HNE (reviewed by Hiemstra et al., 1998).
Nonetheless, proteinase 3 is capable of producing emphysema when instilled
IT in hamsters (Kao et al., 1988), and may potentially contribute to human disease.
Two other noteable features of proteinase 3 are the molecule's antimicrobial capacity
(Gabay et al., 1989), and the specific association between autoantibodies to
proteinase 3 and Wegener's granulomatosis (Ludemann et al., 1991).
1.4.3. Cathepsin G.
Cathepsin G is also a serine protease found in active form in azurophil
granules and has approximately 35% homology with mature HNE (Barrett, 1981). In
keeping with HNE, cathepsin G's range of substrate specificity is broad, targets
including matrix proteins, immunoglobulin, fibrinogen and pro-enzymes contained
in neutrophils (McElvaney and Crystal, 1997a). An antimicrobial effect has also
been described for cathepsin G (Shafer et al., 1986). Although the concentration of
cathepsin G in neutrophils closely resembles that of HNE, less is thought to be
released upon neutrophil activation (Campbell et al., 1989).
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1.5. THE INHIBITORS OF HNE
1.5.1. Overview.
The previous section outlined the evidence suggesting a prominent role for
extracellular HNE in the generation of inflammatory lung injury. The available
evidence suggests that endogenous anti-elastase defences may be overcome during
inflammatory episodes, leaving HNE unopposed. A rational strategy in this context
would be up-regulation and restoration of pulmonary anti-elastase activity during
episodes of inflammation. In defining strategies aimed at selectively neutralising
HNE in the lung, it is first necessary to understand the biology of endogenous
pulmonary anti-elastases. In the following sections, the four existing anti-elastase
molecules in the human lung will be discussed. Two of these (aj-PI and CC2-M) are
largely produced outwith the lung, and are thought to be relatively insensitive to
conditions in the local pulmonary milieu. Greater attention will be paid to SLPI and
elafin, low molecular weight inhibitors of HNE which are secreted by pulmonary
epithelial cells in response to changes in the local pulmonary microenvironment.
Particular emphasis will be placed on the biology of elafin. The interaction of
elastase inhibitors with each other and regulation of their production by
inflammatory cytokines will be considered. Finally, the application of synthetic
elastase inhibitors to inflammatory models will be discussed.
1.5.2. Alpha 1-protease inhibitor. 1
As described previously, the association between pulmonary emphysema and
serum deficiency of oci-PI led to recognition of the molecule's importance as a
physiological inhibitor of HNE (Laurell and Eriksson, 1963; Eriksson, 1964; Gadek
et al., 1981).
The human ai-PI gene is located on chromosome 14, and contains 5 exons
and 4 introns (Long et al., 1984). The structure-function relationship of the gene has
been reviewed by Sallenave et al. (1999a).
Alpha]-PI is produced in hepatocytes (Perlino et al., 1987) and released into
the circulation. It behaves as a classical acute phase protein, with serum levels
increasing markedly in response to inflammatory stimuli (Aronsen et al., 1972). Up-
1
Alpha]-protease inhibitor is synonymous with alpha]-antitrypsin.
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regulation of secretion from hepatoma cells in vitro is induced by IL-6 (Perlmutter et
al., 1989). The close association of ai-PI production with "secondary cytokines"
mediating the systemic acute phase response may be of central importance to anti-
elastase biology, as discussed in section 1.5.7. AlphapPI is thought to diffuse into
tissues from serum, and approximately 95% of cci-PI in the lung is thought to have a
hepatic source (reviewed by McElvaney and Crystal, 1997b). Nevertheless,
alternative cellular sources exist in the lung, including macrophages, neutrophils, and
alveolar epithelial cells (Isaacson et al., 1979; Mornex et al., 1986; Venembre et al.,
1994; Paakko et al., 1996; Sallenave et al., 1997a). Interestingly, induction of aj-PI
secretion from alveolar epithelial cells is induced by oncostatin M but not by IL-6,
IL-1 or TNF (Sallenave et al., 1997a).
Alphai-PI is secreted as a glycoprotein consisting of 394 amino acids, with a
molecular mass of 52 kDa. Alphaj-PI is a member of the serpin (serine protease
inhbitor) family of inhibitors, and has the capacity to neutralise a wide range of
serine proteases. However the principal function of apPI is to inhibit HNE. The
molecules form a 1:1 stoichiometric complex, with an association rate constant of
approximately KHlvFsec"1 (Beatty et al., 1980) and a dissociation constant of
approximately 10~14M (Loebermann et al., 1984). These observations suggest potent
inhibition of HNE by oci-PI, leading to the conclusion that cci-PI is the most
powerful inhibitor of HNE in vivo (McElvaney and Crystal, 1997b). The active site
of ai-PI is situated at Met358-Ser359, and forms a bond with the catalytic site of HNE
(Loebermann et al., 1984). The serpin-enzyme complex receptor identified on human
mononuclear phagocytes may play an important part in clearance of ai-Pl-HNE
complexes (Perlmutter et al., 1990).
The biological properties of a.]-PI have led to investigation of the molecule's
potential therapeutic role in inflammatory conditions. Several such studies warrant
attention. Intriguingly, cci-PI has been shown to protect mice against the lethal
effects of TNF (Libert et al., 1996), suggesting an important role in the modulation
of inflammation. In the specific context of human lung disease, aerosolised a]-PI has
been shown to inhibit HNE and reconstitute the ability of BALF to neutralise
pathogenic effects of Pseudomonas aeruginosa in CF (McElvaney et al., 1991).
However the principal therapeutic focus has been on the hereditary deficiency of a]-
PI (reviewed by Eriksson, 1996).
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Consideration of the severe (PiZZ) hereditary form of aj-PI deficiency and
its treatment is instructive in the context of this thesis for a number of reasons.
Firstly it is clear that a significant proportion of individuals with PiZZ deficiency do
not develop emphysema, based on evidence from large Scandinavian and North
American registries (Eriksson, 1996; The Alpha-]-Antitrypsin Deficiency Registry
Study Group, 1998). One interpretation of these data is that, at least in a sub-
population of patients, alternative elastase inhibitors may be sufficient to prevent
clinical lung disease. Secondly, although evidence exists to suggest that
augmentation therapy using recombinant aj-PI slows decline of FEV] (The Alpha-] -
Antitrypsin Deficiency Registry Study Group, 1998), the only randomised, double-
blind placebo controlled trial reported to date did not show a statistically significant
improvement with replacement therapy (Dirksen et al., 1999). This may have
implications for the optimal mode and route of delivery of a]-PI, and/or for the
effectiveness of oti-PI in preventing lung injury mediated by FINE. Finally, as a
single gene defect, a]-PI deficiency is potentially amenable to correction with
somatic gene therapy. The principles of gene therapy are discussed in detail in
section 1.6., but it is worth mentioning that aj-PI gene transfer to the airways is
eminently feasible (Rosenfeld et al., 1991; Canonico et al., 1994), and that trials of
ai-PI gene therapy are under way.
The absence of unequivocal evidence to support a protective effect of a]-PI
replacement therapy raises questions as to whether the desirable inhibitory effects of
a]-PI in vitro are reproduced in vivo. Indeed optimal inhibitory characteristics may
not prevail under conditions of acute inflammatory stress for at least three important
reasons. Firstly, the methionine in the active site of ct]-PI is susceptible to oxidation
and a marked reduction in activity can be induced by biologically relevant oxidants
(Vogelmeier et al., 1997). Secondly, it appears that a]-PI may be extensively cleaved
in inflammatory conditions such as CF and chronic bronchitis (McElvaney and
Crystal, 1997b). Thirdly, evidence suggests that aj-PI may be unable to access the
gap between neutrophil surface and HNE substrate (Campbell and Campbell, 1988;
Owen et al., 1995), which may take on considerable importance on the basis that
FINE can be expressed at the neutrophil surface membrane (Owen et al., 1995) and
that neutrophil adhesion is a powerful stimulus for granule exocytosis (Dahinden et
al., 1983).
Extensive efforts have been made to overcome potential limitations of a]-PI
for therapeutic use, including the engineering of oxidation-resistant mutants. On the
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basis of available evidence it may be reasonable to conclude that oti-PI retains
considerable potential as a therapeutic tool in pulmonary inflammation (especially
when limitations relating to mode of delivery and biochemical structure are
resolved). Against this background however, examination of the function of
alternative anti-elastases seems particularly important.
1.5.3. Alpha2-macroglobulin.
Alpha2-M is a very large glycoprotein (molecular mass 720 kDa) with the
capacity to inhibit a wide variety of proteases, including HNE (reviewed by
McElvaney and Crystal, 1997b). Alpha2-M is produced in hepatocytes (Munck
Petersen et ah, 1988) and secreted into the circulation from where it is thought to
diffuse into tissues. However the considerable size of a2-M limits its concentration
in the lung to molar concentrations below 1% of those described for 0Ci-PI under
basal conditions (McElvaney and Crystal, 1997b). By virtue of its low concentration
in lung, 0C2-M seems unlikely to have a significant role in the immediate inhibition of
extracellular HNE. In this setting it is interesting that alternative functions have been
suggested for 0C2-M, including a role in enhancing antigen presentation (Chu et ah,
1994).
1.5.4. Secretory Leukocyte Protease Inhibitor.2
The observation that oti-PI could not account for all of the anti-elastase
activity of sputum ultimately led to the description and partial characterisation of a
low molecular weight, acid stable "bronchial mucus inhibitor" (synonymous with
SLPI) capable of reducing the proteolytic activity of neutrophil extracts
(Hochstrasser et al, 1972). The molecule was shown to be an inhibitor of HNE
(Ohlsson and Tegner, 1976). SLPI was subsequently shown to be widely distributed
in human tissues, being detectable in bronchial, nasal, salivary, tear, cervical and
semenal secretions (reviewed by McElvaney and Crystal, 1997b; Sallenave et ah,
1999a).
The human SLPI gene spans approximately 2.65 kb, comprising 4 exons and
3 introns (Seemuller et ah, 1986; Thompson and Ohlsson, 1986). A promoter region
2 SLPI has also been known as antileukoprotease, mucus proteinase inhibitor, and bronchial mucus
inhibitor.
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has been identified (Maruyama et ah, 1994), within which resides a short sequence
conferring lung specific expression (Kikuchi et ah, 1997).
SLP1 is a 107 amino acid cationic protein, which is non-glycosylated, and has
a molecular mass of 11.7 kDa (Seemuller et ah, 1986; Thompson and Ohlsson,
1986). The molecule is arranged in a compact, "boomerang" shape, and is
characterised by the presence of two structural domains each containing four
disulphide bridges (Grutter et ah, 1988). The NH2-terminal domain contains heparin-
binding sites (Ying et ah, 1994; Mellet et al., 1995), while the active site resides in
the COOH-terminal domain (Grutter et al., 1988). The reactive site loop contains the
scissile peptide bond Leu72-Met73 (Grutter et al., 1988). SLP1 is capable of inhibiting
HNE, cathepsin G, trypsin, chymotrypsin and mast cell chymase, but does not inhibit
proteinase 3 (reviewed by Sallenave et al., 1999a). SLPI binds HNE tightly with 1:1
stoichiometry (Boudier and Bieth, 1989 and 1992). Importantly the size and compact
structure of SLPI may contribute to its ability to access the gap between neutrophil
and substrate (Rice and Weiss, 1990), and human SLPI has been shown to associate
with elastic fibres in pulmonary connective tissue (Willems et al., 1986). However,
as in the case of cq-PI, the methionine in the active site is susceptible to oxidation
with associated reduction of activity (Vogelmeier et al., 1997).
Importantly the regulation of expression of SLPI appears to differ from that
of cti-PI in that IL-1 and TNF-a effect significant up-regulation of secretion from
alveolar epithelial cells (Sallenave et al., 1994; 1997a). This suggests a differential
response of elastase inhibitors to cytokines, a theme which is returned to in section
1.5.7. Intriguingly, HNE and cathepsin G stimulate expression of SLPI mRNA in
pulmonary epithelial cells (Abbinante-Nissen et al., 1993; Sallenave et al., 1994), but
reduce secretion of SLPI protein (Sallenave et al., 1994). SLPI expression may also
be up-regulated by corticosteroids (Abbinante-Nissen et al., 1995).
The main physiological function of SLPI is thought to be inhibition of HNE,
and the higher concentrations of SLPI associated with upper airway secretions have
suggested an important role in protection of the proximal respiratory tract (Sallenave
et al., 1994; reviewed by McElvaney and Crystal, 1997b). These features prompted
studies testing the protective potential of SLPI in models of inflammation. IT
recombinant human SLPI was found to ameliorate alveolitis induced by immune
complexes in rats (Mulligan et al., 1993b) and emphysema induced by LPS in
hamsters (Rudolphus et al., 1993). A truncated form of recombinant human SLPI
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reduced lung damage mediated by HNE or by sequential administration of LPS and
fMLP in hamsters, the effect being maintained whether the SLPI was administered
IT or intravenously (IV) (Mitsuhashi et ah, 1997). Furthermore, intraperitoneal (IP)
truncated recombinant human SLPI significantly inhibited the development of
bleomycin-induced pulmonary fibrosis in hamsters (Mitsuhashi et ah, 1996).
Recombinant human SLPI was found to be safe when administered to
patients with CF, and a seven day course was associated with a reduction in airway
neutrophilia, FINE, and IL-8 concentration (McElvaney et ah, 1992).
These very encouraging early results suggested therapeutic applications for
SLPI. Interestingly, these data were soon to be complemented by several strands of
evidence suggesting alternative anti-inflammatory functions for SLPI.
In particular the model of immune complex alveolitis developed by Ward and
colleagues (Mulligan et ah, 1993b) has been instructive in understanding SLPI
biology. Thus recombinant human SLPI increases IkBP (an endogenous inhibitor of
the pro-inflammatory nuclear factor NFkB) in the rat lung (Lentsch et ah, 1999), the
effect apparently being dependent on the capacity of SLPI to inhibit trypsin
(Mulligan et ah, 2000). Furthermore endogenous rat SLPI appears to protect against
lung injury by reducing the generation of C5a (Gipson et ah, 1999).
Considerable attention has similarly focused on the anti-inflammatory role of
SLPI in monocyte/macrophage biology. SLPI has been shown to inhibit the
signalling pathways leading to generation of matrix metalloproteinases in LPS-
stimulated human monocytes, the effect being independent of antiprotease activity
(Zhang et ah, 1997). Similarly Ding and colleagues propose that SLPI serves to
reduce the pro-inflammatory response of macrophages to LPS. Their data suggest
that murine macrophage SLPI is induced by LPS (Jin et ah, 1998) and that murine
SLPI is constitutively overexpressed in an LPS-hyporesponsive murine macrophage
cell line (Jin et ah, 1997). In this context it is interesting that SLPI transfected
macrophages can interfere with the uptake of LPS (Ding et ah, 1999).
Furthermore LPS-responsive macrophages can be rendered hyporesponsive by prior
SLPI transfection (Jin et ah, 1997). Interestingly, LPS hyporesponsive monocytes
from patients with sepsis can be reactivated by interferon-y. Against this background
complex mechanisms regulating SLPI production are suggested by the observation
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that the pro-inflammatory transcription factor interferon regulatory factor-1 reduces
SLPI expression (Nguyen et al., 1999).
Extending the anti-inflammatory role of SLPI still further, recombinant
human SLPI has been shown to inhibit both elastase- and allergen-induced airway
hyperresponsiveness (Suzuki et al., 1996; Path et al., 1998; Wright et al., 1999).
Finally, the plethora of novel anti-inflammatory functions ascribed to SLPI
can be extended both to a direct antimicrobial function (discussed in detail in
Chapter 5), and to a profound effect on normal wound healing. The latter effect was
identified in SLPI "knock-out" mice in which skin wounds healed slowly with
impaired matrix accumulation, and persistence of inflammatory cells (Ashcroft et al.,
2000).
The multiple anti-inflammatory functions identified for SLPI clearly suggest
a variety of novel therapeutic strategies. However it is worth noting that therapeutic
implementation of SLPI may not be devoid of problems. In particular recombinant
full-length human SLPI increases the absolute partial thromboplastin time (APTT) in
animal models (Masuda et al., 1995), raising the possibility that systemic
administration of SLPI may predispose to haemorrhage. In addition, the data
outlined above raise theoretical concerns that significant over-expression of SLPI
could lead to immune suppression.
1.5.5. Elafin.3
The early understanding of elafin biology resulted, to a large extent, from the
convergence of data derived from studies in skin and in bronchial secretions. The
specific dermatological implications for elafin will be discussed only briefly in this
section, and greater detail can be extracted from the works of Schalkwijk,
Molhuizen, Wiedow, and Christophers, (early data is reviewed by Molhuizen and
Schalkwijk, 1995).
From a pulmonary perspective, the characterisation of SLPI was greeted with
great interest, as discussed above. However it remained clear that cci-PI, a2-M and
SLPI could not account for all of the anti-elastase activity in airway secretions from
3 Elafin has also been known as elastase-specific inhibitor, skin-derived antileukoprotease, and
trappin-2.
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healthy individuals (Boudier et al., 1987) and patients with chronic bronchitis
(Morrison et al., 1987). The existence in bronchial secretions of a further low
molecular weight antiprotease capable of inhibiting HNE and porcine pancreatic
elastase (PPE) but not cathepsin G had already been described by Hochstrasser et al.
(1981) and by Kramps and Klasen (1985). Against this background the inhibitor was
isolated and purified from the sputum of patients with chronic bronchitis (Sallenave
and Ryle, 1991). The molecule inhibited HNE rapidly and strongly, showed
considerable homology with SLPI, and the putative active site was identified as an
Ala-Met bond (Sallenave and Ryle, 1991). At around the same time Wiedow et al.
(1990) described a low molecular weight inhibitor of HNE and PPE isolated from
psoriatic skin (which they called elafin), whilst Schalkwijk and colleagues isolated
such an inhibitor from psoriatic scales and human keratinocytes (Schalkwijk et al.,
1990; Schalkwijk et al., 1991).
The moiety isolated from sputum by Sallenave and Ryle (1991) was found to
cross-react immunologically with the species described by Kramps and Klasen
(1985), and to have almost complete sequence homology with Wiedow's molecule
(Sallenave et al., 1992). The gene encoding elafin was cloned and sequenced by
Sallenave and Silva (1993) and codes for a 117 amino acid protein, the first 22
amino acids of which represent signal peptide (Sallenave and Silva, 1993). There is
now little doubt that elafin can be proteolytically cleaved into smaller fragments, that
the various fragments described in the foregoing studies were derived from the same
molecule, and that the species described by Hochstrasser et al. (1981) and by
Kramps and Klasen (1985) was indeed elafin.
It is now clear that elafin is a potent inhibitor of the elastolytic enzymes
HNE, PPE and proteinase 3 (Wiedow et al., 1990; Sallenave and Ryle, 1991;
Wiedow et al., 1991; Ying and Simon, 2001), but does not inhibit cathepsin G,
trypsin, chymotrypsin or plasmin (Wiedow et al., 1990; Tsunemi et al., 1992). As
such there are important differences in the inhibitory profiles of elafin, SLPI and CC]-
PI (reviewed by McElvaney and Crystal, 1997b). Elafin secretion in the human lung
may be associated with production by alveolar epithelium, Clara cells, or tracheal
epithelium (Sallenave et al., 1993; Nara et al., 1994). Interestingly, studies of the
tissue localisation of elafin have found that expression is largely confined to
epithelial surfaces (Nara et al., 1994; Pfundt et al., 1996), although low levels of
expression have been described in neutrophils (Sallenave et al., 1997b) and vascular
smooth muscle (Nara et al., 1994).
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The established structure of elafin has considerable implications for function.
Elafin is a cationic and relatively acid-stable protein which is not glycosylated and
has approximately 40% sequence homology with SLPI (Wiedow et ah, 1990;
Sallenave and Silva, 1993). The molecule has two distinct structural domains. The
COOH-terminal domain is compact and robust on account of four disulphide bonds,
and contains the Ala-Met scissile bond forming the active inhibitory site (Tsunemi et
al., 1996). Elafin and HNE form a fully reversible 1:1 stoichiometric complex (Ying
and Simon, 1993) but the bond formed is tight with a relatively slow rate of
dissociation (Sallenave and Ryle, 1991; Ying and Simon, 1993; Tsunemi et al.,
1996) and elafin may therefore best be regarded as a "pseudo-irreversible inhibitor".
Elafin also forms a fully reversible 1:1 stoichiometric complex with proteinase 3,
though elafin appears to dissociate more rapidly from proteinase 3 than from HNE
(Ying and Simon, 1993, 2001). The methionine in the active site of elafin predicts
for potential oxidation with loss of function. This effect has not been confirmed to
date, though elafin has been shown to be inactivated by PPE and sputum from
patients with CF (Sallenave et al., 1995).
The NH2-terminal domain is characterised by repeated VKGQ motifs
(Sallenave and Silva, 1993). This sequence acts as a substrate for transglutaminase
with the resultant formation of covalent isopeptide bonds between glutamine and
lysine. Transglutaminase has been shown to effect polymerisation of elafin and the
covalent binding of elafin to laminin in vitro (Nara et al., 1994), raising the
intriguing possibility that tissue transglutaminase may anchor elafin to extracellular
matrix in vivo. In this context it may be important that elafin has been identified in
cross linkage with loricrin in the cornified cell envelope of epithelial cells (Steinert
and Marekov, 1995),
Interestingly the four-disulphide core and transglutamination sites found in
elafin are structural determinants of homologous proteins including sodium-
potassium ATPase, and recently identified porcine proteins. This led to the concept
that these molecules belong to a structural family, recently named the "trappin
family" (reviewed by Schalkwijk et al., 1999). This association may suggest
additional functions for elafin, but it remains pertinent to recall the similarities
between elafin and SLPI (which is not a trappin) which are both secreted, cationic
inhibitors of HNE with considerable sequence homology, a similar reactive site (Ala-
Met and Leu-Met respectively), a four-disulphide COOH-terminal domain, and
binding sequences in the NH2-terminal domain.
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Elafin is encoded by a single gene located on chromosome 20 (Molhuizen et
al., 1994) which spans approximately 2.3 kb, and contains 3 exons and 2 introns
(Sallenave and Silva, 1993). A number of putative transcription factor binding sites
have been identified 5' of the elafin gene, and reporter gene constructs have
suggested the presence of positive and negative regulatory sequences for elafin
expression in mammary epithelial cells (Zhang et al., 1995). However the genetic
sequences regulating elafin expression remain poorly understood and require further
characterisation.
Importantly IL-1 and TNF-a are capable of up-regulating expression and
secretion of elafin from pulmonary epithelial cells (Sallenave et al., 1994), the
response being mediated largely by interaction between NFkB and a proximal
promoter region (Bingle et al., 2001). The up-regulation is particularly striking after
the application of IL-1 to alveolar epithelial cells (Sallenave et al., 1994). These
findings may imply a central role for elafin in airway protection during the earliest
phase of inflammatory processes, a point which is returned to in section 1.5.7.
Interestingly HNE up-regulates expression of elafin mRNA in A549 cells, but
secretion of elafin is in fact down-regulated by the application of HNE (Reid et al.,
1999). While pro-inflammatory mediators generally appear to up-regulate expression
of the elafin gene, elafin expression in psoriatic skin may be down-regulated by the
application of topical anti-inflammatory corticosteroids (Kuijpers et al., 1997).
The relative importance of elafin in the clinical setting has been investigated
by obtaining airway secretions from patients with a variety of pulmonary
inflammatory disorders. These studies have suggested that elafin constitutes
approximately 20% of the total anti-elastase antigen retrieved from BALF during
health (Tremblay et al., 1996). No specific hereditary deficiency of elafin (or SLPI)
has yet been described, but it is interesting that the relative contribution of elafin to
the total concentration of elastase inhibitors is reduced in airway secretions from
patients with CF, COPD, asthma, and ARDS associated with sepsis (Sallenave et al.,
1999a and 1999b). In all of these conditions SLPI appears to be disproportionately
up-regulated. The relative reduction in elafin is particularly striking in CF and COPD
(Sallenave et al., 1999a). In contrast elafin levels are increased in BALF from
patients with farmers lung, a form of extrinsic allergic alveolitis characterised by
BALF lymphocytosis (Tremblay et al., 1996). It is certainly intriguing that the
relative contribution of elafin should be reduced in conditions associated with airway
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neutrophilia and airway elastase activity. However the clinical studies should be
interpreted cautiously given the small patient numbers, heterogeneity of patients, and
lack of activity data for individual inhibitors. The situation becomes still more
complex in light of reports suggesting that a proportion of SLP1 and elafin in BALF
may be cell associated (Griese et al., 1997).
In order to characterise the role of elafin in inflammation (and with a view to
exploiting properties of elafin therapeutically), several groups have applied elafin in
animal models of inflammatory injury. These findings are discussed in detail in
Chapters 4 and 6 but in brief, studies thus far have concentrated on the effects of
elafin in models of vascular, myocardial, and skeletal muscle injury, an excess of
exogenous (human) elafin generally resulting in tissue protection (Crinnion et al.,
1994; Cowan et al., 1996; Tiefenbacher et al., 1997; Zaidi et al., 1999; O'Blenes et
al., 2000; Barolet et al., 2001).
1.5.6. Other inhibitors of HNE.
The four principal inhibitors of HNE identified in human airway secretions
are discussed above. Potential therapeutic applications are implied by the properties
of these inhibitors, particularly in the context of HNE-mediated disease. When
considering the therapeutic merits of pulmonary inhibitors of HNE it is worth noting
however that other natural and synthetic inhibitors of HNE exist. Details relating to
the biochemistry and in vivo effects of the many important elastase inhibitors which
are not native to the lung will not be discussed in the forthcoming sections of this
work (these can be found in reviews by Powers, 1983; Schnebli and Braun, 1986;
Snider et al., 1994). However it should be recorded that three particular groups of
inhibitors have played an important part in characterising the biology of HNE,
namely eglin C (a natural inhibitor derived from leeches), chloromethyl ketones, and
a compound named ONO-5046, which has been used to characterise the contribution
of elastase to several animal models of lung disease including pulmonary fibrosis
(Taooka et al., 1997) and bronchial hyperreactivity (Fujimoto et al., 1995).
1.5.7. The regulation of pulmonary elastase inhibitors during inflammation.
The mechanisms regulating each of the important pulmonary elastase
inhibitors suggest that inhibition of HNE may be co-ordinated by the inflammatory
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It seems plausible that elafin and SLPI are up-regulated very early in the
inflammatory response, on the basis that they are produced in local epithelium, and
their secretion is rapidly initiated by the early inflammatory cytokines IL-1 and TNF-
a (Sallenave et al., 1994). The induction of "secondary" cytokines such as IL-6 may
then up-regulate ai-PI secretion from the liver (Perlmutter et al., 1989).
Interestingly, it has been demonstrated that HNE bound to SLPI can be transferred to
cci-PI (Fryksmark et al., 1983), and that the cci-PI-FINE complex can be cleared by
macrophages (Perlmutter et al., 1990). The rapid up-regulation, tissue-binding
capacity and size of elafin and SLPI may therefore suggest a role for these molecules
in neutralising HNE generated adjacent to cellular and interstitial substrates, while
aj-PI may exist to scavenge remaining HNE and to effect the ultimate clearance of
HNE from the lung. This process requires further clarification, but in the meantime
provides an intriguing model.
1.5.8. The attractions of elafin augmentation as a strategy for the amelioration of
inflammatory lung injury.
The information provided earlier in this chapter suggested that inhibition of
extracellular HNE is a desirable therapeutic goal in pulmonary inflammation. The
discussion of elastase inhibitors leads to the important question of which to augment
in order to prevent inflammatory lung injury?
For several reasons, elafin was felt to be a particularly good candidate for the
purposes of this work. Potential advantages over aj-PI include the local production
of elafin and the lower molecular mass. Potential advantages over SLPI include the
observation that elafin is particularly effective against the "elastolytic" neutrophil
enzymes (SLPI does not inhibit proteinase 3), and theoretical concerns relating to
immunosuppressive effects and coagulopathy with the use of SLPI. Additionally, it
has been suggested that SLPI functions primarily to protect proximal airways; in the
context of alveolar epithelial cells it is interesting that, relative to baseline values, IL-
1 up-regulates elafin far more than SLPI (Sallenave et al., 1994), potentially
suggesting a greater importance for elafin in protecting distal airways. Finally, the
profound relative deficiency of elafin in conditions such as COPD may suggest an
argument for its repletion in such disorders.
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The remaining question is how best to deliver elafin to the airway? For
reasons discussed in the following section, gene therapy seems ideally suited for this
purpose.
1.6. PRINCIPLES OF GENE THERAPY
1.6.1. Overview and comparison with delivery of recombinant protein.
Gene therapy may be defined as the transfer of genetic material to effect a
desired biological response. In practical terms the genetic material is usually a
therapeutic transgene engineered to be under the control of a selected promoter
region of DNA, the entire genetic material being enclosed in a "vector" with the
inherent capacity to access target cells and deliver its genetic contents. The last
fifteen years has seen a huge proliferation of interest in gene therapy, with
respiratory applications occupying a prominent position in the field on account of the
ready accessibility of the airways, and the fact that CF is the commonest single gene
defect among Caucasians (reviewed by Greening, 2000). Although pulmonary gene
therapy expanded largely in response to the desire to correct the single gene defect of
CF, gene therapy is being applied to increasingly complex respiratory disorders, as
discussed later in this chapter (reviewed by Curiel et al., 1996; Alton and Geddes,
1997; Simpson et al., 2000).
A central question in considering gene therapy strategies for lung disease is
whether gene therapy offers advantages over more traditional modes of
augmentation such as administration of recombinant protein. In the context of
augmenting elafin levels in and around those pulmonary cells at risk of HNE-
mediated damage, gene therapy has important advantages over recombinant protein.
Firstly, recombinant proteins generally have a short half-life, usually measured in a
few hours (Stolk et al., 1995) thus requiring regular administration, with attendant
implications for cost. In contrast gene therapy can potentially produce therapeutic
concentrations for many months (Snyder et al., 1997). Secondly, it is hard to target
specific cells or to control levels of protein in tissues using recombinant protein.
Infusion of recombinant protein often leads to peaks of protein concentration in
tissues shortly after administration and consequent risk of adverse effects. In contrast
gene therapy offers the potential to use promoters which may be inducible (Gossen
et al., 1995; No et al., 1996) and/or tissue- or cell-specific (Strayer et al., 1998).
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Interestingly, in the context of anti-protease biology, ai-PI gene therapy has recently
been shown to be potentially more efficacious than recombinant protein in oti-PI
deficient patients (Brigham et al., 2000).
Gene therapy strategies have traditionally been classified as "viral" or "non-
viral" according to the vector system used (Table 3). With reference to pulmonary
disease, the predominant gene therapy vectors have been cationic liposomes and
recombinant adenoviruses. The following sections will outline the vectors available
for gene transfer with discussion of their advantages and disadvantages. Particular
emphasis will be placed on the pulmonary application of recombinant adenoviruses.
The clinical application of pulmonary gene therapy will be discussed, as exemplified
by trials in patients with CF.
1.6.2. Non-viral gene therapy.
Cationic liposomes are the most extensively studied vectors in non-viral gene
therapy. Their use rests on the principle that anionic DNA (or RNA) may be bound
within cationic liposomes. Liposome-DNA complexes usually consist of a charged
head group (which interacts electrostatically with nucleic acid), a linker, and a
hydrophobic domain which determines packaging of the complex (Feigner et al.,
1987; Smith et al., 1993). The liposome is incorporated into negatively charged cell
surfaces, with subsequent release of genetic material into the cytoplasm (reviewed by
Schofield and Caskey, 1995; Curiel et al., 1996). The advantages of cationic
liposomes in gene therapy protocols are ease of production, the almost unlimited
capacity to carry DNA, and the relative lack of immunogenicity allowing repeat
administration (Table 3). The major disadvantage is the low rate of transfection and
gene expression achieved using liposomes. This is thought to reflect destruction of
DNA in endosomes (Crystal, 1995). Furthermore, high doses of cationic liposomes
have been shown to provoke significant inflammation (Scheule et al., 1997). As
described in section 1.8. cationic liposomes have been applied with some degree of
success in clinical trials (Porteous et al., 1997; Alton et al., 1999). However at the
time the experimental work in this thesis commenced, the inefficiency of transfection
associated with cationic liposomes was felt to outweigh the potential advantages of
these vectors.
Before considering viral vectors however, it should be noted that non-viral
gene therapy strategies are evolving rapidly, and offer potential future applications in
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Capacity to produce high High High
yield in the lab
DNA carrying capacity E1-, partially E3-deleted
virus ~ 8 kb
"Gutted" virus ~ 30 kb
Practically unlimited
Transfection efficiency High Low
in the lung
Duration of expression Transient Transient
in the lung
Host inflammatory Intense, limiting Mild; re-administration
response in the lung re-administration feasible
Table 3. Vectors used in pulmonary gene therapy.
A. Vectors applied in clinical and/or laboratory pulmonary gene therapy protocols.
* denotes the most commonly applied vectors in respiratory gene therapy.
B. A comparison of the relative advantages and disadvantages of adenoviral and
liposomal vectors. The high natural tropism of adenovirus for respiratory epithelium
makes this vector extremely attractive, particularly for protocols requiring transient
expression of transgene.
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the lung and other organs. Interestingly, simple "naked" DNA (ie not enclosed in a
vector) may lead to striking gene expression under certain circumstances,
exemplified by the improvement in ischaemic ulcers after single intramuscular
injection of plasmid DNA encoding the vascular endothelial growth factor (VEGF)
gene (Baumgartner et ah, 1998). Similarly conjugation of DNA with ligands
identifying specific cell surface receptors may allow enhanced gene delivery to cells
in the lung (Curiel et al., 1992; Curiel et al., 1996; Jenkins et ah, 2000).
Finally, the traditional boundaries between non-viral and viral gene delivery
have been crossed in recent years by strategies aiming to capitalise on the advantages
of each. Thus receptor-mediated gene transfer may be enhanced by incorporation of
viral structures involved in nuclear localisation (Cristiano et ah, 1993), and the
efficiency of viral transfection may be combined with the high DNA
carrying capacity of liposomes in Sendai virus-liposome complexes (Schofield and
Caskey, 1995; O'Blenes et ah, 2000).
1.6.3. Viral gene transfer.
Adenoviruses are ideally suited to the transfer of transgenes to the respiratory
tract on account of their natural tropism for respiratory epithelium and their ability to
transfect non-dividing airway epithelial cells (reviewed by Kremer and Perricaudet,
1995). A separate section (1.7.) is therefore devoted to adenoviral gene therapy,
while this section will briefly consider other viruses of importance to gene therapy
protocols.
In this respect, retroviruses occupy an important position, and were used in
the significant majority of early clinical gene therapy trials. Advantages of
retroviruses include the ability to integrate therapeutic transgene into the host
genome thus establishing stable transfection (Miller, 1992). However retroviruses
largely depend upon active cell division to achieve infection (Miller, 1992). Whilst
these properties make retroviruses attractive for targeting tumour cells, the relatively
terminal differentiation of cells lining the respiratory tract and pleural cavity has
largely precluded the use of retroviruses in respiratory applications other than cancer
(Roth et al., 1996; Tan et al., 1996).
In contrast the lentivirus genus of retroviruses (which include human
immunodeficiency virus 1 (HIV-1)) may find a more prominent place in respiratory
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gene therapy on account of the ability of lentiviruses to transfect non-dividing cells
(Naldini et al., 1996; Goldman et al., 1997a; Buchschacher and Wong-Staal, 2000).
However concerns remain over the consequences of integrating genetic material into
the host genome (Poeschla et ah, 1998).
Finally, AAV vectors show signs of making a significant impact in
respiratory gene therapy. AAV is a defective parvovirus capable of efficiently
transfecting respiratory epithelial cells (Flotte et ah, 1992; Curiel et ah, 1996).
Recombinant vectors are stable and appear to have relatively low immunogenicity
(Kremer and Perricaudet, 1995). However the carrying capacity of recombinant
AAV vectors is small (around 4.7 kb) and the potential for non-site-specific
integration (Kremer and Perricaudet, 1995) has raised concerns regarding long-term
safety. Furthermore, production of recombinant AAV traditionally requires the
presence of a helper virus (usually adenovirus), and practical difficulties exist in
generating sufficient yield of recombinant AAV free of contamination with
adenovirus or wild-type AAV (Kremer and Perricaudet, 1995). This said, AAV
vectors have provided long-term gene expression in animal models, with particular
reference to factor IX gene transfer in mice and dogs (Herzog et ah, 1999; Snyder et
ah, 1999). Furthermore a phase 1 trial in which AAV encoding CFTR was instilled
into the sinuses of patients with CF has shown encouraging results (Wagner et ah,
1998).
1.7. ADENOVIRAL VECTORS FOR GENE THERAPY
This section will outline the merits of adenovirus as a gene therapy vector,
the genomic properties of adenovirus, and the techniques used to generate
adenovirus in the laboratory . The problems associated with adenovirus will be
discussed with particular reference to host immunity. Finally, novel ways to
circumvent the host immune response against adenovirus will be considered.
1.7.1. The merits of adenovirus as a gene therapy vector.
As mentioned above, adenoviruses are such attractive tools for respiratory
gene therapy because they have evolved exquisitely efficient mechanisms for the
delivery of DNA to the nuclei of respiratory epithelial cells. Recombinant
adenoviruses can efficiently infect both dividing and non-dividing cells in a wide
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variety of target organs, and do not integrate into the host genome (reviewed by
Kremer and Perricaudet, 1995). In addition, adenovirus can be produced in high
yield in the laboratory, and is a relatively stable virus in vivo (Hitt et al., 1995).
Furthermore, adenovirus has proved to be relatively safe in the hundreds of gene
therapy protocols in which it has been applied, although this observation has been
challenged by important cases in which adenovirus was delivered in very high dose
(Crystal et al., 1994; Hollon, 2000).
1.7.2. The structure of adenovirus.
Adenoviruses belong to the family Adenoviridae, and are double-stranded
DNA viruses. Although several serotypes have been identified, serotypes 2 and 5 are
most commonly modified for use in gene therapy protocols. The adenoviral genome
is approximately 36 kb in size and comprises two functionally distinct units, the
early regions (El A, E1B, E2A, E2B, E3 and E4, which are transcribed prior to viral
replication) and the late regions (LI-5, which are transcribed after viral replication).
In general the late regions code for structural proteins. The early regions have a
number of functions central to initiating viral transcription, regulating host protein
synthesis, and circumventing host immune responses (reviewed by Wold et al., 1994;
Kremer and Perricaudet, 1995). The El region initiates viral transcription and is the
only region which must be transcribed without the aid of trans activators encoded by
adenovirus (Kremer and Perricaudet, 1995). Viral propagation is thus critically
dependent on the El region. The implication for gene therapy is that deletion of El
renders adenovirus replication-deficient whilst freeing space for the insertion of
therapeutic transgene.
Wild-type adenovirus capsid takes the form of an icosahedron of
approximately 80 nm in diameter. Adherent to the capsid are penton subunits, from
which project fibre protein. Elegant studies have demonstrated that the knob of the
adenoviral fibre protein engages a specific receptor (the Coxsackie-adenovirus
receptor, CAR) on cell surfaces (Bergelson et al., 1997), but that internalisation
signals are dependent upon interaction between the penton base and specific cell
integrins (Wickham et al., 1993). While these findings significantly advanced
understanding of adenovirus biology, there is little doubt that CAR-independent
mechanisms of internalisation exist (Flidaka et al., 1999). Once inside cells, efficient
mechanisms transport the adenovirus to the nucleus with consequent disassembly
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and release of genetic material into an epichromosomal location (Greber et al., 1993;
Kremer and Perricaudet, 1995; Greber et al., 1996).
1.7.3. Construction of recombinant adenovirus vectors.
An efficient method for generating recombinant adenoviruses deleted in El
has been described and developed by Frank Graham's group at McMaster University
(Graham and Prevec, 1991; Bett et al., 1994; Hitt et ah, 1995). The absolute
requirement for El in initiating viral transcription is central to this system.
The method, which was used to generate the adenoviruses used in this work
(Addison et al., 1997; Sallenave et al., 1998), is illustrated schematically in Figure 5.
In brief, two plasmids are used to co-transfect the 293 cell line, an embryonal kidney
cell line which can produce El in trans (Graham et al., 1977). The first plasmid
contains all adenoviral sequences required to produce infectious virus when
transfected into 293 cells, with the critical exception of the packaging sequence
required to encapsidate adenoviral DNA (Bett et al., 1994). The second plasmid is a
shuttle plasmid deleted in El but containing left-end sequences including a
packaging signal, an appropriate promoter, a polylinker sequence, and a further short
adenoviral sequence sharing homology with DNA in the first plasmid. The transgene
of interest (for example elafin cDNA) is cloned into the polylinker site downstream
of the promoter sequence. When the two plasmids are cotransfected into 293 cells,
homologous recombination occurs within the short segment common to both
plasmids, resulting in an El deleted (and thus replication-deficient) construct
containing transgene and packaging sequences. As El is provided in trans by the 293
cell, packaged adenovirus is produced but crucially remains replication-deficient.
With deletion of El alone there is space for an insert of approximately 4.7 kb.
However the E3 region is not essential for viral replication in vitro (Haj-Ahmad and
Graham, 1986), and so plasmids have been designed which are also partially deleted
in E3, thus freeing up approximately 8.3 kb for insertion of larger transgenes (Bett et
al., 1994).
This system is capable of generating high yields of recombinant adenovirus
in vitro. The stock produced tends to be relatively pure, however for in vivo use it is
customary to purify 293 cell lysates using CsCl banding, specifically to remove
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Figure 5. Production of recombinant, replication-deficient adenovirus.
Two complementary circular plasmids are co-transfected into 293 cells (the plasmids are
depicted in linear form for convenience). The larger plasmid may be deleted in E3 (E3-)
but contains all the sequences required to produce infectious virions in 293 cells, except
for the necessary packaging sequence (\j/—). The smaller shuttle plasmid contains
packaging sequences (\|/+) but El (which is crucial for viral replication) is deleted (E1-)
and replaced with the desired promoter and transgene (in this case the murine
cytomegalovirus promoter (mCMV; represented by hatched boxis) and elafin (represented
by open boxes) respectively). Homologous recombination (X) occurs within 293 cells (a).
This yields viral genome containing packaging sequences and transgene but deleted in El
and E3 (b). 293 cells produce El in trans, and so viral particles containing transgene are
produced, but are themselves El-deficient (c).
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dialysis to remove CsCl, and transfection of non-permissive cell lines to exclude the
presence of replication competent adenovirus (Fallaux et al., 1999).
1.7.4. Problems associated with the use of recombinant adenoviruses.
A number of theoretical concerns surround the use of recombinant
adenoviruses in humans. These include the potential for oncogenicity; the El region
can confer oncogenicity in rodents (Bernards and van der Eb, 1984), and replication
deficient virus can induce inappropriate cyclin expression in vitro (Wersto et al.,
1998). Furthermore, El A sequences may be detected in the lungs of healthy
individuals and patients with COPD (Matsuse et al., 1992), raising the potential for
generation of replication competent virus after administration of El-deleted
adenovirus in vivo. In addition, it has been suggested that the apical surface of
bronchial epithelium is relatively resistant to transfection with adenovirus (Pickles et
al., 1998).
The considerable experience of experimental and clinical pulmonary gene
therapy generated in recent years fortunately suggests that these theoretical concerns
do not pose significant impediments to successful gene transfer in practice (Kremer
and Perricaudet, 1995). However, two very important concerns remain, namely
fulminant adenoviral pneumonia (which is extremely rare but may be catastrophic)
and host immune responses to adenovirus (which represent the greatest hurdle to be
overcome in adenoviral gene therapy).
Severe pneumonia associated with wild-type adenovirus is well recognised
and can occur in outbreaks among immunocompetent adults (Klinger et al., 1998).
At least two patients treated with high doses of recombinant adenoviruses have had
pneumonic illness, one of whom died (Crystal et al., 1994; Hollon, 2000). These
tragic events have profound implications for dosage scheduling in future clinical
trials.
While adenoviral pneumonia should be readily preventable in future gene
therapy protocols, the problem of host immunity to adenovirus is so important as to
prevent any form of prolonged transgene expression in clinical practice using
adenoviral vectors. The immune response to adenovirus delivered to the lung can
broadly be divided into three components. Firstly, innate immune mechanisms
sequester a considerable proportion of adenovirus, this largely refecting rapid
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internalisation by alveolar macrophages (Kuzmin et ah, 1997; Worgall et ah, 1997a).
The importance of macrophages to adenoviral gene therapy is returned to in detail in
Chapter 4. Secondly, a profound MHC-restricted cytotoxic T lymphocyte response is
generated against adenovirus, resulting in florid inflammation and elimination of
transfected cells (Yang et ah, 1994 and 1996; Wilson, 1996). In recent years
evidence has also emerged to implicate CD4+ cells in the early specific response to
adenovirus (van Ginkel et ah, 1997). The combined effect of innate immunity and
the cytotoxic T cell response is to limit significantly the persistence of a single dose
of adenovirus. The third immune mechanism, namely the generation of both local
and systemic neutralising antibodies to adenovirus (Yei et ah, 1994; van Ginkel et
ah, 1995), significantly reduces the capacity for effective repeat administration.
Importantly, the immune response may be directed not only against adenoviral
proteins but also against heterologous DNA or protein, a point returned to in Chapter
4 (van Ginkel et ah, 1995; Song et ah, 1997a; van Ginkel et ah, 1997; McLachlan et
ah, 2000).
A critical point in the study of anti-adenoviral immunity is that the bulk of
the evidence has been generated in rodents. Whether the response generated in
humans is mediated by similar mechanisms remains controversial. Thus healthy
volunteers were noted to have significantly reduced expression of transgene after
administration of adenovirus to the lung without a significant rise in neutralising
antibodies or in T lympocyte proliferation to adenoviral antigens (Harvey et ah,
2001). Alternative mechanisms of elimination in humans are implied, though the
study group was small. The situation in patients with CF has been more fully
evaluated but varying results have emerged. For example, generation of anti-
adenovirus neutralising antibodies has been described by Zabner et ah (1996) while
other groups have found neutralising antibodies to play little if any part in anti-
adenoviral immunity (Crystal et ah, 1994; Harvey et ah, 1999; Zuckerman et ah,
1999). In contrast there is no doubt that cell-mediated immunity against adenovirus
may be elicited in CF (Crystal et ah, 1994; Zuckerman et ah, 1999).
1.7.5. Methods available to improve the efficiency of adenoviral gene therapy.
The limitations imposed upon adenoviral gene therapy by host immune
responses have generated significant efforts aimed at ameliorating these. In general
two strategies have emerged, aimed either at making adenoviral vectors less
immunogenic or at co-administration of immunosuppressants.
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Recent years have seen the development of "gutted" adenoviruses which
contain inverse terminal repeats and packaging signals, but no other sequences
encoding viral proteins (Fisher et ah, 1996; Kochanek et al., 1996; Parks et al.,
1996). These vectors are generated using a helper adenovirus which is deleted of
packaging sequences, but which can express structural adenoviral genes in trans.
These vectors have the distinct advantages of significantly reduced immunogenicity
and an increased carrying capacity for large transgenes (Haecker et al., 1996; Chen
et al., 1997; Schiedner et al., 1998). Although the requirement for a purification step
to remove helper virus partially limits generation of high yields of "gutted"
adenovirus, these vectors seem poised to make a significant contribution to
adenoviral gene therapy.
Concomitant use of immunosuppressants to deliver adenovirus is potentially
less attractive in human subjects. Nonetheless significant advances have been
demonstrated in animal models, particularly using techniques to block co-stimulatory
molecules involved in immune recognition. Thus transgene expression is enhanced
and repeat administration facilitated by blockade of the T cell receptor, by
simultaneous administration of ligands blocking CD40 and CD28, and by
administration of CTLA4Ig, a chimaeric inhibitor of co-stimulatory molecules (Kay
et al., 1995; Wilson and Kay, 1995; Scaria et al., 1997; Zsengeller et al., 1997; Jooss
et al., 1998; Wilson et al., 1998). Other strategies which have been employed with
success in the laboratory include immune modulation using IL-12 (Yang et al.,
1995), induction of immune tolerance using oral administration of adenovirus (Ilan
et al., 1997) and administration of immunosuppressant drugs (Vilquin et al., 1995;
Kaplan and Smith, 1997). The application of these technologies to humans requires
critical evaluation.
In parallel to improvements aimed at curtailing host immune responses,
advances may also be expected in the transfection capabilities of adenovirus, and in
the power and specificity of gene expression. For example tropism may be expanded
by conjugating adenoviral fibre proteins with ligands for cell surface receptors
(Rogers et al., 1997). Enhanced expression may be attained through the use of
inducible promoters which may be selectively activated (or deactivated) using
exogenous chemical "switches" such as tetracycline (Gossen et al., 1995) or
ecdysone (No et al., 1996). Interestingly, sequences may be engineered into
adenoviral genomes to "insulate" heterologous promoters against the modifying
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effects of viral regulatory elements, thus optimising specificity of expression
(Steinwaerder and Lieber, 2000). Additionally, tissue-specific and cell-specific
promoters may be used to target expression in, for example, type II alveolar
epithelial cells and Clara cells (Glasser et al., 1994; Strayer et al., 1998).
1.8. THE APPLICATION OF GENE THERAPY TO RESPIRATORY
DISEASE
Respiratory gene therapy has largely evolved from the stimulus to correct the
single gene defect of CF. It is instructive to consider CF gene therapy in order to
gauge progress in clinical application. CF gene therapy will therefore be considered
briefly, followed by the rationale for expanding application of gene therapy to more
complex respiratory disorders.
When considering CF gene therapy it is important to acknowledge that
conceptual advances have been enormously helped by the development of CFTR
"knock-out" mice (reviewed by Grubb and Boucher, 1999) and the subsequent
application of gene therapy in these models (Alton et al., 1993). Turning to the
situation in humans, a number of small studies have applied the CFTR gene to the
nose, sinuses and airways of patients with CF. The vectors employed have been
mostly adenoviruses (Zabner et al., 1993; Crystal et al., 1994; Hay et al., 1995;
Knowles et al., 1995; Zabner et al., 1996; Bellon et al., 1997; Zuckerman et al.,
1999) or cationic liposomes (Caplen et al., 1995; Gill et al., 1997; Porteous et al.,
1997; Alton et al., 1999; Hyde et al., 2000) though AAV has also been used (Wagner
et al., 1998). In general terms, application of vectors has proved to be safe although
studies using adenovirus have been associated with varying levels of inflammation
as alluded to earlier (Crystal et al., 1994; Knowles et al., 1995). Proof of principle for
transfer of CFTR cDNA to respiratory epithelium has been provided in all studies to
date. Importantly, this has been amply demonstrated in the lower respiratory tract for
both adenoviral and liposomal vectors (Crystal et al., 1994; Bellon et al., 1997; Alton
et al., 1999; Zuckerman et al., 1999). Furthermore some studies have demonstrated
partial functional correction of the electrophysiological phenotype characteristic of
CF (Zabner et al., 1993; Caplen et al., 1995; Hay et al., 1995; Alton et al., 1999),
though this has not been a universal finding (Knowles et al., 1995). Unfortunately all
studies to date have been characterised by a disappointingly low proportion of cells
transduced, and by short-lived expression of CFTR.
42
Perhaps the most detailed and encouraging study so far was a randomised,
placebo-conrolled, double blind trial using nebulised liposomes encoding CFTR
(Alton et al., 1999). Although the study recruited patients with relatively early
impairment of lung function, and despite transient side effects being common, the
trial demonstrated a significant improvement in lower airway potential difference as
well as a reduction in bacterial adherence in the treated group (Alton et al., 1999).
Thus while CF gene therapy is a very considerable way from effecting lasting
benefit, significant advances have been made. Basic research in CF knock-out mice
continues to provide tantalising leads for clinical gene therapy as exemplified by the
observation that only a small proportion of CF cells need be transfected with CFTR
to effect phenotypic correction (Dorin et al., 1996), and the observation that a single
intra-amniotic administration of adenovirus encoding CFTR can reverse the CF
phenotype (Larson et al., 1997).
To some extent the study of CF exemplifies the advances and continued
challenges in gene therapy. However gene therapy has expanded its horizons well
beyond monogenic disorders such as CF and cci-PI deficieny, and clinical
applications are being developed particularly for lung cancer and mesothelioma
(reviewed by Simpson et al., 2000). Indeed the potential use of gene therapy is being
investigated in a plethora of increasingly complex respiratory conditions in the
laboratory, and it is against this background that the experiments described in this
thesis were performed.
1.9. SUMMARY
This introduction has outlined the importance of the neutrophil in acute
pulmonary inflammation, and has suggested a central role for HNE in acute
inflammatory injury. Consideration of endogenous inhibitors of HNE has suggested
an important role for elafin, a low molecular weight, cationic molecule which is up-
regulated by early inflammatory cytokines. Augmentation of endogenous inhibitors
of HNE appears to be an attractive strategy for the attenuation of neutrophil-
mediated lung injury. Furthermore, the rationale for using adenovirus to target
expression of protective molecules in the lung has been presented. These principles
generated the hypotheses central to this work.
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1.10. CENTRAL HYPOTHESES
The initial hypothesis driving this work was that genetic augmentation of
host defence molecules in pulmonary epithelial cells would result in protection
against damage mediated by acute inflammatory stimuli both in vitro and in
complex in vivo models oflung injury . The model used to test this hypothesis in
vitro centred around the transfection of A549 cells (derived from alveolar
epithelium) with adenovirus encoding human elafin cDNA, with subsequent
exposure of the cells to HNE or activated human neutrophils. The data generated by
the subsequent experiments are described in Chapter 3.
Before extending these principles to study models of lung injury, it was first
considered important to assess the effect of elafin gene augmentation on neutrophil
migration to the lung, in view of the known influence of elastase on neutrophil
extravasation. Thus a further principal hypothesis was that elafin gene
augmentation in vivo would influence the neutrophil influx characteristic of
pulmonary inflammation. The model chosen to test this hypothesis involved
transfection of murine airways with adenovirus encoding human elafin cDNA,
followed by IT challenge with bacterial LPS. The results arising from this model are
described in Chapter 4.
The findings in Chapter 4, in conjunction with elafin's properties as a low
molecular weight, cationic inhibitor of HNE expressed predominantly at epithelial
sites and up-regulated in response to early inflammatory cytokines, stimulated the
further hypothesis that elafin has intrinsic antimicrobial activity. This was tested by
applying elafin (and its structural domains) to Pseudomonas aeruginosa and
Staphylococcus aureus in vitro. The results are presented in Chapter 5.
Data generated by experiments in Chapters 3, 4 and 5 were ultimately used to
test the key hypothesis that elafin gene augmentation couldprotect the pulmonary
epithelium in in vivo models ofacute inflammatory lung injury. The model
employed involved transfection of murine airways with adenovirus encoding human
elafin, followed by challenge with IT Pseudomonas aeruginosa. Results from this





2.1.1. Reagents prepared specifically for studies of elafin biology.
2.1.1.1 .Adenoviral constructs.
Two E1-, partially E3-deleted adenoviral constructs of serotype 5 were used.
Details of their preparation are described below and followed the principles outlined
in section 1.7.3. These vectors were available in-house from the outset of this work.
The first (Ad-elafin) consists of human elafin cDNA downstream of the mCMV
promoter, and was constructed by Dr Jean-Michel Sallenave in Professor Jack
Gauldie's laboratory at McMaster University, Hamilton, Ontario, Canada (Sallenave
et ah, 1998). The second was used throughout this work as a control vector, and
contains the lacZ reporter gene downstream of the mCM V promoter (Ad-lacZ). Ad-
lacZ was originally constructed by Dr Christina Addison and her colleagues in
Professor Frank Graham's laboratory at McMaster University (Addison et ah, 1997).
Amplification and purification of the batches used in this study were performed by
Dr Sallenave, Mr Duncan Chong and Mrs Xueya Feng in Professor Gauldie's
laboratory at McMaster University. The techniques used are reviewed by Hitt et al.
(1995).
For the preparation of Ad-elafin, full-length human elafin cDNA (538 bp)
was obtained by reverse transcriptase polymerase chain reaction (RT-PCR) from
total RNA extracted from the bronchial epithelial cell line NC1-H322, which shares
phenotypic characteristics with Clara cells and is known to secrete elafin (Sallenave
et ah, 1993). As described by Sallenave et al. (1998) elafin cDNA was ultimately
cloned into a shuttle plasmid (pDK6) containing Ad5 sequences from 0-1 mu and
9.8-15.8 map units (mu), a polyadenylation signal, and a 1.4 kb fragment of the
mCMV immediate early promoter (Dorsch-Hasler et al., 1985). The polylinker site
into which elafin cDNA was cloned is downstream of the mCMV promoter. The
resulting plasmid was cotransfected with pBHGlO in 293 eels (Sallenave et al.,
1998). PBHGlO lacks a packaging sequence and is partially E3-deleted (ie it
contains the entire Ad5 gene sequence apart from 0.5-3.7 mu and 78-85.6 mu).
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Homologous recombination resulted in E1-, partially E3-deleted adenovirus
encoding elafin cDNA downstream of the mCMV promoter. The resulting Ad-elafin
vector was purified as described below.
Ad-lacZ was prepared using the same principles. In brief, Ad-lacZ was cloned into
plasmid pMH5 (from which pDK6 was derived) downstream of the same 1.4 kb
mCMV promoter fragment (Dorsch-Hasler et ah, 1985). The resulting plasmid was
cotransfected with pBHGlO in 293 cells (Addison et al., 1997).
With reference to purification and titering of both vectors, crude 293 cell
lysates were prepared and added to 293N3S cells in spinner culture flasks. After 3 to
4 days the presence of inclusion bodies was observed in at least 90% of cells. Cells
were pelleted, lysed then "banded" using step/continuous CsCl gradients. The
adenovirus band was collected and further desalted using PD-10 column
chromatography.
2.1.1.2. Recombinant human elafin.
A truncated recombinant human elafin (57 amino acids in length, H2N-
39AQE 95Q-OH, approximately 6 kDa, representing the COOH-terminus of pro-
elafin) was available in-house, and was originally a kind gift from Dr J Fitton, ICI
Pharmaceuticals, Macclesfield, UK.
2.1.1.3.Synthetic human elafin peptides.
Elafin peptides were prepared by Albachem (Edinburgh, UK) using standard
techniques described elsewhere (Morrison et al., 1998). The established gene
sequence for human elafin (Sallenave and Silva, 1993) was used to derive amino
acid sequences. Four peptides were supplied, namely
Folded full-length elafin (H2N-1AVT 95Q-OH), molecular weight 9925 Da.
Unfolded full-length elafin.
Folded NH2-terminal domain (H2N-1AVT 50K-OH), molecular weight 5172
Da.
• Folded COOH-terminal domain (H2N-51PGS 95Q-OH), molecular weight
4776 Da.
The molecular mass of each moiety was determined by mass specrometry
(Albachem) and corresponded to the predicted mass in each case.
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The amino acids demarcating the end of the NH2-terminal domain and the start of
the COOH-terminal doman were determined from the known crystal structure of a
fragment of elafin complexed to PPE (Tsunemi et al., 1996), and from the known
structure and sequence of human SLPI (Griitter et al., 1988).
2.1.1.4.Antiserum raised in rabbits against human elafin.
Antiserum raised against a COOH-terminal 2.5 kDa fraction of human elafin
was prepared by Dr Jean-Michel Sallenave as described elsewhere (Sallenave et al.,
1992), and was available in-house from the outset of this work.
2.1.1.5.Bacteria.
Pseudomonas aeruginosa strain PAO1 (an extensively characterised clinical
strain (reviewed by Govan and Deretic, 1996; Stover et al., 2000)), and
Staphylococcus aureus strain CI705 (Morrison et al., 1998) were available in-house,
and were kindly provided by Professor John Govan, Department of Medical
Microbiology, University of Edinburgh.
2.1.2. Source of other reagents used.
All reagents were from Sigma, Poole, Dorset, UK, with the exception of
those listed below.
L-glutamine, penicillin-streptomycin, trypsin-ethylene diamine tetraacetic acid
(EDTA), Trizol, and Iscove's medium were from Gibco BRL, Paisley, Scotland, UK.
5-bromo-4-chloro-3-indolyl-|3-D-galactopyranoside (X-gal) was from Promega,
Madison, USA.
111 Indium was from Dupont, NEN Life Sciences, Brussels, Belgium.
Dextran and Percoll were from Pharmacia, Uppsala, Sweden.
HNE was from Elastin Products, Owensville, MO, USA.
PAF and fMLP were from Calbiochem, Nottingham, UK.
Tetramethylbenzidine (TMB) was from Boehringer Mannheim, Mannheim,
Germany.
Gelatin, avidin-biotin and avidin-biotin buffer were from BDH, Poole, Dorset, UK.
LPS (from Escherichia coli 0127:B8 in all experiments described), yeast extract and
Pseudomonas Isolation Agar (PIA) were from Difco Laboratories, Detroit, MI, USA.
Nitrocellulose membrane was from Millipore, Watford, UK.
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Dried skimmed milk was used in the form of Marvel, Premier Brands UK, Moreton,
UK.
Murine anti-rabbit immunoglobulin complexed to peroxidase and 3,3'-
diaminobenzidine tetrachloride (DAB) were from DAKO, Glostrup, Denmark.
Enhanced chemiluminescence (ECL) kit was from Amersham Pharmacia, Little
Chalfont, UK.
X-omat radiographic film was from Kodak, Chalon-sur-Saone, France.
Tryptone soya broth (TSB), nutrient agar and Columbia agar were from Unipath,
Basingstoke, UK.
Recominant human SLPI, and enzyme-linked immunosorbent assay (ELISA)s for
human IL-1, IL-8, human TNF-a, murine TNF-a and macrophage inflammatory
protein 2 (MIP-2) were from R&D Systems, Abingdon, UK..
2,2,2-tribromoethanol was from Aldrich, Gillingham, UK.
Nutrient broth was from Oxoid, Basingstoke, UK.
Assay of protein concentration, and NHS-LC-Biotin kit were from Pierce, Rockford,
IL, USA.
Murine albumin ELISA was from Bethyl Laboratories, Montgomery, TX, USA.
Diff-quik stain was from Dade Diagnostika, Germany.
Normal goat serum was from the Scottish Antibody Production Unit, Edinburgh.
2.1.3. Plastic-ware.
24-well tissue culture plates and Transwell polycarbonate filters were from
Corning Costar, Cambridge, MA, USA.
Plates for elafin ELISA were from Linbro, Flow Laboratories, McLean, VA, USA.
Nylon tubing for IT instillation was from Portex, Hythe, Kent.
2.1.4. Mice.




2.2.1. Preparation of human serum, neutrophils and peripheral blood-derived
mononuclear cells.
The method used followed that described by Haslett et al. (1985). Fresh
whole blood was obtained from healthy volunteers and added to sodium citrate (final
concentration 0.38%). 50ml aliquots of blood in plastic tubes were centrifuged at
350g for 20 minutes at room temperature to yield platelet rich plasma (PRP) above a
red cell pellet. PRP was aspirated and decanted into glass tubes; autologous serum
was prepared by adding CaCb and incubating at 37°C. Immediately after aspiration
of PRP, dextran was gently mixed with the red cell pellet (0.25ml dextran per ml of
red cell pellet) and incubated at room temperature for 30 minutes to allow
sedimentation. The uppermost, leukocyte rich layer was gently aspirated, and saline
added to a final volume of 50ml. The suspension was centrifuged at 350g for 6
minutes at room temperature yielding a white cell pellet which was gently
resuspended in 2.5ml of 55% Percoll (prepared in phosphate buffered saline (PBS)).
The suspension was gently layered onto 2.5ml of 70% Percoll, which had in turn
been gently layered onto 2.5ml of 81% Percoll (ie forming a sequential Percoll
density gradient, cells being suspended in the uppermost layer). The Percoll gradient
was centrifuged at 700g for 20 minutes at room temperature. This results in
peripheral blood-derived mononuclear cells (PBMCs) being suspended in a band at
the interface between 55% and 70% Percoll, while polymorphonuclear leukocytes
exist in a band between 70% and 81% Percoll. Each band was gently aspirated and
washed twice with PBS, each wash being followed by centrifugation at 220g for 5
minutes at room temperature. The resultant pellets were each suspended in PBS.
Small aliquots were taken from each for quantification using a haemacytometer, for
assessment of cell morphology and cell type by flow cytometry, and for differential
cell count by preparation of cytospins stained using Diff-quik. Neutrophil
preparations were deemed satisfactory for further analysis if >95% of the
polymorphonuclear band consisted of neutrophils.
Neutrophils and PBMCs were used immediately after preparation. If the
subsequent experimental protocol required that cells be suspended in medium other
than PBS, cells were centrifuged again at 220g for 5 minutes at room temperature,
PBS discarded, and cells suspended at known concentration in the medium of choice.
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2.2.2. Preparation of A549 cells.
A549 cells (Giard et al., 1973) were available in-house. Cells were suspended
in Dulbecco's Modified Eagles Medium (DMEM) containing 10% foetal calf serum
(FCS), penicillin G (final concentration 100 U/ml), streptomycin sulfate (final
concentration 100|ig/ml) and L-glutamine (final concentration 2pM), then seeded
onto 24-well plastic tissue culture plates and incubated at 37°C in a humidified
incubator containing 5%CC>2. Cells were used in further experiments only once full
confluence was achieved.
Estimation of the number of cells in each confluent monolayer was
performed by washing cells with PBS then adding trypsin and incubating at 37°C.
Cells were agitated to obviate clumping, and detachment was confirmed by light
microscopy. Cells were counted using a haemacytometer. Cell viability was assessed
by staining with trypan blue, with exclusion indicating viability. Standard 24-well
plastic plates were used, and at confluence each well contained approximately
300,000 A549 cells.
2.2.3. Transfection of A549 cells with adenoviral constructs.
Adenoviral constructs of known concentration were diluted in DMEM
containing 5% FCS, penicillin G (final concentration 100 U/ml), streptomycin
sulfate (final concentration 100pg/ml) and L-glutamine (final concentration 2pM).
A549 cells were washed with PBS and adenovirus applied at a multiplicity of
infection (moi) of 0-50 plaque forming units (pfu) (total volume 1 OOptl per well) for
30 minutes at 37°C. Cells were washed repeatedly with PBS to remove excess virus
and incubated overnight at 37°C in DMEM containing 10% FCS, penicillin G (final
concentration 100 U/ml), streptomycin sulfate (final concentration 100p,g/ml) and L-
glutamine (final concentration 2pM). The following day, except where otherwise
stated, cells were washed to remove all traces of serum, and 400)itl of fresh serum-
free DMEM containing penicillin G (final concentration 100 U/ml), streptomycin
sulfate (final concentration 100pg/ml) and L-glutamine (final concentration 2pM)
was added. The rationale for using serum-free medium stems from the fact that
serum contains a high concentration of elastase inhibitors, and many of the
experiments described were designed specifically to determine whether Ad-elafin
could confer protection against the effects of HNE.
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Experiments assessing the effects of elafin augmentation were performed
using Ad-elafin to stimulate elafin expression, Ad-lacZ as a viral control, and vehicle
alone as a non-viral control.
2.2.4. Staining for (3-galactosidase in A549 cells.
A549 cells, transfected as described in section 2.2.3., were washed with PBS.
Serum-free DMEM containing penicillin G (final concentration 100 U/ml),
streptomycin sulfate (final concentration 100p.g/ml) and L-glutamine (final
concentration 2pM) was added and the cells incubated at 37°C for 24 hours. Medium
was discarded and 200pl of fixative added for 10 minutes at room temperature
(fixative comprised 0.2% glutaraldehyde, 0.8% formaldehyde, 2mM MgCl2, in
PBS). Fixative was discarded and 200pl of staining solution added for 5 hours at
37°C (staining solution comprised 5mM K4Fe(CN)6, 5mM K.3Fe3(CN)6, 2mM
MgCl2, 0.05% Triton X-100, 0.5 mg/ml X-gal, in PBS). Cells were washed with
PBS and photographs were taken.
2.2.5. Labelling of A549 cells with 111 Indium.
The technique used was adapted from that described for radiolabelling of
human endothelial cells (Smedley et al., 1986). Radiolabelled indium was incubated
with 4xlO"3M tropolone for 1 minute at room temperature (final concentration of
'"Indium 75pCi/ml). 40|il of the resulting solution (3pCi of 11 'Indium, final
concentration of tropolone 4xlO"4M) was added directly to transfected (and
untransfected) A549 cells at the end of the overnight incubation in DMEM
containing 10% FCS. Incubation proceeded for 15 minutes at room temperature.
Supernatants were gently aspirated, and cells were washed three times with PBS.
400|il of fresh, serum-free DMEM containing penicillin G (final concentration 100
U/ml), streptomycin sulfate (final concentration 100|ig/ml) and L-glutamine (final
concentration 2|iM) was added to each well in keeping with the scheme outlined in
section 2.2.3.
In each experiment performed 40pl of the '"Indium solution applied directly
to cells (ie 3pCi of "'Indium in 4xlO"3M tropolone) was added to scintillation fluid
and radioactivity measured in a scintillation analyser. The supernatant and three
washes retrieved from representative wells were also added to scintillation fluid and
assessed for radioactivity; the sum of radioactivity from these aliquots was
/£• ■'ls\
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subtracted from that in the initial 111 Indium solution. Incorporation of n l Indium was
estimated by dividing the resulting radioactivity (assumed to be incorporated) by that
in the initial 111 Indium solution.
Further confirmation of incorporation was provided by lysing representative
monolayers using Tryzol, then estimating radioactivity in the resulting suspensions.
2.2.6. Assessment of damage to A549 cells induced by addition of HNE or
activated human neutrophils.
A schematic representation of the experiments performed is shown in Figure
1. A549 cells transfected as described in section 2.2.3. were washed with PBS to
remove serum, and 400ju.l of serum-free DMEM containing penicillin G (final
concentration 100 U/ml), streptomycin sulfate (final concentration 100p,g/ml) and L-
glutamine (final concentration 2|iM) were added to each monolayer. Cells were
incubated at 37°C for 24-72 hours depending on the experimental conditions
required. HNE was added directly at a final concentration ranging from 0-4 pg/ml
and cells were incubated for a further 16 hours at 37°C. Damage to the monolayer
was assessed morphologically by light microscopy, and quantified by aspirating and
agitating the supernatant (to obviate cell clumping), staining with trypan blue, and
counting cells using a haemacytometer. In a variation of these experiments A549
cells were radiolabelled with 111 Indium as described above and damage to the
monolayer quantified by measuring radioactivity in supernatants using a scintillation
analyser.
In a separate set of experiments the same protocol was employed with the
exception that activated human neutrophils substituted for HNE. Neutrophils were
prepared fresh from whole blood as described in section 2.2.1. and suspended in
serum-free DMEM containing penicillin G (final concentration 100 U/ml),
streptomycin sulfate (final concentration lOOjlg/ml) and L-glutamine (final
concentration 2|iM). 40pl of neutrophil suspension (incorporating either lxlO6,
1.5x106 or 2xl06 neutrophils in different experiments) was added directly to wells
containing A549 cells which had been incubated for 24-72 hours (depending on the
experimental conditions required) at 37°C in 400pl of serum-free DMEM containing
penicillin G (final concentration 100 U/ml), streptomycin sulfate (final concentration
100p.g/ml) and L-glutamine (final concentration 2pM). Immediately upon addition
of neutrophils, 1% bovine serum albumin (BSA) (final concentration) was added to
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Grow A549 cells to confluence in DMEM containing 10% FCS
Add Ad-elafin, Ad-lacZ or vehicle alone
for 30 minutes at 37°C
Wash to remove residual virus
Replace medium with DMEM containing 10% FCS and incubate
overnig ht at 37°C
Wash to remove residual serum containing medium
Incubate in serum-free DMEM for 24-72 hours at 37°C
Add HNE (or neutrophils) directly and incubate for 16 hours at 37°C
Assess damage to monolayer
Figure 1. Outline of the principal stages of experiments assessing the effect of Ad-
elafin on A549 cell damage mediated by HNE or activated human neutrophils.
53
all wells. At this point neutrophils were stimulated in one of two ways. In the first
phorbol myristate acetate (PMA) was added (final concentration 1 ng/ml). In the
second the priming agent PAF was added (final concentration 10"9M) for 1 hour at
37°C followed by the addition of fMLP (final concentration 10"7M). The
concentrations of PAF and fMLP described were determined from preliminary
experiments using PAF in the dose range 10"9M to 10"1 'M, and fMLP in the range
10"7M to 10"9M, optimal degranulation of human neutrophils occurring with the
combination of 10"9M PAF and 10"7M fMLP. Irrespective of the neutrophil stimulant
used, incubation proceeded at 37°C. 16 hours after the addition of neutrophils,
damage to the monolayer was assessed morphologically using light microscopy.
In a variation of these experiments, A549 cells were radiolabelled with
11 1 Indium as described above, and neutrophils stimulated using PAF (10~9M) and
fMLP (10"7M). Damage to the monolayer was assessed by measuring radioactivity
in cell supernatants at the end of the experiment. To control for the theoretical
possibility of non-specific leak of radiolabel from A549 cells, radioactivity in
supernatants from cells not exposed to neutrophils was subtracted from that in
supernatants from cells exposed to activated neutrophils.
2.2.7. Rabbit anti-human elafin polyclonal antibody; preparation, confirmation of
activity against elafin, and addition to A549 cells.
Immune serum raised against human elafin in rabbits (Sallenave et al., 1992)
was passed over a protein A-sepharose column, and the column washed with 0.1M
Tris, pH 8.0. Elution was performed using 0.1M glycine, pH3.0, buffered with 1M
Tris, pH 8.0. The concentration of the eluent was established by measuring
absorbance at 280nm.
Varying concentrations of the eluted fraction were incubated with lOOng of
recombinant human elafin for 30 minutes at 37°C. HNE (0-1200ng) was then added,
with further incubation for 30 minutes at 37°C. The final volume of the elafin/anti-
elafin/HNE mixture was 50(iil. Elastase activity was measured as described in section
2.2.12.
Upon determination of the concentration of anti-elafin antibody required to
neutralise 2 ng/pl of elafin, an excess of anti-elafin antibody was added to
transfected A549 cells which had been incubated for 24 hours in serum-free DMEM
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containing penicillin G (final concentration 100 U/ml), streptomycin sulfate (final
concentration 100|!g/ml) and L-glutamine (final concentration 2pM). HNE (4 flg/ml
final concentration) was added directly to supernatants and damage to the A549
monolayer was assessed 16 hours later by light microscopy (as described in section
2.2.6. above). Supernatants were retrieved for measurement of residual elastase
activity as described in section 2.2.12.
2.2.8. Neutrophil migration assay.
A549 cells were transfected as described in section 2.2.3. Cells were washed
with PBS to remove residual serum, and medium replaced with 400pl of serum-free
phenol red-free(PRF)-DMEM containing penicillin G (final concentration 100
U/ml), streptomycin sulfate (final concentration lOOpg/ml) and L-glutamine (final
concentration 2pM). Cells were incubated for 48 hours at 37°C. 1% BSA (final
concentration) was then added directly to each well.
Human neutrophils were prepared as described in section 2.2.1. and
suspended in PRF-DMEM containing 1% BSA (final concentration), penicillin G
(final concentration 100 U/ml), streptomycin sulfate (final concentration 100pg/ml)
and L-glutamine (final concentration 2pM). 100pl of the suspension (containing
1.25xl06 neutrophils) was added to polycarbonate filters of 3pm pore size. Filters
were immediately placed into wells containing A549 cells, such that the base of the
filter was just in contact with A549 cell supernatant. Incubation proceeded at 37°C
for 20 minutes, at which point filters were removed and discarded. Lysis of
neutrophils which had migrated through the filter was then achieved by direct
addition of Triton X-100 (final concentration 0.4%). The resulting lysate was
acidified using 12.5pl of Na citrate-acetate buffer, pH4.2.
MPO activity was used as an index of neutrophil content and was measured
by adding 1 OOjllI of MPO-specific chromogenic substrate (0.1 mg/ml TMB, 0.03%
H2O2, in 0.1 M Na acetate-citrate, pH 4.9) to lOOjul of lysed supernatant and
quantifying the change in absorbance at 630nm as a function of time. The number of
neutrophils in lysates was estimated by extrapolation from standard curves prepared
by lysing known quantities of neutrophils and plotting against the change in
absorbance at 630nm after addition of TMB and H2O2. Because the rate of migration
of neutrophils from different donors varied considerably (89,000-299,000, median
237,000, n=4) neutrophil migration was expressed relative to maximal migration for
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each donor. PRF-DMEM was used in these experiments because the blue colour
generated by addition of chromogenic substrate is poorly detected in medium
containing phenol red.
A number of variations of this experiment were performed. In the first, an
excess of anti-elafin immunoglobulin was added to cells prior to the addition of
neutrophil-containing inserts. In the second, recombinant human elafin was added to
cell-containing and cell-free wells prior to the addition of inserts. In the third anti-
human-IL-8 was added to cells prior to the addition of inserts.
2.2.9. Addition of LPS to A549 cells.
A549 cells were transfected as described in section 2.2.3.. After incubation in
DMEM containing 10% FCS, penicillin G (final concentration 100 U/ml),
streptomycin sulfate (final concentration 100pg/ml) and L-glutamine (final
concentration 2pM) for 48 hours, LPS was added directly to cells at a final
concentration ranging between 0 and 1000 p.g/ml (ie in experiments using LPS
serum was present in supernatants throughout unless otherwise stated). Cells were
incubated for a further 24 hours at 37°C and supernatants were retrieved. In a
variation of these conditions LPS was added immediately after transfection at the
first point of exposure to DMEM containing 10% FCS, penicillin G (final
concentration 100 U/ml), streptomycin sulfate (final concentration 100|ig/ml) and L-
glutamine (final concentration 2pM). Cells were incubated for 72 hours at 37°C and
supernatants were retrieved.
The viability of A549 cells treated with LPS was assessed by aspirating
supernatants from representative wells, staining with trypan blue and assessing the
proportion of viable cells using a haemacytometer. The remaining monolayers were
washed with PBS and treated with trypsin to detach cells. Cells were agitated to
prevent clumping, stained with trypan blue, and assessed using a haemacytometer.
2.2.10. Elafin ELISA.
The ELISA was performed on 96 well plastic plates. Wells were coated
overnight at 4°C with anti-elafin IgG in carbonate buffer, pH 9.6 (final concentration
IgG 7.7 p,g/ml), with the exception that "blank" wells received buffer alone. The
plate was washed with wash buffer (0.1% Tween-20 in PBS, pH 7.4).
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Gelatin (final concentration 1% in PBS, pH 7.4) was added to all wells (as a
blocking agent) for 2 hours at 37°C and the plate washed with wash buffer, prior to
the addition of samples and standard.
Standards comprised recombinant human elafin diluted in 1% gelatin, and
were applied in triplicate at a dose range from 0.5 to 30 ng/ml ("blanks" received 1%
gelatin alone). Samples were serially diluted in 1% gelatin; all dilutions were applied
in duplicate. The volume of each standard and sample was lOOpl, and incubation
proceeded for 2 hours at 37°C, after which all wells were washed with wash buffer.
Anti-elafm IgG, biotinylated using an NHS-LC-Biotin kit, was diluted in 1% gelatin
and added to each well (except "blanks" which received 1% gelatin alone) for 2
hours at 37°C. The plate was washed with wash buffer.
Streptavidin-biotin-horseradish peroxidase complex (final concentration 10
ng/ml in 1% gelatin) was added to each well (except "blanks" which received 1%
gelatin alone) for 2 hours at 37°C. The plate was washed with wash buffer. Substrate
(comprising 0.006% H2O2 and 1 mg/ml 2,2' azino bis 3-ethyl benzthiazolidine
sulfonic acid, in 0.1 M citric acid, pH 4.0) was added to all wells and absorbance read
at 550nm. Standard curves were constructed by plotting absorbance against elafin
concentration, and the elafin concentration in samples determined by extrapolation
from the curve.
2.2.11. "Dot-blot" detection of elafin.
Samples of conditioned medium from transfected A549 cells were applied
directly to a nitrocellulose membrane at room temperature and allowed to dry. PBS
(as a negative control) and recombinant human elafin at a final concentration of 0.1
or 1 pg/ml (as positive control) were also applied. The membrane was added to an
excess of blocking solution, comprising 5% dried skimmed milk and 0.05% Tween
20 in PBS. Incubation proceeded overnight at 4°C with continuous orbital shaking.
The blocking solution was discarded and anti-elafin IgG (diluted one
thousand-fold in blocking solution, final volume 10ml) was added for 1 hour at room
temperature with continuous orbital shaking. The membrane was washed with an
excess of PBS-Tween (0.05% Tween 20 in PBS).
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Murine anti-rabbit immunoglobulin conjugated to peroxidase (diluted five
thousand-fold in blocking solution) was then added for 20 minutes at room
temperature with continuous orbital shaking. The membrane was washed with
blocking solution for 15 minutes at room temperature, and then washed with PBS-
Tween. Chemiluminescence was developed using a standard ECL kit, and the
membrane developed on X-omat radiographic-quality film.
2.2.12. Assessment of elastase activity.
Equal volumes (50pil unless otherwise stated) of sample and elastase-specific
substrate were added to 96 well plastic plates. Substrate consisted of 0.1 mg/ml N-
methoxysuccinyl-ala-ala-pro-val p-nitroanilide in 50mM Tris, 0.1% Triton, 0.5M
NaCl, pH 8.0. Absorbance at 405nm was measured serially, immediately from the
time of addition of substrate. Absorbance was plotted against time and, within the
linear portion of the plot, change of absorbance was measured.
In all cases blanks consisted of equivalent volumes of substrate and the
unconditioned medium in which the experiment was performed (for example when
measuring elastase activity in supernatant from A549 cells incubated in DMEM to
which HNE was added, blanks consisted of DMEM and substrate).
When considering samples in which the concentration of elastase was
unknown (for example after addition of neutrophils), experiments included a well in
which purified HNE replaced sample, and acted as a standard.
When considering samples in which the concentration of elastase was pre¬
determined (for example where HNE had been added to A549 cell conditioned
medium to give a final concentration of 4|ig/ml), elastase activity in supernatants
from transfected cells was expressed relative to the elastase activity in supernatants
from untransfected cells.
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2.2.13. Measurement of elastase inhibitory activity (EIA).
The principles of measurement of EIA are an extension of those for
measurement of elastase activity.
Samples were serially diluted in 50mM Tris, 0.1% Triton, 0.5M NaCl, pH
8.0. 1 Optl of each dilution was added to 50ng of HNE in 1 Ojj.1 of 50mM Tris, 0.1%
Triton, 0.5M NaCl, pH 8.0. The final volume was made up to 50pl with 50mM Tris,
0.1% Triton, 0.5M NaCl, pH 8.0. Plates were inubated for 30 minutes at 37°C. In all
experiments one solution consisted of lOpl HNE and 40pl 50mM Tris, 0.1% Triton,
0.5M NaCl, pH 8.0 (ie no sample).
To each sample/HNE/buffer mix of 50pl was added 50(il of elastase substrate
(0.1 mg/ml N-methoxysuccinyl-ala-ala-pro-val p-nitroanilide in 50mM Tris, 0.1%
Triton, 0.5M NaCl, pH 8.0). Absorbance at 405nm was plotted against time and,
within the linear portion of the plot, change of absorbance was measured. Change of
absorbance was then plotted against volume of sample. On the assumption that HNE
forms 1:1 stoichiometric complexes with its natural inhibitors in samples generated
in vitro and in vivo, extrapolation of the resultant curve to the abscissa indicates the
volume of sample which completely inhibits the known starting concentration
(0.5ng/pl) of HNE (after Bieth, 1980). The molar concentration of elastase inhibitors
in the sample (ie the EIA) can then be calculated.
2.2.14. Culture of monocyte-derived macrophages.
PBMCs were freshly prepared as described in section 2.2.1., and suspended
in serum-free Iscove's medium containing penicillin G (final concentration 100
U/ml) and streptomycin sulfate (final concentration 100pg/ml) at a concentration of
approximately 4xl06 cells/ml. The suspension was added to 24-well plastic tissue
culture plates and incubated for 1 hour at 37°C. Non-adherent cells were washed off
with warm serum-free Iscove's medium containing penicillin G (final concentration
100 U/ml) and streptomycin sulfate (final concentration 100pg/ml). Medium was
then changed to Iscove's medium containing 10% heat inactivated autologous serum
(HIAS), penicillin G (final concentration 100 U/ml) and streptomycin sulfate (final
concentration 100pg/ml). Cells were incubated at 37°C. After 3 days cells were
washed again with addition of fresh Iscove's medium containing 10% HIAS,
penicillin G (final concentration 100 U/ml) and streptomycin sulfate (final
59
concentration 100pg/ml). This protocol selects out monocytes, as lymphocyte
populations tend to be non-adherent. Under these conditions monocytes differentiate
to a macrophage phenotype within approximately 5 days of collection (Wright et al.,
1983). Cells were therefore transfected either 5 or 6 days from the time of obtaining
PBMCs.
2.2.15. Transfection of monocyte-derived macrophages with adenoviral constructs.
The principles of transfection are as described for transfection of A549 cells
(section 2.2.3.). Adenoviral constructs of known concentration were diluted in
Iscove's medium containing 5% HIAS, penicillin G (final concentration 100 U/ml)
and streptomycin sulfate (final concentration 100 pg/ml). Monocyte-derived
macrophages were washed with PBS and adenovirus applied at an moi of 0-100 pfu
(total volume 1 OOpil per well) for 30 minutes at 37°C. Cells were washed with PBS
to remove excess virus and incubated overnight at 37°C in Iscove's medium
containing 10% HIAS, penicillin G (final concentration 100 U/ml) and streptomycin
sulfate (final concentration 100 |Ug/ml).
2.2.16. Staining of monocyte-derived macrophages for (3-galactosidase.
The principles of (3-galactosidase staining are as described in section 2.2.4.
Monocyte-derived macrophages were transfected as described in section 2.2.15. and
incubated at 37°C for 48 hours. Medium was discarded and 200|il of fixative added
for 10 minutes at room temperature (fixative comprised 0.2% glutaraldehyde, 0.8%
formaldehyde, 2mM MgCb, in PBS). Fixative was discarded and 200p,l of staining
solution added for 5 hours at 37°C (staining solution comprised 5mM K.4Fe(CN)6,
5mM K3Fe3(CN)6, 2mM MgCh, 0.05% Triton X-100, 0.5 mg/ml X-gal, in PBS).
Cells were washed with PBS and photomicrographs were taken.
2.2.17. Addition of LPS to monocyte-derived macrophages.
The principles of LPS stimulation are as described in section 2.2.9.
Monocyte-derived macrophages were transfected as described in section 2.2.15.
After incubation in Iscove's medium containing 10% HIAS, penicillin G (final
concentration 100 U/ml) and streptomycin sulfate (final concentration 100 p.g/ml)
for 48 hours, LPS was added directly to cells at a final concentration ranging
60
between 0 and 1000 pg/ml. Cells were incubated for a further 24 hours at 37°C and
supernatants retrieved.
In one variation of this experiment, LPS was added immediately upon
addition of Iscove's medium containing 10% HIAS, penicillin G (final concentration
100 U/ml) and streptomycin sulfate (final concentration 100 p.g/ml), and in another
HIAS was replaced throughout by FCS.
The viability of monocyte-derived macrophages treated with LPS was
assessed by aspirating supernatants from representative wells, staining with trypan
blue and assessing cells using a haemacytometer. The remaining adherent cells were
washed with PBS and then detached using trypsin. Cells were agitated to prevent
clumping, stained with trypan blue, and observed using a haemacytometer.
2.2.18. Establishment of growth curves for Pseudomonas aeruginosa PAOl and
Staphylococcus aureus CI705.
Colonies of Pseudomonas aeruginosa PAOl and Staphylococcus aureus
CI705 were used to inoculate freshly autoclaved TSB. Incubation proceeded
overnight in an orbital shaker at 37°C. lOOpl of the resultant suspensions were added
to 10ml of freshly autoclaved TSB, and incubated for 6 hours in an orbital shaker at
37°C. At the beginning of the experiment, and at each hour of the 6 hour incubation,
a lOOpl aliquot of the bacterial suspension was serially diluted in normal saline.
From the serial dilutions, 100p.l aliquots were plated out on nutrient agar and
incubated overnight at 37°C. In addition, at the beginning of the experiment, lOOpl
aliquots of normal saline alone and TSB alone were plated out on nutrient agar and
incubated overnight at 37°C, in order to exclude bacterial contamination. Colonies
were counted at 24 hours, and the colony count plotted against time.
2.2.19. Assay to determine the effects of elafin on Pseudomonas aeruginosa and
Staphylococcus aureus in vitro.
Colonies of P. aeruginosa PAOl and S. aureus CI 705 were used to inoculate
freshly autoclaved TSB. Incubation proceeded overnight in an orbital shaker at 37°C.
1 OOpl of the resultant suspensions were added to 10ml of freshly autoclaved TSB,
and incubated for 3 hours (growth of each organism was known to be in logarithmic
phase at this time point) in an orbital shaker at 37°C. The resulting suspensions
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produced were centrifuged at 3200g for 20 minutes at room temperature, washed
with 0.01M phosphate buffer (0.008M K2HPO4 and 0.002M KH2PO4) and
centrifuged again under the same conditions. The pellet was resuspended in 0.01M
phosphate buffer and diluted according to pre-constructed growth curves (as
described in section 2.2.18) to yield an estimated bacterial concentration of 5x104
colony forming units (cfu)/ml.
3 Opil aliquots of each bacterial suspension were incubated with elafin peptide
fragments (serially diluted in 0.01M phosphate buffer), or with human serum
albumin (HSA) (serially diluted in 0.01M phosphate buffer) as a protein control, or
with recombinant human SLPI (serially diluted in 0.01M phosphate buffer). The
volume of each preparation of elafin, HSA or SLPI was 90pl, and the final
concentration of elafin or HSA ranged from l-25pM (in experiments using SLPI the
final concentration ranged from 1-1 OpM). In each experiment, the positive control
consisted of 30pl of bacterial suspension and 90pl of 0.01M phosphate buffer, while
negative controls consisted of30pl of 0.01 M phosphate buffer and 90pl of elafin or
HSA (each in the dose range 0-25 pM). Incubation proceeded for 2 hours at 37°C.
Serial dilutions were made in 0.01M phosphate buffer, and lOOpl aliquots were
plated onto Columbia agar. Plates were incubated for 16 hours at 37°C and colonies
counted.
The number of colonies grown after incubation with elafin or SLPI in each
experiment was expressed relative to the number of colonies in positive controls, and
relative to the number of colonies grown upon incubation with the equimolar
concentration of HSA.
2.2.20. Quantification of elafin, elastase activity, elastase inhibitory activity,
myeloperoxidase, IL-8, TNF-a, and IL-1 in conditioned media in vitro.
Elafin concentration was established by ELISA as described in section
2.2.10. Elastase activity was estimated as described in section 2.2.12 and EIA as
described in section 2.2.13. MPO activity was assessed as described in section 2.2.7.
Concentrations of human IL-8, TNF-a and IL-1 were determined using commercial
ELISA kits.
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2.2.21. Intratracheal administration of test substances in mice.
The technique of IT administration has been described elsewhere (McLachlan
et al., 2000). Mice were anaesthetised by IP injection of approximately lOpl of
avertin per gramme of body weight (avertin comprised 1.25% 2,2,2-tribromoethanol
and 2.5% 2-methyl-2-butanol). Mice were gently manipulated into a position of
spinal extension, such that the long axis of the thorax was approximately
perpendicular to the horizontal. The upper incisors were hooked over a horizontal
wire strut, and the mandible pulled down by application of a light weight to the
lower incisors. A bright light source was applied directly to the thoracic wall to
provide transillumination of the upper mediastinum and larynx. The tongue was
gently moved to one side using forceps. In this way, a clear view of the larynx and
vocal cords was obtained.
The test substance was added to the plastic chamber of a blunted 25G needle
(at a volume of 30-40pl depending on the experimental protocol). The blunted
needle was passed between and just distal to the cords under direct vision. A 1ml
syringe containing 200(il of air was gently connected to the needle, and the test
substance expelled by depressing the plunger. Mice were wanned during recovery
from anaesthetic.
In preliminary experiments trypan blue was administered IT in order to
establish the distribution of instillate using this system.
2.2.22. Intranasal and intraperitoneal administration of test substances in mice.
Intranasal administration was performed by gently applying 30jul of test
substance drop-wise around the nares of mice. In preliminary experiments trypan
blue was administered IN in order to establish the distribution of instillate using this
system.
Intraperitoneal administration was performed by injecting 200pl of test
substance into the peritoneal cavity percutaneously.
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2.2.23. Retrieval and preparation of murine bronchoalveolar lavage fluid.
BALF was prepared ex vivo. Mice were killed by IP injection of avertin (as
described in section 2.2.21.) followed by transection of the abdominal aorta. The
trachea, main bronchi and lungs were dissected from the thoracic cavity en bloc.
Flexible nylon tubing of internal diameter 0.75mm was inserted into the trachea and
secured with silk ties. 200|il or 250jli1 of PBS (depending on experimental protocol)
was instilled immediately, and the lungs gently massaged to ensure adequate
distribution and admixture. BALF was gently aspirated via the flexible nylon tubing.
This process was repeated once. The total volume of BALF retrieved was measured.
BALF was centrifuged at 330g for 10 minutes at 4°C. Supernatants were
immediately frozen at -80°C prior to later use. Pellets were resuspended in a known
volume of PBS, and an aliquot used to count the total number of cells using a
haemacytometer. A second aliquot was used to prepare cytospins, followed by
staining with Diff-quik. Preparation of cytospins allowed calculation of differential
cell counts.
2.2.24. Preparation of murine lungs for histological analysis.
Lungs were retrieved from mice as described in section 2.2.23. Lungs were
inflated and fixed in formalin. The Department of Pathology, University of
Edinburgh, kindly embedded the lungs in paraffin wax, prepared sections of 3|iun
thickness, and stained with haematoxylin and eosin.
2.2.25. Preparation of murine serum.
Whole blood was immediately aspirated from the peritoneal cavity after
transection of the abdominal aorta, as described in section 2.2.23. Blood was
centrifuged at 13,800g for 30 minutes at 4°C to prepare serum. Serum was stored at -
80°C prior to use.
2.2.26. Studies of the effect of Ad-elafin on LPS-induced pulmonary neutrophilia in
vivo.
These studies were preceded by two sets of preliminary experiments. In the
first set doses of Ad-elafin ranging from 3xl07 pfu to lxlO9 pfu were instilled IT
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(volume of each instillation 30JU.1). Mice were killed at intervals of up to 8 days post-
administration. In the second set LPS was instilled IT in doses ranging from 0.1 pg to
0.5pg (volume of each instillation 30jll1). Mice were killed at 24 hours. Serum,
BALF and lungs were retrieved as described in sections 2.2.23.-25.
On the basis of the preliminary experiments a protocol was devised whereby
on day 0 mice received an IT instillation of Ad-elafin (3x107 pfu in PBS), Ad-lacZ
(3xl07 pfu in PBS) or PBS (volume of each instillation 30pl); on day 5 mice from
each group received an instillation of either PBS or 0.5pg LPS (volume of each
instillation 30pl). The mice were killed on day 6 and BALF, lungs and serum were
retrieved as described in sections 2.2.23.-25.
2.2.27. Staining of (3-galactosidase in Ad-lacZ transfected murine lungs.
Mice received an IT instillation of Ad-lacZ (3xl07 pfu in BPS, final volume
30pl) followed 5 days later by an IT instillation of LPS (either 0.5pg or 5pg, final
volume 30pl). The mice were killed 24 hours later and lungs retrieved as described
in section 2.2.23. 250pl of fixative (PBS containing 2% formaldehyde and 0.2%
glutaraldehyde) was instilled, and the end of the trachea tied off with a silk suture.
The lungs were immersed in a tube containing 2% formaldehyde and 0.2%
glutaraldehyde in PBS, and incubated at 4°C for 1 hour. The surface of the lungs was
washed with PBS and fixative was poured out of the lung. 250pl of PBS was
instilled IT and discarded; this process was repeated once. 250pl of staining solution
(as described in section 2.2.4) was then instilled, the trachea was tied off with a silk
suture, and the lungs incubated overnight at 37°C. The Department of Pathology,
University of Edinburgh kindly photographed the lungs, which they then embedded
in paraffin wax, sectioned, and stained with nuclear fast red.
2.2.28. Immunohistochemical localisation of human elafin in murine lungs.
Mice were treated IT with Ad-elafin (3xl07 pfu), Ad-lacZ (3xl07 pfu), or
PBS on day 0, and with PBS or 0.5pg LPS on day 5, then were killed on day 6 as
described in section 2.2.23. Blocks of paraffin-embedded lung were prepared as in
section 2.2.24. Sections 3 pm thick were prepared and mounted on glass slides.
Slides were incubated in xylene for 45 minutes at room temperature, then in
99.8% ethanol for 3 minutes at room temperature. The slides were washed with tap
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water followed by incubation for 30 minutes at room temperature in methanol
containing 3% H2O2. The slides were rinsed sequentially in water and Tris buffered
saline (TBS), then exposed to decreasing concentrations of ethanol (90%, 70% and
50% respectively, each for 30 seconds). Non-specific binding sites were blocked by
incubating with 20% normal goat serum (NGS) in TBS (total volume 1 OOjul per
slide) for 20 minutes at room temperature. 1 OOpl of primary antibody was applied
overnight at room temperature and comprised rabbit anti-human elafin IgG diluted
1000-fold into 20% NGS in TBS. Two controls were used, namely TBS alone and
pre-immune rabbit serum diluted 1000-fold into 20% NGS in TBS (in each case
1 OOpil was applied at room temperature overnight).
Slides were washed with TBS, then treated for 30 minutes at room
temperature with goat anti-rabbit immunoglobulin diluted 300-fold into 20% NGS in
TBS. Further washes in TBS were performed prior to addition of avidin-biotin-
horseradish peroxidase (HRP) in avidin-biotin buffer for 30 minutes at room
temperature. Slides were again washed in TBS prior to addition of acetate buffer,
pH5.0 for 5 minutes at room temperature.
Substrate (DAB containing 1.5% H2O2) was added for 10 minutes at room
temperature, prior to washing with water. Slides were then treated sequentially with
haematoxylin and Scott's Tap Water Solution before being washed with water.
Finally, slides were exposed to increasing concentrations of ethanol (50%, 70% and
90% respectively), and mounted using standard mounting fluid.
2.2.29. Preparation of Pseudomonas aeruginosa PAOl for administration in vivo.
Pseudomonas aeruginosa PAOl was inoculated into nutrient broth
containing 0.5% yeast extract, and incubated overnight at 37°C with continuous
orbital shaking. The bacterial suspension was centrifuged at 3200g for 15 minutes at
room temperature, and the pellet washed in 0.01M phosphate buffer, pH7.0. The
pellet was resuspended in 0.01M phosphate buffer and the absorbance at 590nm
measured. The absorbance value was adjusted to between 1.40 and 1.45 by dilution
with 0.01M phosphate buffer (in some preliminary experiments further dilutions
were made). 34-40|il aliquots of the final suspension (depending on the experimental
protocol) were used immediately for IT instillation. Simultaneously, an aliquot was
serially diluted, plated onto PIA, and incubated at 37°C overnight, so that the viable
bacteria in the starting instillate could be quantified.
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2.2.30. Preparation of biological fluids and organs after IT delivery of
Pseudomonas aeruginosa PAO1 to mice.
BALF was prepared as described in section 2.2.23., with the exception that a
50|ll1 aliquot of whole BALF was serially diluted and applied to PIA. Colonies were
counted after overnight incubation at 37°C.
Whole blood was retrieved as described in section 2.2.25. and lOOpl was
applied immediately to PIA. Colonies were counted after overnight incubation at
37°C. Whole blood which was not used to assess bacterial counts was used to
prepare serum as described in 2.2.25.
The spleen was dissected free, placed in 1ml of 0.01M phosphate buffer and
homogenised for 30 seconds at room temperature using an Omni hand held
homogeniser (Camlab, Cambridge, UK). An aliquot of 1 OOpil was applied to PIA.
Colonies were counted after overnight incubation at 37°C.
The right lung was dissected free, placed in 1ml of 0.01M phosphate buffer
and homogenised for 1 minute at room temperature. The homogenate was serially
diluted in 0.01M phosphate buffer. lOOpl aliquots were applied to PIA. Colonies
were counted after overnight incubation at 37°C.
The left lung was dissected free, weighed, and immediately snap frozen in
liquid nitrogen. Upon thawing lungs were immediately placed in homogenisation
buffer, consisting of lOOmM sodium acetate, 20mM EDTA, 1% hexadecyl trimethyl
ammonium bromide (after LeVine et al., 1998). Homogenisation proceeded for 1
minute at room temperature. The homogenate was then centrifuged at 8200g for 30
minutes at room temperature. The supernatant was aspirated and immediately used to
determine the concentration of MPO as described in section 2.2.8.
In each experimental protocol involving IT instillation of Pseudomonas
aeruginosa PAOl, a number of representative mice did not have lungs removed for
homogenisation. Instead, lungs were fixed and used for histological analysis as
described in section 2.2.24.
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2.2.31. Studies of the effect of Ad-elafin on lung injury induced by Pseudomonas
aeruginosa.
Preliminary experiments were performed in which varying doses of
Pseudomonas aeruginosa PAOl were prepared and administered IT as described in
sections 2.2.21. and 2.2.29. Mice were killed at either 4 hours or 24 hours. The aim
of these experiments was to determine a dose of Pseudomonas aeruginosa PAO1
which would consistently produce sublethal lung injury.
On the basis of the preliminary experiments, the following protocol was
designed. On day 0, mice received an IT instillation of Ad-elafin (3xl07 pfu in PBS),
Ad-lacZ (3xl07 pfu in PBS) or PBS (volume of each instillation 40pl); on day 5
mice from each group received an IT instillation of Pseudomonas aeruginosa PAO 1
(34pl of a suspension with an absorbance value of between 1.40 and 1.44 at 590nm).
Mice were killed on day 6. BALF, serum, spleen and lungs were retrieved as
described in section 2.2.30.
2.2.32. Quantification of elafin, EIA, protein, albumin, MPO, MIP-2, TNF-a,
murine keratinocyte-derived chemokine (mK.C), monocyte chemotactic
protein 1 (MCP-1) and MlP-la in murine BALF.
Elafin concentrations were quantified by ELISA as described in section
2.2.10. EIA was estimated as described in section 2.2.13. Protein concentration was
measured using a kit based on the bicinchoninic acid method, using albumin as
standard. Murine albumin concentrations were measured using a commercial ELISA
kit. MPO activity was measured by adding 50(il of BALF directly to 50pl of MPO
substrate (0.1 mg/ml TMB, 0.03% H2O2, in 0.1 M Na acetate-citrate, pH 4.9) and
quantifying the change in absorbance at 630nm, as described in section 2.2.8.
MIP-2 and TNF-a concentrations were established using commercial ELISA kits.
MlP-la, mKC and MCP-1 ELISAs were kindly performed by Professor T.
Standiford, University of Michigan, Ann Arbor, MI, USA.
2.2.33. Statistical analysis.
When numerical variables were normally distributed, Student's t-test was
used. When numerical variables did not conform to a normal distribution, non-
parametric statistical analysis was performed. Three group comparisons were
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performed using the Kruskal-Wallis test. Paired comparisons were analysed using
Wilcoxon's signed rank test, unpaired comparisons using the Mann-Whitney U-test,
and correlations using Spearman's rank correlation test. Nominal data were analysed
using the chi-squared test.
Statistical significance was assigned to a p value of <0.05.
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CHAPTER 3
THE EFFECT OF ELAFIN GENE AUGMENTATION ON HNE-
AND NEUTROPHIL-MEDIATED CELL DAMAGE IN VITRO
3.1. AIMS
The experiments described in this chapter were performed with the aim of
answering three fundamental questions.
Firstly, is the Ad-elafin vector capable of efficiently transfecting pulmonary
epithelial cells with subsequent expression of functional human elafin at a level
higher than that produced constitutively?
If so, is genetic augmentation of human elafin sufficient to protect pulmonary
epithelial cells against the damaging effects of purified HNE?
If so, is genetic augmentation of human elafin capable of protecting
pulmonary epithelial cells against the damaging effects of whole, activated human
neutrophils?
3.2. RESULTS
3.2.1. Adenoviral transfection of A549 cells.
Transfection of A549 cells with recombinant adenovirus (Ad-lacZ) was
readily achieved, with transfection efficiency approaching 100% at an moi of 50 pfu
(Figure 1). However evidence was still required for expression of functional human
elafin after Ad-elafin transfection. Elafin was secreted from A549 cells in a dose-
dependent manner after treatment with Ad-elafin (Figure 2A). There was no
associated increase in elafin secretion upon transfection with Ad-lacZ, indicating that
viral transfection per se was not responsible for the secretion stimulated by Ad-elafin
(Figure 2A). Furthermore Ad-elafin transfection resulted in a corresponding dose-
dependent inhibition of purified HNE (Figure 2B). Once again, transfection with Ad-
lacZ did not stimulate elastase inhibition, thus effectively excluding the possibility
that viral infection may have driven significant release of elastase
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Figure 1. Adenovirus efficiently transfects A549 cells.
A549 cells were treated with Ad-lacZ (PANEL A; moi of 50 pfu - original
magnification x 200) or vehicle alone (PANEL B - original magnification x 150) and
incubated in serum-free DMEM for 24 hours. Cells were then treated with X-gal stain.
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Figure 2. Functional elafin is secreted by A549 cells transfected with Ad-elafin.
A549 cells were transfected with Ad-elafin or Ad-lacZ (dose range 1-50 moi) or
vehicle alone, then incubated in serum-free DMEM for 48 hours. HNE (final
concentration 4 pg/ml) was added for 16 hours and supernatants retrieved.
Elafin concentration (PANEL A) and elastase activity (PANEL B) were measured.
Elastase activity is expressed relative to that in supernatants retrieved from
untransfected cells.
Results are derived from a single representative experiment.
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inhibitors after Ad-elafin treatment (Figure 2B). These data suggested that Ad-elafin
transfection was capable of generating high concentrations of functionally active
human elafin from A549 cells.
Ad-elafin transfection was not associated with overt morphological damage
to the cellular monolayer (as evidenced by light microscopy). This impression was
corroborated when A549 cell monolayers treated with Ad-elafin or Ad-lacZ (each at
moi of 50 pfu) and incubated in serum-free DMEM for 48 hours were detached using
trypsin, washed, and exposed to trypan blue. The percentage of non-viable cells (ie
those staining positively for trypan blue) was 14% among untransfected cells, 9%
among Ad-lacZ treated cells, and 12% among Ad-elafin treated cells. However viral
transfection was associated with a higher rate of extrusion of cells from A549 cell
monolayers; 6,100 untransfected cells, 12,200 Ad-lacZ treated cells, and 16,000 Ad-
elafin treated cells were recovered from supernatants after incubation in serum-free
medium for 3 days (all values are means of 3 separate experiments, no significant
differences between groups; confluent monolayers typically contain approximately
300,000 cells). In none of these experiments were deficiencies in the monolayer
found, suggesting that cells extruded were replaced (or at least that the
corresponding surface area was covered).
Given that transfection with Ad-elafin at an moi of 50 generated marked
elastase inhibition without morphological damage to the epithelial monolayer, elafin
production at this dose was characterised further. Although the concentration of
elafin produced by Ad-elafin transfection was variable it was in general
approximately 100 times that from either untransfected or Ad-lacZ treated cells
(Figure 3).
Elafin was secreted from untransfected (and Ad-lacZ treated) A549 cells in
all experiments performed (Figure 3). Constitutive elastase inhibition by A549 cells
was simply demonstrated by adding known concentrations of HNE to serum-free
DMEM which had either been incubated with A549 cells at 37°C for 24 hours, or
incubated in wells containing no cells at 37°C for 24 hours (Figure 4A). Elastase
activity was lower in the conditioned medium, thereby suggesting generation of
elastase inhibitors by A549 cells (Figure 4A). While the experiment described in
Figure 2 suggested that elafin augmentation accounts for the increase in anti-elastase










Figure 3. Ad-elafin transfection results in augmentation of elafin secretion from
A549 cells.
A549 cells were treated with Ad-elafin or Ad-lacZ (moi 50 in each case) or vehicle
alone, and incubated in serum-free medium for 48-72 hours. Supernatants were
retrieved and elafin concentration measured. Data are presented as means and
standard deviations (n=4).
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Figure 4. A549 cells have constitutive elastase inhibitory capacity which is
augmented by transfection with Ad-elafin.
PANEL A - Increasing concentrations of HNE were added to serum-free DMEM
which had been incubated with untransfected A549 cells ('Cells present'), or in wells
containing no cells ('Cells absent') for 24 hours. Elastase activity was measured as a
function of time, and is represented as absorbance at 405nm (A405nm) after the
addition of elastase specific substrate. Results are derived from a single representative
experiment.
PANEL B - A549 cells were treated with Ad-elafin or Ad-lacZ (each at 50 moi) or
vehicle alone and incubated in serum-free DMEM for 48 hours. Increasing volumes
of supernatant were incubated with HNE (22.5ng in lOpl) for 30 minutes. Elastase
activity was measure as described for PANEL A.
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cells stimulated the need to characterise the relative contribution of elafin to total
EIA in A549 cells, whether they be untransfected or treated with adenovirus.
Transfected (moi of 50 for Ad-lacZ and Ad-elafin) and untransfected A549
cells were therefore incubated in serum-free DMEM for 48 hours and supernatant
retrieved. The concentration of elafin in conditioned medium was 2.3 ng/ml from
untransfected cells, 0.3 ng/ml from Ad-lacZ treated cells, and 180 ng/ml from Ad-
elafin treated cells. For each condition increasing volumes of supernatant were
incubated with a known concentration of HNE (22.5 ng in 1 OjllI) and the resulting
elastase activity measured, leading to the generation of the curves described in
Figure 4B. The HNE used in this experiment was known to be approximately 50%
active. Extrapolation of the curves to the abscissa allows an estimate of the minimum
quantity of medium required to inhibit completely the known concentration of HNE,
assuming 1:1 stoichiometric binding of elastase inhibitors with HNE and 50%
activity of HNE (after Bieth, 1980). Under these conditions estimated EIAs of
conditioned medium were calculated at 0.8 nM for untransfected cells, 0.75 nM for
Ad-lacZ treated cells and 9.1 nM for Ad-elafin treated cells.
Although a number of variables influence these calculations, some limited
conclusions can be drawn. Firstly, given the known concentration of elafin antigen in
conditioned media, then even if elafin were fully active it would contribute no more
than 29% to the total EIA of untransfected cells, and no more than 4% to the EIA of
Ad-lacZ treated cells. Therefore it can be confidently stated that the majority of EIA
constitutively produced by A549 cells is not attributable to elafin. Furthermore one
can confidently conclude that adenoviral transfection (with Ad-lacZ) does not up-
regulate EIA. On the other hand Ad-elafin markedly up-regulated EIA in A549 cells.
The data described in this section suggested that adenoviral augmentation of
elafin may be capable of inhibiting HNE-mediated damage of A549 cells.
3.2.2. The effect of Ad-elafin transfection on HNE-mediated damage of A549 cells.
The application of purified HNE resulted in a characteristic pattern of
damage to untransfected A549 cells incubated in serum-free medium. In general
final concentrations of HNE of approximately 1 p.g/ml resulted in cells taking on a
more spindle shaped morphology, with gaps beginning to appear between cells. At 2
|ag/ml gaps between cells were more pronounced, some cells were seen to detach
76
from the monolayer, and those remaining in contact with the plate were rounded and
granular. At 4 pg/ml cellular detachment was invariably present, and the few cells
remaining in contact with plates were rounded and granular. At 4 |ag/ml of HNE
cells often detached in sheets (ie within the sheet cell contacts appeared to be
preserved), although individual cells were also identified in supernatants. Because
HNE at 4 jug/ml was invariably associated with severe cellular damage and
detachment, this concentration was used in most experiments designed to assess
whether Ad-elafin could ameliorate HNE-mediated damage.
In a preliminary experiment it was demonstrated that Ad-elafin transfection
(moi ranging from 10-50) could markedly reduce the number of cells released from
A549 monolayers after application of HNE at 4 |ag/ml for 24 hours (Figure 5A). This
protective effect was associated with inhibition of residual elastase activity which
was almost completely abolished when Ad-elafin was applied at an moi of 50
(Figure 5B). Ad-lacZ treatment was also associated with a reduction in detachment
and with a modest inhibition of elastase activity, the protective effect being less
pronounced than that observed after Ad-elafin treatment (Figure 5).
A time course study demonstrated that HNE-mediated detachment of Ad-
lacZ treated cells began between 12 and 24 hours after application of the enzyme
(Figure 6A). Prior treatment of A549 cells with Ad-elafin conferred marked
protection against cellular detachment (Figure 6A). However, detachment of Ad-
elafin treated A549 cells did occur, despite the fact that an moi of 50 was associated
with almost complete inhibition of HNE throughout the 24 hour period (Figure 6B).
The preliminary experiments described stimulated more comprehensive
studies of the effects of Ad-elafin (moi of 50) in protecting epithelial cells against
HNE. Application of HNE at 2 ju.g/m 1 to Ad-lacZ treated cells (or untransfected
cells) consistently resulted in disruption of the epithelial monolayer (Figure 7, Panel
B), with rounding and spindling of cells most pronounced around areas of
denudation. The destructive process continued in a dose-dependent manner, such that
HNE at 4 (ig/ml resulted in almost complete separation of cells from their plastic
base, the remaining cells being small and rounded (Figure 7, Panel C). In contrast
pre-treatment with Ad-elafin resulted in considerable protection against the effects of
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Figure 5. Ad-elafin transfection of A549 cells is associated with a reduction in
HNE-mediated cell detachment and elastase activity.
A549 cells were treated with Ad-elafin or Ad-lacZ (dose range 10-50 moi) or vehicle
alone, and incubated in serum-free medium for 72 hours prior to the addition of HNE
(final concentration 4pg/ml) for 24 hours. Supernatants were retrieved for
measurement of cell count (PANEL A) and residual elastase activity (PANEL B; data
expressed relative to the elastase activity in supernatants from untransfected cells).























Figure 6. HNE-mediated detachment of A549 cells occurs after 12 hours.
A549 cells were treated with Ad-elafin or Ad-lacZ (50 moi in each case) and
incubated in serum-free medium for 3 days prior to the addition of HNE (final
concentration 4pg/ml) for 24 hours. Cell count (PANEL A) and residual elastase
activity (relative to that in supernatants from Ad-lacZ cells at 2 hours) were measured
in the retrieved supernatants.







Figure 7. Transfection of A549 cells with Ad-elafin confers protection against
HNE-mediated cell damage.
A549 cells were treated with Ad-elafin or Ad-lacZ (moi 50 in each case) or vehicle
alone and incubated in serum-free medium for 2 days prior to the addition of HNE
(final concentration ranging from 2-4pg/ml) for 16 hours.
PANEL A - appearance of untransfected cells to which no HNE was added.
PANEL B - appearance ofAd-lacZ treated cells exposed to HNE at 2|ig/ml.
PANEL C - appearance ofAd-lacZ treated cells exposed to HNE at 4pg/ml.
PANEL D - appearance ofAd-elafin treated cells exposed to HNE at 4pg/ml
(original magnification x 100 in each case).
The morphological appearance ofuntransfected cells resembled that ofAd-lacZ treated
cells at all doses of HNE. The blue colour was conferred by a photographic filter used
to enhance contrast.
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The protective effect was quantified by determining the number of epithelial
cells liberated into supernatants after application of HNE at 4 p,g/ml (Figure 8). Ad-
elafin transfection was associated with a dose-dependent reduction in cell
detachment, in keeping with the appearances in Figure 7. Interestingly there was
considerable variation in the degree of protection conferred by Ad-elafm at an moi of
10, but very consistent protection with an moi of 50. This proved to be consistent
with morphological findings, in that protection was invariably conferred by an moi
of 50 (Figure 7) but was not universally observed at an moi of 10. A further point to
make is that Ad-lacZ transfection resulted in a 23% reduction in detachment as
compared with untransfected cells (Figure 8), but this did not reach statistical
significance.
Pursuing the theme of HNE-mediated damage of A549 cells further, a
separate experiment was performed in which Ad-elafin and Ad-lacZ transfected cells
(moi of 50 in each case) were incubated in serum-free medium for 24 hours prior to
addition of FINE (4 pg/ml). Sixteen hours later, the number of cells in supernatants
tended towards the pattern described in Figure 8 (ie release of 45000 untransfected
cells, 45000 Ad-lacZ treated cells, and 3750 Ad-elafin treated cells). The cells
remaining attached to the plastic base were incubated with trypsin until full
detachment was established, at which point 400 pi of serum containing medium was
immediately added to neutralise trypsin. The cells were spun and resuspended for
counting. Surprisingly, no untransfected cells or Ad-lacZ treated cells were identified
at light microscopy, despite there being complete denudation of cells from the plastic
plates. In contrast, the expected number of Ad-elafin cells were retrieved (ie 97.7%
of the count retrieved from Ad-elafin treated cells to which HNE had not been
applied). These data imply that HNE had lysed the untransfected/Ad-lacZ treated
cells and/or that a proportion of significantly damaged cells had been rendered
susceptible to lysis by trypsin. Importantly, 95% of the Ad-elafin treated cells
exposed to HNE remained viable (as compared to 86%, 91% and 88% respectively
in untransfected, Ad-lacZ treated and Ad-elafin treated cells to which no HNE was
added). In summary, Ad-elafin treatment preserves both adhesion and viability of an
epithelial cell monolayer exposed to HNE.
Further quantitative evidence for a protective effect of Ad-elafin was
provided by studying radiolabelled A549 cells (Figure 9). In keeping with the
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Figure 8. Transfection of A549 ceils with Ad-elafin results in a dose-dependent
inhibition of HNE-mediated cell detachment.
A549 cells were treated with Ad-elafin (moi 10 or 50) or Ad-lacZ (moi 50) or vehicle
alone, and incubated in serum-free medium for 48-72 hours prior to the addition of
HNE (final concentration 4pg/ml). The number of cells in retrieved supernatants was
estimated.
Data are presented as medians and interquartile ranges (n=7, except in the case of Ad-
elafin at 10 moi, where n=4). * = Significant difference, p<0.05, when compared to










Figure 9. Ad-elafin transfection reduces release of11 'indium from radiolabeled
A549 cells.
Radiolabeled A549 cells were treated with Ad-elafin or Ad-lacZ (moi of 50 for each)
or vehicle alone, and incubated in serum-free medium for 24 hours prior to the
addition of HNE (final concentration 4 pg/ml) for a further 16 hours. Radioactive
label in retrieved supernatants was quantified. Results are derived from a single
experiment.
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Interestingly the addition of HNE to Ad-elafin treated cells was associated
with a reduction in the concentration of elafin detectable by ELISA (Figure 10, Panel
A) or dot-blot assay (Figure 10, Panel B). A similar reduction in detectable elafin
was observed after addition of HNE to untransfected and Ad-lacZ treated cells
(Figure 10). The dot-blot assay reinforces two points made previously. Firstly Ad-
elafin transfection results in a dose-dependent increase in elafin secretion. Secondly,
there is further evidence to support the trend for a small reduction in elafin secretion
from Ad-lacZ treated cells as compared with untransfected cells.
The reduction in detectable elafin antigen after addition of HNE (Figure 10)
was studied further in the absence of A549 cells. Recombinant elafin (at a
concentration of 10 ng/ml) was incubated with increasing concentrations of HNE to
give molar ratios (HNE:elafin) of 1:2 and 2:1. The elafin concentration was
measured by ELISA. When no HNE was added, 10.3 ng/ml was detected. At a molar
ratio of 1:2 5.9 ng/ml was detected, and at a ratio of 2:1 4.3 ng/ml was detected. It
seems likely therefore that complexed elafin is less easily detected by anti-elafin
antibody than is "free" elafin, and/or that elafin is cleaved by HNE yielding
undetectable fragments.
The protection conferred against HNE by transfection of A549 cells with Ad-
elafin (Figures 7,8 and 9) was associated with a significant inhibition of HNE
activity (Figure 11). The inhibition was dose-dependent, with almost complete
inhibition of HNE at an moi of 50. Ad-lacZ treatment did not result in significant
elastase inhibition as compared with that observed in untransfected cells.
The protective effect of Ad-elafin was examined further by assessing the
influence of anti-elafin antibody. Preliminary experiments established a
concentration of anti-elafin antibody (80 pg/ml) which consistently neutralised the
inhibitory effects of 800 ng/ml of elafin. The experiments described in Figures 8 and
11 were therefore repeated, with the exception that an excess of anti-elafin antibody
(or control antibody) was incubated with supernatants for 1 hour prior to the addition
of HNE (Figure 12). The characteristic reduction in cell detachment associated with
Ad-elafin transfection was again observed (Figure 12, Panel A) and control antibody
had no influence on this process. However anti-elafin antibody resulted in a partial
restoration of HNE-induced cell detachment. In accordance with this finding, anti-
elafin antibody also conferred partial restoration of morphological cell damage.
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Figure 10. The presence of HNE leads to reduced concentrations of detectable
elafin antigen.
A549 cells were treated with Ad-elafin or Ad-lacZ (moi of 10-50 for each) or vehicle
alone and incubated in serum-free medium for 72 hours prior to the addition of HNE
(final concentration 4pg/ml) or vehicle alone for a further 16 hours.
Panel A illustrates elafin concentration (measured by ELISA) in supernatants from Ad-
elafin treated cells (moi of 50) receiving vehicle (HNE-) or HNE (HNE+).
Panel B represents a dot-blot assay; E50=Ad-elafin (moi 50), E10 = Ad-elafin (moi 10),
L50 = Ad-lacZ (moi 50), U = untransfected;HNE- = vehicle alone added to cells, HNE+
= HNE added to cells; PBS = PBS negative control; rh-elafin = recombinant human
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Figure 11. Transfection of A549 cells with Ad-elafin results in a dose-dependent
inhibition of elastase activity.
A549 cells were treated with Ad-elafin (moi 10 or 50) or Ad-lacZ (moi 50) or vehicle
alone, and incubated in serum-free medium for 48-72 hours prior to the addition of
HNE (final concentration 4pg/ml). Residual elastase activity was measured in
supernatants after 16 hours of exposure to HNE.
Elastase activity was expressed relative to the elastase activity in supernatants from
untransfected cells. Data are presented as medians and interquartile ranges (n=l 1,
except in the case of Ad-elafin at 10 moi, where n=7); The "Untransfected" column
has no error bars because the value obtained was regarded as unity in all experiments.
* = Significant difference,p<0.05, comparing Ad-elafin (moi 10) with untransfected
cells and Ad-lacZ. ** = Significant difference,p<0.005, comparing Ad-elafin (moi
50) with untransfected cells and Ad-lacZ. # = Significant difference, p<0.05,
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Figure 12. Ad-elailn's protective effect against HNE-mediated damage of A549
cells is partially prevented by anti-elafin antibody.
A549 cells were treated with Ad-elafin (moi of 50) or vehicle alone, and incubated in
serum-free medium for 48 hours. Ad-elafin treated cells then received an excess of
anti-elafin antibody, an excess of anti-IL-8 antibody, or vehicle alone for 1 hour. All
cells were then treated with HNE (final concentration 4pg/ml) for 16 hours. Cell
counts (PANEL A) and elastase activity (PANEL B) were measured in supernatants.
Elastase activity was expressed relative to the elastase activity in supernatants from
untransfected cells. Data are presented as means from 2 separate experiments.
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elafin was not influenced by control antibody (Figure 12, Panel B), while anti-elafm
antibody resulted in partial restoration of elastase activity.
Taken together, the evidence described in this section was supportive of the
hypothesis that elafin gene augmentation could protect pulmonary epithelial cells
against HNE. Experiments were therefore performed to determine whether this
principle could be extended to protection against the effects of whole activated
neutrophils.
3.2.3. The effect of Ad-elafin transfection on neutrophil-mediated damage of A549
cells.
Preliminary experiments were performed to determine the effectiveness of
neutrophil degranulation in response to activating stimuli. In the first of these PMA
(1 ng/ml) was added to freshly activated neutrophils and the elastase activity in
supernatants compared with that of varying concentrations of HNE at 24 hours
(Figure 13). PMA stimulated 1 million neutrophils to release elastase acivity similar
to that associated with 4 p.g/ml of HNE, suggesting effective PMA-mediated
degranulation.
The preliminary findings were followed by experiments in which PMA
stimulated neutrophils were applied to transfected and untransfected A549 cells. Ad-
elafin transfection was associated with almost complete inhibition of released
elastase activity, whilst Ad-lacZ had no effect (Figure 14). The inhibition of elastase
activity was associated with morphological protection at light microscopy.
These findings stimulated experiments to determine whether similar findings
were observed in vitro using degranulating stimuli of closer relevance to pulmonary
inflammation in vivo (ie PAF and fMLP). Preliminary experiments were again
performed to establish optimal conditions for neutrophil degranulation (Figure 15). It
was determined that PAF (10"9M) followed by fMLP (10~7M) effected release of
elastase activity at 24 hours which approximated to that effected by purified HNE at
a concentration of 4 p.g/ml. These concentrations of PAF and fMLP were therefore
used in experiments to determine whether Ad-elafin could confer A549 cells with
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Figure 13. The effect of PMA on neutrophil degranulation.
PMA (final concentration 1 ng/ml) or vehicle alone (-) were incubated with either
lxl06 (first two columns) or 2xl06 (third and fourth columns) freshly prepared
neutrophils (neuts) for 24 hours at 37°C. For comparison, HNE at a final
concentration of 0.5-4 pg/ml (remaining four columns) was incubated in cell-free
medium for the same time.
Elastase activity was determined by adding elastase-specific substrate and measuring









Figure 14. Transfection of A549 cells with Ad-elafin results in inhibition of HNE
released by PMA stimulated neutrophils.
A549 cells were treated with Ad-elafin or Ad-lacZ (moi 50 for each) or vehicle alone,
and incubated in serum-free medium for 48-72 hours prior to the addition of 1 million
freshly isolated human neutrophils and PMA (final concentration 1 ng/ml). Elastase
activity was measured in supernatants after 16 hours. Elastase activity was expressed
relative to the elastase activity in supernatants from untransfected A549 cells.
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Figure 15. Neutrophil degranulation is effectively stimulated by PAF and 1MLP.
Freshly isolated human neutrophils (1 million per well) were incubated at 37°C in the
presence of PAF (final concentration 10_I1M to 10~9M). After 2 hours fMFP was
added (final concentration 10"9M to 10"7M) for a further 22 hours at 37°C.
Supernatants were collected and elastase activity determined by the addition of
elastase-specific substrate and measurement of absorbance at 405nm. For comparison,
HNE was added to cell-free wells at 37°C, with measurement of elastase activity at 24
hours.
Results are derived from a single representative experiment.
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Ad-elafin transfection was associated with considerable morphological
protection of the epithelial monolayer (Figure 16). Interestingly neutrophil-mediated
damage of Ad-lacZ treated (and untransfected) cells differed slightly from HNE-
mediated damage in that spindling of cells was less commonly observed (compare
with Figure 7). Denudation of epithelium was confined to areas populated by clusters
of neutrophils (Figure 16, Panel A). Degranulation did occur in Ad-elafm treated
cells, as MPO levels in medium obtained from untransfected, Ad-lacZ treated and
Ad-elafin treated cells were similar (data not shown).
Neutrophil-mediated damage to A549 cells was quantified using
radiolabelling methods rather than by counting cells, largely because counting was
hindered by the large number of neutrophils in supernatants. 111 Indium release from
Ad-elafin treated A549 cells was significantly lower than from Ad-lacZ treated cells
(Figure 17). The difference in release of radiolabel between Ad-elafin treated cells
and untransfected cells approached statistical significance (p = 0.09). Neutrophil
degranulation is subject to considerable variation between donors, and this was
certainly the case in the experiments described, as evidenced by the wide
interquartile ranges (Figure 17). The difference in the level of111 Indium release from
untransfected cells and Ad-lacZ treated cells did not approach statistical significance
(p = 0.89). However the higher rate of release from Ad-lacZ treated cells suggests an
effect of adenovirus on radiolabel efflux. The mechanism for this adenoviral effect is
unlikely to be detachment of cells as, if anything, Ad-lacZ treatment of A549 cells
was associated with protection against detachment (Figure 8).
The protection provided by Ad-elafin transfection was associated with a
significant inhibition of elastase activity in cell supernatants (Figure 18) suggesting
that elafin augmentation was responsible for the protective effect. Elastase inhibition
was almost complete using Ad-elafin at an moi of 50.
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Figure 16. Transfection of A549 cells with Ad-elafin confers protection against
damage mediated by neutrophil degranulation.
A549 cells were treated with Ad-elafin or Ad-lacZ (moi 50 in each case) or vehicle
alone and incubated in serum-free medium for 24 hours prior to the addition of BSA
and PAF (10"9M). 2xl06 freshly isolated human neutrophils were introduced, fMLP
(10"7M) was added 1 hour later and incubation proceeded for a further 15 hours.
PANEL A- appearance ofAd-lacZ teated cells.
PANEL B- appearance of Ad-elafin teated cells (original magnification x 150 in each
case).
The morphological appearance of untransfected cells closely resembled that of
Ad-lacZ treated cells. The blue colour was conferred by a photographic filter used to
enhance contrast. Clusters of neutrophils are indicated by arrows.
Untransfected cells to which neutrophils were not added are exemplified in
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Figure 17.Transfection with Ad-elafin protects A549 cells against neutrophil-
mediated damage.
A549 cells were treated with Ad-elafin or Ad-lacZ (moi of 50 in each case) or vehicle
alone, then incubated with 11 indium. The cells were incubated in serum-free medium
for 24 hours prior to the addition of BSA and PAF (10"9M). 2 x 106 freshly isolated
human neutrophils were introduced, fMLP (10"7M) was added 1 hour later, and
incubation proceeded for a further 15 hours. Supernatants were retrieved and
radioactivity measured.
Data represent medians and interquartile ranges (n=8).








0 - -1 - — 1 ——
Untransfected Ad-lacZ Ad-elafin
Figure 18. Transfection of A549 cells with Ad-elafin significantly inhibits the
activity of elastase released by activated human neutrophils.
A549 cells were treated with Ad-elafin or Ad-lacZ (moi of 50 in each case) or vehicle
alone, and incubated in serum-free medium for 24 hours prior to the addition of BSA
and PAF (10"9M). 2 x 106 freshly isolated human neutrophils were introduced, fMLP
(10"7M) was added 1 hour later, and incubation proceeded for a further 15 hours.
Supernatants were retrieved and elastase activity measured.
Elastase activity was expressed relative to the residual elastase activity in medium
from untransfected cells. Data represent means and standard deviations (n=4).
* = Significant difference, p<0.05, when compared with both other conditions.
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3.3. DISCUSSION
The data presented in this chapter lead to three principal conclusions, namely
that adenoviral augmentation of functional elafin is readily achieved in A549 cells,
that genetic augmentation of elafin can protect these cells against HNE-mediated
damage, and that this principle can be extended to protection against damage
associated with whole, activated human neutrophils.
A549 cells were explanted from the resected right lower lobe of a 58 year old
male with alveolar cell carcinoma (Giard et al, 1973), and a fundamental question
therefore is whether data derived from A549 cells are relevant to the situation in the
human lung? Soon after their isolation it was established that A549 cells possessed
features characteristic of type II pneumocytes, including the presence of lamellar
bodies and production of surfactant (Lieber et al, 1976). Importantly, serial passage
did not alter the observed phenotypic characteristics (Lieber et al, 1976). Of
particular relevance to the data presented here, primary human type II pneumocytes
have been shown to secrete elafin (and SLPI), the secretion being up-regulated by
IL-1 and TNF (Witherden et al, 1999). The latter characteristics are shared with
A549 cells (Sallenave et al, 1994). Again specifically in the context of the present
study, it is worth noting that the efficient adenoviral transfection of A549 cells
(Figure 1) was similarly described in primary cultures of human foetal type II
pneumocytes (Alcorn et al, 1997). On the basis of this evidence it seems likely that
similar receptors for adenovirus entry are present on type II pneumocytes and A549
cells. Against this background, and given both the extensive international laboratory
experience with A549 cells and their ready accessibility, it was felt that A549 cells
were plausible surrogates for type II pneumocytes in vitro.
The data presented in Figure 4 confirm the finding that native (untransfected)
A549 cells constitutively generate EIA. It was already known that A549 cells could
produce SLPI, elafin and cci-PI (Sallenave et al., 1993; Venembre et al., 1994;
Sallenave et al., 1997b). The observation that elafin makes a small contribution to
measured EIA is broadly in keeping with the finding that A549 cells produce 25
times more SLPI than elafin (Sallenave et al., 1993). Interpretation of the data
presented in this chapter with regard to the contribution of elafin to EIA should be
tempered by the fact that A549 cells were cultured in serum-free medium (because
of the high concentration of elastase inhibitors in serum). It could be argued that the
lack of nutrients may have altered generation of EIA. While this cannot be entirely
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excluded, secretion of elafin antigen from untransfected (and Ad-lacZ transfected)
A549 cells was similar in the presence and absence of serum (for comparison, data
relating to serum-containing medium is shown in Chapter 4, Figures 12 and 13, left
hand columns).
The finding that Ad-lacZ did not increase elafin or EIA secretion from A549
cells (Figures 3 and 4) has fundamental implications for the data in this chapter.
There is little doubt that the phenotype of A549 cells may be altered by viral
infection. Respiratory syncitial virus (RSV) stimulates secretion of IL-6, IL-8 and
soluble TNF receptor type I from A549 cells (Arnold et al., 1994) and adenoviral
infection increases expression of ICAM-1 from A549 cells (Stark et ah, 1996). It is
interesting therefore that Ad-lacZ did not up-regulate secretion of EIA or elafin
(indeed, if anything there was a small decrease in secretion of each). The
encouraging message is that the marked augmentation of elafin secretion after
transfection with Ad-elafin is attributable to the transgene and not to viral infection
per se (Figures 2 and 3). It was similarly encouraging that the elafin produced was
associated with significant anti-elastase activity (Figure 4).
The considerable genetic augmentation of elafin described was sufficient to
ameliorate HNE-induced damage of A549 cells (Figures 7,8 and 9). Synthetic
inhibitors of elastase have previously been shown to protect A549 cells against HNE
(Ayars et ah, 1984), and genetic augmentation of CC]-PI using liposomal gene transfer
extended the principle in a CF bronchial epithelial cell line (Canonico et ah, 1996).
Furthermore, differentiated human keratinocytes which secrete elafin in response to
biochemical stimuli are protected against detachment induced by very high doses (10
(ig/ml) of HNE (Pfundt et ah, 1996). However the data in this chapter are the first to
describe protection of pulmonary epithelial cells conferred using adenoviral
augmentation of an endogenous pulmonary elastase inhibitor. Interestingly, the
concentration of HNE which could be inhibited by Ad-elafin transfection is within
the range of concentrations found in BALF from patients with pneumonia (Boutten
et ah, 1996). Certain aspects of the data describing inhibition of HNE by Ad-elafin
merit closer attention.
In keeping with the findings here (Figure 8), detachment has been the
predominant injury induced in A549 cells by HNE in other studies (Ayars et ah,
1984; van Wetering et ah, 1997). However a propensity to HNE-mediated cell lysis
was also described in adherent untransfected and Ad-lacZ transfected cells in this
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study, the effect being markedly inhibited by Ad-elafin transfection. Interestingly
Ayars et al. (1984) noted that detachment was the predominant process at 1 pg/ml of
HNE, but that lysis predominated at concentrations of 10 |ig/ml and above. In
summary, in this study Ad-elafin transfection appeared to protect against both
detachment and lysis, in that the epithelial monolayer remained relatively intact and,
more importantly, the remaining adherent cells remained viable.
The results described here differ in some respects from those in the careful
characterisation of HNE-mediated damage performed by Ayars et al. (1984) in that
higher doses of HNE required to be applied for longer to effect damage in this study
(Figure 6). In this context it is surprising that detachment was not invariably seen
when concentrations of HNE of 1-2 jug/ml were applied to untransfected cells. Given
that the HNE used was approximately 50% active these conditions predict for 16-33
nM HNE and approximately 0.8 nM of EIA (Figure 4). In the same way it is
interesting that Ad-elafin transfection (generating approximately 9.1 nM of EIA)
effectively inhibited 4 pg/ml (approximating to 66 nM) of HNE. This raises the
intriguing possibility that cellular (and/or matrix) targets neutralise a proportion of
the HNE applied.
In this context it is interesting that while Ad-elafin transfection effected rapid
and almost complete inhibition of HNE in cell supernatants (Figure 6), damage to the
cells (albeit limited) still occurred by 16 hours (Figures 7 and 8). It remains plausible
that a proportion of the HNE comes into contact with intercellular attachments and in
so doing evades detection by elafin and effects a gradual proteolytic detachment. In
favour of such a hypothesis is the observed potential for elastase to bind connective
tissue in humans and hamsters (Watanabe et al., 1990; Rudolphus et al., 1992), and
the relative resistance of bound HNE to inhibition (Morrison et al., 1990).
A further interesting observation was the relative reduction in elafin detected
by ELISA after addition of HNE to Ad-elafin treated cells (Figure 10). One potential
explanation is that the anti-elafin antibody used is less capable of detecting pre¬
formed elafin-HNE complex; the antibody was raised against a COOH-terminal
fragment of elafin which may potentially be masked upon binding with HNE. An
alternative explanation may lie in the observed reduction of elafin secretion from
A549 cells stimulated with HNE (Reid et al., 1999). A further potential explanation
may be proteolytic degradation of elafin by HNE, though this may be less likely
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given that elafin is known to retain almost full activity upon dissociation with HNE
in vitro (Ying and Simon, 1993).
The fact that protection conferred by Ad-elafin transfection was associated
with an increase in elafin antigen and an increase in anti-elastase activity suggested
that elafin was the moiety directly responsible for protection against HNE.
Interestingly, neutralisation of elafin using anti-elafin antibody resulted in a partial
(but incomplete) restoration of HNE-mediated cell detachment and HNE activity
(Figure 12). It therefore appears that elafin is, at least in part, directly responsible for
the protection observed. Two possibilities exist to explain the residual inhibition of
HNE-mediated damage after incubation with an excess of anti-elafin antibody. The
first is that optimal conditions did not exist for binding of the high concentrations of
antibody used to elafin in the complex conditioned medium described here (Figure
12). The second is that an alternative moiety (which must by definition have anti-
elastase activity) is induced. In my opinion the former explanation seems more
likely, for a number of reasons. Firstly, a putative anti-elastase would require to be
induced specifically by elafin (as no such inhibition was observed in Ad-lacZ treated
cells). In the only study to date in which SLPI levels were quantified in association
with markedly augmented levels of elafin from A549 cells, only a modest rise in
SLPI levels was detected (Sallenave et al., 1994). In addition, the rise in EIA
generated by Ad-elafin transfection in this study can be explained by an increase in
elafin alone. Finally, while the anti-elafin antibody was proven to be effective in
serum-free DM EM in a cell-free system in vitro, it may have been less effective in
conditioned medium containing HNE. Establishing optimal conditions for antibody
binding can be notoriously difficult in complex media, and HNE itself is capable of
degrading immunoglobulins in vitro (Baici et al., 1980).
Irrespective of the issues raised above, this chapter provides unequivocal
evidence for a protective effect of Ad-elafin against HNE-mediated damage of A549
cells. This provided the impetus to examine whether this principle could be extended
to protection against neutrophil-mediated damage. Significant degranulation of
neutrophils was achieved, using mechanistically distinct agents in the form of PMA
(Figure 13) and a combination of the priming agent PAF and the secretagogue fMLP
(Figure 15). Protection of A549 cells by Ad-elafin transfection was demonstrated at
light microscopy whether PMA or PAF/fMLP was used as the stimulus to
degranulation (appearances after PMA stimulation closely resembled those in Figure
16 in which degranulation was mediated by PAF/fMLP stimulation), the protection
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being associated with almost complete inhibition of HNE (Figures 14 and 18).
Protection against the effects of neutrophil degranulation may be considered
surprising at first glance, given that elafin is known to inhibit specifically only two
neutrophil proteases (HNE and proteinase 3), leaving an array of potentially
cytotoxic degranulation products to damage cells (as discussed in section 1.3.2.).
However previous studies have demonstrated that elastase inhibitors are
significantly more effective than anti-oxidants in ameliorating neutrophil mediated
damage to microvascular endothelial cells from adipose tissue (Smedley et ah,
1986), human pulmonary artery endothelial cells (Furuno et al., 1997) and A549
cells (Ayars et ah, 1984). In addition keratinocytes which do not secrete elafin could
be markedly protected against neutrophil-mediated detachment by (extremely high
doses of) recombinant elafin (50 jig/ml), whilst anti-oxidants had little effect
(Pfundt, et ah, 1996).
The minimal effect of anti-oxidants in the studies cited above is intriguing
given the propensity for neutrophils to release activated oxygen species upon
degranulation (reviewed by Weiss, 1989). The important implication for this study is
that, despite elafin containing a methionine in its reactive site (Tsunemi et ah, 1996)
and therefore being susceptible to inactivation by changes in redox potential
(Tsunemi et ah, 1992), Ad-elafin can still generate anti-elastase activity in complex,
cell-containing media. This may have important consequences as SLPI and 0Ci-Pl can
both be significantly inactivated by PMA-stimulated human neutrophils (Vogelmeier
et ah, 1997). Exactly how elafin's reactive site evaded oxidation is uncertain, though
it is clear that A549 cells are capable of constitutively producing anti-oxidants such
as glutathione (Li et ah, 1994; Jarvinen et ah, 2000).
As in the case of HNE-mediated damage, it is instructive to consider the
effects of activated neutrophils in damaging susceptible cells and their interstitium,
be those cells transfected with adenovirus or not. Approximately 98% of damage to
A549 cells by PMA-activated neutrophils has been shown to be due to detachment,
with the other 2% attributable to lysis (Ayars et ah, 1984). As was the case for HNE-
mediated damage, Ayars et ah (1984) described much more rapid neutrophil-
mediated damage of untransfected A549 cells than was observed here. In contrast,
Wang et ah (1998) described a time course more in keeping with that observed here.
The latter group extended their studies to examine the effect of RSV infection on
susceptibility to neutrophil damage. They found that RSV per se was associated with
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A549 cell damage, and that RSV potentiated the damaging effects of neutrophils
(Wang et ah, 1998). The relevance of this observation to the present study is that the
adenovirus-mediated up-regulation of ICAM-1 referred to previously (Stark et al.,
1996) may enhance neutrophil adhesion to A549 cells. This mechanism may in part
explain the augmented (though statistically non-significant) neutrophil-mediated
damage to Ad-lacZ treated cells as compared with untransfected cells in Figure 17.
Certainly neutrophil adhesion appears to be important in effecting damage of
neutrophil substrate. In this context it is worth observing that neutrophil-mediated
damage of labelled fibronectin has been shown to occur in a characteristically
pericellular distribution (Campbell and Campbell, 1988). A strikingly pericellular
distribution of damage around clusters of neutrophils was observed in this study also
(Figure 16). The concept of adhesion-dependent neutrophil-mediated damage
subsequently led to the discovery that elastase could be bound and concentrated at
the neutrophil membrane (Bangalore and Travis, 1994; Owen et al., 1995). This
consolidated interest in data showing that aj-PI was excluded from the critical space
between membrane and substrate (Campbell and Campbell, 1988). Certainly it was
demonstrated that membrane bound HNE is less susceptible to inhibition by
endogenous anti-elastases than is the free form (Bangalore and Travis, 1994). In
general it has emerged that elastase inhibitors of low molecular weight and net
positive charge may be best able to access membrane bound HNE (Owen et al.,
1995). Against this background it seems possible that elafin, as a low molecular
weight cationic inhibitor of elastase, may be particularly well suited to inhibiting
membrane bound HNE. Whether this mechanism contributes to the observed
protective effect of Ad-elafin remains unknown.
One study has suggested that neutrophil granule fractions containing
defensins (rather than FINE) account for neutrophil-mediated damage to A549 cells
(Okrent et al., 1990). While neither the concentration nor the activity of HNE in the
relevant granule fraction was determined in the study by Okrent et al. (1990), it is
hard to ignore the effect of the defensin fraction. Subsequent studies have indicated
that HNE and defensins have quite separate destructive capabilities towards A549
cells, HNE generally inducing detachment and defensins inducing lysis (van
Wetering et al., 1997). Intriguingly, neutrophil defensins inhibit HNE-mediated
detachment of A549 cells, and HNE inhibits defensin-mediated lysis (van Wetering
et al., 1997). Taken together, these strands of evidence could be interpreted as
suggesting that the protective effect of Ad-elafin in this study is not related to
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inhibition of extracellular HNE, but instead is due either to an effect on defensin
release and/or to a specific effect on degranulation. A specific effect of elafin on
degranulation is unlikely, as MPO was easily detected in supernatant from Ad-elafin
treated cells in a representative experiment. Whether elafin augmentation influences
defensin biology is unproven. Conversely it seems that defensins have no significant
effect on elafin production in primary bronchial epithelial cells (van Wetering et al.,
2000). On balance it must be concluded that more evidence exists to support an anti-
elastase mechanism for the protection afforded against activated neutrophils by Ad-
elafin. This conclusion is reached on the basis of reduced elastase activity in
supernatants from Ad-elafin treated cells (Figure 18), and the striking resemblance of
results derived using HNE in place of neutrophils (compare Figures 7,9 and 11 with
Figures 16,17 and 18).
Taken together the results of this chapter indicate that genetic augmentation
of functional elafin in pulmonary epithelial cells is feasible, and that protection can
be provided against HNE- and neutrophil-mediated damage. The potential
extrapolation of the protective data to in vivo situations must be partially tempered
by recognition of the fact these experiments were necessarily performed using A549
cells cultured in serum-free medium. None the less the results are strongly
supportive of the concept that HNE plays a critical role in neutrophil-mediated injury
of tissues (Smedley et al., 1986; Pfundt et al., 1996; Furuno et al., 1997). They
furthermore provide the necessary proof of principle to proceed towards studies of




THE EFFECT OF ELAFIN GENE AUGMENTATION ON AIRWAY
NEUTROPHILIA INDUCED BY LPS IN MICE
4.1. AIMS
The demonstration of Ad-elafin's protective effect against neutrophil-
mediated damage in vitro stimulated the hypothesis that Ad-elafin may confer tissue
protection in inflammatory lung disorders characterised by neutrophil influx and
generation of free elastase. In identifying conditions for which Ad-elafin might be
specifically targeted it was first necessary to determine the effect of elafin
augmentation on pulmonary neutrophil extravasation, given that elastase may play a
role in this process.
Against this background a fundamental aim of this chapter was to determine
whether Ad-elafin transfection could generate human elafin in murine airways.
Assuming this target to be achievable, the principal aim was to determine the effect
of elafin augmentation on acute pulmonary neutrophilia induced by LPS.
As discussed in section 1.7.4., adenovirus itself induces pulmonary
inflammation, and in this context a further aim was to characterise and minimise
vector-induced inflammation in the murine lung.
The remaining aim of the work in this chapter was to characterise the effect
of LPS on Ad-elafin secretion from transfected cells in vitro.
4.2. RESULTS
4.2.1. Normal composition of BALF in C57/B16 mice.
Two key points of reference must be made in prefacing the data in this
chapter, namely the cell count and protein concentration in BALF retrieved from
normal mice. Four healthy C57/B16 mice were killed and BALF retrieved - the
median cell count was 184,000, 98% of which were alveolar macrophages, and 2%
neutrophils. The median protein concentration in BALF was 0.45 g/1. No human
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elafin was detected in BALF from any of the mice in keeping with experiments
previously performed by Dr Jean-Michel Sallenave, in which the anti-human elafin
antibody used in this work showed no cross-reactivity with murine serum or BALF.
The BALF from mice treated IT with PBS alone shows a similar cellular
composition and protein concentration to BALF retrieved from normal, untreated
mice. Data described throughout the remainder of this work will illustrate that the
macrophage is the predominant cell type in normal BALF regardless of the fact that
total cell numbers are subject to considerable variability. For the purposes of this
study, based on my experience in the lab, the "normal" cell count in mice exposed to
vehicle alone is considered to be approximately 200,000 with a normal range of
80,000-400,000, over 95% of which should be alveolar macrophages. A normal
BALF protein concentration is considered to be less than 0.55 g/1.
The need to establish these reference values related to the importance of
determining the degree of adenovirus-induced neutrophilia in BALF in subsequent
experiments. Given that one of the principal aims of this chapter was to determine
the effect of adenoviral augmentation of elafin on LPS-induced neutrophilia, it
became desirable to effect elafin expression with the minimal degree of vector-
induced inflammation possible.
4.2.2. Intranasal and intraperitoneal administration of Ad-elafin.
Initial experiments employed the IN route to determine the effects of Ad-
elafin administration in murine airways (Table 1). Human elafin was undoubtedly
generated in murine airways, none of which was found circulating in serum from any
of the mice studied. Neither elafin generation nor increasing dose of adenovirus were
associated with a significant elevation in the total cell count in BALF (Table 1).
However a considerable degree of variability was inherent in the system. In
particular, no elafin could be detected in BALF from 4 of the mice studied. This led
to concerns relating to the reproducibility of vector distribution using the IN route.
Three mice therefore received an IN dose of trypan blue, followed 4 hours later by
sacrifice and retrieval of lungs. Macroscopic examination revealed that dye was
confined to the apical regions of the lungs, with no staining of the bases; in two mice
staining was visible in the stomach, indicating that a proportion of the dose was
swallowed. Furthermore the apical staining in the lungs was variable in its intensity

































Table1.IntranasaladministrationofAd-el finsu siv ri bleexp e sionhum nlafiBALF. 78QC57/B16micereceivedanintr nasalstillat onofAd- l fi(3x10pfu,3x fr1 )t t lvolum0pl.M werekill deither5dayslato9ter.Serumar tri v dnthhum ne afic ncentrationmeasured.BALFw o retrievedandtho alwhitcelounthumelaficonce tra ionstim te .I3sep r ta sr ei ing0PBS intranasallydkilleonday5-9theav r gec llountBALFwa233,300,dnohume afisde cti ith r orserum. Resultsrepresentmedian(n=3i achgro p).
On the basis of these findings it was concluded that human elafin could be
generated in murine airways for at least 9 days but that the variability of elafin
expression, along with the strikingly regional distribution of vector, precluded IN
administration for experiments studying the effect of elafin augmentation on
pulmonary neutrophilia.
Studies were also performed using the IP route, principally with the aim of
generating circulating elafin to determine whether transfer to the airspaces could be
achieved (Table 2). Elafin was only detectable in serum from 3 of 18 mice (one
receiving 3xl08 pfu, the other 2 receiving lxlO9 pfu. The 3 mice in question were
killed on day 5. No elafin was detected in serum from any of the 6 mice studied on
day 9. No elafin was detected in BALF from any of the animals sacrificed on day 5
or day 9. These data made it clear that an alternative means of administration would
be required to effect consistently reliable expression of human elafin in murine
airways.
4.2.3. Intratracheal administration of Ad-elafin.
Three mice received an IT instillation of trypan blue. In marked contrast to
the distribution of dye after IN administration, dye was distributed to each lobe of
both lungs, with minimal variation between animals. No dye was seen
macroscopically in stomach. Varying doses of Ad-elafin were therefore instilled IT,
and elafin levels were measured in BALF over the course of 8 days (Figure 1). Elafin
was detected in BALF from 26 of the 27 animals studied. Interestingly, low dose Ad-
elafin resulted in expression of human elafin without an increase in either total cell
count or neutrophil count when compared with PBS treated mice. Although elafin
expression was generally more efficient at higher doses of vector, these were (with
the exception of BALF from mice treated with high dose Ad-elafin retrieved on day
8) associated with varying degrees of airway neutrophilia.
It is unclear why high dose (lxl 09 pfu) administration resulted in lower
levels of elafin expression and less pronounced BALF leukocytosis than was
observed after administration of an intermediate dose (3x108 pfu). This unexpected
finding is returned to in the discussion (section 4.3.1.1.) but does not detract from the
principal conclusions derived from these experiments, that low-dose Ad-elafin
(3xl07 pfu) could consistently generate human elafin in murine airways without




















































Figure 1. Intratracheal administration of Ad-elafin generates human elafin in
BALF, but at higher doses of vector this is accompanied by significant vector-
associated neutrophilia.
C57/B16 mice received an IT instillation of Ad-elafin at a dose of either 3xl07 pfu,
8 93x10 pfu, or 1x10 pfu (n=9 in each group). Within each group, mice were killed at
day 3, day 6 or day 8 (n=3 in each subgroup). Two mice received PBS IT; one was
sacrificed at 24 hours, one at 48 hours.
BALF was retrieved from each mouse. Total cell count, neutrophil count and elafin
concentration in BALF were estimated.
Columns represent median cell counts in BALF. Shading indicates the number of
neutrophils, open boxes indicate the number of cells other than neutrophils. Median
elafin concentrations in BALF are indicated in bold print.
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using this dose were relatively low, it may be assumed that higher local
concentrations are generated in epithelial lining fluid (and possibly at tissue level).
The absence of vector-induced neutrophilia was considered critical given that the
principal aim of this chapter was to determine the effect of Ad-elafin transfection on
LPS-induced neutrophilia. For these reasons it was decided that low dose Ad-elafin
should be used in experiments to determine the effect of elafin gene augmentation on
LPS-induced pulmonary neutrophilia.
4.2.4. Experiments to establish a dose of LPS generating moderate airway
neutrophilia.
Further preliminary experiments were required to establish a dose of LPS
which would generate moderate airway neutrophilia. Given that there was no
specific preliminary data to indicate whether elafin augmentation was likely to
augment or ameliorate LPS-induced neutrophilia (if indeed it was to have any effect
at all), then the degree of neutrophilia induced in control mice needed to be sensitive
to a change in either direction. That is, moderate neutrophilia was required, as a
striking LPS-induced neutrophilia would preclude detection of any augmentation by
elafin, and a low-grade neutrophilia would preclude detection of any inhibition by
elafin.
Experiments were therefore performed to establish the time-course and dose-
dependence of LPS-mediated neutrophilia (Figures 2 and 3). IT LPS (7.5jng) caused
a progressive and striking rise in BALF neutrophil count over 48 hours, with a
corresponding rise in M1P-2 concentrations in BALF (Figure 2). On the basis of this
experiment it was concluded that a lower dose of LPS was required, but that
augmentation of neutrophil count was likely to be achievable by 24 hours even with
lower doses of LPS. Therefore mice were given either 0.1 pg or 0.5pg of LPS IT, and
killed at 24 hours. Whilst 0.1 pg resulted in a low-grade neutrophilia, 0.5pg resulted
in a moderate neutrophilia, neutrophils comprising approximately 50% of the total
cells in BALF (Figure 3).
4.2.5. The effect of Ad-elafin on LPS-induced airway neutrophilia.
The results described thus far indicated that Ad-elafin (3x107 pfu delivered
IT) could consistently generate human elafin in murine airways for at least 8 days




















Figure 2. Intratracheal LPS administration results in a time-dependent increase
in airway neutrophilia.
C57/B16 mice received an IT instillation of 7.5pg of LPS and were killed either 6, 24
or 48 hours later. One representative mouse received PBS via the IT route and was
killed at 48 hours. Total cell count, neutrophil count and MIP-2 concentrations were
established in BALF.
Neutrophil count ('Neuts') in BALF is indicated by shaded boxes, and the remaining
number of cells in BALF ('Other') is indicated by open boxes. Results represent










Figure 3. Intratracheal administration of LPS results in a dose-dependent
increase in airway neutrophilia.
C57/B16 mice received an IT instillation of either 0.1 or 0.5pg of LPS (n=2 in each
group) and were killed 24 hours later. Total cell count and neutrophil count were
established in BALF.
Neutrophil count ('Neuts') in BALF is indicated by shaded boxes, and the remaining
number of cells in BALF ('Other') by open boxes. Results are presented as the
average cell count for the 2 mice in each group.
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moderate airway neutrophilia at 24 hours. These conditions satisfied the necessary
criteria to study the effect of Ad-elafin on LPS-induced neutrophilia in vivo using the
experimental protocol described in Table 3.
In assessing the effect of Ad-elafin on LPS-mediated neutrophilia it was
considered necessary to determine whether adenoviral transgene expression was
achieved in the distal lung, given that migration of neutrophils into airways is most
likely to proceed in and around distal airspaces. Figure 4 demonstrates that alveolar
and bronchial epithelium (as well as alveolar macrophages) were accessed by
adenovirus under the experimental conditions described in Table 3.
Interestingly, Ad-elafin resulted in a striking and statistically significant
augmentation of the airway neutrophilia associated with LPS (Figure 5). The
enhancement of neutrophil count was similarly represented in cytospins derived from
BALF (Figure 6). The effect did not appear to be confined to "lavageable"
neutrophils loose in the airways, as a similar pattern of appearance was observed in
histological sections (Figure 6). A small (statistically non-significant) rise in total
macrophage count was also observed in Ad-elafin/LPS mice.
Importantly the enhancement of airway neutrophilia in Ad-elafin/LPS mice
was not associated with significant disruption of the alveolar-capillary membrane, as
BALF protein concentrations were lower in Ad-elafin/LPS mice than in either of the
other groups receiving LPS despite more than a doubling in neutrophil migration
(Figure 5). Interestingly, the neutrophilia induced by LPS in the absence of Ad-elafin
was associated with minor disruption of the alveolar-capillary membrane, there
being only a small increment in BALF protein concentration when comparing
PBS/PBS mice with PBS/LPS mice or Ad-lacZ/PBS mice with Ad-lacZ/LPS mice
(indeed a similar pattern was also observed when comparing Ad-elafin/PBS mice
with Ad-elafin/LPS mice) (Figure 5). For each comparison the small increment in
BALF protein concentration was not statistically significant, and for all groups
studied in Figure 5 protein concentrations generally remained in (or just above) the
normal range. Thus it appears that in the model studied, LPS-mediated neutrophilia
induces little or no lung injury at 24 hours, while the augmentation of LPS-induced
neutrophilia associated with Ad-elafin treatment is not attended by alveolar-capillary
membrane disruption.
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n DAYO DAY 5 DAY 6
4 PBS PBS Mice killed for retrieval of...
SERUM
8 PBS LPS
MIP-2 and elafin concentration.
BALF
4 Ad-lacZ PBS
For total cell count, differential cell
count, cytospin.
Concentrations of elafin, MlP-la, MIP-2,
8 Ad-lacZ LPS
TNF-a, MCP-1, mKC, protein.
Inhibition of HNE.
4 Ad-elafin PBS LUNGS
Histology and immunohistochemistry.
8 Ad-elafin LPS
Table 3. Experimental protocol used to determine the effect of Ad-elafin
transfection on LPS-mediated airway neutrophilia.
On day 0 C57/B16 mice received an IT instillation (30pl) of PBS or Ad-lacZ (3xl07
7
pfu) or Ad-elafin (3x10 pfu), n=12 in each group. Five days later, 8 mice in each
group received IT LPS (0.5pg in 30pl) and the remaining 4 mice in each group




Figure 4. Intratracheal administration of adenovirus results in transfection of
airway epithelium.
C57/B16 mice received an IT instillation ofAd-lacZ (3xl07pfu) followed five days
later by an IT instillation of 0.5 |ig of LPS. Twenty-four hours later mice were killed.
The lungs were retreived and stained with X-gal solution. A blue colour indicates
expression of transgene.
Panel A illustrates expression of transgene in bronchial epithelium (original
magnification x 40) .
Panel B illustrates expression of transgene in alveolar epithelium. Alveolar
















neuts other neuts other neuts other neuts other neuts other neuts other
Treatment day 0 —PBS— Ad-lacZ Ad-elafin —PBS— Ad-lacZ Ad-elafin
Treatment day 5 -PBS- -PBS- -PBS- -LPS- -LPS- -LPS—
BALF protein (g/1) 0.31 0.34 0.14 0.51 0.47 0.42
BALF MIP-2 (pg/ml) 0 4 0 257 122 318
Figure 5. LPS-induced airway neutrophilia is enhanced by Ad-elafin.
As outlined in Table 3, C57/B16 mice received an IT instillation of Ad-elafin or Ad-lacZ
(3xl07 pfu) or PBS (n=12 in each group). Five days later 4 mice in each group received PBS
IT, and the remaining 8 mice in each group received 0.5pg LPS IT. Twenty-four hours later
mice were killed and both serum and BALF retrieved. BALF total cell count, neutrophil
count, protein concentration and MIP-2 concentration were measured.
Neutrophil count ('Neuts') in BALF is indicated by shaded boxes, and the remaining number
of cells in BALF ('Other') by open boxes. Cell counts are presented as medians and
interquartile ranges. Protein and MIP-2 concentrations are presented as medians.
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The concentration of the neutrophil chemokine MIP-2 in BALF from mice
treated with LPS broadly followed the pattern of airway neutrophilia (ie highest
levels in Ad-elafin/LPS mice, intermediate levels in PBS/LPS mice and lowest levels
in Ad-lacZ/LPS mice) (Figure 5). However the correlation between MIP-2 and elafin
concentrations in BALF from Ad-elafin/LPS mice was not statistically significant
(r=0.39, /?=0.36). Insufficient BALF was available to quantify other chemokines
from individual mice. Instead equal volumes of BALF from the mice in each group
described in Figure 5 were pooled for analysis of TNF-a, MlP-la, MCP-1 and mKC
levels.4 With the limitations of pooled samples in mind it was nonetheless interesting
that TNF-a and MlP-la concentrations followed the same pattern as described for
airway neutrophilia and MIP-2 (ie highest levels in Ad-elafin/LPS mice,
intermediate levels in PBS/LPS mice and lowest levels in Ad-lacZ/LPS mice). In
contrast no mKC was detected in BALF from any of the groups, while MCP-1 was
higher in PBS/LPS mice than in Ad-elafin/LPS mice than in Ad-lacZ/LPS mice.
Several additional points are made in Figure 5. For example, the cellular
composition of BALF from PBS/PBS mice was almost identical to that of BALF
from Ad-lacZ/PBS and Ad-elafin/PBS mice. The total cell count in BALF from Ad-
elafin/PBS mice was a little higher than that from the other two groups, but remained
well within the limits considered normal for BALF cell counts (see section 4.2.1.). It
appears therefore that overt vector-induced neutrophilia did not occur in this
experiment. This is supported by the cytospins and sections in Figure 6, in which
BALF and lungs from Ad-elafin/PBS mice are seen to be virtually devoid of
neutrophils (an identical picture was observed in PBS/PBS mice and Ad-lacZ/PBS
mice, data not shown). Extending this theme, the observation that the protein
concentration in BALF was similar in Ad-lacZ (or Ad-elafin)/PBS mice and in
PBS/PBS mice implies that viral infection at the doses used did not compromise
integrity of the alveolar-capillary membrane.
Under these circumstances it is extremely unlikely that Ad-elafin's effect on
LPS-induced neutrophilia could be attributable to adenovirus per se, as virus was
neither associated with neutrophilia nor epithelial leak. This is further supported by
the observation that Ad-lacZ/LPS treatment was associated, if anything, with a small
fall in neutrophil count relative to that in PBS/LPS mice (Figure 5).
41 performed the MIP-2 ELISAs described in this work. However TNF-a ELISA was performed by
Dr Jean-Michel Sallenave, and ELISAs for MlP-la, MCP-1 and mKC were performed by Professor
T. Standiford, University of Michigan, Ann Arbor, USA.
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In seeking potential explanations for the effect of Ad-elafin in augmenting
LPS-induced neutrophilia, it is useful to consider BALF elafin levels (Figure 7).
Elafin was not detected in BALF from any of the 24 mice which did not receive Ad-
elafin. In contrast elafin was found in low concentration in BALF from Ad-
elafin/PBS mice, with a significant (20-fold) up-regulation in Ad-elafin/LPS mice
(Figure 7). There are three immediate implications arising from this observation.
Firstly, as the anti-elafm antibody used in the elafin ELISA does not
recognise murine proteins, and as the Ad-elafin construct does not contain a 5'
untranslated region, it appears that LPS (either directly or indirectly) stimulates the
mCMV promoter to drive expression of human elafin. Further support for this
phenomenon was provided by experiments in which mice were treated IT with Ad-
lacZ (3xl07 pfu), followed 5 days later by either 0.5p,g or 5|lg of LPS IT. Lungs
were retrieved 24 hours later and stained for (3-galactosidase (the product of the lacZ
gene). LPS resulted in a dose-dependent increase in expression of (3-galactosidase
which in turn is under the control of the mCMV promoter (Figure 8).
Secondly, it might intuitively be supposed that augmented levels of elafin
may influence neutrophil migration by an effect on murine elastase. Certainly human
elafin is capable of inhibiting murine elastase in vitro (personal communication from
Professor G. Lungarella, University of Siena, to Dr Jean-Michel Sallenave). The
capacity of BALF to inhibit elastase was measured in a crude way, owing to
limitations in the volume of BALF available from each mouse. 10p,l of BALF was
simply incubated with 10pl (lOOng) of HNE for 30 minutes at 37°C before
application of methoxysuccinyl-ala-ala-pro-val p-nitroanilide. The mean inhibition
of HNE for each group was as follows: PBS/PBS, 75%; Ad-lacZ/PBS, 80%; Ad-
elafin/PBS, 75%; PBS/LPS, 84%, Ad-lacZ/LPS, 81%, Ad-elafin/LPS, 79%. Whilst
recognising the necessarily crude nature of this experiment it appears that no striking
augmentation of elastase inhibitors in BALF occurred after Ad-elafin transfection.
Thirdly, it could potentially be argued that elafin influences neutrophil
migration through a direct or indirect concentration-dependent chemotactic function.
However neutrophil counts were lower in Ad-elafin/PBS mice than in Ad-lacZ (or
PBS)/PBS mice. Similarly the correlation between elafin concentration and
neutrophil count in Ad-elafin/LPS mice was not statistically significant. Therefore,
while a direct effect of high concentrations of elafin on neutrophil migration cannot








Figure 7. LPS significantly enhances elafin expression in Ad-elafin treated mice.
C57/B16 mice were treated IT with Ad-elafin (3xl07pfu) followed five days later by
PBS (n=4) or 0.5pg LPS (n=8), as described in Table 3. BALF was retrieved 24 hours
later and the concentration of human elafin determined by ELISA.
Results represent medians and interquartile ranges.
** = significant difference, ^<0.01, when comparing the two groups.
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Figure 8. LPS stimulates expression driven by the mCMV promoter in vivo.
C57/B16 mice were treated IT with Ad-lacZ (3xl07pfu) followed five days later by
either 0.5 or 5|ig of LPS.Twenty-four hours later mice were killed. Lungs were
removed and stained with X-gal solution.Expression of transgene is indicated by blue
colour.
PANEL A: Appearance of lungs stained after Ad-lacZ then 0.5jig LPS.
PANEL B: Appearance of lungs stained after Ad-lacZ then 5pg LPS.
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explain the observations in Figure 5.
The observation of markedly elevated human elafin concentrations in BALF
from mice treated with Ad-elafin then LPS prompted immunohistochemical studies
aiming to determine the cellular sources of elafin after transfection (Figure 9).5 6
Surprisingly few cells were seen to stain positively for elafin antigen. Those that did
included alveolar epithelial cells (Figure 9, Panels A and B) as well as inflammatory
cells in alveolar spaces (Figure 9, Panels C and D). One striking feature was the
detection of elafin on the brush border of ciliated bronchial epithelium (Figure 9,
Panel E). Whilst staining of lumenal interfaces is a recognised artefactual effect in
immunohistochemistry, the fact that control sections did not reveal similar staining
(Figure 9, Panel FI) suggests that elafin does indeed concentrate on or around cilia,
possibly reflecting high levels of secretion.
To summarise this section, low dose Ad-elafin administration generated
human elafin in the murine airway without producing overt vector-induced
inflammation. Ad-elafin was associated with a significant augmentation of LPS-
induced pulmonary neutrophilia, and LPS induced a significant up-regulation of
elafin transgene expression in murine airways.
4.2.6. The effect of Ad-elafin transfection on human neutrophil migration in vitro.
Transfection of A549 cells with Ad-elafin resulted in an increase in migration
of human neutrophils across a polycarbonate filter of 3p,m pore size (Figure 10). A
viral effect appeared to contribute to the enhanced neutrophil migration, as Ad-lacZ
transfection was consistently associated with higher neutrophil migration than was
observed for untransfected cells (Figure 10), the difference approaching but not
reaching statistical significance.
To confirm whether neutrophils were responsive to chemotactic stimuli in
this system two wells containing untransfected A549 cells were prepared.
Immediately prior to neutrophil-containing inserts being placed into the wells, fMLP
(final concentration 10"8M) was added to the insert being placed in the first well, and
5 Immunohistochemical staining was performed by myself and Mr Koen Schepers, a visiting student
from the University of Leiden, who I helped to supervise during his attachment to Dr Sallenave's lab.
6 Slides of psoriatic skin (as positive control) were kindly provided by Dr Liz Sabin, Department of
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Figure 9. immunohistochemical localisation of elafin after Ad-elafin transfection.
C57/B16 mice were treated as described in Table 3. Lungs were removed, fixed and
sectioned. The presence of human elafin antigen was determined by
immunohistochemistry using rabbit anti-human elafin immunoglobulin as primary antibody
(PBS and pre-immune rabbit serum were used as controls). Secondary antibody comprised
goat anti-rabbit immunoglobulin complexed to peroxidase. Upon addition of peroxidase
substrate, positive staining is indicated by brown colour.
PANELS A-E: Ad-elafin/LPS mice,showing staining in alveolar epithelium
(A (original magnification x 400) and B (original magnification x 200)), inflammatory cells (C
(original magnification x 200) and D (original magnification x 200)) and bronchial epithelial
cilia (E (original magnification x 100)).
PANEL F: Positive control (psoriasis in human skin; original magnification x 100).
PANELS G AND H: Negative controls - Ad-lacZ/LPS mouse stained with anti-elafin antibody
(G (original magnification x 40)), and Ad-elafin/LPS mouse stained with pre-immune serum
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Figure 10. Ad-elafin transfection enhances neutrophil migration in vitro.
A549 cells were transfected with Ad-elafin or Ad-lacZ (moi of 50 for each) or vehicle
alone and incubated in serum-free medium for 48 hours. 1.25x106 freshly isolated
human neutrophils were applied to inserts housing polycarbonate filters of 3pm pore
size. The inserts were immediately placed in wells containing the A549 cells such that
the bottom of each insert was in contact with conditioned medium, and incubated for
20 minutes at 37°C. Inserts were removed and discarded. Conditioned medium was
treated with Triton X-100 to lyse migrated neutrophils prior to the addition of Na
acetate-citrate buffer, pH 4.2. MPO activity was measured as a marker of neutrophil
migration. Neutrophils from a single donor were used in each experiment, and each
condition was performed in quadruplicate. In each experiment results were expressed
relative to the well in which maximal neutrophil migration was observed.
Results are presented as means and standard deviations from 4 separate experiments.
* = significant difference when comparing Ad-elafin treatment with either of the
other conditions, p<0.05.
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to the A549 cells of the second well (ie the first well had a potential chemotactic
gradient favouring retention of neutrophils in the insert, while the second had a
gradient favouring migration). At the end of the incubation period, the ratio of
neutrophils in the insert to the number migrated was 5.9:1 in the first well and 1.8:1
in the second well. As such, neutrophils in this system were appropriately responsive
to chemotactic stimuli.
Furthermore, in a separate experiment, neutrophil-containing inserts were
incubated with Ad-elafin transfected A549 cells, and the elafin concentration in each
compartment measured at the end of the experiment. The concentration of elafin in
A549 cell conditioned medium was 95 ng/ml while the concentration in inserts was
17 ng/ml. This indicates that, while some elafin did permeate through the filter, a
clear elafin gradient persisted throughout the incubation period. The demonstration
of neutrophil responsiveness to chemokines and of preservation of potential
chemotactic gradients in this experimental system suggest that the effects observed
in Figure 10 were not non-specific.
Further experiments were performed in an attempt to identify factors
influencing the observed increase in neutrophil migration associated with Ad-elafin.
In 2 separate experiments, an excess of anti-elafin antibody was incubated with
A549 cells prior to the addition of inserts. This resulted in loss of the effect of Ad-
elafin over and above that attributable to Ad-lacZ (ie in the presence of antibody,
mean % of maximal neutrophil migration was 64% for Ad-elafin transfected cells,
61% for Ad-lacZ treated cells, and 29% for untransfected cells). This suggested that
the difference in neutrophil migration when comparing Ad-lacZ treatment and Ad-
elafin treatment was indeed due to elafin.
Interestingly however, in a further experiment, addition of recombinant
human elafin (final concentrations 50 and 100 ng/ml) to washed untransfected cells
did not augment neutrophil migration (% of maximal neutrophil migration 46% for
untransfected cells, 53% for untransfected cells incubated with 50 ng/ml elafin, 46%
for untransfected cells incubated with 100 ng/ml elafin; for comparison the % of
maximal migration for Ad-elafin transfected cells in the same experiment was 76%).
Similarly, adding recombinant human elafin (final concentration 10~7M to 10"4M) to
wells in the absence of A549 cells had no effect on neutrophil migration (% of
maximal neutrophil migration 1% for medium alone, and 1%, 1%, 0% and 1% for
elafin at 10"7M, 10"6M, 10"5M and 10~4M respectively). It appears therefore that
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neutrophil migration in this system is induced by A549 cells, the effect being
enhanced by Ad-elafin transfection.
The lack of effect attributable to recombinant elafin in this system was
consistent with further studies in which recombinant elafin was not found to have
direct neutrophil chemotactic activity in a cell-free chemotaxis assay.7 Interpretation
of these data should however take into account the fact that recombinant elafin used
in these experiments is a truncated molecule with much of the NH2-terminal end of
full-length elafin unrepresented.
On the basis that Ad-elafin transfection may induce generation of a
chemotactic factor, levels of IL-8 were measured in conditioned media after
incubation with neutrophil-containing inserts (Figure 11). Higher levels of
expression of IL-8 from untransfected cells than from Ad-elafin transfected cells
suggested that induction of IL-8 was not the mechanism responsible for the effect of
Ad-elafin described in Figure 10. Pre-incubation of A549 cells with an excess of
anti-human-IL-8 had little effect on neutrophil migration in this system (11%, 0%
and 7% reduction in maximal neutrophil migration associated with untransfected
cells, Ad-lacZ treated cells, and Ad-elafin treated cells, respectively).
4.2.7. The effect of LPS on elafin secretion from transfected and untransfected
A549 cells.
The demonstration of LPS-inducible secretion of elafin after Ad-elafin
infection of murine airways (section 4.2.5.) led to the suggestion that targeted
transfection of human cell lines may also allow for inflammation-specific transgene
expression. Given that alveolar epithelial cells and alveolar macrophages are logical
targets for gene therapy strategies aimed at the distal airway, A549 cells and
macrophages were identified as cells in which to pursue such a hypothesis.
In untransfected A549 cells LPS stimulated a dose-dependent increase in
elafin secretion above the levels produced constitutively (Figure 12). Transfection
with Ad-lacZ at an moi of 50 appeared to lead to a slight dampening of the response
to LPS, particularly at lower doses (0.1-1 pg/ml) (Figure 12). In keeping with
7 The chemotaxis assay was kindly performed by Dr Marie-Helene Ruchaud-Sparagano, Rayne
Laboratory, University of Edinburgh.
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Figure 11. Increased neutrophil migration induced by Ad-elafin transfection of
A549 cells is not associated with augmented IL-8 secretion.
A549 cells were treated with Ad-elafin or Ad-lacZ (moi of 50 in each case) or vehicle
alone prior to the addition of inserts containing 1.25xl06 neutrophils, using the protocol
outlined in Figure 10. IL-8 concentrations in conditioned media were measured by
ELISA.
Results represent medians and interquartile ranges derived from 3 separate experiments.










0 0.1 1 10 100 1000
LPS (|ig/ml)
0 0.1 1 10 100 1000
LPS (|ig/ml)
0 0.1 1 10 100 1000
LPS (pg/ml)
Figure 12. LPS augments elafin secretion from untransfected A549 cells, but only
high concentrations of LPS increase elafin secretion from cells transfected with Ad-
elafin at an moi of 50.
A549 cells were treated with Ad-elafin or Ad-lacZ (each at 50 moi) or vehicle alone and
incubated in serum-containing medium for 48 hours. LPS was added over the dose range
0-1000 pg/ml for 24 hours, and elafin concentration was measured in supernatants by
ELISA.
Data represent medians and interquartile ranges illustrated on a logarithmic scale, n=5.
* = significant difference, p<0.05 when compared with the baseline value (ie where no
LPS added) for each treatment. In addition, for each of the concentrations of LPS applied,
clafin levels were higher in supernatants from Ad-elafm treated cells than in supernatants
from untransfected or Ad-lacZ treated cells (p<0.05 in each case).
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findings in Chapter 3, Ad-elafin transfection of A549 cells at an moi of 50 resulted in
high levels of elafin secretion even in the absence of LPS (Figure 12). LPS
generally had little effect on this high baseline level of elafin production, except at
extremely high concentrations (lmg/ml) (Figure 12). To determine whether the
apparent lack of LPS-responsiveness of transfected cells relative to untransfected
cells was due to increased susceptibility of transfected cells to LPS toxicity, cell
viability was measured at the conclusion of a representative experiment. For each
treatment cell viability in monolayers approximated closely to that described in
section 3.2.1., with no obvious toxic effect of LPS observed (data not shown).
On balance it was felt unlikely that LPS toxicity was responsible for the
relative LPS-unresponsiveness of cells treated with Ad-elafin at an moi of 50.
Instead it was considered possible that the powerful mCMV promoter was
stimulating near maximal expression of elafin transgene in A549 cells at baseline,
leaving little capacity for significant increase upon addition of LPS. Therefore, the
experiments were repeated using adenoviral transfection at an moi of 1 (Figure 13).
Despite the reduced dose of adenovirus, Ad-lacZ transfection was again
associated with a relative blunting of the characteristic effect of LPS on
untransfected cells (Figure 13). In contrast LPS stimulation of Ad-elafin transfected
cells resulted in a dose-dependent increase in elafin secretion (Figure 13). The
magnitude of the LPS-induced rise in elafin secretion was higher in Ad-elafin treated
cells than in untransfected (or Ad-lacZ treated) cells, and it is assumed that the
increment is attributable to elafin expression driven by the mCMV promoter.
4.2.8. The effect of LPS on elafin secretion from transfected and untransfected
monocyte-derived macrophages.
Adenoviral transfection of monocyte-derived macrophages proved to be
feasible, with a transfection efficiency calculated at approximately 16% (Figure 14).
Experiments were therefore carried out to determine whether LPS could up-regulate
elafin secretion from macrophages (Figure 15). It must be emphasised that these
experiments were performed using autologous human serum (as a source of LPS
binding protein), and that human serum is known to contain elafin (Molhuizen and
Schalkwijk, 1995). In this study the concentration of elafin in medium containing
10% autologous human serum was approximately 1.7 ng/ml. It is immediately
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Figure 13. LPS up-regulates elafin secretion from A549 cells transfected with
Ad-elafin at an moi of 1.
A549 cells were treated with Ad-elafin or Ad-lacZ (each at 1 moi) or vehicle alone
and incubated in serum-containing medium for 48 hours. LPS was added over the
dose range 0-1000 pg/ml for 24 hours, and elafin concentration was measured in
supernatants by ELISA.
Data represent medians and interquartile ranges, n=5.
* = significant difference, p<0.05 when compared with the baseline value (ie where
no LPS added) for each treatment. In addition, for each of the concentrations of LPS
applied, elafin levels were higher in supernatants from Ad-elafin treated cells than in





Figure 14. Transfection of monocyte-derived macrophages with Ad-lacZ.
Monocyte-derived macrophages were treated with Ad-lacZ (PANEL A; moi of 50 -
original magnification x 100) or vehicle alone (PANEL B - original magnification x
100) and incubated in serum-containing Iscove's Medium for 48 hours. Cells were then
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Figure 15. LPS up-regulates elafin production from Ad-elafin transfected
monocyte-derived macrophages.
Monocyte-derived macrophages were treated with Ad-elafm or Ad-lacZ (each at 50
moi) or vehicle alone and incubated in serum-containing medium for 48 hours. LPS
was added over the dose range 0-1000 pg/ml for 24 hours, and elafin concentration
was measured in supernatants by ELISA.
Data represent medians and interquartile ranges, n=6.
* = significant difference, p<0.05 when compared with the baseline value (ie where
no LPS added) for each treatment. # = significant difference, p<0.05 compared with
elafin levels from Ad-elafin treated cells receiving the equivalent dose of LPS.
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and Ad-lacZ treated macrophages exposed to LPS approximated to the level
attributable to human serum. Intriguingly, there appeared to be a trend for LPS to
reduce slightly the concentration of elafin in conditioned medium from untransfected
macrophages, this becoming statistically significant at 10 |ig/ml LPS (Figure 15).
In contrast, Ad-elafin transfection was associated with elafin secretion which
was stimulated by exposure to LPS, though this effect was only statistically
significant when extremely high concentrations (1 mg/ml) of LPS were applied
(Figure 15). One striking feature of Figure 15 is the size of the error bars, reflecting
the considerable inter-individual variation in elafin secretion in response to LPS.
When the data in Figure 15 were analysed donor by donor, it became apparent that
macrophages from 3 donors readily secreted elafin in response to LPS, whilst no
definite LPS-induced up-regulation of elafin secretion was observed in macrophages
from the remaining 3 donors.
The apparent absence of elafin production in untransfected and Ad-lacZ
transfected macrophages exposed to LPS raised three questions. Firstly, were the
macrophages isolated intrinsically resistant to LPS? Secondly, did LPS induce
macrophage death thereby precluding evidence of LPS-mediated up-regulation of
elafin? Thirdly, are monocyte-derived macrophages capable of constitutively
producing elafin?
Taking these questions in turn, IL-8 secretion was measured in a subset of
macrophages exposed to LPS (Table 4). The characteristic LPS-dependent increase
in IL-8 secretion in both transfected and untransfected macrophages indicated not
only that the cells were LPS-responsive, but that adenoviral transfection did not
obviously affect the response. With regard to the susceptibility of isolated
macrophages to LPS toxicity, the significant majority of macrophages were adherent
to plastic wells, and cell viability approximated to 100% irrespective of transfection
or dose of LPS. It was therefore concluded that LPS (or viral) toxicity did not appear
to explain the apparent lack of secretion of endogenous elafin in response to LPS.
This leaves the question of whether elafin can be produced constitutively by
human monocyte-derived macrophages. Two strands of evidence suggest that
macrophages are capable of producing elafin when exposed to LPS. Firstly, in 2
separate experiments the protocol described in Figure 15 was followed with the
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0 0.1
Dose of LPS (pg/ml)
1 10 100 1000
Untransfected 11.2 56.8 63.8 67.1 88.6 87.3
Ad-lacZ 7.5 46.8 56.7 65.8 89.7 95.5
Ad-elafin 11.9 46.3 58.0 63.7 86.7 87.7
Table 4. LPS treatment of monocyte-derived macrophages was associated with
an appropriate rise in IL-8 secretion.
Monocyte-derived macrophages were treated with Ad-elafin or Ad-lacZ (each at 50
moi) or vehicle alone and incubated in serum-containing medium for 48 hours. LPS
was added over the dose range 0-1000 pg/ml for 24 hours, and IL-8 concentration
(shown in bold print and expressed in pg/ml) was measured in supernatants by
ELISA. Data are derived from a single representative experiment.
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exception that FCS replaced autologous human serum. In one of these experiments
no elafin was detected in supernatants from untransfected or Ad-lacZ treated
macrophages either in the absence or presence of LPS. A similar pattern emerged in
the second experiment, with the exception of Ad-lacZ treated macrophages
stimulated with LPS at 1 mg/ml, in which elafin was unequivocally detected at a
concentration of 1.1 ng/ml. Secondly, Ad-lacZ transfected macrophages from 1 of
the 6 donors contributing to the data in Figure 15 were associated with a small but
unequivocal increase in elafin levels when comparing application of 1 |ig/ml LPS
and no LPS. In summary therefore, human monocyte-derived macrophages appear to
be capable of generating elafin, but in this study this was only achieved in
macrophages transfected with adenovirus and exposed to LPS; no elafm was
detected in untransfected macrophages in the absence of LPS.
In this context the LPS-induced up-regulation of elafin secretion from Ad-
elafin treated macrophages from some (but not all) donors (Figure 15) is very likely
to result from the effect of LPS on the mCMV promoter. In 2 separate experiments,
the timing of exposure to LPS was altered to coincide with the timing of adenoviral
transfection (ie supernatants were retrieved 72 hours after Ad-elafin transfection with
LPS applied throughout; in contrast, in Figure 15 supernatants were recovered 72
hours after transfection but LPS was applied only during the final 24 hours). Figure
16 demonstrates the striking up-regulation of elafin secretion with relatively low
concentrations of LPS under these circumstances, reinforcing the point that Ad-
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Figure 16. LPS-mediated up-regulation of elafin secretion from Ad-elafin
transfected macrophages appears more efficient if LPS is applied at the time of
transfection.
Monocyte-derived macrophages were treated with Ad-elafin (50 moi) and LPS (over
the dose range 0-10 pg/ml) and incubated in serum-containing medium for 72 hours.
Elafin concentration was measured in supernatants by ELISA.




The principal conclusion arising from the data in this chapter is that Ad-elafin
transfection of murine airways enhances LPS-induced neutrophilia. In interpreting
these data a number of potential technical limitations should first be considered.
These include factors relating to the route of administration used, the strain of mouse
used, the control vector used, the structure of murine airways, and the anti-elastase
properties of the murine lung.
4.3.1.1. Route of administration.
The variable distribution of vehicle associated with the IN route was
disappointing, given that IN application is quick, simple, non-invasive and easily
repeatable. The inherent variability is still more disappointing when it is considered
that IN administration of Ad-elafin generated impressive elafin concentrations in the
airways without obvious increases in BALF cell count (Table 1). The apparent lack
of vector-induced inflammation should be interpreted cautiously however, in that IN
administration of trypan blue resulted in almost exclusively apical deposition of dye.
It is plausible therefore that there was indeed regional cellular influx (and high elafin
expression) in the apices, but that BALF (which is presumed to mix fluids from all
regions of the lung) dilutes out this effect. The IP route was similarly unsuitable to
the requirements of this study in that serum levels of elafin were disappointingly low
(Table 2).
In contrast, the IT route resulted in dispersion of vector to all regions of the
lung, and consistently generated human elafin. The other principal advantage of the
IT route over the IN route was the reassurance that all of the dose given entered the
airways (in contrast to the variable gastrointestinal deposition associated with the
nasal route). Despite these considerable advantages, the IT route is not without
potential problems. For example, slightly deeper anaesthesia is required for this more
invasive procedure and it is quite possible that a degree of airway trauma is induced
by the small head of pressure used to instil vehicle. These problems were considered
of negligible importance in this study as mice generally tolerated the procedure well,
and mice in all groups were treated equally. Of potentially more concern was the
variability in responsiveness of mice to the same IT stimulus. Using the example of
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PBS/LPS mice in Figure 5, total cell count ranged from 120,000 to 1,364,000,
though the percentage of neutrophils in BALF was less variable (55%-78% of total
cell count). The observed variability is likely to represent either differences in the
response of individual mice or variability in deposition of LPS in airways. In this
context the relatively consistent percentage of neutrophils in the airway is reassuring,
as the percentage was characteristic of good LPS exposure even in mice with
relatively low total cell counts.
This theme becomes important in the context of ensuring equitable exposure
to adenovirus in individual mice. Figure 1 provided valuable data in describing
vector-induced neutrophilia associated with doses of adenovirus at 3xl08 pfu and
lxl 09 pfu. However the higher total cell (and neutrophil) counts in mice receiving
3xl08 pfu as compared with those receiving lxlO9 pfu was unexpected. Again it
seems likely either that deposition of virus was variable, or that mice have a
markedly variable inflammatory response to overtly immunogenic doses of virus.
While there may have been some variability in viral infection, there is little doubt
that transfection was efficient using the IT route, as elafin was detected in BALF
from 38 of the 39 Ad-elafin treated mice described in this chapter, and Ad-lacZ
transfection proved efficient as assessed by X-gal staining (Figure 4), a system
which probably under-represents efficiency of adenoviral transfection (Couffinhal et
al., 1997). It should be mentioned also that variability both in transgene expression
and immune response is well recognised after IT delivery in rodent models, as
exemplified by two important early gene therapy studies using doses of adenovirus
similar to those described here (Rosenfeld et al., 1991; van Ginkel et al., 1995).
Importantly in the context of this study, the problem of variability was much
less pronounced when adenovirus was applied at 3xl07 pfu, as illustrated by
consistent low level expression of elafin using Ad-elafin at this dose (Figure 1 and
left hand column of Figure 7), and the consistently normal composition of BALF
retrieved from Ad-elafin and Ad-lacZ treated mice not exposed to LPS (Figures 1
and 5). On the basis of the available evidence therefore, it seems that variability in
the innate immune response to adenovirus becomes important above a certain dose
threshold (in this case somewhere between 3xl07 pfu and 3xl08 pfu), but below this
threshold overt vector induced inflammation is low or absent. Indeed the
determination of a dose of adenovirus causing little inflammation in the airways
whilst allowing transgene expression may have far reaching consequences for gene
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therapy. This point is expanded upon later in this chapter when discussing the effect
of LPS administration on transgene expression.
In summary, the IT route was safe and provided efficient and reproducible
delivery of LPS and adenovirus to the airways. IT administration of adenovirus at
low dose (3xl07 pfu) was associated with efficient transgene expression with
minimal variability in the total cell count (or neutrophil count) in BALF.
4.3.1.2. Strain of mouse used.
C57/B16 mice were used principally because this strain has been extensively
studied in gene therapy protocols, and because of local experience with this strain as
a background for the generation of elafin transgenic and CFTR "knockout" models
(Dorin et ah, 1992). Interestingly the C57/B16 mouse seems to be relatively tolerant
of recombinant adenovirus, allowing prolonged heterologous transgene expression,
particularly after intravenous administration (Barr et ah, 1995; Michou et ah, 1997).
This is consistent with the expression of elafin in BALF for at least 8 days via the IT
route (Figure 1) and at least 9 days via the IN route (Table 1), with no obvious
extinction of signal when considering vector doses of 3x107 pfu. C57/B16 mice
therefore appeared well suited to the development of models requiring transgene
expression for a few days only.
4.3.1.3. Comparison of Ad-elafin and Ad-lacZ vectors.
Adenoviral vectors encoding the (3-galactosidase gene from E. coli, or the
luciferase fire-fly gene have become established as standard controls in the field of
gene therapy. This largely reflects the fact that both can be usefully applied as
"reporter" genes to provide a simple visual read out of transfection efficiency, as is
demonstrated by staining for the presence of (3-galactosidase at various points in this
thesis. The considerable experience with these vectors has cemented their place as
routinely used viral controls. However, potential criticisms of these vectors can be
made. In the context of this work, a potential cricticism is the use of a bacterial gene
expressing an intracellular product (as in Ad-lacZ) with a human gene expressing a
secreted product (as in Ad-elafin). The immune response to adenovirus (Yang et ah,
1994; van Ginkel et ah, 1995) has already been discussed in section 1.7.4. There is
no doubt that murine immune responses are generated against bacterial and human
gene products, and that the response to each is different (Kaplan et ah, 1997; Michou
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et al., 1997; Song et al., 1997a; McLachlan et al., 2000). In general human genes
persist for longer than bacterial genes in C57/B16 mice (Michou et ah, 1997; Song et
ah, 1997a). However evidence exists to suggest that the complete elimination of Ad-
lacZ from the lungs of C57/B16 mice occurs after day 10 (Michou et al., 1997).
On balance, whilst the intrinsic differences between Ad-lacZ and Ad-elafin
need to be considered, the available evidence suggests that these had little impact on
the results in this chapter. In particular, the vast majority of the genetic sequences in
the two vectors are viral and of identical composition (Addison et ah, 1997;
Sallenave et ah, 1998). In addition, persistence of Ad-lacZ was readily demonstrated
at 6 days in this study (Figure 4). Finally, using cellular content of BALF as a very
crude index of immune response, no obvious differences were apparent when
comparing Ad-lacZ/PBS and Ad-elafin/PBS mice (Figure 5).
4.3.1.4. The structure of murine airways, and the anti-elastase properties of murine
lungs.
The murine lung differs considerably from the human lung. Principal
differences include the predominance of Clara cells throughout murine airways (in
contrast to their characteristic presence in respiratory bronchioles in humans), and
the relative paucity of cells producing mucus (Pack et ah, 1981). Ms. Bianca
Hiemskerk has isolated murine Clara cells in this laboratory, and she and I have
demonstrated their efficient transfection with adenovirus in vitro (data not shown).
With regard to murine anti-proteases, the predominant species in plasma are
0C]-PI and contrapsin (Takahara and Sinohara, 1983). In contrast to the situation in
man, five structurally related aj-PI genes have been isolated in the mouse (Borriello
and Krauter, 1991), but only the two species containing a methionine in the active
site are capable of inhibiting HNE (Paterson and Moore, 1996). On the other hand,
contrapsin has no activity against elastase (Takahara and Sinohara, 1983). In recent
years murine SLPI has also been identified as a single copy gene in mice, and the
gene product efficiently inhibits HNE (Zitnik et ah, 1997). However, to date a
murine homologue of elafin has not been convincingly identified. The data in this
chapter confirm that BALF from PBS/PBS mice is capable of inhibiting HNE
efficiently, and it is presumed that most if not all of the constitutive elastase
inhibition is provided by aj-PI and/or SLPI. Importantly, if a murine homologue of
elafin does exist it does not cross-react with the antibody in the elafin ELISA used
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here, as elafin was not detectable in BALF from any of the control animals in this
work.
4.3.2. Augmentation of LPS-induced neutrophilia by Ad-elafin.
The striking augmentation of LPS-induced neutrophilia by Ad-elafin (Figures
5 and 6) seems unlikely to have been influenced significantly by the factors
discussed in the previous section. In particular, the available evidence implies that
the bacterial gene in Ad-lacZ would, if anything, tend towards increased
inflammation over the effect of the human transgene in Ad-elafin. Furthermore, any
confounding effect of the inherently variable response of murine lungs to
inflammatory stimuli was (at least to some degree) reduced by using a system in
which delivery is directly visualised, and by using relatively high numbers of mice.
Finally, in vitro evidence using genetic augmentation of elafin in human epithelial
cells provided support for an effect of Ad-elafin in promoting neutrophil migration
(Figure 10).
This section will therefore address the consequences of the pattern of elafin
secretion in murine airways, and consider how elafin may potentially exert its effect
on neutrophil recruitment.
4.3.2.1. The effect of LPS on expression of elafin in murine airways transfected with
low dose Ad-elafin.
A potentially important finding described in this chapter is the 20-fold
increase in elafin secretion induced by LPS in Ad-elafin treated mice (Figure 7). This
observation strongly implies that the mCMV promoter is activated by LPS, a
conclusion supported by the LPS-dependent increase in (3-galactosidase expression
in the lung (Figure 8). Interestingly LPS is similarly known to stimulate the human
CMV promoter (Loser et al., 1998). The inducibility of the mCMV promoter by LPS
is in keeping with the description of LPS-induced stimulation of promoters from
murine acute phase protein genes such as complement factor 3 and serum amyloid
A3 (Varley et al., 1995). The potential may therefore exist to design vectors for gene
therapy protocols which are up-regulated specifically in response to local
inflammation. While extremely elegant and well characterised inducible promoters
such as the tetracycline- and ecdysone-inducible gene expression systems already
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exist, these are necessarily dependent on administration of an exogenous "switch"
(Gossen etal., 1995; Kistner et ah, 1996; No et ah, 1996).
The potential advantage of the mCMV promoter in this setting is its inherent
strength (Sallenave et ah, 1998). In this chapter the significant LPS-induced
generation of elafin (Figure 7) was achieved using a vector dose low enough to avoid
overt airway inflammation as assessed by neutrophil influx and BALF protein
concentration (Figure 5). Indeed the dose of Ad-elafin used here is considerably
lower than doses used in conventional IT gene therapy protocols. It appears therefore
that appropriate selection of powerful, inflammation-specific promoters could allow
significant transgene expression whilst avoiding vector-induced tissue injury.
Despite the marked induction of elafin secretion by LPS, surprisingly few
cells stained positively for human elafin (Figure 9). Two potential explanations arise.
Firstly, the antibody used may have been inefficient at detecting elafin in histological
sections from mouse lung. Against this argument is the intense staining found in
histological sections of skin from patients with psoriasis (Figure 9, Panel F),
although it remains possible that staining is less efficient in murine than in human
tissue. Alternatively, it may indeed be that small numbers of airway cells are
transfected but that these produce significant quantities of elafin, which in turn are
secreted. Elafin is known to contain a signal peptide and to be rapidly secreted
(Sallenave et ah, 1993). Furthermore, intracellular demonstration of elafin has been
localised to secretory apparatus in keratinocytes (Pfundt et ah, 1996). Similarly the
observation that elafin appeared to coat brush borders may imply rapid secretion but
slow clearance from the lung (Figure 9, Panel E). Interestingly, interstitial staining
was also conspicuous by its absence, despite the potential for elafin to bind
interstitial substrate (Schalkwijk et ah, 1999). This could potentially be explained by
the fact that tissue binding is mediated by sequences in the NF^-terminal domain of
elafin, which may potentially be cleaved from the COOH-terminus upon tissue
binding (Schalkwijk et ah, 1999) thus obviating recognition by the antibody used in
experiments described here (which was raised against the COOH-terminus of elafin).
If it were indeed the case that Ad-elafin transfection was only required in a
small number of cells in order to effect elafin expression this would consolidate the
impression that mCMV containing vectors may be appropriate in the therapeutic
setting.
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4.3.2.2. Could Ad-elafin's effect on LPS-induced neutrophilia be mediated by a
direct effect of human elafin?
The observation that the enhancement of LPS-induced neutrophilia by Ad-
elafin transfection was associated with up-regulated elafin secretion (Figures 5 and
7) raised the possibility that elafin may exert a direct effect on neutrophil migration
into the lung. Any such inference needs to be viewed in the light of evidence relating
to the role of elastase and its inhibitors in neutrophil migration.
There is a considerable body of evidence suggesting a role for neutrophil
elastase in neutrophil migration. In the context of this study, LPS has previously
been shown to up-regulate expression of active, surface bound HNE on neutrophils
(Owen et al., 1995). HNE stimulates the expression of CD 18 and CD1 lb by
neutrophils (Woodman et al, 1993) and furthermore appears to be an endogenous
ligand for the CD 1 lb/CD 18 integrin complex thereby affecting neutrophil adhesion
by competing with alternative ligands such as fibronectin, C3bi and ICAM-1 (Cai
and Wright, 1996). HNE is capable of increasing epithelial cell permeability
(Peterson et al., 1995), and can generate chemotactic fragments from the fibrin
degradation products resulting from inflammatory processes (Leavell et al., 1996).
Conversely, HNE may potentially reduce chemotactic potential by cleaving IL-8
(Leavell et al., 1997).
The relationship between elastase and neutrophil migration becomes
considerably more complex when considering the role of elastase inhibitors.
In the elegant intravital microscopy studies performed by Woodman et al.
(1993), synthetic elastase inhibitor inhibited neutrophil adhesion to, and migration
across, vessels in the rat mesentery. A separate group suggested that elastase
inhibition by a synthetic compound reduced neutrophil migration in vitro by
inhibiting the activation of gelatinase B (Delclaux et al., 1996).
In support of an inhibitory role for anti-elastases, apPI was shown to inhibit
HNE-induced epithelial permeability (Peterson et al., 1995), to inhibit neutrophil
migration in response to fMLP (Stockley et al., 1990), and to neutralise partially the
chemotactic activity of bronchial epithelial cells induced by LPS (Koyama et al.,
1995). However, other studies have suggested that the concentration and
conformation of aj-PI may dynamically alter the molecule's effect on neutrophil
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migration. Thus low concentrations of cci-PI were found to stimulate chemotaxis and
chemokinesis, whilst higher concentrations had an inhibitory effect (Aoshiba et ah,
1993). Furthermore oxidised aj-PI and low molecular weight cleavage products of
oci-PI have been shown to increase neutrophil motility (Banda et ah, 1988; Stockley
et ah, 1990), as have elastase-aj-PI complexes (Joslin et ah, 1992).
SLP1 has been shown to have mild inhibitory effects on fMLP-stimulated
neutrophil chemotaxis (Stockley et ah, 1990), and to have no effect on migration
across primary human pulmonary vascular endothelial cells (Mackarel et ah, 1999).
It should be noted that all of the studies cited in relation to neutrophil
migration in this section describe in vitro experiments, with the exception of the
work by Woodman et ah (1993). The recurring theme in animal studies is for SLPI
or elafin to exert an inhibitory effect on neutrophil extravasation. For example
truncated recombinant SLPI inhibited the pulmonary neutrophilia associated with
inhaled HNE in guinea pigs (Suzuki et ah, 1996), while anti-SLPI antibody
administered IT to rats resulted in an increased chemotactic activity of BALF
(Gipson et ah, 1999). Along similar lines, intravenous truncated (57 amino acid)
human elafin (total of approximately 3mg at intervals over a 3 hour period) reduced
neutrophil recruitment in a hindlimb ischaemia-reperfusion model in rats (Crinnion
et ah, 1994). The same elafin preparation (intravenous bolus of 0.67mg, followed by
approximately 2.15 mg/h for 2-3 hours) significantly reduced neutrophil recruitment
to the heart in a rat model of myocardial infarction or repetitive myocardial
ischaemia (Tiefenbacher et ah, 1997). In a more recent study, human elafin cDNA
(identical to that described in this work) was incorporated into Sendai virus, and the
resulting complex used to transfect excised, homologous jugular vein grafts from
rabbits ex vivo. The transfected segments were grafted into an excised portion of the
right common carotid artery (O'Blenes et ah, 2000). This manipulation resulted in a
reduction in graft neutrophilia (O'Blenes et ah, 2000).
In summary, elastase would appear to have at least some role in neutrophil
migration. While SLPI may have little effect on this process in vitro, a-1 PI appears
to have a pleiotropic role, possibly suggesting an inhibitory effect for the native
molecule but a stimulatory effect for digested, complexed and oxidised forms as
might be found in the setting of inflammation. Flowever in vivo studies to date
suggest an inhibitory effect of low molecular weight elastase inhibitors on neutrophil
migration.
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In returning to the question of whether elafin had a direct effect on LPS-
mediated neutrophil migration in this study, certain points relating to the existing
literature require attention. The first thing to note is that no other data exist with
regard either to the effect of elafin on neutrophil migration to the lung in vivo, or to
its effect in vitro. Secondly, the in vivo studies using elafin (Crinnion et ah, 1994;
Tiefenbacher, 1997; O'Blese et ah, 2000) and SLPI (Suzuki et al., 1996; Gipson et
ah, 1999) were fundamentally different from the experiments in this chapter, in that
the effect of elastase inhibitors was assessed in the setting of conditions known to
produce significant tissue damage in control animals (secondary to vascular
pathology in the case of the elafin studies). In experiments described here little if any
tissue damage was induced by 0.5pg of LPS in control mice, as assessed
histologically (Figure 6) and by protein concentrations in BALF (Figure 5). In other
words the intention of the experiments described here was simply to determine the
effect of elafin augmentation on LPS-mediated neutrophil migration into previously
healthy lung, whereas the intention of the other studies described was to determine
whether elafin (or SLPI) had tissue protective effects. Furthermore, the studies by
Crinnion et al. (1994) and Tiefenbacher et al. (1997) used truncated elafin at
concentrations far higher than those achieved here.
Some circumstantial evidence in this chapter implies that the effect of elafin
on neutrophil migration was not direct. For example, if human elafin exerted a
specific chemotactic activity, Ad-elafin/PBS mice might have been expected to have
higher numbers of neutrophils in BALF than Ad-lacZ/PBS mice, and a significant
correlation might have been expected between the elafin concentration and
neutrophil count in Ad-elafin/LPS mice. Neither of these conditions were satisfied.
Furthermore if elafin exerted its effect through anti-elastase activity, one might have
expected BALF from Ad-elafin/LPS mice to have augmented activity against HNE,
which proved not to be the case. Finally recombinant elafin did not exert chemotactic
activity in vitro (though it must be recalled that the moiety used was a truncated form
of elafin).
In conclusion, no evidence has arisen specifically to support a direct action of
elafin on neutrophil migration, either with regard to anti-protease activity or a direct
chemotactic effect. However an as yet unidentified direct mechanism cannot be
excluded at this stage. In this context two specific theoretical possibilites are worthy
of brief consideration. The first stems from literature suggesting a pro-inflammatory
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role for fragmented or complexed cci-PI, and contends that elafin complexes or
fragments may exert a similar effect. Although the antibody used in this study can
(with reduced efficiency) recognise elafin incubated with HNE (section 3.2.2.), there
is no evidence to say whether it recognises elafin complexed to murine elastase. A
second intriguing possibility is suggested by experiments showing that elastase and
elastase inhibitors may specifically interact with the presentation of LPS to
inflammatory cells. In particular SLPI is capable of binding LPS (Ding et al., 1999),
and HNE can degrade CD 14 (Le-Barillec et al., 1999). It could therefore be argued
that the effects reported here are due to inhibition of elastase-mediated proteolysis of
CD 14 and/or to a chemotactic effect of elafin/LPS complexes. Such mechanisms
would reconcile the fact that a pro-migratory action of elafin has not been noted in in
vivo systems from which LPS is absent, and this area deserves further study.
However it is insufficient to explain the small pro-migratory effect of human elafin
in vitro.
4.3.2.3. Is Ad-elafin's effect on LPS-induced neutrophilia mediated by an indirect
action of human elafin?
If human elafin enhances neutrophil migration in the murine lung partly or
wholly via an indirect mechanism, then it seems most likely that an effect of elafin
on the expression and/or function of neutrophil chemoattractants is involved. A
number of well characterised murine neutrophil and macrophage chemokines have
been described (reviewed by Haelens et al., 1996). Given the 24-hour exposure to
LPS in the experiments described here, and the limited quantity of BALF available
from each mouse, it was decided to concentrate primarily on the C-X-C neutrophil
chemokine MIP-2, then use remaining BALF to study the other molecules listed in
Table 3.
The data indicate that the pattern of MIP-2 generation was broadly in keeping
with the pattern of airway neutrophilia after exposure to LPS (ie the concentration of
MIP-2 was higher in Ad-elafin mice than in PBS mice than in Ad-lacZ mice (Figure
5)). Interestingly, adenovirus transfection per se seemed to be associated with a
down-regulation of MIP-2 secretion. These data could be taken to infer a role for
elafin in stimulating MIP-2 expression directly. There are however strands of
evidence opposing this possibility. Firstly, the correlation between MIP-2 expression
and elafin production was not statistically significant. Secondly, subsequent
experiments performed in this laboratory by Dr Jean-Michel Sallenave and Ms.
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Bianca Hiemskerk showed that MIP-2 was not up-regulated from Ad-elafin
transfected murine Clara cells exposed to LPS.
A very similar situation exists when considering TNF-a, which (in pooled
samples) also mirrored airway neutrophilia after LPS administration in being present
in higher concentrations in BALF from Ad-elafin/LPS mice than from PBS/LPS
mice than from Ad-lacZ/LPS mice. Dr Sallenave and Ms. Hiemskerk showed that
TNF-a was down-regulated from Ad-elafin transfected murine alveolar
macrophages exposed to LPS.
MlP-la is known to be secreted preferentially by alveolar macrophages in
response to LPS, and is both a macrophage and neutrophil chemokine (VanOtteren et
al., 1994; Standiford et al., 1995). The pattern of expression of MlP-la in pooled
BALF paralleled the BALF macrophage and neutrophil counts in this study (Figure 5
and Table 4). This could potentially be in keeping with a role for Ad-elafin in
augmenting LPS-induced monocyte migraton also.
What is clear from these data is that Ad-elafin appears to be associated with
up-regulation of more than one chemokine after LPS administration. Dr Sallenave
and Ms. Hiemskerks' data suggest that elafin itself is unlikely to stimulate the genes
for MIP-2 and TNF-a directly, and the absence of neutrophilia in Ad-elafin/PBS
mice (Figure 5) would tend to support this view. One can do little more than
speculate as to potential mechanisms involved, but it is again tempting to invoke a
situation whereby elafin leads to more efficient presentation of the inflammatory
stimulus (ie LPS) leading to an appropriate up-regulation of inflammatory
chemokines. With this and the previously noted proteolysis of CD 14 in mind (Le-
Barillec et al., 1999), it is intriguing that TNF-a production was found to be CD14-
dependent in a rabbit model of pulmonary LPS exposure (Ishii et al., 1993).
Irrespective of the mechanism of Ad-elafin's augmentation of LPS-induced
neutrophilia, it is worth emphasising that the doubling of airway neutrophilia
observed was not associated with an increase in protein leak across the alveolar-
epithelial barrier (Figure 5). The dissociation of neutrophil influx and epithelial
permeability after administration of LPS to the lungs has been described elsewhere
in mice (Chignard and Balloy, 2000), rats (Yang et al., 1998) and humans
(Sandstrom et al., 1992). The specific implication for this body of work relates to the
apparent safety of IT Ad-elafin in vivo.
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Turning now to the effect of Ad-elafin on neutrophil migration in vitro, an
indirect effect of elafin may also explain the small pro-migratory effect described in
Figure 10, as recombinant human elafin itself had no effect. However it must be
recalled that the moiety used was truncated. Interestingly the small pro-migratory
effect induced by Ad-elafin was not attributable to augmentation of IL-8 from A549
cells, as higher levels of IL-8 were consistently found in supernatants from
untransfected cells (Figure 11). Furthermore, IL-8 seemed to contribute relatively
little to neutrophil migration in this system, as anti-IL-8 antibodies made little
impression on rates of migration. In this setting, while the in vitro experiments were
supportive of a role for Ad-elafin in augmenting neutrophil migration, the principal
conclusion is that elafin's effect is likely to be via stimulation of endogenous
neutrophil chemoattractants, but the nature of these remains undefined.
In contrast to experiments performed in mice, a clear effect of adenovirus
itself was present in vitro (Figure 10). It seems likely that the chemoattractant(s)
induced by adenovirus differs from that induced by elafin, as anti-elafin antibody
resulted in equivalent levels of chemoattractant activity from Ad-lacZ and Ad-elafin
transfected cells which remained far in excess of those from untransfected cells.
Amin et al. (1995) also showed that adenoviral transfection of A549 cells results in
enhanced neutrophil chemoattractant activity, but in contrast to the observations in
Figure 11 they found that transfected cells produced higher concentrations of IL-8
than did untransfected cells. Furthermore in their hands IL-8 was responsible for
virtually all of the chemoattractant activity (Amin et al., 1995). The results described
here in Figure 11 have been reproduced in the absence of neutrophils several times in
this lab (ie Ad-lacZ transfected cells consistently produce less IL-8 than do
untransfected cells), and these results are therefore markedly at odds with those of
Amin et al. (1995). The reason for this discrepancy remains unclear. A separate
group found no significant change in IL-8 secretion from Ad-lacZ transfected human
bronchial epithelial cells (Noah et al., 1996).
To summarise this section, low dose Ad-elafin delivered by the IT route
consistently produces human elafin in murine airways without inducing overt injury.
Both epithelial cells and inflammatory cells appear to be transfected. Human elafin
expression is significantly up-regulated in the presence of LPS and in turn Ad-elafin
transfection is associated with a significant augmentation in LPS-induced
neutrophilia. The precise mechanism by which elafin effects this augmentation
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remains unclear. The pro-migratory effect of Ad-elafm on neutrophils can be
extended to human epithelial cells in vitro.
4.3.3. The effect of LPS on elafin secretion from human epithelial cells and
macrophages.
As described previously, the demonstration of LPS-inducible transgene
expression in mice led to studies aimed at determining whether this effect was
reproducible in human cells. A549 cells and peripheral blood monocyte-derived
macrophages were studied in view of their ready accessibility, and because the cells
likely to encounter IT adenovirus first are considered to be epithelial cells and
macrophages.
4.3.3.1. The effect of LPS on adenovirus-transfected A549 cells.
The significant up-regulation of elafin from untransfected A549 cells exposed
to LPS (Figures 12 and 13) indicates that elafin secretion is responsive both to
exogenous inflammatory mediators and to endogenous early cytokines such as IL-1
and TNF (Sallenave et al., 1994). Conversely, elafin secretion from A549 cells is
reduced by the application of HNE (Reid et al., 1999). The mechanisms by which
elafin secretion is up-regulated by LPS remain to be elucidated. While a stimulatory
effect on the endogenous elafin promoter may be inferred from data in this chapter,
Bingle et al. (2001) described no effect of LPS on elafin mRNA expresson from
primary type II alveolar epithelial cells.
Importantly from the point of view of these specific experiments however, it
can be confidently stated that adenoviral transfection per se does not augment elafin
secretion in response to LPS. A further technical point is that basal elafin secretion
does not appear to be markedly influenced by the presence or absence of serum,
constitutive levels being similar in Figures 12 and 13 in this chapter and in Figure 3,
Chapter 3.
The pattern of elafin secretion from Ad-elafin treated cells exposed to LPS
was quite different to that from control cells (Figures 12 and 13). It seems likely that
the relative unresponsiveness to LPS of cells transfected with moi 50 reflects a near
maximal stimulation of elafin secretion by A549 cells even in the absence of LPS
(Figure 12). In contrast, in cells treated with moi 1, the LPS-dependent increase in
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elafin secretion over and above that seen in control cells can be assumed to result
from stimulation of the mCMV promoter. As such the mCMV-elafm transgene
complex is sensitive to LPS both in human cells in vitro and in murine lungs.
However it should be noted that relatively high concentrations of LPS (1 fig/ml)
were required to stimulate a small up-regulation in vitro, in contrast to the striking
response seen in vivo (Figure 7). This difference is likely to reflect an action of
numerous LPS-induced inflammatory mediators on the mCMV promoter in the more
complex in vivo situation.
4.3.3.2. The effect of LPS on adenovirus-transfected monocyte-derived
macrophages.
The results of this study suggest that human monocyte-derived macrophages
are capable of producing elafin, but this was only induced after stimulation with high
doses of Ad-lacZ and LPS. A separate group has recently described the presence of
human elafin mRNA in stimulated alveolar macrophages but not in peripheral blood
monocytes (Mihaila and Tremblay, 2001).
A potential criticism of the experiments in this chapter is that peripheral
blood monocyte-derived macrophages were used instead of alveolar macrophages.
There is good evidence to suggest that macrophage populations derived from
different biological compartments have different phenotypic characteristics
(Campbell et al., 1991; VanOtteren et ah, 1994), possibly relating, in the case of
alveolar macrophages, to different prevailing oxygen tensions (Peters-Golden et ah,
1990). For the purposes of this study, blood-derived macrophages were felt to be of
sufficient interest for a number of reasons. Firstly, as discussed later in this section,
adenoviral transfection efficiency of alveolar and peripheral blood monocyte-derived
macrophages is thought to be similar. Secondly, in the broader context of gene
therapy, ex vivo transfection of either population is a legitimate target. Thirdly, from
a purely practical viewpoint, peripheral blood monocyte-derived macrophages are
considerably more accessible, using a much less invasive technique.
In contrast to the situation described in control cells, Ad-elafin was capable
of generating elafin in macrophages from at least some donors, and the mCMV
promoter appeared to be sensitive to LPS in these macrophages (Figure 15). The
factors determining which donors' macrophages express elafin remain unclear.
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The rate of macrophage transfection by adenovirus in this study closely
approximates to that described elsewhere for both monocyte-derived macrophages
(Haddada et al., 1993; Schneider et al., 1997) and alveolar macrophages (Worgall et
al., 1999a). Indeed the marked discrepancy in transfection efficiency of macrophages
(Figure 14) and A549 cells (Figure 1, Chapter 3) has been described elsewhere and
attributed to the differences in expression of the CAR receptor on the two cell types
(Kaner et al., 1999).
Similarly, the factors determining macrophage transfection efficiency in vivo
require to be further characterised. Macrophages effect rapid clearance of adenovirus
administered IT, and in so doing initiate an immune response (Kuzmin et al., 1997;
Worgall et al., 1997b; Zsengeller et al., 2000). However there is little doubt that
some macrophages allow expression of transgene in vivo for several days.
Immunochemical staining in this study identified occasional macrophages expressing
human elafin 6 days after IT transfection (Figure 9). This is in keeping with, for
example, expression of human transgene in rat alveolar macrophages 3 days after IT
instillation (Danel et al., 1998) and of labelled murine transgene in alveolar
macrophages at least 2 weeks after ex vivo transfection (Worgall et al., 1999a).
The importance of these issues relates to whether macrophages represent a
useful target for gene therapy in the lung, whether they be transfected in vivo or ex
vivo. The data in Figure 16 could suggest that under the appropriate conditions,
transgene expression can be markedly up-regulated ex vivo. These data find some
resonance in two recent elegant studies. One of these described functional pulmonary
expression of transgene after sequential ex vivo transfection of alveolar macrophages
and IT reconstitution (Worgall et al., 1999a). The other described ex vivo
transfection of monocyte-derived macrophages resulting in functional correction of
the characteristic genetic defect of X-linked chronic granulomatous disease
(Schneider et al., 1997).
If the macrophage is to be a useful target for gene therapy, then transfection
efficiency will need to be improved. The scope certainly exists to achieve this in that
simply applying adenovirus to cells in suspension (as opposed to adherent cells)
increases efficiency approximately 3-fold (Schneider et al., 1997), while work
performed by Dr P. Henriksen in this lab has demonstrated that incubation with
calcium phosphate precipitate increases efficiency still further. In tandem with these
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observations, novel receptor-targeting offers alternative routes of transgene delivery
to macrophages (Ferkol et al., 1998).
To summarise this section, and place it in the context of previous sections,
the constitutive expression of elafin in pulmonary epithelial cells is up-regulated by
LPS, while neither constitutive nor LPS-inducible elafin could be detected in
untransfected peripheral blood monocyte-derived macrophages. Ad-elafin
transfection of both A549 cells and macrophages resulted in increased elafin
secretion in response to LPS, apparently attributable to a stimulatory effect on the
powerful mCMV promoter.
4.4. SUMMARY
The data in this chapter have demonstrated efficient, consistent, and LPS-
inducible expression of human elafin in the murine lung using Ad-elafin at doses
which preclude significant vector-induced neutrophilia or epithelial disruption.
These conditions suggested a potential role for Ad-elafin in preventing tissue injury
in animal models.
Elafin is a low molecular weight, cationic inhibitor of HNE (and proteinase
3) expressed principally at epithelial surfaces subject to environmental exposure such
as the airways, skin and oral cavity (Wiedow et al., 1990; Sallenave and Ryle, 1991;
Nara et al., 1994). Secretion may be rapidly up-regulated by early inflammatory
cytokines (Sallenave et al., 1994) or by LPS. Elafin appears to be able to augment
LPS-induced neutrophil recruitment without increasing epithelial permeability, and
furthermore can protect pulmonary epithelium against the deleterious effects of HNE
liberated extracellularly. From a teleological viewpoint, this combination of
properties strongly suggested a physiological role for elafin in early innate immunity.
Given that the immune system has evolved to protect against microbial pathogens,
and that several endogenous antibiotics are small cationic peptides (reviewed by
Hancock, 1997), the hypothesis was formed that elafin may have direct antimicrobial
activity against pulmonary pathogens.
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CHAPTER 5
ANTIMICROBIAL EFFECTS OF ELAFIN
5.1. AIMS AND BACKGROUND
The primary aim of the work described in this chapter was to determine
whether elafin has intrinsic antimicrobial activity. In the event of an antimicrobial
effect being demonstrated then secondary aims were to determine whether protein
folding was a prerequisite for antimicrobial function, and to determine the relative
contributions of the distinct structural domains of elafin.
The various forms of elafin used in these experiments have been described in
Chapter 2 (sections 2.1.1.2. and 2.1.1.3.). In brief, they included recombinant human
elafin (approximately 6 kDa) comprising the COOH-terminal end of the molecule,
and a range of synthetically engineered molecules. The synthetic molecules included
full length folded elafin (approximately 9.9 kDa), full length unfolded elafin, the
NH2-terminal domain (approximately 5.2 kDa) and the COOH-terminal domain
(approximately 4.8 kDa). For comparitive purposes, recombinant human SLPI
(approximately 11.7 kDa) was studied.
Most previous studies assessing the potential antimicrobial effects of peptides
have compared bacterial colony counts in the presence of test peptide with those in
buffer/vehicle. In the experiments described in this chapter a second control was
used in the form of equimolar concentrations of human serum albumin (HSA), to
control for any potential non-specific effect of protein. HSA is a circulating anionic
molecule which is found in BALF in the context of lung epithelial leak.
The effect of elafin was assessed against two bacteria, namely P. aeruginosa
and S. aureus. These bacteria were selected for four principal reasons. Firstly, both
are important pulmonary pathogens, particularly in the context of CF (reviewed by
Govan and Nelson, 1992; Hutchison and Govan, 1999) and in the setting of immune
compromise (Maurer et ah, 1992; Wade et ah, 1995). Secondly, it seemed desirable
to test elafin against both Gram positive (S. aureus) and Gram negative {P.
aeruginosa) organisms. Thirdly, as one of the major challenges facing medicine is
the development of novel strategies to combat antimicrobial resistance, it seemed
pertinent to study two bacteria with a propensity for clinically important resistance
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mechanisms (reviewed by Hancock, 1998; Waldvogel, 1999). Finally, a wealth of
exprerience in the biology of these organisms exists locally within related research
groups interested in CF (Davidson et ah, 1995; Govan and Deretic, 1996). The
following sections briefly discuss P. aeruginosa and S. aureus, with a little more
emphasis on the former as P. aeruginosa features prominently in Chapter 6.
5.1.1. Pseudomonas aeruginosa strain PAO1.
P. aeruginosa is a ubiquitous environmental nonfermentative Gram negative
bacillus. P. aeruginosa may cause pulmonary infection in the setting of breached
host defence, for example in ventilator-associated pneumonia (Meduri et al., 1998)
or after lung transplantation (Maurer et ah, 1992). However, with regard to
pulmonary disease, P. aeruginosa is most closely associated with CF, resulting in
colonisation of over 90% of patients by adulthood (Davis et ah, 1996; Hutchison and
Govan, 1999; Greening, 2000).
Factors governing adherance and internalisation of P. aeruginosa to airway
epithelial cells have received considerable attention, particularly with regard to
differences between CF cells and non-CF cells. Thus it has been suggested that
CFTR itself regulates clearance of P. aeruginosa in the healthy lung (Pier et ah,
1996; Davies et ah, 1997), whilst in patients with CF, excessive and inducible
expression of asialoGM) provides a substrate for adhesion of P. aeruginosa (Saiman
and Prince, 1993). It is certainly the case that P. aeruginosa elaborates a number of
potent virulence factors including LPS, exotoxins, haemolysins, and proteases
(Vasil, 1986). In addition P. aeruginosa secretes a well characterised elastase
(Morihara et ah, 1965), though it should be noted that this molecule is a
metalloprotease not a serine protease, and as such its structure does not predict for
inhibition by elafin, SLPI or aj-PI. In addition to the range of virulence factors
produced by P. aeruginosa, in the lungs of patients with CF this organism has the
remarkable capacity to change from a non-mucoid phenotype to a mucoid phenotype
characterised by production of alginate and the generation of a complex biofilm
which greatly enhances evasion of host defences (Hutchison and Govan, 1999).
Colonisation with mucoid P. aeruginosa is associated with a poor prognosis
(Pedersen et ah, 1992), forming the rationale for aggressive strategies aimed at
eradication of the organism at an early (non-mucoid) stage in the disease (Valerius et
ah, 1991; Frederiksen et ah, 1997).
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In conjunction with the inherent virulence of the organism, eradication of P.
aeruginosa is also hindered in clinical practice by high levels of instrinsic resistance
to commonly used antimicrobial agents (Hancock, 1998). Resistance is mediated
principally through reduced outer membrane permeability of the organism, though
antibiotic efflux pumps and induction of enzymes capable of degrading
antimicrobials also contribute. The combination of antimicrobial resistance and
unique colonisation characteristics renders effective clearance of P. aeruginosa
extremely difficult.
The strain of P. aeruginosa used in this work (PAOl) is the best
characterised of all laboratory strains, and indeed the complete genome sequence has
recently been characterised (Stover et al., 2000). PAOl was originally isolated from
a skin wound in a patient in Melbourne, Australia, and is non-mucoid in phenotype
(Holloway, 1955). Initial colonisation of the lung in CF is with non-mucoid strains
(Govan and Deretic, 1996). PAOl is known to generate pulmonary pathology in
rodent models (George et al., 1993), and stimulates elastase release in hamster
airways (Melby et al., 1985).
5.1.2. Staphylococcus aureus strain C1705.
S.aureus is a Gram positive coccus which has long been recognised to have
an association with abscess formation and sepsis (reviewed by Lowy, 1998).
S.aureus can cause a severe, cavitating form of community acquired pneumonia,
often in patients with pre-existing debility. It is also closely associated with lung
disease in CF (Govan and Nelson, 1992).
In keeping with the themes developed for P.aeruginosa, S.aureus produces
potent virulence factors, for example toxins, coagulase, proteases and hyaluronidase.
In addition, S. aureus is increasingly characterised by the emergence of antimicrobial
resistance. Thus while (3-lactamase expression may eradicate susceptibility to
penicillin, the presence of the mec gene confers methicillin-resistance and
consequently greatly reduced therapeutic options (Chambers, 1997). This alarming
clinical situation has been compounded by the emergence of isolates resistant to
vancomycin (Hiramatsu et al., 1997). The strain used in this study is a clinical isolate




Both PA01 and CI705 grew efficiently in TSB with logarithmic phase
growth for each strain occurring at around 3 hours (Figure 1). This time point was
therefore used to establish growth in subsequent experiments.
The remaining requirement was to establish whether synthetically generated
full-length folded elafin was functionally active. This was assessed by measuring the
anti-elastase activity of the molecule and its derivatives (Figure 2). Full-length
folded elafin, the synthetic COOH-terminal domain of elafin and recombinant elafin
all inhibited HNE, the elastase inhibitory activity of each moiety being strikingly
similar (Figure 2). A slightly higher elastase inhibitory activity was observed for
recombinant SLPI (Figure 2). In contrast the NH2-terminal domain of elafin and full-
length unfolded elafin had no detectable anti-elastase activity (Figure 2).
Finally, neat aliquots of each of the synthetic moieties, recombinant elafin,
recombinant SLPI, and HSA were plated out on Columbia agar and incubated
overnight at 37°C. No growth was detected for any of the species used, effectively
excluding bacterial contamination of the test substances.
5.2.2. The effect of elafin on P. aeruginosa PAOl.
Elafin treatment resulted in significantly fewer PAOl colonies than did either
of the controls used (Figure 3). The effect of elafin was significant throughout the
dose range studied (l-25pM) and maximal at 2.5|iM. At this concentration,
eradication of PAOl was almost complete. There was an inverse dose-response
relationship over the range 2.5-25|iM. The effect of elafin appeared to be
bactericidal, at least in part, as for all concentrations of elafin (l-25p,M) the colony
count from samples taken at the end of 2 hours incubation with PAOl was
significantly lower than the count from samples containing PAO1 and phosphate




Figure 1. Growth curves for PAOl and C1705.
Samples of PAOl and CI 705 were incubated in TSB overnight. Aliquots of the
resulting suspensions were diluted 100 times in fresh TSB and incubated at 37°C.
Aliquots were removed at hourly intervals, plated out on agar, and incubated









Figure 3. Elafin has antimicrobial activity against Pseudomonas aeruginosa PAOl.
1 OOjal of a suspension of PAOl was incubated in TSB at 37°C for 3 hours, washed and
resuspended in phosphate buffer. 30pl aliquots of PAOl suspension were then incubated
with 90pl of elafin in concentrations ranging from l-25pM in phosphate buffer, using
either 90pl of HSA (l-25pM in phosphate buffer; A) or phosphate buffer alone (B) as
control. Samples were incubated for 2 hours at 37°C then plated on Columbia agar and
incubated overnight at 37°C prior to colony counting.
In the phosphate buffer control the median concentration of PAOl was approximately
79,600 cfu/ml.
Data points represent medians and interquartile ranges, n = 8-13 for each data point.
** = significant difference, /?<0.01, compared with control. *** = significant difference,
/?<0.001, compared with control.
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Figures 4 and 5 illustrate the effects of different elafin moieties against P.
aeruginosa. Several points arise. Importantly the FISA control also appeared to have
some antimicrobial activity relative to phosphate buffer (Figure 4). However this
effect was considerably less than the effect of equimolar concentrations of full-
length folded elafin (Figures 4 and 5).
At low concentrations (1 and 2.5pM) the full-length folded elafin molecule
had considerably greater antimicrobial activity than either the COOH- or NH2-
terminal domains. However the NH2-terminal domain had at least as powerful
antimicrobial activity as the full-length folded molecule at higher concentrations
(Figures 4 and 5). Interestingly, while unfolded elafin and the NH2-terminal domain
had no demonstrable anti-elastase activity, they each had some antimicrobial activity
(Figures 2 and 4). A further important point is that the dose-response curves for all
moieties tested (with the exception of the NH2-terminal domain) appeared to be
parallel.
When compared directly with recombinant human SLPI in 3 separate
experiments, elafin appeared to have an equivalent effect at 1 pM, and a greater
effect at 2.5 and lOpM (Figure 6). However these results should be interpreted with
some caution as the average activity of elafin against PAOl in the experiments
described in Figure 6 was slightly higher than the average activity in the experiments
described in Figures 3B and 4. This apparent discrepancy is explained by the
variability inherent to these experiments (as reflected in the error bars in Figure 3). It
seems reasonabe to conclude that elafin and SLPI had approximately equivalent
activity against PAOl across the concentration range tested.
In a single separate experiment, 0.5pM full length folded elafin and 0.5pM
SLPI were added together to PAOl, and the effect compared with that of either 1 pM
elafin or lpM SLPI respectively. The purpose of this experiment was to determine
whether there was synergy in the bactericidal effect of the molecules but this was not
demonstrated (the colony count relative to that in phosphate buffer was 11% in the
presence of elafin alone, 17% in the presence of SLPI alone, and 13% in the
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Figure 6. Comparison of the antimicrobial activity of elafin and SLPI against
Pseudomonas aeruginosa PAOl.
lOOpl of a suspension of PAOl was incubated in TSB at 37°C for 3 hours, washed
and resuspended in phosphate buffer. 30pl aliquots of PAOl suspension were then
incubated with either 90pl of full-length folded elafin or 90pl of recombinant human
SLPI (in concentrations ranging from 1-1 OpM in phosphate buffer) or 90pl of
phosphate buffer alone. Samples were incubated for 2 hours at 37°C then plated on
Columbia agar and incubated overnight at 37°C prior to colony counting. Results are
expressed relative to the colony count in buffer alone (in which the median
concentration of PAOl was approximately 168,200 cfu/ml).
Data points represent medians, n = 3 for each data point.
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5.2.3. The effect of elafin on S.aureus C1705.
Elafin also exerted a powerful antimicrobial effect on C1705 (Figure 7). In
contrast to the situation described for PAOl, the effect of elafin was generally dose-
dependent with no significant effect at l|iM, and maximal effect at 25p.M (Figure 7).
Once again the effect appeared to be bactericidal as the CI705 count after 2 hours of
incubation with elafin was lower than the count from samples containing buffer and
bacteria taken prior to the 2 hour incubation period; this effect reached statistical
significance when elafin was applied at 10 and 25pM (p<0.05 in each case).
In the case of CI 705 full-length folded elafin had greater antimicrobial
activity than either the COOH- or NH2-terminal domains at all concentrations tested
over the dose range 2.5-25|iM (Figures 8 and 9). Indeed while the full-length folded
elafin molecule was significantly active against CI705 the NH2-terminus had no
significant effect until a dose of 25p,M was reached, when the effect remained
minimal (Figures 8 and 9). Similarly the COOH-terminus had relatively little effect
on CI 705 at any of the concentrations tested (Figures 8 and 9).
In contrast unfolded elafin had antimicrobial activity (albeit less than the
folded molecule) which closely paralleled that of the folded molecule, at least over
the concentration range 1 to 10pM (Figures 8 and 9).
In contrast to the situation described for PAOl, HSA appeared to have no
antimicrobial effect on CI705. Indeed the counts retrieved from HSA controls were
considerably higher than those from controls using phosphate buffer (Figure 8).
When compared directly in 3 separate experiments, neither lpM elafin nor
1 jliM SLPI appeared to have any effect against CI705 (Figure 10). At 2.5p,M elafin
appeared to have no effect, while SLPI had a modest antimicrobial effect. At 10pM,
both molecules had a modest effect. However, as with the direct comparison of
elafin and SLPI using PAOl these results should be interpreted cautiously, in that on
this occasion the effect of elafin described in Figure 10 is slightly less than that
described in Figures 7B and 8. On balance the conclusion arising is that elafin and
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Figure 7. Elafin has antimicrobial activity against Staphylococcus aureus C1705.
lOOpl of a suspension of CI 705 was incubated in TSB at 37°C for 3 hours, washed and
resuspended in phosphate buffer. 30pl aliquots of CI 705 suspension were then incubated with
90pl of elafin in concentrations ranging from l-25pM in phosphate buffer, using either 90pl of
HSA (l-25pM in phosphate buffer; A) or phosphate buffer alone (B) as control. Samples were
incubated for 2 hours at 37°C then plated on Columbia agar and incubated overnight at 37°C
prior to colony counting.
In the phosphate buffer control the median concentration of CI 705 was approximately 25,300
cfu/ml.
Data points represent medians and interquartile ranges, n = 5 for each data point.
* = significant difference, p<0.05, compared with control. ** = significant difference, p<0.01,
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Figure 10. Comparison of the antimicrobial activity of elafin and SLPI against
Staphylococcus aureus CI705.
lOOpl of a suspension of CI 705 was incubated in TSB at 37°C for 3 hours, washed and
resuspended in phosphate buffer. 30pl aliquots of CI 705 suspension were then incubated
with either 90pl of full length folded elafin or 90pl of recombinant human SLPI (in
concentrations ranging from 1-1 OpM in phosphate buffer) or 90pl of phosphate buffer
alone. Samples were incubated for 2 hours at 37°C then plated on Columbia agar and
incubated overnight at 37°C prior to colony counting. Results are expressed relative to
colony counts in buffer alone (in which the median concentration of CI705 was
approximately 30,300 cfu/ml).
Data points represent medians, n = 3 for each data point.
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5.3. DISCUSSION
The principal novel observation arising from these data is that elafin has an
unequivocal antimicrobial effect against both P. aeruginosa and S. aureus (Figures 3
and 7).
The availability of elafin fragments and unfolded elafin allowed a number of
additional conclusions to be made, which have importance for the understanding of
elafin biology generally. Firstly, the demonstration that all of elafin's anti-elastase
activity could be accounted for by the COOH-terminus (Figure 2) provides
supportive evidence for a single elastase inhibitory site in elafin, especially when
considered in conjunction with the molecule's derived amino-acid sequence
(Sallenave and Silva, 1993). However confirmation will only be forthcoming when
the crystallographic structure of full-length elafin bound to HNE is available. It has
previously been suggested that SLPI has a single inhibitory site for HNE but two
reactive sites for combination with other enzymes such as cathepsin G (Boudier and
Bieth, 1992). Secondly, the data in this chapter demonstrate antimicrobial effects for
both the NH2-terminus and COOH-terminus of elafin (Figure 5), adding to the
known functional attributes of these domains outlined in section 1.5.5. The
demonstration of antimicrobial activity but no anti-elastase activity for the NH2-
terminus of elafin (and unfolded elafin) indicates that most (and perhaps all) of
elafin's antimicrobial effects are independent of anti-elastase activity.
It appears that elafin can be added to the array of endogenous cationic
antimicrobial polypeptides expressed in man, even if elafin is a little larger than most
of the molecules categorised in this way (Hancock, 1997). The prevailing view is
that most cationic peptides exert their effect through interference with, and
permeabilisation of, the bacterial cytoplasmic membrane (Hancock, 1997). Certainly
PAOl can be killed in this way (Sawyer et al., 1988). This raises the question of
whether net charge alone can explain the effects of elafin described here.
The net charge of the NH2-terminus of elafin is +5, while that of the COOH-
terminus is +2. If an effect based entirely on net charge were to be invoked, then one
might expect the effect of the NH2-terminus to be intermediate between that of the
COOH-terminus and the full-length moleule. This was not observed for either PAOl
or CI705 (Figures 5 and 8). Indeed the more positively charged NH2-terminus
appeared only to exert a marked antimicrobial activity when applied at high
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concentrations to PAOl (Figure 5). Furthermore, in the case of PAOl an
antimicrobial effect of HSA (which carries a net negative charge) was observed. On
these grounds it seems most unlikely that the effects described here can be attributed
solely to net charge. However a more subtle charge-related effect cannot be excluded
at this stage, as it has been suggested that critical antimicrobial effects may be
attributable to individual arginine residues, or to short positively charged fragments
of amino acids within cationic peptides (Shafer et ah, 1996).
While net charge appears not to be the sole determinant of elafin's
antimicrobial activity, a number of limited inferences can be made from trends
emerging in this chapter. For example for both PAOl and CI705 the most effective
concentrations of elafin (1 to 2.5pM, and 25pM respectively) were characterised by
a greater effect of the whole molecule than the sum of its component parts (Figures 5
and 8). This could be interpreted as indicating a synergistic effect of the two
domains, and possibly dual mechanisms of action. Curiously however, polypeptide
folding did not appear to be critical, as for both organisms unfolded elafin exerted an
antimicrobial effect, albeit weaker than that of the folded molecule. No firm
conclusions should be drawn from these observations, but it is tempting to speculate
that each of elafin's domains effect a separate antimicrobial function which is not
crucially dependent on tertiary structure.
A further interesting point in assessing the antimicrobial activity of elafin is
that the effects on PAOl and CI705 appeared to be quite distinct (compare Figures 5
and 8). In particular the effect of elafin on PAOl was maximal at low concentrations
while the effect on CI705 was maximal at higher concentrations. Similarly, while
high concentrations of the NH2-terminus appeared to have a significant antimicrobial
effect against PAOl, this moiety had minimal effect against CI705. Why elafin's
effect on PAOl should reveal an inverse dose-response relationship (Figure 3) is
unclear. One potential explanation could be that P. aeruginosa uses elafin as
nutrient, given the propensity of this organism to survive and grow in the presence of
limited nutritional sources (Terry et ah, 1991); a critical balance between elafin
killing bacteria on one hand and providing a source of nutrition on the other may be
tipped more in favour of killing at lower concentrations of elafin.
The emerging picture is of a complex interaction between elafin and
components of individual bacteria or classes of bacteria. This degree of complexity
is in keeping with recent observations made in relation to other antimicrobial
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peptides. For example it is now recognised that cationic peptides may have diverse
intracellular targets in addition to activity against cytoplasmic membranes (Xiong et
al., 1999; Friedrich et ah, 2000). Furthermore, it is now clear that cationic peptides
can interact not only with important components of Gram-negative bacteria such as
LPS (Scott et ah 2000), including that native to P. aeruginosa (Peterson et ah, 1985),
but also with critical structures of Gram-positive bacteria, such as teichoic acid in S.
aureus (Scott et ah, 1999). Additional complexity is afforded by the observation of
synergistic activity for endogenous antimicrobial peptides, as has been demonstrated
against S. aureus (Nagaoka et ah, 2000). This field of research continues to expand,
and it seems likely that the specific mechanisms responsible for elafin's antimicrobial
effect will be complex.
When considering the antimicrobial role of elafin in the broader context of
pulmonary defence, it is worthwhile first considering the known effects of elafin's
"sister molecule" SLPI, and the interactions between bacteria and protease inhibitors
generally.
SLPI has been shown to have activity against a wide variety of clinically
important micro-organisms. These have included bacteria such as Staphylococcus
epidermidis and Escherichia coli (Hiemstra et ah, 1996; Wiedow et ah, 1998), fungi
such as Candida albicans and Aspergillus fumigatus (Tomee et ah, 1997; Wiedow et
ah, 1998), and viruses such as Sendai virus, influenza A, and HIV-1 (McNeely et ah,
1995; McNeely et ah, 1997; Kido et ah, 1999). In the specific context of this study,
SLPI has been shown to have activity against S. aureus (Hiemstra et ah, 1996) and
P. aeruginosa (Wiedow et ah, 1998) and to bind LPS from P. aeruginosa (Ding et
ah, 1999). The antimicrobial activity of SLPI against S. aureus and P. aeruginosa in
comparable studies (Hiemstra et ah, 1996; Wiedow et ah, 1998) was more profound
than that described here (Figures 6 and 10). Interestingly, the studies of Hiemstra et
ah (1996) showed that the antimicrobial effects of SLPI were independent of the
molecule's anti-elastase activity, but in contrast to the findings described here for
elafin, they also described a profound effect for the structural NH2-terminus against
S. aureus. The lower levels of antimicrobial activity described for SLPI and the
relative inactivity of the NH2-terminus described in this work may reflect the
different strains of P. aeruginosa and S. aureus used. Both the considerable
homology between SLPI and elafin, and the broadly similar antimicrobial activities
described in this chapter (Figures 6 and 10) raise speculation as to whether elafin
may have similarly diverse patterns of antimicrobial activity. In this regard it is
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interesting that SLPI and elafin did not display synergistic activity against S. aureus
or P. aeruginosa, especially when significant synergistic interactions against E. coli
have been demonstrated for the combination of SLPI, lysozyme and lactoferrin
(Singh et ah, 2000).
Although the work described by Hiemstra et al. (1996) in relation to SLPI
and the results described here in relation to elafin clearly dissociate antimicrobial
activity from anti-elastase activity, this is not to say that bacteria cannot influence the
function of anti-elastases. It is known that elastase produced by P. aeruginosa and
protease produced by S. aureus can inactivate SLPI and cCj-PI, though interestingly
SLPI seemed considerably less susceptible to proteolytic degradation (Sponer et ah,
1991). Extending these observations, alginate, a characteristic product of mucoid P.
aeruginosa, has been shown to accelerate binding of SLPI to HNE but to inhibit
association of HNE and 0C]-PI (Ying et ah, 1996). These general principles can be
observed in other cationic antimicrobial peptides, in that defensins can block the
inhibition of HNE by 0Ci-PI (Panyutich et ah, 1995). In addition, whilst no direct
evidence exists to demonstrate an influence of proteases and antiproteases in the
adhesion of S. aureus to host tissues, it is intriguing that elastin-binding protein
should be considered an important determinant of Staphylococcal colonisation (Park
et ah, 1991). It is likely therefore that the complex interaction between elafin and
bacteria described here are still more complex in the infected and inflamed
respiratory tract.
SLPI and elafin therefore appear to join an impressive array of endogenous
human antimicrobial polypeptides, many of which are detectable in the lung. Perhaps
the best characterised of the endogenous pulmonary antimicrobial agents are the
defensins, which also exhibit a broad range of antimicrobial activity against Gram-
positive and Gram-negative pathogens, in addition to antiviral and antifungal
functions (Ganz et ah, 1985; Lehrer et ah, 1993). The inextricable link between
defensins and anti-elastases touched upon in Chapter 3 is thus reinforced in this
chapter, hinting at dynamic interactions between these groups of molecules (van
Wetering et ah, 2000). Among the other endogenous cationic antimicrobial peptides
potentially liberated into human airways are lactoferrin and lysozyme (Ellison and
Giehl, 1991), cathelicidins including LL-37/human CAP-18 (Bals et ah, 1998), and
BPI (Elsbach and Weiss, 1993). The relative contribution of these endogenous
peptides in health and during pulmonary inflammation has not yet been elucidated.
However it is interesting that, in a single study of patients free from infection and
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having bronchoscopy for investigation of suspected bronchial carcinoma, the most
prominent antimicrobial agents in BALF were lysozyme and human neutrophil
defensins 1, 2 and 3 (Schnapp and Flarris, 1998).
Several features of endogenous cationic antimicrobial peptides make them
attractive for therapeutic development. These include a broad-spectrum of
antimicrobial activity for most cationic peptides (Lehrer et ah, 1993; Turner et ah,
1998), and a tendency for synergy with conventional antibiotics (Giacometti et ah,
2000), presumably as a consequence of increased permeability of the cytoplasmic
membrane (Hancock, 1997). Additional attractions include the ability to clear
organisms associated with high levels of resistance to conventional antibiotics, as has
been demonstrated here for PAOl and by others (Turner et ah, 1998), and the
theoretical potential for reduced emergence of resistance to cationic peptides when
used in a therapeutic context (Hancock, 1997).
However cationic peptides could also present unique problems, dictating that
further characterisation of these molecules is required before their application is
broadened significantly. These problems include potential cytotoxicity when applied
to mammalian cells as has already been discussed in the context of the defensins
(Lichtenstein et ah, 1986), the recognition of inherent resistance to cationic peptides
in certain human pathogens (Groisman, 1994; Bayer et ah, 2000; MacFarlane et ah,
2000; Ganz et ah, 2001; Peschel et ah, 2001), and (specifically in the context of CF)
the ongoing debate as to whether cationic peptides are biologically active in the
presence of high salt concentrations (Smith et al, 1996; Goldman et ah, 1997b;
Nagaoka et ah, 2000; Travis et ah, 2000).
5.4. SUMMARY
The data in this chapter indicate that elafin has antimicrobial activity against
Gram-positive and Gram-negative respiratory pathogens. These findings add weight
to the theory that elafin may play an important role in innate immunity, being a
rapidly inducible antimicrobial agent expressed at epithelial surfaces, with the
potential to recruit neutrophils whilst protecting tissue against extracellular HNE and
proteinase 3.
172
This combination of properties, allied to the demonstration of efficient elafin
gene transfer to the murine lung, suggested that appropriate criteria prevailed to test
the hypothesis that genetic augmentation may confer protection in an animal model
of acute inflammatory lung injury.
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CHAPTER 6
THE EFFECT OF ELAFIN GENE AUGMENTATION ON ACUTE
LUNG INJURY MEDIATED BY PSEUDOMONAS AERUGINOSA
6.1. AIMS
The aim of the work in this chapter was to determine whether genetic
augmentation of human elafin could protect lung tissue in an animal model of acute
inflammatory injury. Experiments described in previous chapters demonstrated that
elafin augmentation was feasible using IT administration of Ad-elafm. They also
suggested that elafin may have an important role in early innate immunity. For a
number of reasons it seemed appropriate to study the effects of elafin augmentation
on acute lung injury induced by P. aeruginosa. For example, murine pneumonia is
readily induced by P. aeruginosa, novel strategies for elimination of this bacterium
are required on account of its pathogenicity and antibiotic resistance, and elafin has
in vitro effects both against the organism itself and against activated neutrophils.
6.2. RESULTS
6.2.1. Bacterial growth and MPO activity in lungs from normal C57/B16 mice.
The total cell count, differential cell count and protein concentration of
BALF from normal (untreated) mice were established in section 4.2.1., and act as
normal values for cross-reference. Extending these themes to the context of this
chapter, 4 normal mice were sacrificed for retrieval of BALF and lungs. BALF and
homogenised right lung from each of the mice was plated onto PIA without dilution
and no growth was detected. Left lungs were weighed and homogenised, and MPO
activity estimated. The median MPO activity in undiluted homogenate (assessed by
adding MPO-specific substrate and measuring change in absorbance at 630nm as a
function of time) was 84 absorbance units/minute. When corrected for weight the
median level was 0.88 absorbance units/minute/mg.
174
6.2.2. Preliminary experiments to determine the effects of P. aeruginosa on murine
lungs.
Preliminary experiments were performed to characterise the pulmonary
damage induced in murine lungs after IT administration of P. aeruginosa, and to
determine total lung MPO activity as a surrogate for neutrophil accumulation (Figure
1). All mice tolerated the procedure well. Administration of P. aeruginosa resulted
in a dose-dependent increase in BALF protein concentrations (taken to reflect
disruption of the alveolar-capillary membrane) (Figure 1). While protein
concentrations using the highest dose of P. aeruginosa were considerably above
normal at both time points analysed, injury appeared to be more pronounced at 4
hours than at 24 hours (Figure 1). In keeping with these findings bacteria were
isolated from lung in a dose-dependent fashion at both time points, many more
bacteria being isolated at 4 hours (Figure 1). However there was considerable
variability in the number of bacteria retrieved from individual mice.
MPO activity in homogenised lung approximated to normal levels in mice
receiving the lower dose of P. aeruginosa but showed an apparently sustained
elevation in mice receiving the higher concentration of bacteria (Figure 1).
It must be emphasised that a number of technical problems accompanied this
initial, preliminary experiment, and the results should be interpreted cautiously. For
example the initial dose of P. aeruginosa was suggested on the basis of historical
experience in the Department of Microbiology. The intention had been to produce
bacterial growth consistently at 24 hours, but this did not occur in this experiment.
Secondly, while the 24 hour time point was strictly observed, technical
considerations relating to the checking of absorbance of bacterial suspensions, and
the variable time taken for anaesthesia/dosing/repeat anaesthesia/organ retrieval
meant that "4 hours" in fact represented between 4 and 6 hours in practice. Thirdly,
lung MPO levels were not corrected for lung weight in this initial experiment.
Finally small numbers were studied, and thus comparison between groups is made
difficult by the inherent variability in bacterial counts.
Despite these experimental limitations, it seemed reasonable to make the
cautious conclusion that IT P.aeruginosa appears to be attended by rapid neutrophil
accumulation in the lung, and that the inflammatory process damages the alveolar-







































Figure 1. P. aeruginosa delivered IT is associated with lung injury in mice.
A suspension of P. aeruginosa PAOl was prepared with an absorbance at 590 nm of
1.42. The suspension was diluted 8-fold ('high dose') and 800-fold (Tow dose') in 0.01M
phosphate buffer. High dose or low dose was given IT to mice (40pl instillations, n=6 in
each group). From each group 3 mice were killed at 4 hours and 3 at 24 hours. Protein
concentration and colony count (on PIA) were determined in BALF. MPO was measured
in lung homogenates. Results are expressed as medians.
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capacity to clear P. aeruginosa rapidly.
On the basis of these findings a second preliminary experiment was
performed in which 5 mice received 40pl of IT P. aeruginosa suspension
(absorbance at 590nm of 1.45) and were killed 4 hours later. Median protein
concentration in BALF was 2.1 g/1 (range 0.7 - 3.8 g/1) and MPO activity in
undiluted lung homogenates (corrected for lung weight) were 3.25 absorbance
units/minute/mg. BALF and homogenised lung were diluted 100-fold in phosphate
buffer and applied to PIA overnight at 37°C. In 4 of the mice a lawn of bacteria
emerged precluding accurate colony counting. A few scattered colonies were found
in undiluted whole blood (range 0-17 colonies) and undiluted splenic homogenates
(range 2-8 colonies) applied to PIA. In the fifth mouse no colonies were found in
homogenised lung, and 7 colonies were found in undiluted BALF. Interestingly the
blood from this mouse yielded 42 colonies.
Together these experiments illustrated the capacity for P. aeruginosa to
injure lung tissue, but also exemplified technical difficulties and the variability in
response of individual mice.
Before proceeding to study whether Ad-elafin could protect the murine lung
against the effects of P. aeruginosa, it was also necessary to determine whether
adenoviral transfection altered the susceptibility of mice to "background" bacterial
infection/colonisation. Mice therefore received IT Ad-elafin (3xl07 pfu), Ad-lacZ
(3xl07 pfu) or PBS (n=4 in each group), followed 5 days later by IT administration
of PBS. The mice tolerated the procedure well and were killed 4 hours later.
Undiluted whole blood, homogenised spleen, homogenised lung and BALF were
plated onto PIA and no growth was detected in samples from any of the mice, thus
excluding propensity to colonisation with P. aeruginosa. Elafin was detectable in
BALF from all Ad-elafin mice (median 3.6 ng/ml) and undetectable in BALF from
control mice.
With these preliminary observations in place, experiments were performed to
establish the effect of Ad-elafin on lung injury mediated by P. aeruginosa at 4 hours
and 24 hours.
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6.2.3. The effect of Ad-elafin on lung injury induced by P. aeruginosa at 4 hours.
Mice received IT Ad-elafin (3x107 pfu), Ad-lacZ (3xl07 pfu) or PBS (n=4 in
each group), followed 5 days later by IT administration of P. aeruginosa PAOl
(40pl of a suspension with an absorbance at 590nm of 1.42). The mice were killed 4
hours later, with retrieval of BALF and lungs. Interestingly, the highest bacterial
counts were retrieved from Ad-lacZ treated mice, while a relative pulmonary
neutrophilia was found both in Ad-lacZ and Ad-elafin treated mice (Table 1). In
contrast, all groups had a modest elevation in BALF protein concentration, this being
least pronounced in the Ad-lacZ treated animals. Median elafin concentration in
BALF from Ad-elafin mice was 7.5 ng/ml (/?<0.001 when compared to mice
receiving PBS for 4 hours on day 5 as opposed to receiving P. aeruginosa for 4
hours).
The small groups studied precluded detailed conclusions, but it appeared that
Ad-elafin had no obvious protective effect in the first 4 hours after exposure to P.
aeruginosa. However technical difficulties continued to make adherance to the 4
hour time point difficult. This problem was compounded by the fact that inherent
variability in the biological responses of mice suggested that larger groups of mice
were required to observe meaningful differences. These considerations (along with
the experience gained in studying mice 24 hours after exposure to LPS as described
in Chapter 4) led to more detailed examination of the effect of elafin gene
augmentation on lung injury mediated by P. aeruginosa at 24 hours.
6.2.4. The effect of Ad-elafin on lung injury induced by P. aeruginosa at 24 hours.
The protocol designed for this set of experiments is summarised in Table 2.
The original intention was to study 20 mice in each group. However 2 mice died
immediately after the first anaesthesia. Two further mice (treated with Ad-elafin)
died immediately after anaesthesia on day 5. All of these mice appeared healthy and
well prior to anaesthesia. Finally, in two mice BALF could not be retrieved on
account of a leak of fluid from the lung caused by surgical trauma. Both death under
anaesthesia and surgical trauma to the lungs on dissection of the heart, lungs and
trachea from the thoracic cage are occasional complications of the procedure
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Table1.heffectofAd-ela inninjurymediatedbyITP.a rugi osat4o rs. Micere eiveda40plITinstillationofAd-lacZ(3xl 7pfu),Ad- lafin(3xl07 u)orPBS(n=4chgro p).F veysterllmice receiveda40plITinstillationofsus ensionfP.aerugi saAOlw thabs rbancet590 mf1.42.llmicwerk l d hourslater.BALFandlungswerer trieved.Me su m ntsp rformedoBALFi clu et talandiff tialc lount,ba r l colonyunt(onPIA)a dproteinc ncentra ion.B cte all nyu t(PIA)a dMPOctivitywerealsoestablishedi homogenisedlung.Resultsarexp essedmedians.
n DAYO DAY 5 DAY 6
Mice killed with retrieval of....
20 PBS P. aeruginosa SERUM for PAOl colony count.
SPLEEN for PAOl colony count.
20 Ad-lacZ P. aeruginosa
BALF for total cell count,
neutrophil count, macrophage
count; PAOl colony count;
concentrations of protein, albumin,
elafin, MPO, EIA, mKC.
20 Ad-elafin P. aeruginosa LUNGS for PAOl colony count,
MPO, histology.
Table 2. Outline of experiments to determine the effect of Ad-elafin transfection
on lung injury mediated by P. aeruginosa at 24 hours in C57/B16 mice.
C57/B16 mice received an IT instillation (40pl) of PBS or Ad-lacZ (3xl07 pfu) or Ad-
elafin (3xl07 pfu). Five days later, the mice in each group received IT P. aeruginosa
(34 pi). Twenty-four hours later mice were killed. Serum, spleen, BALF and lungs
were retrieved.
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Four aliquots of the bacterial suspension (absorbance at 590nm of 1.42-1.44)
prepared were plated on PIA immediately prior to dosing, and incubated overnight at
37°C. The mean colony count was 2.2xlOn cfu/ml.
The principal aim of this set of experiments was to determine whether Ad-
elafin protected the lung against acute inflammatory injury, as assessed by protein
concentrations measured in BALF. Ad-elafin was associated with a significant
reduction in acute lung injury (Figure 2). There was, none the less, considerable
variability in protein concentrations (as evidenced by the error bars in Figure 2), and
it was certainly not the case that all Ad-elafin treated mice were protected as
compared with controls. In assessing the degree of protection conferred, it is
necessary to recall the "normal" protein concentration in BALF, the median value
calculated in Chapter 4 being 0.45 g/1. The average degree of protection conferred in
this experiment therefore approximates to
[(median BALF protein concentration in control mice - 0.45 g/1) - (median BALF protein
concentration in Ad-elafin mice - 0.45 g/1)] + (median BALF protein concentration in control mice -
0.45 g/1)
Thus the average reduction in acute lung injury relative to Ad-lacZ mice was
approximately 43% and the average reduction relative to PBS mice was
approximately 46%.
A similar trend was observed when studying murine albumin concentrations
in BALF (Figure 3). The average concentration in Ad-elafin treated mice was
significantly lower than that in mice treated with PBS, with Ad-lacZ treated mice
having an intermediate level. Variability in BALF albumin levels was high,
emphasising the wide range of responses within each group of mice.
The BALF retrieved from control mice generally appeared haemorrhagic in
comparison with that from Ad-elafin mice. Histological apperances also suggested
less severe damage in Ad-elafin treated animals (Figure 4). Damage occurred in all
lobes of the lung, suggesting widespread distribution of the bacterial suspension.
Taking these strands of information together it appeared that control mice were
subject to a diffuse bronchopneumonia, characterised by pulmonary neutrophilia and












Figure 2. Ad-elafin significantly protects the murine lung against injury
mediated by P. aeruginosa.
Mice were treated as described in Table 2. Protein concentration was measured in
BALF.
For the PBS group n=18, for the Ad-lacZ group n=20, for the Ad-elafin group n=16.
Results are expressed as means and standard deviations.






Figure 3. Ad-elafin administration results in a relative reduction in BALF
albumin concentrations provoked by IT P. aeruginosa.
Mice were treated as described in Table 2. Albumin concentration was measured in
BALF.
For the PBS group n=18, for the Ad-lacZ group n=20, for the Ad-elafin group n=16.
Results are expressed as medians and interquartile ranges.
* = significant difference,p<0.05 when compared with the PBS group.
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Figure 4. Ad-elafin protects the lung against injury mediated by P.aeruginosa:
histology.
Mice were treated as described in Table 2. Lungs were removed, fixed in paraffin,
sectioned and stained with haematoxylin and eosin. Histological sections from
representative mice are shown. Marked protection is conferred by Ad-elafin.
PANEL A: IT PBS followed by IT P. aeruginosa.
PANEL B: IT Ad-lacZ followed by IT P. aeruginosa.
PANEL C: IT Ad-elafin followed by IT P. aeruginosa (original magnification x 40 in
each case).
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The Ad-elafin treated mice had a median elafin concentration in BALF of 8.5
ng/ml (interquartile range 5.9-10.4 ng/ml). Fifteen of the 16 mice had detectable
levels of elafin. None of the control mice had detectable human elafin.
The protection associated with elafin was accompanied by a significant
reduction in the number of P. aeruginosa colonies isolated from BALF (Figure 5).
The average number of colonies retrieved from the BALF of Ad-lacZ mice was
considerably lower than the number from PBS mice, but the difference did not
achieve statistical significance (Figure 5). With regard to the effect of Ad-elafin a
similar pattern was found when analysing the number of P. aeruginosa colonies in
whole lung homogenates there being, on average, markedly fewer colonies in lungs
from Ad-elafin treated mice (Figure 6). The differences noted in lung homogenates
approached, but did not reach, statistical significance (/?=0.08 when comparing Ad-
elafin and Ad-lacZ mice,/?=0.07 when comparing Ad-elafin and PBS mice). It
should be emphasised that the ordinate describes a logarithmic scale in Figures 5 and
6. Among Ad-elafin mice there was a significant negative correlation between the
elafin concentration in BALF and the (log transformed) P. aeruginosa colony count
in both BALF (r=-0.75,/?<0.05), and lung (r=-0.85,/><0.01).
The trend for more effective elimination of bacteria in Ad-elafin treated mice
was also observed in whole blood and spenic homogenates applied to P1A. Colonies
were detectable in the blood of 31% of Ad-elafin mice as opposed to 44% of Ad-
lacZ mice and 61% of PBS mice. Similarly colonies were detectable in splenic
homogenates from 19% of Ad-elafin mice in contrast to 40% of Ad-lacZ mice and
44% of PBS mice.
With regard to the cellular content of BALF, no significant difference was
found in the total cell count or neutrophil count when comparing the 3 groups of
mice (Figures 7 and 8). There was a trend for virus-treated mice to have lower cell
counts than PBS treated animals, but this did not attain statistical significance.
In contrast Ad-elafin treatment was associated with a trend towards lower
levels of neutrophil recruitment to the lung as manifest by a lower level of MPO
activity in lung homogenates (Figure 9). While the available volumes of BALF
limited the opportunities to measure multiple neutrophil chemokines, the level of
mKC was kindly measured by Professor T. Standiford and colleagues (Ann Arbor,
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Figure 5. Ad-elafin administration significantly increases clearance of P. aeruginosa
from BALF.
Mice were treated as described in Table 2. P. aeruginosa colony counts were established
in BALF.
For the PBS group n=18, for the Ad-lacZ group n=20, for the Ad-elafin group n-16.
Results are expressed as medians and interquartile ranges.














Figure 6. Ad-elafin administration is associated with increased clearance of P.
aeruginosa from lung.
Mice were treated as described in Table 2. P. aeruginosa colony counts were
established in homogenised lung.
For the PBS group n=20, for the Ad-lacZ group n=20, for the Ad-elafin group n=16.
Results are expressed as medians and interquartile ranges.










Figure 7. Total cell count in BALF from mice receiving IT P. aeruginosa.
Mice were treated as described in Table 2. The total cell count in BALF was established.
For the PBS group n=18, for the Ad-lacZ group n=20, for the Ad-elafin group n=16.
Results are expressed as medians and interquartile ranges.







Figure 8. Neutrophil count in BALF from mice receiving IT P. aeruginosa.
Mice were treated as described in Table 2. The neutrophil count in BALF was
established.
For the PBS group n=17, for the Ad-lacZ group n=19, for the Ad-elafin group n=16.
Results are expressed as medians and interquartile ranges.








Figure 9. MPO activity in homogenised lungs from mice receiving IT P.
aeruginosa.
Mice were treated as described in Table 2. The MPO level in homogenised lung was
established.
For the PBS group n=20, for the Ad-lacZ group n=17, for the Ad-elafin group n=14.
Results are expressed as medians and interquartile ranges.
No significant differences were observed when comparing groups.
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in Ad-elafin mice, 0.34 ng/ml in Ad-lacZ mice, and 0.25 ng/ml in PBS mice;
significant difference comparing Ad-elafin and Ad-lacZ mice,/?<0.05). Similarly,
there was a suggestion that Ad-elafin treatment was associated with inhibition of
neutrophil degranulation in that there was less MPO detectable in BALF from Ad-
elafin mice (Figure 10). While the trend in all these neutrophil-related parameters
was towards a reduction among Ad-elafin mice, it must be stated that the only
statistically significant difference was as described for mKC comparisons. In
keeping with all parameters measured in these experiments, there was considerable
variation in the values obtained from mice within the same group (as reflected in the
error bars in Figures 9 and 10).
In contrast, a different pattern was observed when considering macrophage
counts in BALF. Median macrophage count (and interquartile range) was 300000
(150000-510000) for PBS treated mice, 220000 (120000-460000) for Ad-lacZ
treated mice and 310000 (170000-560000) for Ad-elafin treated mice (no significant
difference between groups).
Despite the striking influx of neutrophils to airways and lung parenchyma in
each of the groups studied, no mouse was found to have spontaneous elastase
activity in BALF. As such a relative excess of elastase inhibitors prevailed in all
mice. The average EIA was in the low pM range for all groups studied, but was
lower in the Ad-elafin mice than in either of the control groups, the difference
becoming statistically significant when comparing Ad-elafin and PBS mice (Figure
11). In the Ad-elafin mice, human elafin appears to have contributed less than 1% of
the measured EIA. This observation is based on the following assumptions:
if it is assumed that the elafin produced has a molecular mass of around 10 kDa, then
the average elafin concentration in BALF of 8.5 ng/ml predicts for a concentration of
0.85 nM. If all of the elafin were assumed to be active (and given that the average
EIA in BALF from Ad-elafin mice was 0.73 pM) then the contribution of human
elafin to total EIA would be approximately (0.85 nM x 100) 730 nM = 0.12%.
A strong correlation was found between EIA and protein concentration in
BALF, suggesting that EIA may have developed in response to injury in this model
(Figure 12). Protein concentration in BALF also correlated with other markers of
lung injury (for albumin concentration r=0.87,/?<0.0001), with bacterial indices (for
bacteria in BALF r=0.67,/?<0.0001; for bacteria in lung r=0.60,/?<0.0001), and with








Figure 10. MPO activity in BALF from mice receiving IT P. aeruginosa.
Mice were treated as described in Table 2. The MPO activity in BALF was
established.
For the PBS group n=17, for the Ad-lacZ group n=20, for the Ad-elafin group n=16.
Results are expressed as medians and interquartile ranges.








Figure 11. Ad-elafin administration is associated with a relative reduction in the
elastase inhibitory activity of BALF from mice treated with IT P. aeruginosa.
Mice were treated as described in Table 2. EIA was measured in BALF.
For the PBS group n=18, for the Ad-lacZ group n=20, for the Ad-elafin group n-16.
Results are expressed as medians and interquartile ranges.
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Figure 12. EIA and protein concentration are closely correlated in BALF after
injury with IT P.aeruginosa.
Mice were treated as described in Table 2. EIA and protein concentration were
measured in BALF.
The correlation described is statistically significant (r=0.82; a>=0.0001).
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BALF r=0.75,/><0.0001). No significant correlation was found between protein
concentration and macrophage count in BALF.
6.3. DISCUSSION
The principal finding in this chapter relates to the significant tissue protection
conferred by Ad-elafin in an animal model of acute inflammatory lung injury.
Discussion of these data will focus on the model used to initiate lung injury, on the
role of elafin (and adenovirus) in effecting protection, and on the emerging potential
for gene therapy strategies in models of pulmonary infection.
6.3.1. Lung injury induced by P. aeruginosa PAO1.
Lung injury induced by P. aeruginosa is well described and has for example
been demonstrated using strain PAOl (George et ah, 1993). Two broad categories of
model exist, the first involving IT instillation of a slurry of P. aeruginosa laden
microscopic beads, and the second involving IT instillation of a bacterial suspension
in the absence of beads. In general the peak of lung injury is produced later in the
bead model (as for example in van Heeckeren et ah, 2000). It should be noted that
murine models of P. aeruginosa lung injury described in the literature commonly use
different bacterial strains and are applied to a variety of different strains of mouse, so
difficulties exist in attempting to extrapolate from one study to another.
In this study damage was readily induced in the lungs of mice 24 hours after
IT instillation of P. aeruginosa as reflected in the haemorrhagic appearance of BALF
and histological appearances of lungs from control mice (Figure 4). Indeed the
bronchopneumonia induced in this study was typical of that described elsewhere (as
for example in Gosselin et ah, 1998). The principal end-point used to assess alveolar
epithelial injury in this study was the protein concentration in BALF. This
measurement is widely used as a marker of lung injury, and increased concentrations
are thought to represent significant leak across a disrupted alveolar-capillary
membrane (reviewed by Pittet et ah, 1997). The technique is simple and
reproducible, and unlike other methods for measuring alveolar-capillary leak avoids
the requirement for systemic infusion of, for example, radioactivity or marker dye.
Potential problems in measuring protein concentration include the inability to extract
insoluble "hyalinised" protein in severe lung injury, and the fact that passage of ions,
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proteins and fluid across the alveolar-capillary membrane is a dynamic and rapidly
changing process (Folkesson et ah, 1991; Hastings et al., 1992; Pittet et ah, 1997).
With regard to the latter issue Figure 1 illustrated that a relatively low dose of P.
aeruginosa appeared to cause rapid disruption of epithelial integrity by 4 hours, with
a reduction in injury by 24 hours, potentially reflecting early resolution and repair. In
contrast, the higher dose of P. aeruginosa used in the main body of experiments
appeared to induce relatively mild damage at 4 hours, with pronounced damage
evident at 24 hours (compare protein concentrations in Table 1 and Figure 2).
Against this background the question of bacterial clearance by control mice is
important to the model used here, both for understanding the potential protective
effects of human elafin, and for attempting to assess whether bacterial or host
mediators are responsible for lung damage.
Importantly there can be no doubt that mice in this study had considerable
capacity to clear P. aeruginosa, as in control mice the bacterial yield from BALF and
lung was still far below the instilled dose, despite the significant lung damage
experienced (Figures 5 and 6). The clearance pattern in the model described here is
very similar to that reported elsewhere in C57/B16 mice administered PAOl
(Cressman et al., 1998) or a PAOl auxotroph (Yu et al., 1998). It seems likely that a
variety of mechanisms are involved in the clearance of P. aeruginosa from control
mice, with important roles being ascribed to the CXCR2 receptor (Tsai et al., 2000),
surfactant protein-A (LeVine et al., 1998), IL-4 (Jain-Voro et al., 1998), and IL-10
(Yu et al., 1998), although the latter mechanism may not be applicable in PAOl
infections (Sawa et al., 1997). Intuitively it seems likely that antimicrobial molecules
expressed in the airways contribute to bacterial clearance in mice. Certainly in
humans several antimicrobial agents are found in airway secretions under basal
conditions (Travis et al., 1999). Interestingly, the ability of mice within each control
group to clear bacteria was subject to enormous variation, and indeed variability of
biological response was a characteristic of all measured parameters in this chapter.
The model described here was also consistent with published observations
regarding the relative kinetics of bacterial eradication and neutrophil influx (Jain-
Voro et al., 1998), both being considerably enhanced at 24 hours as compared with
4-6 hours (compare Table 1, Figure 5 and Figure 8). Against this background, the
question of whether the major contribution to lung injury in control mice is from
bacterial products or host inflammatory cells is difficult to answer. Theoretical
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arguments relating to the potential of both P. aeruginosa and neutrophils to damage
lung tissue during episodes of infection have been well developed (Weiss, 1989;
Fick, 1989; Goldberg and Pier, 1996). In the context of this study the increase in
BALF protein concentration appeared to be paralleled by increasing neutrophil
accumulation at a time when bacterial counts were falling dramatically (compare
Table 1, Figure 5 and Figure 8). This may support a role for neutrophils in effecting
damage, as may the observation that free MPO was readily detectable in BALF from
control mice, suggesting degranulation, and by inference activation (Figure 10).
Furthermore in human pneumonia metabolic activity of neutrophils appears to be a
post-migratory event (Jones et ah, 1997). In contrast, it may be argued that damage
(albeit mild) was induced 4 hours after administration of P. aeruginosa at a time
when bacteria were prevalent and neutrophil accumulation was low (Table 1).
Furthermore, the level of neutrophil accumulation at 4 hours (Table 1) was lower
than that described in response to LPS in Chapter 4 (Figure 5), when no lung injury
was detected. A similar argument has been forwarded to suggest that neutrophils are
not important in mediating lung injury upon administration of P. aeruginosa in rats
(Delclaux et ah, 1997).
It is important to acknowledge that the model described here was not
designed to distinguish between the relative contributions to injury from bacteria and
neutrophils. On balance it seems there is no firm evidence to suggest predominance
of either mechanism, but there is a suggestion that bacteria may make a contribution
to early lung damage, while neutrophils may contribute to damage in later stages.
A few technical points relating to the model described in this chapter should
be mentioned. Firstly, the sudden, massive administration of bacteria to generate
lung injury in no way resembles the pathogenesis of pneumonia under "natural
circumstances". It is important to emphasise that the primary intention of this study
was to examine the effects of Ad-elafin on acute lung injury, rather than to model
acquired pneumonia. Irrespective of these considerations, the histological end-point
was typical for bronchopneumonia (Figure 4). In this setting it is worth noting that
the dose of P. aeruginosa used here (approximately 2.2x1011 cfu/ml, or
approximately 7.5x109 cfu per instillation) is higher than that used in most other
studies of experimental pneumonia. Why this dose should have been required to
achieve reproducible sublethal pneumonia in the mice studied here is unclear.
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Secondly, the method of IT administration does involve using a small head of
pressure (generated by air in a syringe barrel) to propel instillate, and a minor
element of barotrauma in delicate mouse lung cannot be excluded. However this
technique was constant for mice in all groups, and it seems unlikely that it
contributed to alveolar damage as protein levels in mice receiving no instillate were
similar to those receiving PBS alone (see Chapter 4).
Thirdly, the protection conferred by Ad-elafin should potentially be set
against the observation that 2 mice died under anaesthesia 5 days after receiving Ad-
elafin. However it seems highly unlikely that Ad-elafin is associated with an
increased susceptibility to anaesthetic complication, as anaesthetic deaths occur
periodically in mice and no other Ad-elafin treated mice died under these
circumstances (either in these experiments or in those described in Chapter 4).
Furthermore the 2 mice in question appeared healthy before the anaesthetic, and the
most likely scenario is that the deaths of these mice was related to an idiosyncratic
response to anaesthetic rather than to any effect of elafin.
Fourthly, the absence of P. aeruginosa in untreated animals or in virus
treated animals not exposed to IT bacteria effectively excluded background
colonisation with P. aeruginosa.
Finally, it should be emphasised that the relatively non-invasive method of IT
delivery in this model (as opposed to the traditional method of surgical exposure of
the trachea, followed by cannulation, instillation and closure of the wound) was
designed to minimise systemic upset.
6.3.2. The role of Ad-elafin in conferring protection against lung injury mediated
by P. aeruginosa.
The protection conferred by Ad-elafin against Pseudomonas lung injury is
best exemplified by the significant reduction in BALF protein (Figure 2). At the time
of writing I am not aware of other studies describing a protective effect for
molecules with dual anti-elastase/antimicrobial activity against bacterial lung injury
in vivo. The magnitude of the protective effect is worthy of attention. On one hand it
could be argued that the protection was variable, and indeed ineffective in certain
mice. On the other hand, bearing in mind the complexity and redundancy inherent in
acute inflammation (as described in section 1.2.), it could be argued that a reduction
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in severe lung injury of over 40% following a low dose of a single protective vector
is extremely encouraging.
The protection was accompanied by the presence of human elafin in murine
airways. Two interesting points arise in connection with the elafin concentrations
detected in BALF. Firstly, in keeping with data in Chapter 4 (Figure 7), Ad-elafin
mice exposed to P. aeruginosa for 4 hours had significantly higher elafin levels than
did those exposed to PBS. These data again suggest the ability of the mCMV
promoter to be activated by inflammatory stimuli. Secondly however, the magnitude
of the rise in elafin concentration after application of bacteria was much smaller than
that in response to E. coli LPS in Chapter 4 (median elafin levels 24 hours after P.
aeruginosa 8.5 ng/ml as opposed to 120 ng/ml 24 hours after LPS (Figure 7, Chapter
4)). The implication would appear to be either that different inflammatory stimuli
have different effects on the mCMV promoter and/or that elafin is less easily
detectable (perhaps due to binding or degradation) in more complex inflammatory
BALF.
Earlier chapters have demonstrated the ability of elafin to eradicate bacteria
and to influence damage associated with both elastase and whole activated
neutrophils in vitro. As mentioned in section 6.3.1. neither bacteria nor neutrophils
emerge as the predominant mediator of injury in the model described in this chapter,
and the protection conferred by Ad-elafin is associated with reductions in both
bacterial numbers (Figures 5 and 6) and neutrophil-related parameters (Figures 9 and
10). Therefore it is perhaps not surprising that no definitive mechanism emerges to
explain protection. Nevertheless, some informative observations can be made.
For example the protection in Ad-elafin treated mice was accompanied by a
significant reduction in bacteria retrieved from BALF (Figure 5) and the only
parameters to correlate significantly with BALF elafin concentration in this study
were the (log transformed) bacterial counts in BALF and lung. This implies (but
does not confirm) an important antimicrobial action for elafin in this system. It is
notable that the reduction in colonies retrieved from homogenised lung in Ad-elafin
mice did not quite attain statistical significance, though there was a trend in this
direction. In many respects BALF is the preferred medium for assessing the effect of
Ad-elafin on bacterial counts, partly because elafin is a secreted protein, and partly
because BALF should reflect the "average" effect from all airways. In contrast, lung
colonisation was assessed only in the right lung of each mouse, and it is feasible that
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distribution of instillate may favour one lung over another in individual mice, thus
introducing variability into the measurement. Importantly, Ad-elafin seemed to be
capable of inhibiting haematogenous spread of Pseudomonas as reflected in lower
rates of bacteria in whole blood or spleen.
The feasibility of elafin as a direct antimicrobial moiety in this system is
supported by the data in Chapter 5 and by the ability of cationic antimicrobial
peptides to bind Pseudomonas LPS in vitro (Peterson et al., 1985). Furthermore the
human cathelicidin CAP-18 can augment antimicrobial function in a CF bronchial
xenograft model (Bals et al., 1999a), and protect mice against the effects of P.
aeruginosa in vivo either when administered as synthetic peptide (Kirikae et al.,
1998) or via an adenoviral vector (Bals et al., 1999b).
If the effect of Ad-elafin in this model is indeed to eradicate bacteria
independently of the effect of neutrophils, it must be re-emphasised that the effect is
not protective in all mice, and that the effect must be additive to that of powerful
endogenous clearance mechanisms. Furthermore, although the numbers of mice
studied in Table 1 are small, it would appear that elafin exerts its principal effect
after 4 hours, at which point bacterial loads are already falling. The inference may be
that elafin has an indirect antimicrobial effect through induction of as yet
unidentified mechanisms.
Elafin's capacity to inhibit elastase clearly raises the possibility of an anti-
elastase effect in mediating protection in the model described here. Certainly elastase
is a feasible mediator of lung injury both in pneumonia generally, and in the setting
of airway disease associated with Pseudomonas. For example free, active elastase
can be retrieved in BALF from humans with pneumonia (Boutten et al., 1996), and
elastase activity in circulating granulocytes is increased during experimental canine
pneumonia (Lonky et al., 1980). In the context of P. aeruginosa associated with CF,
HNE appears to be able to reduce opsonisation and phagocytosis by cleaving
complement receptors on neutrophils (Berger et al., 1989; Tosi et al., 1990), while
evidence suggests that FINE (as opposed to Pseudomonas proteases) is a key
mediator of lung injury (Meyer and Zimmerman, 1993; Venaille et al., 1998). In
specific relation to experimental pneumonia associated with PAOl, free elastase
activity is generated in hamster airways after IT administration (Melby et al., 1985).
Finally, Pseudomonas elastase is capable of inactivating human ai-PI and SLPI
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(Sponer et al., 1991) and it remains feasible that anti-elastases are functionally
depleted in the presence of P. aeruginosa.
Despite this background however, no elastase activity was detected in BALF
from any of the mice studied in this chapter. Indeed, the EIA was lower in Ad-elafin
mice than in controls (Figure 11), and human elafin was calculated to comprise less
than 1% of the EIA, if indeed it contributed at all. It must therefore be concluded that
the effect of Ad-elafin in this study is not attributable to inhibition of free elastase in
the airways. Attention should therefore be turned to the number and function of
neutrophils if an anti-neutrophil activity of Ad-elafin is to be invoked. Before doing
so however, it is worth briefly considering the EIA in these experiments. Both the
reduction in EIA in Ad-elafin mice (Figure 11) and the strong correlation between
EIA and protein concentration in BALF (Figure 12) suggest that EIA is generated as
a response to injury. A similar effect has been described in humans with acute lung
disease (Sallenave et ah, 1999b). The exact composition of the EIA remains
unexplained, and the tools to dissect this question were not immediately available at
the time these experiments were performed. With regard to the two major
antiproteinases in murine serum, 0Cj-PI is thought not to be a significant acute phase
reactant (Baumann et ah, 1983), and contrapsin does not inhibit elastase (Takahara
and Sinohara, 1983). Interestingly, murine SLPI mRNA levels are significantly
increased in the lungs of C57/B16 mice exposed to Streptococcal pneumonia (Abe et
ah, 1997) and murine SLPI may potentially have contributed to EIA in this study.
Whether Ad-elafin's protective effect in this model had anything to do with
neutrophil migration is debatable. The absolute number of neutrophils in BALF from
Ad-elafin mice was in fact higher than in Ad-lacZ mice, despite injury being
significantly less in the former group (compare Figures 2 and 8). However there was
a trend towards fewer neutrophils in lung tissue among Ad-elafin mice (Figure 9). At
this juncture it is worth reflecting that Ad-elafin administration was associated with a
significant increase in neutrophil recruitment in Chapter 4 (Figure 5). In interpreting
this apparent discrepancy it should be observed that BALF neutrophil counts in
PBS/Pseudomonas mice in this chapter are 13 times higher than those in PBS/LPS
mice described in Chapter 4 (Figure 5), reflecting the much more potent
inflammatory stimulus in this chapter. Furthermore, elafin levels were 14 times
higher in Ad-elafin/LPS mice (Figure 7, Chapter 4) than in Ad-e\afm/Pseudomonas
mice in this chapter. It remains feasible that elafin may only facilitate neutrophil
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recruitment when in high concentration and/or in the presence of intact lung
parenchyma.
On balance the small, statistically non-significant difference between
neutrophil counts in Ad-lacZ and Ad-elafin mice (Figures 8 and 9), and the striking
difference in BALF protein levels when comparing the same groups mitigates
against a direct role for neutrophil migration in explaining the protective effect of
Ad-elafin.
In considering whether Ad-elafin's protective effect is via an effect on
neutrophils, it is finally necessary to consider neutrophil activation. Figure 10
suggests that Ad-elafin administration was associated with markedly reduced
degranulation of airway neutrophils in some mice, though the variability in
individual mice dictated that the effect was not statistically significant. This raises
the intriguing possibility that elafin may inhibit degranulation of neutrophils, which
could theoretically explain the tissue protection conferred in the experiments
described in this chapter, and the lack of tissue damage despite a doubling in airway
neutrophils in Chapter 4, Figure 5. It must be emphasised that there is no firm
evidence to support this hypothesis, and it should therefore be regarded simply as an
area requiring further attention.
Turning briefly to the role of macrophages, it is unlikely that these cells
induced tissue injury associated with P. aeruginosa, as numbers were higher in Ad-
elafin mice than in controls. It is worth recalling that alveolar macrophages were also
increased among Ad-elafin/LPS mice in Chapter 4, and an effect of elafin on
macrophage recruitment cannot be excluded at this point.
In attempting to summarise this section it is clear that Ad-elafin augmented
the defence of murine airways against P. aeruginosa. While the mechanism involved
is not clear, the available evidence suggests that it is at least in part mediated by
acceleration in the rate of bacterial clearance, whether this effect be direct or
indirect.
6.3.3. The potential protective effect of Ad-lacZ.
At various points in this chapter a trend has arisen towards a protective effect
against Pseudomonas in Ad-lacZ treated mice as compared with PBS treated mice.
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This was particularly striking when considering bacterial load in BALF (Figure 5),
but was also apparent when considering albumin concentration and neutrophil count
in BALF (Figures 3 and 8), and the number of Pseudomonas colonies retrieved from
blood and spleen. Furthermore, BALF protein concentration was lower in Ad-lacZ
treated mice than in PBS treated mice studied 4 hours after administration of
Pseudomonas (Table 1). This trend is to some degree mirrored by relative reductions
in HNE-mediated cell detachment (Chapter 3, Figure 8), LPS-mediated neutrophilia
(Chapter 4, Figure 5), and IL-8 levels released from A549 cells (Chapter 4, Figure
11). It must be strongly emphasised that none of these differences reached statistical
significance (indeed no significant differences were found comparing vehicle
treatment with Ad-lacZ treatment in vitro or in vivo in any of the experiments
described in this thesis). Furthermore, a pro-inflammatory tendency was observed for
Ad-lacZ when studying neutrophil migration in vitro (Chapter 4, Figure 10).
Nevertheless the apparent trend towards a protective effect of Ad-lacZ in vivo
is intriguing and to some extent is consistent with findings elsewhere. For example
replication deficient adenovirus has been shown to stimulate clearance of
Helicobacterfelis from the stomach of C57/B16 mice in an IL-12- and IFN-y-
dependent manner (Jiang et ah, 1999), and a similar null adenovirus appeared to
enhance clearance of P. aeruginosa PAOl from the lungs of rats (Worgall et ah,
1999b). The implication may be that low grade stimulation of innate or adaptive
immunity by adenovirus may promote bacterial clearance under specific conditions.
This may suggest potential therapeutic applications, and in this context it is worth
noting that reduction in tumour size has been linked to the immunogenicity of
adenoviral vectors in animal models (Song et ah, 1997b).
6.3.4. Gene therapy for pulmonary infection.
The finding that Ad-elafin confers protection against acute inflammatory lung
injury mediated by P. aeruginosa adds to emerging data describing a role for gene
therapy in infection.
To a large extent this field evolved with the concept that key cytokines play
impotant roles in the regulation of inflammation. For example adenovirus encoding
IL-12 was shown to protect mice against the lethal effects of Klebsiella pneumoniae
(Greenberger et ah, 1996). At around the same time it was demonstrated that IL-10
gene therapy could dampen the expression of inflammatory cytokines in murine
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endotoxaemia (Xing et al., 1997), with subsequent demonstration that adenovirus
encoding IL-10 could protect against tissue injury in a porcine model of pneumonia
induced by Actinobacilluspleuropneumoniae (Morrison et al., 2000).
Extending this theme further, IT adenoviral transfer of interferon-y has been
shown to enhance clearance of P. aeruginosa from the lungs of rats (Lei et al.,
1997). This intervention was also demonstrated to enhance eradication of
Pneumocystis carinii in an elegant model of pulmonary infection in CD4 depleted
mice (Kolls et al., 1999).
These intriguing strategies have been accompanied recently by novel variants
all concerned with clearance of Pseudomonas. For example it was demonstrated that
pulmonary host defences are impaired during systemic sepsis partly on account of
local TNF depletion, and that IT TNF gene therapy restored clearance of P.
aeruginosa from the lung in the course of experimental sepsis (Chen et al., 2000). In
addition, a strategy aimed at directly enhancing antimicrobial activity in the lung
showed that adenovirus encoding the endogenous antibiotic CAP-18 enhances
clearance of P. aeruginosa (Bals et al., 1999b). Finally, a fascinating strategy using
adenovirus encoding Fey receptors conferred the capacity for phagocytosis on
pulmonary epithelial cells, thus enhancing clearance of P. aeruginosa (Worgall et
al., 1999b).
While the work presented in this chapter and the studies described in this
section suggest novel therapeutic strategies for acute bacterial lung injury, it should
be noted that all of the interventions used were preventive in that gene therapy was
administered prior to bacterial pathogens. A major challenge will be to develop gene
therapy strategies which promote resolution of pre-existing pulmonary inflammation.
It is already known that such inflammation impairs the transfer of adenovirus (Otake
et al., 1998; van Heeckeren et al., 1998), and imaginative strategies will be required
to define and overcome the barriers to effective transfection.
In summary, the work in this chapter has demonstrated that elafin gene
augmentation is capable of reducing tissue injury in an animal model of acute
inflammation mediated by P. aeruginosa, an organism associated with intrinsic
antimicrobial resistance. This effect was achieved using a single IT administration of
adenovirus at a dose previously shown to produce minimal vector-induced
inflammation. Although the mechanism of protection remains uncertain, the
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available evidence suggests that enhanced clearance of bacteria was at least partly
responsible.
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CONCLUDING REMARKS AND FUTURE DIRECTIONS
The experiments described in this thesis have confirmed that elafin gene
augmentation is feasible both in vitro and in vivo. They have shown that elafin
augmentation protects pulmonary epithelium against damage mediated by HNE and
by activated human neutrophils. This led to experiments demonstrating that elafin
gene augmentation may enhance LPS-mediated pulmonary neutrophilia in mice. The
characteristics of elafin suggested intrinsic antimicrobial properties, and these were
confirmed by demonstrating activity against Gram-positive and Gram-negative
pulmonary pathogens.
These data prompted experiments in which elafin gene augmentation was
found to confer murine lungs with significant protection against sublethal pneumonia
induced by P. aeruginosa. Collectively these findings infer an important role for
elafin in host innate immunity and suggest that elafin gene augmentation may have
therapeutic potential.
An additional finding was that elafin expression could be achieved using
doses of adenovirus low enough to circumvent overt vector-induced inflammation.
Furthermore it was found that the mCMV promoter within the Ad-elafin vector was
markedly up-regulated in response to inflammatory stimuli, as reflected by a 20-fold
increase in elafin expression in response to LPS in vivo. Together these findings
suggest means of optimising expression in adenoviral gene therapy protocols whilst
minimising viral toxicity.
While these experiments may have furthered understanding of elafin biology
and of the potential application of antiproteases in gene therapy protocols, a huge
number of important questions remain unanswered and should form the focus of
future research.
For example the interaction of elafin with other molecules central to innate
immunity requires to be elucidated, including the relationship with other anti-
elastases in clearing HNE from the airways and interstitium. The role (if any) for
interstitial binding of elafin in inflammatory responses requires to be characterised in
the lung. The effect of oxidants on the methionine in the active site of elafin requires
attention, as does the question of whether elafin fragments found in human airway
secretions retain biological activity. The effect of elafin on neutrophil and alveolar
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macrophage function requires definition, and the conditions under which elafin helps
recruit neutrophils need to be clarified. Importantly the mechanism for elafin's
antimicrobial activity also requires to be unravelled.
Finally, this work set out with the ultimate aim of determining whether elafin
gene augmentation could protect tissue against inflammatory injury. While the
principle of protection has been demonstrated by delivering Ad-elafin prior to
application of injurious stimuli, it remains to be seen whether (and under which
conditions) elafin gene augmentation can ameliorate existing inflammation.
Dissecting these questions may allow further progress towards the goal of defining
conditions for safe, effective, and sustained gene therapy.
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PUBLICATIONS ARISING FROM THIS WORK
Three publications have arisen directly from the work presented in this thesis.
Copies are found in the following section.
In addition I contributed to one other original paper during my time in the lab
(Sallenave et al., 1998), and to a review article on respiratory gene therapy (Simpson
et al., 2000). Copies of these articles are not included in the following section, but
both are cited in the body of the thesis.
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During acute pulmonary infection, tissue injury may be secondary to the effects of bacterial products or to the effects of the host
inflammatory response. An attractive strategy for tissue protection in this setting would combine antimicrobial activity with
inhibition of human neutrophil elastase (HNE), a key effector of neutrophil-mediated tissue injury. We postulated that genetic
augmentation of elafin (an endogenous inhibitor of HNE with intrinsic antimicrobial activity) could protect the lung against acute
inflammatory injury without detriment to host defense. A replication-deficient adenovirus encoding ciafin cDNA significantly
protected A549 cells against the injurious effects of both HNE and whole activated human neutrophils in vitro. Intratracheal
replication-deficient adenovirus encoding ciafin cDNA significantly protected murine lungs against injury mediated by Pseudo-
monas aeruginosa in vivo. Genetic augmentation of elafin therefore has the capacity to protect the lung against the injurious effects
of both bacterial pathogens resistant to conventional antibiotics and activated neutrophils. The Journal of Immunology, 2001,
167: 1778-1786.
Toxic products released by neutrophils, especially humanneutrophil elastase (HNE).3 have been implicated in thepathogenesis of a variety of inflammatory disorders char¬
acterized by pulmonary neutrophilia, including cystic fibrosis
|(CF). non-CF bronchiectasis, emphysema, and bacterial pneumo-
hia (1—4). The therapeutic rationale for depleting circulating neu¬
trophils in such conditions is negated by the propensity for over¬
whelming sepsis in neutropenic patients and by the observation
that mice deficient in neutrophil elastase are predisposed to Gram-
negative sepsis (5). This argument applies especially in the context
of bacterial pneumonia. In such situations, inhibition of extracel¬
lular HNE by agents also possessing antimicrobial properties
would be an attractive strategy in attempting to protect the lung
from inflammatory injury.
Inhibitors of HNE are thought to comprise part of the human
innate immune system. Three distinct antielastases have been de¬
scribed in the human lung; o,-protease inhibitor, secretory leuko¬
cyte protease inhibitor (SLPD- and elafin (elastase-specific inhib¬
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itor) (6). Elafin (7, 8) is a potent inhibitor of HNE and proteinase
3 produced in the skin (9-11). and in the airways (12). which is
up-regulated in response to early inflammatory cytokines such as
TNF and IL-1 (13). Elafin. along with SLPI. also shares charac¬
teristics with antimicrobial defensin-like molecules in being a low
m.w. cationic peptide with the ability to eliminate pulmonary
pathogens (14-16).
We therefore hypothesized that local augmentation of elafin by
constitutive lung cells would confer protection against inflamma¬
tory injury, especially when the lung was challenged by bacterial
pathogens. In these studies, we used an adenoviral gene transfer
approach for a number of reasons, including the natural tropism of
adenovirus for the respiratory epithelium, the potential to regulate
transgene expression using carefully selected promoters (17. 18).
and the well-described ability to express antielastases in the lung
using adenoviral gene therapy (17, 19). Against this background,
we demonstrate for the first time that A549 cells transfected with
adenovirus encoding human elafin in vitro protects not only
against HNE-induced damage but also against injury caused by
primed and activated human neutrophils. We also show for the first
time that intrachaeheal (i.t) transfer of adenovirus encoding a hu¬
man gene with dual antielastase and antimicrobial properties pro¬
tects murine lungs against acute inflammatory injury caused by
Pseudomonas aeruginosa, a bacterial pathogen commonly resis¬
tant to conventional antibiotics (20, 21). Our findings extend the
observed potential for gene therapy strategies in the management
of pulmonary injury and infection (22-26) by demonstrating that
the protection conferred in vivo was achieved using doses of ad¬




The adenoviral constructs used have been described in detail elsewhere
(17. IS). In brief, human elafin cDNA (encoding full length elafin) was
cloned into pDK6 downstream of a 1.4-kb fragment of the murine CMV
promoter (27). PDK6 and pBHGlO were used to cotransfect 293 cells
Copyright © 2tK)i by The American Association of Immunoiogists 0022-1767/D1/S02.00
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(which generate the product of the adenoviral El region in trans). Homol¬
ogous recombination resulted in the generation of E1-, partially E3-deleted
adenovirus encoding human elafin cDNA (Ad-elaiin). The second virus
used (E1-. partially E3-deleted adenovirus encoding lacZ cDNA (Ad-
lacZ)) was constiucted in the same manner witli the exception that lacZ
cDNA (under the control of the same murine CMV promoter fragment)
was cloned in place of elaiin cDNA (17. 18).
Preparation of human neutrophils
Fresh citrated whole blood was obtained from healthy volunteers. Neutro¬
phils were prepared by dextran sedimentation and Percoll gradient extrac¬
tion using a standard technique described elsewhere (28). BSA (Sigma.
Poole. U.K.) at a final concentration of 1% was added to cell supernatants
before addition of neutrophils. Neutrophils were activated by the sequential
addition to cell supernatants of platelet-activating factor (PAF) (Calbio-
chern, Nottingham. U.K.) at a final concentration of 10~v M. and fMLP
(Calbioehem). final concentration 10*7 M.
In vitro transfection experiments
A549 cells were used in in vitro transfection experiments. A549 cells are
derived from bronchioloalveolar cell carcinoma (29) and share several phe-
notypic characteristics with type II alveolar epithelial cells (29, 30). Indeed,
several features of A549 cells have been reproduced in primary cell lines;
in particular elafin is expressed by pulmonary epithelial cell lines and up-
regulated in response to IL-1 and TNF, features characteristic of A549 cells
(13, 30).
A549 cells were incubated at 37°C (and 5% C02) in DMEM (Sigma)
containing 10% FCS (Sigma), penicillin G (final concentration. 100 U/ml;
Life Technologies, Paisley, U.K.), streptomycin sulfate (final concentra¬
tion, 100 pgtml; Life Technologies), and 1% L-glutamine (final concen¬
tration, 2 mM; Life Technologies) and grown to confluence in 24-well
plates (Coming Costar, High Wycombe, U.K.). Cells were washed with
PBS (Sigma) and then incubated for 30 min at 37°C with one of three
treatments: Ad-elafin in DMEM containing 5% FCS; Ad-lacZ in DMEM
containing 5% FCS; or DMEM containing 59c FCS with no virus added.
[Adenovirus was applied at a multiplicity of infection (moi) of 50 PFU
.(except in dose-response experiments where adenovirus was applied over
the dose range 0-50 PFU). Cells were washed with PBS. and the medium
was changed to DMEM containing 10% FCS, before incubation overnight
at 37°C. Cells were washed extensively using PBS and incubated at 37°C
in serum-free DMEM before the addition of either purified HNE at a final
concentration of 4 pg/mi (Elastin Products, Owensville, MO) or 2 X 10''
human neutrophils (activated by PAF and fMLP as above). After 16 h, the
damage to the monolayer was assessed morphologically by light micros¬
copy or by counting the number of A549 cells liberated into the
supernatant.
In a variation of these experiments, A549 cells were radiolabeled with
'"In. using a variation on methods described previously (31). "'In (Du-
Pont. NEN Life Sciences, Brassels, Belgium) was incubated with 4 X 10*3
M tropolone (Sigma) for 1 min. " 'In (3 /zCi) was added to A549 cells at
the end of the overnight incubation in DMEM containing 10% FCS (final
concentration of tropolone. 4 X 10~J M). Damage to the monolayer after
addition of human neutrophils was assessed 16 h later by measuring ra¬
dioactivity in the supernatant using a scintillation analyzer (model 1900TR;
Canberra Packard, Pangboume, U.K.). It is weil established that neutro¬
phils from different healthy individuals may respond very differently to the
effects of priming agents. In preliminary experiments, 2 X 10'' neutrophils,
activated with 10~" M PAF and 10*7 M fMLP. caused 30-70% damage
to untransfected A549 cells at 16 h in the significant majority of individ¬
uals. A protocol was therefore devised whereby neuuophils causing <30%
or >70% damage to untransfected monolayers were excluded from anal¬
ysis. In subsequent experiments, 10 healthy volunteers donated neutrophils.
In eight of these the protocol was satisfied (in one of the remaining cases,
100% of untransfected A549 cells were damaged at 16 h. and in the other
no untransfected A549 cells were morphologically damaged at 16 hi.
To correct for the theoretical risk of nonspecific leakage of "1 In from
A549 cells, radioactivity in supernatants from ceils that did not have neu¬
trophils applied was subtracted from the count in neutrophil-treated cells
for all conditions studied.
Preparation of P. aeruginosa PAOl
P. aeruginosa PAOl, a well-characterized type strain used in many genetic
(21) and animal studies, and the first strain of P. aeruginosa to be fully
sequenced (32). was inoculated into nutrient broth (Oxoid, Basingstoke,
U.K.) containing 0.5% yeast extract (Difcc, Detroit, MP and incubated
overnight at 37°C in an orbital incubator at 200 rpm (3). The culture was
centrifuged at 4500 rpm at room temperature for 15 min, and the bacteria
were washed in 0.01 M phosphate buffer. pH 7.0. The bacterial suspension
used in in vivo experiments was prepared in the same butter to provide a
population density of ~2.2 X 10'' CFU/ml when cultured on Pseudomo-
nas Isolation Agar (Difco).
In vivo experiments
Female C57BL/6 mice between 6 and 8 wk old were from Harlan Olac
(Bicester, U.K.). Mice were anesthetized using i.p. avertin (—10 pl/g body
weight; avertin comprised 1.25% 2,2,2-tribromoethanol (Aldrieh. Gilling-
ham, U.K.) and 2.5% 2-methyl-2-butanol (Sigma)). In all experiments in¬
volving i.t. administration, the vocal cords were viewed directly, and a
blunted catheter was passed beyond them according to methods previously
described by our group (33). Treatments of known volume were instilled
directly, and body fluids or organs extracted as described below. Prelimi¬
nary experiments in which trypan blue was administered i.t. consistently
revealed a similar distribution of dye to all lobes of the lung macroscop-
ically (data not shown). All mice were euthanized under anesthesia (using
avertin) by transection of the abdominal aorta.
In one set of preliminary experiments, four mice that had not received
any form of i.t. treatment were anesthetized as above and euthanized. The
lungs and trachea were removed en bloc and bronchoalveolar lavage fluid
(BALF) was obtained by instillation of two separate aliquots of 250 pi
sterile PBS. BALF was serially diluted, inoculated onto Pseudomonas Iso¬
lation Agar, and incubated at 37°C overnight. The remaining BALF was
centrifuged at 2000 rpm for 10 min at 4°C. The pellet was resuspended in
PBS; the total cell count was established and cytospins were prepared to
estimate differential ceil count. The supernatant was stored at -40°C be¬
fore further use.
In a further set of preliminary experiments mice were anesthetized as
above and received an i,t. instillation of either Ad-elafin (3 X 107 PFU)
suspended in PBS, Ad-lacZ (3 X 107 PFU) suspended in PBS. or PBS
alone (n = 4 in each group). Five days later, mice were anesthetized in the
same way and given i.t. PBS. After 24 h. mice were euthanized as above.
BALF was prepared to establish P. aeruginosa PAOl colony counts and
differential cell counts as described above (with the exception that BALF
was prepared using aliquots of 250 /A and then 200 /zl).4
In the ensuing experiments, Ad-elafin (3 X 107 PFU) suspended in PBS.
Ad-/flcZ (3 X 107 PFU) suspended in PBS. or PBS alone were instilled by
i.t. injection in a final volume of 40 jA (PBS group n = IS. Ad-/acZ group
» = 20. Ad-elafin group n = 16). Five days later, mice were anesthetized
in the same way, and a direct i.t. instillation of P. aeruginosa PAOl was
administered (—2.2 X 10'1 CFU/ml suspended in 0.01 M phosphate buffer;
final volume, 34 pi). In preliminary experiments, we found that P. aerugi¬
nosa PAO1 at this predetermined dose consistently produced a sublethal
pneumonia. Twenty-four hours after administration of P. aeruginosa
PAOl. mice were anesthetized and euthanized by transection of the ab¬
dominal aorta. Whole blood was retrieved; an aliquot of 100 pi was in¬
oculated onto Pseudomonas Isolation Agar and incubated at 37°C over¬
night. The spleen was stored in 0.01 M phosphate buffer and homogenized
for 30 s using an Omni hand-held homogenizer (Camlab. Cambridge.
U.K.); an aliquot of 100 pi was inoculated onto Pseudonwnas Isolation
Agar and incubated at 37°C overnight. The lungs and trachea were re¬
moved en bloc, and BALF was obtained as described above. P. aeruginosa
colony counts and differential cell counts in BALF were established as
described above. The left lung was weighed, snap frozen in liquid nitrogen,
and stored at — 80°C. Immediately upon thawing, the lung was placed in
homogenization butter (100 inM sodium acetate. 20 mM EDTA. 1% hexa-
decyltrimelhylammonium bromide (all Sigma)) as described elsewhere
(34), and homogenized for 1 min. The homogenate was centrifuged at
10.000 rpm for 30 min at room temperature. The supernatant was used
immediately to determine the concenuation of myeloperoxidase (MPO) in
the homogenized lung (as an index of the number of neutrophils in both
pulmonary parenchyma and circulation) (34).
In separate experiments, three additional mice from each group (i.e..
PBS then P. aeruginosa PAOl; M-lacZ then P. aeruginosa PAOl; Ad-
elafin then P. aeruginosa PAOl) were euthanized 24 h after administration
of P. aeruginosa PAOl, and the lungs were removed en bloc before fixing
in formalin and embedding in paraffin wax. Sections 3 pra diick were cut
and stained using hematoxylin and eosin.
Assays
Levels of human elafin Ag were measured using a sandwich ELISA avail¬
able in-house, performed on 96-well plates (Linbro: Flow Laboratories.
4 Other data relating to these control mice have been submitted elsewhere, but the data
presented in this article do not appear elsewhere.
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McLean. VA). In brief, the primary Ab was polyclonal rabbit anti-human
elafin Ig, gelatin (BDH. Poole. U.K.) was used as a blocking agent, the
sample (or purified recombinant elafin as standard) was applied, and the
secondary Ab was biotinylated polyclonal rabbit anti-human elafin Ig (bi-
otin was from Pierce. Rockford, IL). Streptavidin-HPO complex (Sigma)
and then chromogenic substrate (2.2'-azinobis(3-ethylbenzthiazolme-6-
sulfonic acid); Sigma) were added sequentially and the OD350 of die prod¬
uct was quantified using a Dynatech M5000 Plate Reader (Dynex, Billing-
ham, U.K.).
Elastase activity was measured by applying the elastase-specifie chro¬
mogenic substrate tV-methoxysuccinyl-Ala-AIa-Pro-Val p-nitroanilide
(Sigma), and measuring change of OD4H5. Elastase-inhibitory activity
(EIAI was measured by adding sample (serially diluted in buffer (50 rnM
Tris. 0.1% Triton. 0.5 M sodium chloride, pH 8); final volume. 10 ^d), or
buffer alone to a known quantity of purified HNE (50 ng in 10 /xi) and
incubating for 30 min at 37°C before adding 50 /A A-methoxysuccinyl-
Ala-Ala-Pro-Vai p-nitroanilide and measuring change of OD405. Plots of
OD (reflecting HNE activity) against concentration of sample were con¬
structed. As described elsewhere (35). EIA was derived from extrapolation
of the curve to the abscissa.
MPO activity was calculated by addition of chromogenic substrate (0.1
mg/ml tetramethylbenzidine (DAKO, Denmark), 0.03% hydrogen perox¬
ide (Sigma) in 0.1 M sodium acetate, pH 4.9) and measurement of the
change of OD,)J0. To measure MPO activity in homogenized lung super-
natants. samples were diluted in homogenization butter, and lOCE/xl ali-
quots (in triplicate) added to 100 /A chromogenic substrate. To measure
MPO activity in BALE. 50-/d aliquots of BALE were treated with 10 /A
sodium acetate butter. pH 4.2. before addition of 100 /d chromogenic
substrate.
Protein was measured using the bicinchoninic acid method (Pierce) us¬
ing purified albumin (Pierce) as standard.
Commercial ELISA kits were used to measure concentrations of murine
albumin (Bethyl Laboratories. Montgomery, TX) and human IL-8 (R&D
Systems. Abingdon, U.K.).
Measurements of murine keratinocyte-derived chemokine (mKC) con¬
centration in BALF. using an ELISA. were kindly performed by Professor
T. Standiford (University of Michigan. Ann Arbor, MI).
Statistics
The parameters studied were not normally distributed, and nonparametric
tests were applied. For comparisons involving three groups, the Kruskal-
Wallis test was used, and comparisons between pairs of groups were per¬
formed using the Mann-Whitney U test. Paired data were studied using
Wilcoxon's rank sum test. Nominal data were compared using the y2 test.
Correlations were studied using Spearman's rank correlation test.
Results
Effects ofadenoviral augmentation of elafin on damage
mediated by HNE and activated human neutrophils in vitro
Transfection of A549 cells with Ad-elafin resulted in a dose-de-
pendent increase in both secretion of elafin Ag and antielastase
activity, indicating that elafin production was efficient and that the
elafin produced was functionally active (Fig. I). Adenoviral trans¬
fection did not increase secretion of IL-8 above that from untrans-
fected cells. Indeed Ad-lacZ and Ad-elafin transfection (each at an
moi of 50 PFU) resulted in LL-8 levels that were, respectively, 54
and 63% of those from untransfected cells (n = 3; p — 0.05 com¬
paring the three groups).
Ad-elafin significantly protected A549 cells against injury in¬
duced by HNE as assessed morphologically (Fig. 2. a-c). This
observation was supported by a significant reduction in the number
of cells released from pulmonary epithelial monolayers after treat¬
ment with HNE (Fig. 2d). The protection conferred was associated
with significant and almost complete inhibition of HNE (Fig. 2c).
When human neutrophils, activated with a combination of prim¬
ing agents (PAF) and secretogogues (fMLP), were used in place of
purified HNE. morphological evidence of protection was again
conferred by Ad-elafin (Fig. 3, a and b). This was associated with
a reduction in release of ! "In from radiolabeled epithelial cells
(Fig. 3c). The protection conferred by Ad-elafin was associated
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FIGURE 1. Transfection of pulmonary epithelial cells with Ad-elafin
results in dose-dependent production of elafin and anti-elastase activity.
A549 cells were treated with Ad-elafin (moi 0-50 PFU) or Ad-IacZ (moi
0-50 PFU) for 30 min at 37°C. Cells were washed with PBS to remove
residua! virus and then incubated overnight at 37°C in medium containing
serum. Cells were extensively washed with PBS to remove serum and
incubated at 37°C for 24 h in serum-free medium. Supernatants were re¬
trieved 16 h later. Two aliquots of supernatant were prepared. A known
quantity of HNE was added to the fir st aliquot, and residual HNE activity
measured using a chroinogenic substrate assay specific for HNE. In the
second aliquot, elafin concentration was determined by ELISA. Bottom,
Dose-dependent increase in elafin secretion after Ad-elafin transfection
(heavy line) but not after Ad-lacZ transfection (broken line); top, corre¬
sponding dose-dependent generation of antielastase activity after Ad-elafin
(heavy line), but not Ad-lacZ (broken line) transfection.
Preliminary in vivo experiments
In mice receiving no i.t. treatments (i.e.. normal mice), the median
total cell count in BALF was 1.84 X 105, with macrophages com¬
prising >95% of the count in all animals. The remaining cells in
BALF were almost exclusively neutrophils, as is characteristic of
BALF from normal mice. Median protein concentration in BALF
was 0.45 g/L (range, 0.43-0.53 g/L). In mice receiving i.t. vector
and/or PBS. very similar trends were observed (Table I).Total cell
counts were similar, and the alveolar macrophage was the predom¬
inant cell type, with the neutrophil comprising a median of 0.7% of
cells in BALF among PBS/PBS mice, 3.4% in Ad-/f7<;Z/PBS mice,
and 0.6% of Ad-elafin/PBS mice (no significant difference). Sim¬
ilarly. adenovirus administration itself did not significantly influ¬
ence the concentration of protein in BALF characteristic of un¬
treated animals or those treated sequentially with vehicle alone
(Table I). Therefore, adenovirus administration per se was not as¬
sociated with significant airway inflammation as assessed by cel¬
lular content and protein concentration of BALF. No bacterial
growth was obtained on Pseudomonas Isolation Agar plates inoc¬
ulated with BALF (Table I), blood, homogenized spleen, or ho¬
mogenized lung from untreated, vehicle-treated, or virus-treated
mice, reflecting the absence of either commensal or contaminating
P. aeruginosa in our laboratory.
Effects ofAd-elafin transfection on lung injury mediated by P.
aeruginosa in vivo
Delivery of Ad-elafin i.t. followed by P. aeruginosa PAOl re¬
sulted in a median human elafin concentration in BALF of 8.5
ng/rnl (interquartile range. 5.9-10.4 ng/ml). No human elafin was
detected in any of the mice given Ad-/acZ (as viral control) or PBS
Ad-lacZ
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FIGURE 2. Ad-elafin transfection protects pulmonary epithelial cells against HNE in vitro. A549 cells were treated with Ad-elaiin (moi 50 PFU),
Ad-lacZ (moi 50 PFU), or medium alone (unlransfected cells) for 30 min at 37°C. Cells were washed with PBS to remove residual virus and then incubated
overnight at 37°C in medium containing seium. Cells were extensively washed with PBS to remove serum and incubated at 37°C for 48 h in serum-free
medium. HNE was then added directly to the supernatant (final concentration, 4 /tg/ml) and incubated at 37°C for 16 h. Photomicrographs of cell layers
were taken (using a blue filter to optimize contrast), cells in the supernatant were counted, and the residual HNE activity of supernatants was measured using
a chromogenic substrate assay specific for HNE. a, Untransfected cells, with no HNE added; b. Ad-iacZ-trealed cells, after addition of HNE (appearances
of untransfected cells treated with HNE were almost identical); c, Ad-elafin-treated cells, after addition of HNE; cl. cell counts in supernatants retrieved
after addition of HNE (n = 6). Results were expressed relative to the count in supernatants from untransfected cells, which was regarded as 100% in each
experiment. Values represent medians (and interquartile ranges) from the six experiments performed. **, Significantly lower compared with either of the
other treatments, /> < 0.01. e. Residual HNE activity in supernatants (n = 6). Results were expressed relative to the HNE activity in supernatants from
juntransfected cells, which was regarded as 100% in each experiment. The values shown represent medians (and interquartile ranges) from the six
'experiments performed. ***, Significantly lower compared with each of the other treatments, p < 0.005.
(as nonviral control) and then P. aeruginosa PAOl. confirming
that antielafin IgG does not cross-react with murine or bacterial
proteins. Histologically, the administration of P. aeruginosa PAOl
in control mice was associated with a patchy, multilobar pneumo¬
nia, associated with extravasation of neutrophils into alveolar air¬
spaces (Fig. 4, a and c) with associated protein leak. These effects
were much less pronounced in mice receiving Ad-elafin (Fig. 4b)
in which there was a significant reduction in the concentrations of
protein and albumin in BALF (Fig. 4d).
i The protection conferred by Ad-elafin was associated with a
significant reduction in the quantity of bacteria retrieved from
BALF (Fig. 4d). Indeed, among the mice receiving Ad-elafin. the
concentration of eiafin in BALF significantly and inversely corre¬
lated with the number of P. aeruginosa PAOl colonies (log trans¬
formed) in BALF (r = —0.75; p = 0.02). Administration of Ad-
elafin was also associated with a significantly lower incidence of
bacterial growth in blood (colonies detected in 31% of Ad-elafin
mice, 44% of Ad-torZ mice, and 61% of PBS mice, p < 0.05) and
Spleen (colonies detected in 19% of Ad-elafin mice, 40% of Ad-
lacZ mice, and 44% of PBS mice, p < 0.05).
j In none of the mice studied was elastase activity detected in
BALF, reflecting a relative excess of elastase inhibitors in BALF
from all animals. However, the total EIA in BALF was lower in
the Ad-elafin group than in either of the control groups (Fig. 5).
In addition, BALF from mice receiving Ad-elafin contained sig¬
nificantly lower concentrations of the murine neutrophil chenio-
kine rnKC than did BALF from mice receiving control virus (Ta¬
ble II). In keeping with this finding, a trend was observed toward
lower concentrations of MPO in homogenized lung (reflecting
lung neutrophil count) in mice receiving Ad-elafin (Table II). In¬
deed, considering all mice together, there was a significant corre¬
lation between the concentration of mKC in BALF and the con¬
centration of MPO in homogenized lung (r = 0.43, p < 0.005). A
trend toward lower levels of free MPO in BALF (reflecting neu¬
trophil degranulation products) was also found in mice receiving
Ad-elafin (Table H).
Discussion
We believe these data represent the first description of protection
against acute lung injury conferred by genetic augmentation of a
human pulmonary antielastase/antimicrobial peptide. The findings
support and advance the concept that gene therapy may be used to
obviate acute lung injury generally and that caused by bacterial
infection specifically by manipulation of host defense molecules
(22-26).
Our data indicate that Ad-elafin is capable of protecting A549
cells against acute injury mediated by HNE (Fig. 2). Untransfected
A549 cells constitutively produce small quantities of antielastases.
including eiafin (36), but these were overwhelmed by the concen¬
trations of HNE applied here (Fig. 2b). resulting in cell damage. In
this context, it is interesting both that a similar concentration of
HNE may be found in sputum from patients with CF (3) and that
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Table 1. Ad-elafin administration is not associated with a significant rise in neutrophil count or protein concentration in BALF'
1783
White Blood Cell Neutrophil Count Protein in BALF
n Count (X105) (X105) (g/L) PAOl Colonies
AD-elafin/PBS 4 2.28(1.74-3.60) 0.015 (0-0.023) 0.29(0.25-0.33) 0
AD-/acZ/PBS 4 1.30 (1.02-2.34) 0.045 (0.041 -0.060) 0.45 (0.33-0.58) 0
PBS/PBS 4 1.46 (0.90-2.54) 0.011 (0.003-0.026) 0.38 (0.22-0.46) 0
" C57BL/6 mice received an i.t. dose of one of the following: Ad-elafin (3 X 107 PFU); Ad-lacZ (3 X 107 PFU); or PBS. Five days later, PBS was given i.t. The following
day the mice were sacrificed, and BALF was retrieved. The total number of white blood cells in BALF was determined, and the neutrophil count was derived by differential ceil
counts in cytospins. One aliquot of BALF was cultured overnight to determine the number of P. aeruginosa PAOl colonies (indicating commensal or contaminating bacteria),
and another was centrifuged and used to determine protein concentration. Results represent medians and interquartile ranges.
vector per se did not significantly influence outcome in mice re¬
ceiving bacteria, given that PBS-PAOl mice had a neutrophil
count in BALF of 8.2 X 106 (~200 times the number in mice
treated with vector then PBS (Table I)) and a protein concentration
of 5.7 g/L (—15 times the concentration in mice treated with vector
then PBS (Table I and Fig. 4)). We are not aware of studies dem¬
onstrating significant protective effects after doses of adenovirus as
low rs those used here. Therefore, it appears that gene therapy
protccols using sufficiently powerful promoters (17, 18) and low
concentrations of vector may, at least in part, be able to circumvent
important concerns relating to adenovirus-mediated immune re¬
sponses (40, 41) and inefficiency of transfection of surface epithe¬
lium in the lung (42). Recent advances in vectorology are also
likely to improve adenoviral gene delivery to the airways (43).
In our model of murine P. aeruginosa lung injury, lungs from
control mice showed patchy multilobar consolidation, in keeping
with histological appearances in human pneumonia associated
with this pathogen (Fig. 4). The appearances were associated with
a rise in BALF protein, in turn reflecting disruption of the alveolar-
capillary membrane (44, 45). The significant protection against
lung injury consequent on Ad-elafin transfection, as demonstrated
by BALF protein levels, was also associated with significantly
enhanced elimination of bacteria from the airways (Fig. 4) and
with a significantly lower incidence of hematogenous bacterial dis¬
semination. Elafin therefore appears to be part of a network of
endogenous pulmonary antibiotics which includes the defensins
(14, 16, 46).
The neutrophil may potentially have advantageous or detrimen¬
tal effects in pulmonary inflammation (Ref. 47; reviewed in Ref.
48). Excessive activation of neutrophils certainly appears to be
associated with the potential for tissue damage (48). In the mice
studied here, the presence of MPO in BALF provided evidence of
neutrophil degranulation and by implication neutrophil activation
(Table II). Elafin augmentation was associated with a modest re¬
duction in BALF MPO, potentially supporting the inhibition of
neutrophil-mediated damage seen in vitro (Table II and Fig. 3).
Elafin augmentation was also associated with a reduction in the
neutrophil chemokine mKC, and with a corresponding reduction in
total lung neutrophils (Table II). Importantly, the relative reduction
in pulmonary neutrophilia associated with elafin augmentation did
PBS/PA01 AD-ELAFIN/PAOl AD-LAC 2/PAOl
Protein 5.73 3.27 5.40
concentration (3.37-7.22) (0.73-4.89) (3.88-6.43)
in BALF (g/1)
Albumin 1.95 0.78 1.29




FIGURE 4. Ad-elafin transfection confers protection against acute lung injury induced by P. aeruginosa in vivo. C57BL/6 mice were given an i.t. dose
of one of the following: Ad-elafin (3 X I07 PFU); Ad-iacZ (3 X 107 PFU); or PBS. Five days later, P. aeruginosa PAOl was given i.t. (34 /d of a
suspension of —2.2 X 10" CFU/ml). After 24 h, the mice were sacrificed, and BALF was retrieved. One aliquot of BALF was cultured overnight to
determine the number of P. aeruginosa PAOl colonies, and another was centrifuged and used to determine protein and albumin concentrations. In a
variation of this experiment, lungs were removed en bloc, fixed in formalin, and examined histologically, a, Histological appearance of lung from a
representative mouse treated with PBS and then P. aeruginosa PAO l; h, histological appearance of lung from a representative mouse treated with Ad-elafin
and theri P. aeruginosa PAOl; c, histological appearance of lung from a representative mouse treated with Ad-lacZ then P. aeruginosa PAOl; d, protein
concentration in BALF, albumin concentration in BALF, and P. aeruginosa PAOl colonies in BALF (results represent medians and interquartile ranges).
*, Significant difference by Kruskal-Wallis test, p < 0.05: when comparing groups directly, for eacli parameter, the difference between Ad-elafin/PAOl
and PBS/PAOl was significant,/) < 0.05; Ad-elafin/PAOl was significantly different from Ad-/«cZ/PAOI with respect to protein and PAOl colonies (p <
0.05) but not albumin concentration; no significant differences were observed comparing Ad-LicZ/PAOl and PBS/PAOl.
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Table I. Ad-elafin administration is not associated with a significant rise in neutrophil count or protein concentration in BALF'
1783
White Blood Cell Neutrophil Count Protein in BALF
n Count (X105) (XIO5) (g/LJ PAOl Colonies
AD-elafin/PBS 4 2.28(1.74-3.60) 0.015(0-0.023) 0.29(0.25-0.33) 0
AD-/ncZ/PBS 4 1.30(1.02-2.34) 0.045(0.041-0.060) 0.45(0.33-0.58) 0
PBS/PBS 4 1.46 (0.90-2.54) 0,011 (0,003-0.026) 0.38 (0.22-0,46) 0
" C57BL/6 niiee received an i.t. dose of one of the following: Ad-elafin (3 X 107 PFU); Ad lucZ (3 X 107 PFU): or PBS. Five days later, PBS was given i.t. The following
day the mice were sacrificed, attd BALF was retrieved. The total number of while blood cells in BALF was determined, and the neutrophil count was derived by dilferential cell
counts in cytospins. One aliquot of BALF was cultured overnight to determine the number of P. aeruginosa PAOl colonies (indicating commensal or contaminating bacteria),
and another was centrifuged and used to determine protein concentration. Results represent medians and interquartile ranges.
vector per se did not significantly influence outcome in mice re¬
ceiving bacteria, given that PBS-PAOl mice had a neutrophil
count in BALF of 8.2 X !0f> (—200 times the number in mice
treated with vector then PBS (Table I)) and a protein concentration
of 5.7 g/L (—15 times the concentration in mice treated with vector
then PBS (Table I and Fig. 4)). We are not aware of studies dem¬
onstrating significant protective effects after doses of adenovirus as
low is those used here. Therefore, it appears that gene therapy
protocols using sufficiently powerful promoters (17, 18) and low
concentrations of vector may, at least in part, be able to circumvent
important concerns relating to adenovirus-mediated immune re¬
sponses (40, 41) and inefficiency of transfection of surface epithe¬
lium in the lung (42). Recent advances in vectorology are also
likely to improve adenoviral gene delivery to the airways (43).
In our model of murine P. aeruginosa lung injury, lungs from
control mice showed patchy multilobar consolidation, in keeping
with histological appearances in human pneumonia associated
with this pathogen (Fig. 4). The appearances were associated with
a rise in BALF protein, in turn reflecting disruption of the alveolar-
capillary membrane (44, 45). The significant protection against
lung injury consequent on Ad-elafin transfection, as demonstrated
by BALF protein levels, was also associated with significantly
enhanced elimination of bacteria from the airways (Fig. 4) and
with a significantly lower incidence of hematogenous bacterial dis¬
semination. Elafin therefore appears to be part of a network of
endogenous pulmonary antibiotics which includes the defensins
(14, 16, 46).
The neutrophil may potentially have advantageous or detrimen¬
tal effects in pulmonary inflammation (Ref. 47; reviewed in Ref.
48). Excessive activation of neutrophils certainly appears to be
associated with the potential for tissue damage (48). In the mice
studied here, the presence of MPO in BALF provided evidence of
neutrophil degranulation and by implication neutrophil activation
(Table II). Elafin augmentation was associated with a modest re¬
duction in BALF MPO, potentially supporting the inhibition of
neutrophil-mediated damage seen in vitro (Table II and Fig. 3).
Elafin augmentation was also associated with a reduction in the
neutrophil chemokine mKC, and with a corresponding reduction in
total lung neutrophils (Table II). Importantly, the relative reduction











FIGURE 4. Ad-elafin transfection confers protection against acute lung injury induced by P. aeruginosa in vivo. C57BL/6 mice were given an i.t. dose
of one of the following: Ad-elafin (3 X 107 PFU); Ad-lacZ (3 X 107 PFU); or PBS. Five days later, P. aeruginosa PAOl was given i.t. (34 p.I of a
suspension of —2.2 X 10" CFU/ml). After 24 h, the mice were sacrificed, and BALF was retrieved. One aliquot of BALF was cultured overnight to
determine the number of P. aeruginosa PAOl colonies, and another was centrifuged and used to determine protein and albumin concentrations. In a
variation of this experiment, lungs were removed en bloc, fixed in formalin, and examined histologically, a, Histological appearance of lung from a
representative mouse treated with PBS and then P. aeruginosa PAO l; h, histological appearance of lung from a representative mouse treated with Ad-elafin
and then P. aeruginosa PAOl; c, histological appearance of lung from a representative mouse treated with Ad-lacZ then P. aeruginosa PAOl: d, protein
concentration in BALF, albumin concentration in BALF, and P. aeruginosa PAOl colonies in BALF (results represent medians and interquartile ranges).
*, Significant difference by Kruskal-Wallis test, p < 0.05: when comparing groups directly, for each parameter, the difference between Ad-elafin/PAOl
and PBS/PAOi was significant,/) < 0.05; Ad-elafin/PAOl was significantly different from Ad-/ncZ/PAOl with respect to protein and PAOl colonies (/) <
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IGURE 5. Protection against P. aeruginosa PAOl conferred by Ad-
afin is associated with a reduction in EIA. BALF obtained from the mice
scribed in Fig. 4 was analyzed for EIA. EIA was determined by adding
mple (serially diluted in buffer (Tris 50 mM, 0.1% Triton, 0.5 M sodium
tloride, pH 8)) or buffer alone to a known quantity of purified HNE then
Iding iV-methoxysuccinyl-Ala-Ala-Pro-Vai p-nitroanilide and measuring
tange of OD405. Plots of OD (reflecting HNE activity) against concen-
ition of sample were constructed- Extrapolation of the curve to the ab-
issa determined the EIA of each sample. Values represent medians, with
trs indicating interquartile ranges, a, Significant difference comparing
satment with Ad-elafin then P. aeruginosa PAOl, and treatment with
BS then P. aeruginosa PAOl, p < 0.05.
at preclude tissue protection, despite the observation that neutro-
lilia correlates with reduced mortality in pulmonary infection
tused by Nocardia (47).
Interestingly, no free murine elastase activity was detected in
ALF from any of the mice studied. This can be attributed to the
laracteristic elevation of EIA consequent on severe lung injury,
imposing part of the acute phase response (49). We calculate that
jman elafin contributed less than 1 % of the EIA of BALF in mice
iceiving Ad-elafin. Taken together, these findings suggest that a
irect anti-neutrophii elastase effect does not explain the protective
feet of Ad-elafin. in keeping with the growing body of evidence
lat pulmonary anti-neutrophil elastases harbor several functions
i addition to inhibition of neutrophil elastase (14-16. 50-53).
urthermore. inhibition of Pseudomonas elastase (a metalloelas-
se) does not explain the effects of Ad-elafin in this study, because
afin is an inhibitor of serine proteinases and not metalloprotein-
:es. Against this background, the reduction in EIA associated
ith Ad-elafin administration (Fig. 5) reflects a significant and
ipropnate down-regulation in the acute phase response as a con-
iquence of tissue protection conferred by Ad-elafin. Thus, the
•otective anti-inflammatory effect of elafin is associated with an-
microbial activity, with a reduction in neutrophils in lung tissue,
id with a reduction in the characteristic host response to tissue
'jury.
The relative level of protection provided by Ad-elafin in our in
ivo studies is worthy of note. Ad-elafin effected a 40% reduction
in BALF protein concentrations as compared with control mice
(Fig. 4). Given both the severity of injury in the control mice and
the remarkable complexity and redundancy in pulmonary anti¬
inflammatory responses (6). the degree of protection after one ad¬
ministration of a single human gene is encouraging. Interestingly,
a nonsignificant trend also emerged potentially suggesting a weak
protective effect for adenovims over vehicle alone (indeed the Ad-
lacZ group was included specifically to control for confounding
effects of adenovirus). This was manifest as a trend toward lower
levels of IL-8 secretion and greater with cytoprotection (Fig. 2d) in
vitro and reduction in albumin concentration and EIA in vivo
(Figs. 4 and 5). However, the effect seemed most pronounced with
regard to bacterial loads, with strikingly (although not statistically
significantly) lower levels of bacteria in BALF (Fig. 4) and blood
in Ad-lacZJPAO 1 mice as compared with PBS/PAOl mice. Al¬
though it must be emphasized that these trends did not reach sta¬
tistical significance (whereas differences between Ad-elafin/PAOl
mice and Ad-lacZJPAO I mice generally did attain significance), it
is tempting to speculate that adenoviral treatment per se may have
contributed in some way to bacterial eradication by priming innate
immunity. A similar trend has been observed in studies in which
rats received sequential i.t. administrations of adenovims encoding
FcyR and P. aeruginosa PAOl; delivery of control adenovims (a
null adenovims, expressing no foreign transgene) resulted in
greater clearance of Pseudomonas than did PBS, thus further sug¬
gesting stimulation of innate immunity by adenovims per se (54).
Interestingly, stimulation of adaptive immunity by recombinant
null adenovimses has also been recognized (55), and priming of
immune mechanisms has also been attributed to Ad-lacZ in gene
therapy protocols directed at lung tumors (56).
Overall, our data provide proof of principle for the prevention of
inflammatory lung injury using augmentation of elafin. particularly
in the context of infection with antibiotic-resistant pathogens. P.
aeruginosa PAOl is classically associated with antibiotic resis¬
tance. and the mechanisms responsible have been extensively char¬
acterized (21, 32). More specifically, the approach we describe
may potentially find application in preventing colonization with P.
aeruginosa in CF and in the setting of patients at risk of pneumo¬
nia attributable to P. aeruginosa in intensive care units (57). Nos¬
ocomial Pseudomonas pneumonia is associated with a high mor¬
tality despite conventional treatment, due in part to antibiotic
resistance (21, 58). Current opinion suggests that endogenous cat-
ionic peptide antibiotics, such as elafin. may be less susceptible to
resistance than are conventional antibiotics (59).
In summary, genetic augmentation of elafin proved effective at
protecting pulmonary epithelium against neutrophil-mediated in¬
jury in vitro and against acute injury induced by P. aeruginosa in
vivo. These data support the concept that endogenous defense mol¬
ecules can contribute to innate immunity by protecting tissue
Table A. Administration i.t. ofAd-elafin is associated with a trend toward reduced pulmonary neutrophilicf
PBS/PAOl Ad Elafin/PAOl Ad /ocZ/PAOI
mKC (ng/ml) 0.25(0.04-0.78) 0.15(0.02-0.33)* 0.34(0.27-1.00)
Lung MPO (U/mg wet 577(314-744) 309(104-797) 625(326-804)
weight)
Free MPO in BALF (U) 1.13(0.45-2.28) 0.86 (0.35-1.33) 1.09 (0.31-1.93)
a Whole lungs and BALF were obtained from the mice described in Fig. 4. MPO content of BALF was assessed by adding
the chromogenic substrate tetramethylbenzidine and measuring the change in ODwn as a function of time. The left lung of each
animal was retrieved, weighed, and snap frozen. On thawing, lungs were immediately homogenized, and MPO content was
assessed as described for that in BALF. In addition, mKC levels in BALF were measured by ELISA. Values represent medians,
with interquartile ranges in parentheses.
*. Significant difference comparing group treated with Ad elafin and then P. aeruginosa PAOl and the group treated with
Ad-lacZ and then P. aeruginosa PAOl; p < 0.05.
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gainst microbial damage in vivo, and in so doing they suggest
iovel therapeutic strategies.
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Regulation of Adenovirus-Mediated Elafin Transgene
Expression by Bacterial Lipopolysaccharide
A. JOHN SIMPSON,1 GRAINNE A. CUNNINGHAM,1 DAVID J. PORTEOUS,2 CHRIS HASLETT,1
and JEAN-MICHEL SALLENAVE1
ABSTRACT
Lipopolysaccharide (LPS) is a mediator of inflammatory lung injury. Selective augmentation of host defense
molecules such as elafin (an elastase inhibitor with antimicrobial activity) at the onset of pulmonary inflam¬
mation is an attractive potential therapeutic strategy. The aim of this study was to determine whether elafin
expression could be induced by LPS administered after transfection with adenovirus (Ad) encoding human
elafin downstream of the murine cytomegalovirus (CMV) promoter (known to be potentially responsive to
LPS). In addition, we aimed to determine the effect of local elafin augmentation on neutrophil migration to
the lung. LPS significantly up-regulated elafin expression from pulmonary epithelial cells transfected with
Ad-elafin in vitro. In murine airways expression of human elafin was achieved using doses low enough (3 x
107 plaque forming units) to circumvent overt vector-induced inflammation. LPS significantly up-regulated
human elafin secretion in murine airways treated with Ad-elafin [117 ng/ml in bronchoalveolar lavage fluid
(BALF) after LPS administration, 5.9 ng/ml after PBS,p < 0.01)]. Over-expression of elafin significantly aug¬
mented LPS-mediated neutrophil migration into the airways in vivo (1.30 x 106 neutrophils in BALF after
Ad-eiafin/LPS treatment, 0.54 x 106 after Ad-/acZ/LPS (p < 0.05), 0.63 x 106 after PBS/LPS (p < 0.05)) and
significantly enhanced human neutrophil migration in vitro. These data suggest novel functions for elafin in
neutrophil migration, and that judicious selection of promoters may allow single, low-dose adenoviral ad¬
ministration to effect inflammation-specific expression of potentially therapeutic transgenes.
OVERVIEW SUMMARY
In designing potential therapies for acute pulmonary in¬
flammatory diseases, a desirable aim would be compart¬
mentalized augmentation of host defense molecules induced
specifically by inflammatory mediators. This study demon¬
strates that transfection with adenovirus encoding human
elafin (a low-molecular-weight inhibitor of elastase) down¬
stream of a powerful, lipopolysaccharide (LPS)-responsive
promoter (the mCMV promoter) results in elafin secretion
which is significantly up-regulated in the presence of LPS,
both in vitro and in vivo. The strength of the promoter used
was such that elafin secretion was achieved using doses of
adenovirus low enough to obviate overt vector-induced in¬
flammation. This strategy also defined a novel function for
elafin, namely enhancement of neutrophil recruitment as¬
sociated with LPS administration. Therefore, the potential
exists to design gene therapy vectors offering minimization
of vector dose and disease-specific up-regulation of trans-
gene in the acute setting.
INTRODUCTION
Gene therapy protocols are increasingly being applied inmodels of acute inflammatory lung injury (Greenberger et
al., 1996; Bals etal., 1999; Kolls etal., 1999; Chen etal., 2000).
An attractive strategy in this context is the therapeutic aug¬
mentation of host defense molecules, such as the endogenous
pulmonary anti-elastases alpha-1 protease inhibitor (a-1 PI), se¬
cretory leukocyte protease inhibitor (SLPI), and elafin [also
known as elastase-specific inhibitor (ESI) or skin-derived
antileukoprotease (SKALP)] (reviewed by Sallenave, 2000).
These molecules are potent inhibitors of human neutrophil elas-
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ise (HNE), a proteolytic enzyme implicated in the pathogen-
sis of acute lung injury, and found in excess in bronchoalve-
lar lavage fluid (BALF) or sputum in inflammatory conditions
ich as cystic fibrosis (CF), acute bacterial pneumonia, non-CF
-onchiectasis and emphysema (Gadek et al., 1981; Stockley et
1984; Birrer et al., 1994; Boutten et al., 1996).
Elafin is a cationic, low-molecular-weight (lOkDa) inhibitor
r HNE and proteinase 3, which also has intrinsic antimicro-
al activity against bacterial respiratory pathogens (Wiedow et
., 1990, 1991; Sallenave and Ryle, 1991; Sallenave and Silva,
193; Molhuizen et al., 1993; Schalkwijk et al., 1999; Simp-
m et al., 1999). Secretion of elafin from airway epithelial cells
rapidly and significantly up-regulated by early inflammatory
■tokines such as interleukin (IL)-l and tumor necrosis factor-
(TNF-a) (Sallenave et al., 1994). Therefore, elafin appears
constitute part of the lung's innate immune defense. As such,
gmentation of elafin could potentially be advantageous in
nditions where inflammatory tissue destruction is consequent
ion bacterial infection. Bacterial lipopolysaccharide (LPS) ex-
ts a number of effects in the generation of acute inflamma-
m and is likely to be a key player in the pathogenesis of sep-
shock and acute respiratory distress syndrome. The role of
'S in inducing airway neutrophilia and tissue injury has been
tensively investigated (Morrison and Ryan, 1987; van Helden
al., 1997).
In this setting, we postulated that LPS may influence elafin
tretion from human airway epithelial cells and macrophages,
rthermore, we have previously established adenoviral con-
ucts encoding human elafin cDNA downstream of the pow-
ul murine cytomegalovirus (mCMV) promoter, which is
own to contain LPS-responsive elements (Loser et al., 1998).
; postulated that such vectors may allow induction of elafin
the presence of LPS. A strategy of this nature could be ad-
itageous under conditions where significant transgene ex-
:ssion is of benefit during episodes of acute inflammation,
; undesirable in health . Finally, because antiproteases have been
iwn to exert various influences on pulmonary neutrophil re-
itment (Stockley et al., 1990; Aoshiba et al., 1993; Mackarel
al., 1999), we aimed to determine the effects of elafin aug-
ntation on LPS-induced airway neutrophilia.
METHODS
11 types
\549 cells were available in-house. A549 cells share several
rphological and functional characteristics with type II alve-
■ epithelial cells (Lieber et al., 1976; Sallenave et al., 1994;
:herden et al., 1999).
<resh citrated whole blood was obtained from healthy vol-
;ers. Neutrophils and mononuclear cells were derived using
rocess of dextran (Pharmacia, Uppsala, Sweden) sedimen-
3n and Percol! (Pharmacia) gradient extraction, as described
letail elsewhere (Haslett et al., 1985).
luman macrophages were obtained by plating mononuclear
s on plastic wells (Falcon, Becton Dickinson, Franklin
es, NJ,) at a density of 4 X 106/ml in serum-free Iscove's
lium (Gibco BRL. Paisley, UK) containing penicillin G (fi¬
nal concentration 100 U/ml; Gibco) and streptomycin sulfate
(final concentration 100 /xg/ml; Gibco) and incubating at 37°C.
After 1 hr, nonadherent cells were washed away and Iscove's
medium (containing 10% heat-inactivated autologous serum)
was added. Medium was replenished at 3 days. Under these
conditions, differentiation to a macrophage phenotype is recog¬
nised at 5 days (Wright et al., 1983).
Adenoviral constructs
Two El-partially E3-deIeted type 5 adenoviruses were used.
The first (Ad-elafin) comprised human elafin cDNA down¬
stream of a 1.4 kb fragment of the mCMV immediate early (IE)
promoter (Dorsch-Haslercr al., 1985). Full-length human elafin
cDNA (538 bp) was derived from total RNA extracted from the
bronchial epithelial cell line NCI-H322 (Sallenave et al., 1998).
The second vector (Ad-lacZ) contained the lacZ reporter gene,
again cloned downstream of the 1.4-kb mCMV IE promoter
(Addison et al., 1997). Detailed accounts of methods used to
generate these constructs are described elsewhere (Addison et
al., 1997; Sallenave et al., 1998). In brief, Ad-elafin was iso¬
lated by cloning elafin cDNA into plasmid pDK6, which was
used along with pBHGlO to co-transfect 293 cells with resul¬
tant production of replication-deficient virus (Sallenave et al.,
1998). The Ad-/acZ construct was originally created by Addi¬
son et al. (1997) by cloning lacZ DNA into pMH5, and the re¬
sulting plasmid (pCA35) was used, along with pBHGlO, to co-
transfect 293 cells.
With regard to vector purification and titering, briefly, crude
293 cell lysates were used to infect 293N3S cells in spinner
culture flasks. After 3^1 days, the presence of inclusion bodies
was typically observed in more than 90% of cells. Cells were
pelleted, lysed, and submitted to two consecutive purifications
("banding") using step/continuous CsCl gradients. The adeno¬
virus band was collected and further desalted using PD-10 col¬
umn chromatography (Pharmacia). Titration (in PFU) of the
virus preparations was done in 293 cells using standard tech¬
niques (Graham and Prevec, 1991). The optical density (at 260
nm) of the vector preparations was measured, and the estimated
number of particles per milliliter was calulated using the for¬
mula 0D26onm * dilution X 1012.
The Ad-elafin preparation was estimated to contain 1.8 X 10'°
PFU/ml and 2.4 X 1012 particles/ml (particle:PFU ratio — 133).
The Ad-lacZ preparation was estimated to contain 2.0 X 10'°
PFU/ml and 2.8 X 1012 particles/ml (particle.'PFU ratio —140).
In vitro experiments—effect of LPS on
transfected cells
A549 cells were grown to confluence in 24-well plates (Fal¬
con) using A549 medium, comprising Dulbecco's modified Ea¬
gle's medium (DMEM; Sigma, Poole, UK) with 10% fetal calf
serum (FCS; Sigma), penicillin G (final concentration 100 U/ml),
and streptomycin sulfate (final concentration 100 jug/ml), at 37°C
and 5%CC>2 in a humidified incubator. Cells were washed with
phosphate-buffered saline (PBS; Sigma). A549 medium (modi¬
fied such that the FCS concentration was 5%) with or without
virus construct at a multiplicity of infection (MOI) of 1 plaque
forming unit (PFU) was then added for 30 min at 37°C (final
volume 50 pX). Cells were washed with PBS to remove excess
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virus, and 400 /xl of A549 medium was added. After 48 hours
40/xl of A549 medium containing LPS (from Escherichia coli
0127:B8; Difco Laboratories, Detroit, MI, USA) was added (fi¬
nal concentration of LPS 0, 0.1, 1, 10, or 100 /xg/ml). Cells
were incubated at 37°C for 24 hr and supernatants retrieved and
frozen at — 80°C until further use.
Human monocyte-derived macrophages were washed with
PBS then treated for 30 min at 37°C with Iscove's medium con¬
taining 5% autologous serum, with or without virus construct
at an MOI of 50 PFU. Cells were washed with PBS to remove
residual virus, and then incubated with 400 /xl of Iscove's
medium containing 10% heat-inactivated autologous serum for
48 hr. LPS was serially diluted in Iscove's medium containing
10% autologous serum, and 40-/xl aliquots added directly (fi¬
nal concentration of LPS 0, 0.1, 1, 10, or 100 /xg/ml). The cells
were incubated for 24 hr at 37°C. Cell supernatants were re¬
trieved and frozen at — 80°C until further use.
Preliminary experiments demonstrated that application of
LPS in the dose range 0.1-1000 /xg/ml did not significantly al¬
ter viability of untransfected or adenovirus-transfected A549
cells or macrophages (data not shown).
Transfection efficiency of A549 cells and monocyte-derived
macrophages was determined by infecting with Ad-lacZ as de¬
scribed above, and incubating for 48 hr at 37°C. Medium was
discarded and 200 /xl of fixative (0.2% glutaraldehyde, 0.8%
formaldehyde, 2 mM MgCU in PBS; all Sigma) added for 10
min at room temperature. Fixative was discarded and 200 /xl of
staining solution (5 mM K4Fe[CN]6, 5 mM K3Fe3[CN]6, 2 mM
MgCL, 0.05% Triton X-100, 0.5 mg/ml X-gal in PBS; all Sigma
except for X-gal [Promega, Madison, WI]) added for 5 hr at
37°C. Blue staining was taken to be indicative of transgene ex¬
pression as a marker of transfection efficiency.
In vitro neutrophil migration experiments
A549 cells were grown to confluence in 24-well plastic plates
(Costar, Cambridge, MA) and treated with Ad-elafin (MOI of
50 PFU), Ad-lacZ (MOI of 50 PFU), or medium alone as de¬
scribed above, with the exceptions that Phenol Red-free DMEM
(PRF-DMEM; Sigma) was used, and that medium used after
transfection of A549 cells was serum-free. The volume of
medium in each well was 500 /xl. After 48 hr, fresh human neu¬
trophils were prepared and suspended in PRF-DMEM contain¬
ing 1% bovine serum albumin (BSA; Sigma) at a concentration
of 12.5 X 106 neutrophils/ml. BSA was simultaneously added
to the A549 cell supernatants (1% final concentration). A total
of 100 /xl of the neutrophil suspension was added to a porous
polycarbonate filter insert with a pore size of 3 /xm (Costar).
Each insert was immediately placed into the wells containing
A549 cells such that the insert base was in contact with the su¬
pernatant, and incubated for 20 min at 37°C, after which inserts
were removed and discarded. Lysis of neutrophils that had mi¬
grated through the filter was then achieved by addition of Tri¬
ton X-100 (Sigma) (final concentration 0.4%). The resulting
lysate was acidified using 12.5 /xl of sodium citrate-acetate
buffer (pH 4.2; Sigma). Myeloperoxidase (MPO) activity was
used as an index of neutrophil content and was measured by
adding MPO-specific chromogenic substrate (0.1 mg/ml tetram-
ethylbenzidine (TMB; Boehringer Mannheim, Mannheim, Ger¬
many), 0.03% H202 (Sigma), in 0.1 M sodium acetate-citrate
(pH 4.9; Sigma), and quantifying the change in absorbance at
630 nm using a Dynatech M5000 Plate Reader (Dynex. Billing-
ham, West Sussex, UK). The number of neutrophils in lysates
was estimated by extrapolation from standard curves prepared
by lysing known quantities of neutrophils and plotting against
the change in absorbance at 630 nm after addition of TMB and
H202. Because neutrophils from different donors varied in their
rate of maximal migration (range 89,000-299,000; median
237,000), neutrophil migration was expressed relative to max¬
imal migration for each experiment. In a separate experiment,
an excess of polyclonal rabbit anti-human-elafin IgG was in¬
cubated with cells at 37°C prior to the addition of neutrophils.
In vivo experiments
Female C57/B16 mice aged between 6 and 8 weeks were
from Harlan Olac (Bicester, UK). All treatments were per¬
formed under anesthesia using intraperitoneal avertin (1.25%
2,2,2-tribromoethanol, Aldrich, Gillingham, Dorset, UK; 2.5%
2-methyl-2-butanol, Sigma) at approximately 10 /xl per gram
of body weight. All treatments were delivered by intratracheal
(IT) instillation, using a total volume of 30 /xl administered un¬
der direct visualisation of the larynx (McLachlan et al., 2000).
In all experiments, after the required series of instillations, mice
were sacrificed under anesthesia by transection of the abdom¬
inal aorta. The lungs and trachea were removed en bloc, and
bronchoalveolar lavage was immediately performed by serial
instillation of 250 /xl then 200 /xl of PBS. BALF was centrifuged
at 2000 rpm for 10 minutes at 4°C and the supernatant stored
at -80°C. The remaining pellet was resuspended in fresh PBS,
and an aliquot taken for measurement of total cell count using
a hemacytometer. A separate aliquot was used to prepare cy-
tospins at 300 rpm for 3 min at room temperature. Cytospins
were stained with Diff-quik (Dade Diagnostika, Germany) for
analysis of differential cell count.
Lungs were fixed in formalin (Sigma) and embedded in
paraffin wax. Sections 3 /xm thick were cut, stained with hema¬
toxylin and eosin, and photomicrographs were taken.
In a preliminary experiment aiming to establish the optimal
dose of adenoviral vector, a single IT instillation of Ad-elafin at
either 3 X 107 PFU or 3 X 108 PFU was given, and mice sacri¬
ficed 3, 6, or 8 days after instillation. In a separate preliminary
experiment aiming to establish a dose of LPS producing a mod¬
erate (approximately 50%) pulmonary neutrophilia at 24 hr, a
single IT instillation of either 0.1 /xg or 0.5 /xg of LPS was given,
and mice were sacrificed 24 hr later. E. coli 0127:B8 LPS was
used in all in vivo experiments. As described in detail later, Ad-
elafin at a dose of 3 X 107 PFU consistently generated human
elafin in murine airways without a significant increase in in¬
flammatory cells in the airways, whereas 0.5 /xg of LPS produced
a moderate neutrophilia (Table 1).
Therefore, in subsequent experiments either PBS, or 3 X 107
PFU of Ad-lacZ, or 3 X 107 PFU of Ad-elafin were given IT
(n = 12 in each group). Five days later, 4 mice in each group
received an IT instillation of PBS and the remaining 8 mice in
each group received an IT instillation of 0.5 /xg of LPS. Mice
were sacrificed 24 hr later; BALF and lung histology were per¬
formed as described above.
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In separate experiments, mice were treated IT with 3 X 107
PFU of Ad-lacZ as above, then five days later with either 0.5
fig or 5 fig of LPS. The following day lungs were removed en
bloc and fixed for 60 min at 4°C using 2% formaldehyde con¬
taining 0.2% glutaraldehyde. The fixative was washed out with
PBS and the lungs stained using 5 mM K^Fe (CN)e, 5 mM
K3Fe3 (CN)6, 2 mM MgCU, 0.5 mg/ml 5-bromo-4-chloro-3-in-
dolyl-/3-D-galactopyranoside (all Sigma). Sections were taken
and counterstained with Nuclear Fast Red (Sigma).
Assays
Elafin concentration was measured using a sandwich en¬
zyme-linked immunosorbent assay (ELISA) performed on 96
well plates (Linbro, Flow Laboratories, McLean, VA). In brief,
the primary antibody was polyclonal rabbit anti-human elafin
immunoglobulin. Gelatin (BDH, Poole, Dorset, UK) was used
as a blocking agent, the sample (or purified recombinant elafin
as standard) was applied, and the secondary antibody was bio-
tinylated polyclonal rabbit anti-human elafin immunoglobulin
(biotin was from Pierce, Rockford, IL). Streptavidin-horserad-
ish peroxidase complex (Sigma) then chromogenic substrate
(2,2'-azino-bis [3-ethylbenzthiazoline-6-sulfonic acid; Sigma])
were added sequentially and absorbance of the product at 550
nm was quantified using a Dynatech M5000 Plate Reader.
IL-8, macrophage inflammatory protein (MIP)-2 and murine
TNF-a concentrations were measured using commercial ELISA
kits (R&D Systems, Abingdon, Oxon, UK). ELISA for MIP-
1 a was kindly performed by Professor T. Standiford (Ann Ar¬
bor, MI). Protein levels were measured using the bicinchoninic
acid method (Pierce, Rockford, IL).
Statistical analysis
When data were normally distributed Student's /-test was
used. When data did not conform to a normal distribution, non-
parametric tests were used. Three group comparisons were per¬
formed using the Kruskal-Wallis test. Paired comparisons were
analyzed using Wilcoxon's signed rank test, unpaired compar¬
isons using the Mann-Whitney U-test, and correlations using
Spearman's rank correlation test. Statistical significance was
assigned to p < 0.05.
RESULTS
Effect of LPS on elafin secretion in vitro
In response to LPS, A549 cells transfected with Ad-lacZ se¬
creted concentrations of elafin similar to those secreted by un-
transfected A549 cells, indicating that viral transfection per se
did not significantly influence elafin production (Table 1).
However, in A549 cells transfected with Ad-elafin, LPS stim¬
ulation resulted in significant up-regulation of elafin produc¬
tion, the magnitude of the augmentation being considerably
greater than that seen in untransfected or Ad-/acZ-treated cells
(Table 1).
LPS stimulation did not augment elafin levels in supernatants
from untransfected human macrophages or macrophages trans¬
fected with Ad-lacZ (Table 2). Transfection efficiency of mac¬
rophages was approximately 16% indicating that the lack of
effect in Ad-lacZ treated cells was not due to absence of trans¬
fection. In contrast, LPS appeared to induce a moderate increase
in elafin secretion from macrophages transfected with Ad-elafin
(Table 2).
Effect of elafin over-expression on neutrophil
migration in vitro
Ad-elafin transfection resulted in a significant increase in mi¬
gration of human neutrophils across a polycarbonate filter of 3-
pm pore size (Fig. 1). This effect was not attributable to in¬
duction of IL-8 release, because the median IL-8 concentration
in cell supernatants from untransfected cells was 37.2 pg/ml,
from Ad-/acZ-treated cells 9.3 pg/ml, and from Ad-elafin-
treated cells 23.8 pg/ml (p = 0.05 comparing the three groups).
Preincubation of cells with anti-elafin antibody reduced neu¬
trophil migration in Ad-elafin-treated cells to levels observed
in Ad-/acZ-treated cells (percentage of maximal migration 65%
in Ad-elafin-treated cells, 69% in Ad-/acZ-treated cells, and
21% in untransfected cells).
Table 1. LPS Significantly Increases Secretion of Elafin from A549 Cells Transfected with Ad-elafin
Dose of LPS (/ig/ml)
0 0.1 1 10 100
Untransfected 3.0a 3.4a 45oo 8.4a'b 15.0ab
(2.0-4.7) (2.6-4.2) (3.3-6.4) (5.9-23.0) (10.5-24.9)
Ad-lacZ 3. la 3.5a 5.3a 12.5a-b 10.5a
(2.7-7.2) (3.1-10.5) (3.8-13.1) (5.2-^10.4) (6.3-13.8)
Ad-elafin 15.6 14.8 20.7b 33.4b 37.6b
(12.4-29.8) (10.5-35.4) (16.2-37.0) (20.5-70.6) (23.2-62.6)
A549 cells were treated with medium alone, Ad-lacZ (MOI of 1 PFU), or Ad-elafin (MOI of 1 PFU), then incubated for
18 hr. LPS was added over the concentration range 0-100 fig/m\ for a further 24 h and elafin concentrations measured.
Results represent elafin concentrations (in ng/ml) and are expressed as medians (and interquartile ranges) from five separate
jxperiments.
ap < 0.05 compared with elafin levels from Ad-elafin-treated cells receiving the same dose of LPS.
bp < 0.05 compared with the baseline value (i.e., no addition of LPS) for each given treatment.
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Table 2. LPS Stimulates Expression of Elafin Transgene in Human Macrophages Transfected with AcLElafin
Dose of LPS (pg/ml)
0 0.1 1 10 100
Untransfected 1.2 0.9 0.9a 0.6a-b 0.6a
(0.8-1.5) (0.8-1.1) (0.7-1.0) (0.6-0.9) (0.6-1.1)
Ad-lacZ 0.7 0.8a 0.8a 0.7 0.8a
(0.6-1.8) (0.6-1.0) (0.7-1.0) (0.6-1.3) (0.8-1.0)
Ad-elafin 1.3 1.8 9.6 6.0 6.4
(0.9-11.6) (1.1-24.3) (0.9-23.4) (0.7-11.1) (1.4-23.3)
Human macrophages were treated with medium alone, Ad-lacZ (MOI of 50 PFU), or Ad-elafin (MOl of 50 PFU) and incu¬
bated for 48 hr. LPS was added over the concentration range 0-100 pg/m\ for a further 24 hr and elafin concentrations were
measured.
Results represent elafin concentrations (in ng/ml) and are expressed as medians (and interquartile ranges) from six separate
experiments.
ap < 0.05 compared with elafin levels from Ad-elafin-treated cells receiving the same dose of LPS.
bp < 0.05 compared with the baseline value (i.e., no addition of LPS) for each given treatment.
Effect of human elafin over-expression on LPS-induced
neutrophilia in murine airways
Preliminary experiments indicated that a low dose (3 x 107
PFU) of Ad-elafin administered IT resulted in significant ex¬
pression of human elafin in BALF without overt airway neu¬
trophilia attributable to the vector (Table 3). In keeping with
this observation, low-dose adenovirus administration resulted
in transfection of bronchial and alveolar epithelium in vivo (Fig.
2). Higher doses of adenovirus were associated with significant
airway inflammation (Table 3). Preliminary data further indi¬
cated that moderate airway neutrophilia could be provoked by
administering 0.5 pg of LPS IT (mean BALF neutrophil count
170,200, equating to 54.4% of the total cellular content, n =
2), but not by 0.1 pg of LPS given IT (mean BALF neutrophil
count 47,700, equating to 12.4% of the total cellular content,
n = 2).
On the basis of these experiments mice were treated with ei¬
ther PBS, 3 x 107 PFU Ad-/acZ, or 3 x 107 PFU Ad-elafin de¬
livered IT. Five days later, mice in these three groups were
treated IT with either PBS or 0.5 pg of LPS. Elafin was de¬
tected in BALF from all mice initially receiving Ad-elafin, but
in none of the mice initially treated with PBS or Ad-lacZ, re¬
flecting the established specificity of our ELISA for human
elafin (no murine analogue of elafin has yet been identified; the
absence of detectable elafin in the control animals indicates that,
should such a molecule exist, it does not cross-react with our
anti-human elafin antibody). In mice pre-treated with Ad-elafin,
LPS administration resulted in median BALF elafin levels 20
times higher than did PBS administration (Fig. 3A). Further in¬
dependent evidence for significant activation of the mCMV pro¬
moter by inflammatory signals was provided by the LPS-de-
pendent increase in /3-gaiactosidase expression in mice
transfected with Ad-/acZ (Fig. 3B).
LPS-induced airway neutrophilia was significantly aug¬
mented in mice pretreated with Ad-elafm (Fig. 4A,B), in keep¬
ing with our findings in vitro (Fig. 1). The augmentation of neu¬
trophilia in Ad-elafin/LPS-treated mice was associated with an
increase in both MIP-2 and TNF-a in BALF (Table 4). Among
all mice treated with LPS, BALF neutrophil count correlated
significantly with MIP-2 concentrations (r = 0.61, p < 0.01).
In the absence of LPS, adenoviral transfection per se did not
significantly influence airway neutrophilia, as evidenced by
normal neutrophil counts in BALF after adenoviral transfection
(Table 3), and the absence of a rise in TNF-a in the airways of
mice treated with vector then PBS (median BALF TNF-a lev¬
els 405 pg/ml in PBS/PBS mice, 359 pg/ml in Ad-facZ/PBS







FIG. 1. Elafin augmentation enhances neutrophil migration
in vitro. A549 cells were treated with medium alone, Ad-lacZ
(MOI of 50 PFU), or Ad-elafin (MOI of 50 PFU) and incubated
in serum-free medium for 48 hr. Freshly prepared human neu¬
trophils were added to inserts containing 3-yum pores, which
were immediately placed into wells containing A549 cells for
20 min and then discarded. Migrating neutrophils were lysed
and the MPO content of lysates determined, as an index of neu¬
trophil count. For each of four separate experiments, conditions
were performed in quadruplicate. The maximal rate of neu¬
trophil migration was calculated for each experiment, and mi¬
gration was expressed relative to this value. Results represent
means (and standard deviations) of the percentage maximal mi¬
gration for each treatment. *, p < 0.05 compared with both
other groups.
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Table 3. Intratracheal Administration of Low-Dose Adenovirus Results in Expression
of Human Elafin Without Inducing Significant Airway Neutrophilia
Day 3 Day 6 Day i
X 107 PFU Ad-elafin
Neutrophil count (% of total cells)
Elafin (ng/ml)
X 108 PFU Ad-elafin














C57/B16 mice received IT Ad-elafin (either 3 X 107 PFU or 3 X 108 PFU) and were sacrificed on day 3, day 6, or day 8. Neu¬
trophil and total cell counts were determined in BALF, along with elafin concentration.
Results represent medians; n = 3 in each group.
A trend toward increased numbers of pulmonary macro¬
phages was also observed in mice treated with Ad-elafin and
then LPS (median counts 257,500 after PBS/LPS treatment,
183,400 after Ad-/ncZ/LPS, and 326.600 after Ad-elafin/LPS;
no significant difference). This trend was associated with an in¬
crease in the concentration of MlP-la in BALF from mice re¬
ceiving Ad-elafin/LPS (Table 4). However, in all groups of
mice, the magnitude of the rise in alveolar macrophages was
considerably less than that for airway neutrophils after LPS
administration (for example, comparing PBS/PBS mice with
PBS/LPS mice, macrophages increased 1.8-fold, whereas neu¬
trophils increased over 500-fold).
Despite the augmentation of neutrophil (and to a lesser ex¬
tent macrophage) numbers in the airways of Ad-elafin/LPS-
treated mice, there was no associated enhancement of alveolar-
capillary membrane disruption, mean protein concentrations in
BALF being 0.51 gram/liter (SD 0.49) in PBS/LPS mice, 0.47
gram/liter (0.50) in Ad-/acZ/LPS mice, and 0.42 (0.29) in Ad-
elafin/LPS mice (no significant difference comparing each of
the groups).
DISCUSSION
Selective up-regulation of endogenous defence molecules
during inflammatory tissue injury is an attractive potential ther¬
apeutic goal. It may be especially pertinent to modulate ex¬
pression of anti-inflammatory molecules known to be deficient
in inflammatory conditions, whether that deficiency be hered¬
itary (as in a-1 PI deficiency) (Gadek et al., 1981) or acquired
(as in the reduction in airway elafin described in CF and chronic
obstructive pulmonary disease) (reviewed by Sallenave, 2000).
The data presented here indicate that, in gene therapy proto¬
cols, judicious choice of promoters responsive to inflammatory
mediators may result in selective induction of transgene ex¬
pression in pulmonary inflammation. Furthermore, they support
the concept that up-regulation of endogenous defense molecules
in complex inflammatory conditions may be used to elucidate
novel functions, as evidenced by enhanced LPS-mediated neu¬
trophil migration after elafin augmentation.
The observation that LPS up-regulates elafin expression in
native (untransfected) pulmonary epithelial cells (Table 1) sug¬
gests that the endogenous human elafin promoter may be re¬
sponsive to exogenous inflammatory stimuli. This extends the
body of evidence suggesting that elafin secretion from pul¬
monary epithelial cells may variously be enhanced, unaltered,
or reduced by important endogenous inflammatory mediators
(Sallenave et al., 1994; Reid et al., 1999; van Wetering et al.,
2000).
Adenoviral transfection of pulmonary epithelial cells did not
of itself appear to stimulate elafin release, because application
of Ad-lacZ did not stimulate elafin secretion above that from
untransfected cells (Table 1). The increase in LPS-induced
elafin secretion after low-dose (MOI of 1 PFU) Ad-elafin trans¬
fection over and above that from untransfected cells can there¬
fore be attributed to the Ad-elafin vector (Table 1). Further¬
more, the up-regulation appears to be due to the effects of LPS
on the mCMV promoter at the transcriptional level, because our
construct does not contain a 5' untranslated region (Sallenave
et al., 1998). The pronounced elafin expression observed de¬
spite low dose Ad-elafin transfection confirms the inherent
power of the mCMV promoter (Addison et al., 1997; Loser et
al., 1998; Sallenave et al., 1998).
In contrast to the findings in pulmonary epithelial cells, LPS
stimulation produced modest enhancement of elafin secretion
from Ad-elafin treated macrophages, but not from untransfected
or Ad-/acZ-transfected macrophages (Table 2). These data sug¬
gest that elafin production was derived from the elafin trans-
gene rather than the endogenous elafin gene. In our hands, ad¬
enoviral transfection of macrophages was markedly less
efficient than that observed in A549 cells, as has been described
elsewhere (Kaner et al., 1999).
Transfection occurred at a rate of approximately 16%, in
keeping with similarly low rates of transfection reported by oth¬
ers for monocyte-derived macrophages (Haddada et al., 1993;
Schneider et al., 1997) and alveolar macrophages (Worgall et
al., 1999). However, although adenoviral vectors are rapidly in¬
ternalized and, to a large extent, cleared by alveolar macro¬
phages in vivo (Worgall et al., 1997; Zsengeller et al., 2000),
persistence of potentially therapeutic transgene expression has
been noted in alveolar macrophages in murine models (Danel
et al., 1998; Worgall et al., 1999). We similarly found expres¬
sion of transgene in occasional alveolar macrophages 6 days af¬
ter transfection in our LPS-treated mice (data not shown). This
emphasizes the point that alveolar protection could potentially
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FIG. 2. Intratracheal administration of low-dose adenovirus results in efficient transfection of bronchial and alveolar epithe¬
lium. C57/B16 mice received Ad-elafin (3 X 107 PFU) IT. Five days later, 0.5 /xg of LPS was administered IT and mice were
sacrified 24 hr later. Lung sections were stained with X-gal solution. (Left panel) Positive (blue) staining in bronchial epithelium;
(right panel) positive staining in alveolar epithelium.
be simultaneously and effectively provided by macrophages and
epithelial cells in gene therapy strategies (Danel et al., 1998).
The observation that Ad-elafin and Ad-lacZ transgene expres¬
sion was significantly augmented in response to LPS in murine
airways supports the concept that LPS stimulates the mCMV pro¬
moter powerfully in vivo, either directly or indirectly (Fig. 3). This
suggests potential therapeutic applications whereby expression of
transgenes could be induced selectively in the context of inflam¬
mation, particularly that involving bacterial products such as LPS.
Therefore, our data add the mCMV promoter to the growing list
of promoters that can be activated selectively during inflamma¬
tion or induced using exogenous activators (Gossen et al., 1995;
Varley et al., 1995; No et al., 1996). The strength of the mCMV
promoter was such that we were able to achieve significant trans-
gene expression using doses of adenovirus low enough so as not
to provoke overt vector-induced neutrophilia (Table 3 and panel
a of Fig. 4B). Further evidence for the relative absence of vector-
induced inflammation (or contamination of vector by exogenous
inflammatory mediators) was provided in vivo by lower levels of





FIG. 3. LPS stimulation significantly increases expression of transgenes under the control of the mCMV promoter in murine
lungs. (A) C57/B16 mice received IT Ad-elafin (3 X 107 PFU). Five days later, 4 animals received IT PBS, while another 8 re¬
ceived IT LPS (0.5 /xg). Twenty-four hours later, mice were sacrificed and elafin concentrations measured in BALF. Results rep¬
resent medians and interquartile ranges. ** p < 0.01 comparing the two groups. (B) C57/B16 mice received IT M-lacZ (3 X 107
PFU). Five days later, mice received either 0.5 /xg or 5 /xg of LPS IT. Twenty-four hours later, mice were sacrificed and the
lungs stained with X-gal solution, (a) Treatment with 0.5 /xg of LPS. (b) Treatment with 5 /xg of LPS. A faint blue color was















FIG. 4. Transfection of murine airways with Ad-elafin significantly augments LPS-induced airway neutrophilia. (A) C57/B16
mice received IT PBS, Ad-lacZ (3 X 107 PFU), or Ad-elafin (3 X 107 PFU) (n = 8 in each group). Five days later, mice were
given 0.5 p-g of LPS IT. Twenty-four hours later, animals were sacrificed. Neutrophil and total cell counts were measured in
BALF. Results represent medians and interquartile ranges. * p < 0.05 compared with both other groups. (B) C57/B16 mice were
treated as described above until sacrifice, when lungs were stained with hematoxylin and eosin. For each treatment the upper
panel illustrates lung histology and the lower panel illustrates cytospins from BALF. (a) Mouse receiving Ad-elafin then PBS in¬
stead of LPS. (b) Mouse receiving PBS then LPS. (c) Mouse receiving Ad-lacZ then LPS. (d) Mouse receiving Ad-elafin then
LPS. In a, there is no inflammatory cell infiltrate and the predominant cell type in BALF is the macrophage. In b and c, there is
a moderate cellular infiltrate, with a mixed population of neutrophils and macrophages in BALF. In d, there is a marked in¬
flammatory infiltrate, and the number and proportion of neutrophils in BALF is greater then that in b or c.
and in vitro by lower IL-8 levels in vector-treated A549 cells than
in PBS-treated cells. As such, selective single administration of
adenoviral constructs may, at least in part, obviate concerns re¬
lating to vector-induced inflammation (Yang et al., 1994; van
Ginkel et al., 1995). The absence of vector-induced airway neu¬
trophilia was particularly important in this study because one of
the aims was to determine the effect of human elafin over-ex¬
pression on LPS-induced neutrophilia.
Interestingly LPS inhibits neutrophil mobility and chemo-
taxis in vitro (Dahinden et al., 1983; Haslett et al., 1985) but
causes neutrophil extravasation in tissues such as skin (Cybul-
sky et al., 1988) and lung (Hudson et al., 1977) after local ad¬
ministration in vivo. Clearly, neutrophil chemokines and other
mediators induced by LPS in situ could explain this apparent
paradox but our data suggest for the first time that elafin may
be involved, in that elafin augmentation was associated with
significant enhancement of LPS-induced airway neutrophila in
vivo (Fig. 4). Neutrophil migration was not enhanced in murine
airways exposed to Ad-elafin in the absence of LPS (Table 3);
this may suggest that elafin's effect on neutrophil migration is
dose-dependent, or that the effect is dependent upon collabo¬
ration with LPS or other secondary inflammatory signals. How¬
ever, it is clear from our in vitro data that elafin augmentation
also enhances migration of human neutrophils in a system in
which LPS is not added (Fig. 1). Although our in vitro data
suggest that adenoviral transfection per se contributes in part
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Table 4. Transfection of Murine Airways with AcI-Elafin Augments Levels
of Cytokine Production Associated with LPS Administration
PBS/LPS Ad-\acZ/LPS Ad-elafin/LPS
MIP-2 (pg/ml) 257.4 121.7 318.la
(224.8-303.3) (44.1-234.4) (286.2-369.6)
TNF-a: (pg/ml) 711 617 1319
MlP-la (pg/ml) 188 139 205
C57/B16 mice received IT PBS, Ad-lacZ (3 X 107 PFU), or Ad-elafin (3 X 107
PFU) (n = 8 in each group, as described in Fig. 4). Five days later, mice received 0.5
/xg of LPS IT. Twenty-four hours later, animals were sacrificed, and MIP-2, MlP-la,
and TNF-a concentrations were measured in BALF. For TNF-a and MlP-la, BALF
from mice in each group was pooled to generate sufficient sample.
Results for MIP-2 represent medians (and interquartile ranges).
ap < 0.05 comparing the three groups using the Kruskal-Wallis test. For compar¬
isons between pairs of groups, a significant difference was found comparing Ad-lacZJ
LPS and Ad-elafin/LPS, p < 0.05.
to enhancement of neutrophil migration, this effect was not ob¬
served in our in vivo studies.
The mechanism by which elafin augmentation enhances neu¬
trophilia in our models is unclear. Elafin fragments of 6 kDa
do not influence neutrophil migration across endothelial barri¬
ers in vitro (Mackarel et al., 1999), and elafin has been asso¬
ciated with reduced neutrophil recruitment in models of skele¬
tal muscle reperfusion injury and myocardial ischaemia in vivo
(Crinnion et al., 1994; Tiefenbacher et al.. 1997). It should be
noted that the studies alluded to used elafin fragments (whereas
the whole molecule was generated in our study), and that both
in vivo studies used the intravenous route in rat models, gener¬
ating initial circulating concentrations of elafin far in excess of
those generated in BALF in this study.
Ad-elafin/LPS administration was associated with increased
concentrations of early inflammatory cytokines in BALF (Table
4), raising the possibility that elafin can induce secretion of such
molecules either directly or indirectly. However elafin-medi-
ated augmentation of human neutrophil migration in vitro was
not associated with an elevation of IL-8, one of the main C-X-
C neutrophil chemokines.
HNE appears to have a complex role in modulating neu¬
trophil recruitment (Owen et al., 1995; Cai and Wright. 1996;
Leavell et al., 1997; le-Barillec et al., 1999), and elastase in¬
hibitors have been shown to have varying effects on neutrophil
migration (Stockley etal., 1990; Aoshiba etal., 1993; Mackarel
et al., 1999). We cannot exclude the possibility that an inter¬
action between augmented elafin levels and murine neutrophil
elastase explained the increase in neutrophil migration (cer¬
tainly human elafin can inhibit murine elastase; Prof G Lun-
garella, University of Siena, personal communication). How¬
ever, it remains distinctly possible that elafin's role in
augmenting pulmonary neutrophilia may be unrelated to anti-
elastase activity. Elafin shares certain characteristics with the
defensins in being a low-molecular-weight cationic molecule
with antimicrobial activity. Not only are these characteristics
associated with an avidity for LPS (Peterson et al., 1985), but
human neutrophil defensin has been associated with neutrophil
accumulation in murine models of Gram-negative peritoneal in¬
fection (Welling et al., 1998).
Importantly, the doubling of airway neutrophils associated
with Ad-elafin/LPS treatment (Fig. 4) was not associated with
an increase in protein concentration in BALF, implying preser¬
vation of alveolar-capillary membrane integrity. Indeed, me¬
dian BALF protein concentrations in all three groups of mice
treated with LPS approximated to normal in this study, sug¬
gesting minimal disruption to the membrane in association with
neutrophil influx. In this setting, it is tempting to speculate that
elafin may function as an important regulatory molecule in early
innate immunity; elafin secreted in response to bacterial LPS
may simultaneously provide antimicrobial protection and up-
regulate neutrophil influx while protecting host tissue from the
injurious effects of extracellular HNE. In this context, it is of
considerable interest that SLPI (which shares several charac¬
teristics with elafin) has been shown to have a number of func¬
tions integral to innate immunity (Hiemstra et al, 1996; Jin et
al, 1997; Zhang et al, 1997) and that augmentation of SLPI con¬
fers protection in models of pulmonary inflammation (Mulli¬
gan et al., 1993; Rudolphus et al., 1993; Gipson et al., 1999).
In summary, gene therapy protocols can be designed such
that single, small doses of adenoviral vector generate transgenes
selectively expressed in the presence of inflammatory media¬
tors. Such strategies may have important therapeutic conse¬
quences. Finally, applications such as those described in this
study help to elucidate the functions of transgene products ex¬
pressed in the lung, as evidenced by the demonstration of
elafin's augmentation of LPS-induced neutrophilia.
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Abstract Elafin (elastase-specific inhibitor) is a low molecular
weight inhibitor of neutrophil elastase which is secreted in the
lung. Using synthetic peptides corresponding to full-length elafin
(H2N-'AVT 95Q-OH), the NH2-terminal domain (H2N-
'AVT 50K-OH) and the COOH-terminal domain (H2N-
51 PCS 95Q-OH), we demonstrate that claim's anti-elastase
activity resides exclusively in the COOH-terminus. Several
characteristics of elafin suggest potential anti-microbial activity.
The anti-microbial activity of elafin, and of its two structural
domains, was tested against the respiratory pathogensP.vewfo-
monas aeruginosa and Staphylococcus aureus. Elafin killed both
bacteria efficiently, with 93% killing of P. aeruginosa by 2.5 pM
elafin and 48% killing of S. aureus by 25 pM elafin. For both
organisms, full-length elafin was required to optimise bacterial
killing. These findings represent the first demonstration of co¬
existent anti-proteolytic and anti-microbial functions for elafin.
© 1999 Federation of European Biochemical Societies.
Key words: Elafin; Human neutrophil elastase;
Anti-microbial activity; Pseudomonas aeruginosa-,
Staphylococcus aureus
1. Introduction
As part of the immediate defence against bacterial patho¬
gens, the lung is equipped with a number of endogenous anti¬
microbial peptides, including defensins, secretory leucocyte
protease inhibitor (SLPI), lysozyme and lactoferrin [1-6]. In
addition, bacteria stimulate the recruitment and activation of
neutrophils, resulting in engulfment of organisms and ulti¬
mately their destruction by oxidants or proteolytic enzymes
such as human neutrophil elastase (HNE) [7]. Natural inhib¬
itors of HNE in the lung are thought to play a critical role in
neutralising HNE liberated extracellularly, thus circumventing
proteolytic damage to the host [8],
Elafin (also known as elafin-specific inhibitor (ESI) or skin
anti-leucoprotease (SKALP)) is a low molecular weight (9.9
kDa) inhibitor of HNE and proteinase 3, which is secreted in
the respiratory tract [9,10], Along with oq -protease inhibitor
(cq-PI) [8] and SLPI [11], elafin comprises an integral part of
the 'anti-elastase shield' in the lung [12].
Several features suggest an additional anti-microbial func¬
tion for elafin. In particular, elafin is highly cationic, it is
"Corresponding author. Fax: (44) (131) 650 4384.
E-mail: j.sallenave@ed.ac.uk
Abbreviations: HNE, human neutrophil elastase; oci-PI, cq-protease
inhibitor; SLPI, secretory leucocyte protease inhibitor; HSA, human
serum albumin; TSB, tryptone soya broth; LPS, lipopolysaccharide;
CF, cystic fibrosis
expressed selectively in the lung, the skin and at mucosal
surfaces and SLPI (which has 42% sequence homology with
elafin) has anti-microbial activity [5,13-17],
In this study, we describe an investigation of the anti-micro¬
bial activity of elafin against Pseudomonas aeruginosa and
Staphylococcus aureus, two important pulmonary pathogens
with a particular propensity to antibiotic resistance [18-23].
2. Materials and methods
2.1. Proteins
Elafin peptides were produced synthetically in accordance with the
derivation of amino acids from the established gene sequence [13] and
were supplied by Albachem (Edinburgh, UK), using standardised
protocols described elsewhere [24], Three peptides were provided,
namely full-length elafin (H2N-'AVT 95Q-OH), the NH2-terminus
domain (H2N-'AVT 50K-OH) and the COOH-terminus domain
(H2N-5IPGS 95Q-OH). The terminal amino acid of the NH2 do¬
main and the first amino acid of the COOH domain were determined
by analysis of the established crystal structure of a 57 amino acid
fragment of elafin (H2N-39AQE 95Q-OH) [17], in conjunction with
the established sequence of human SLPI, which has 42% sequence
homology with elafin [13-15,25], The molecular weights of elafin moi¬
eties, determined by mass spectrometry (Albachem, Edinburgh, UK)
were 9925 Da for full-length elafin, 5172 Da for the NH2-terminal
domain and 4776 Da for the COOH-terminal domain.
Human serum albumin (HSA) was purchased from Sigma Chem¬
icals (St. Louis, MO, USA). Recombinant human SLPI was pur¬
chased from R and D Systems (Minneapolis, MN, USA). Lyophilised
preparations of elafin, SLPI and HSA were all reconstituted in 0.01 M
K2HP04/KH2P04, pH 7.4 (phosphate buffer).
2.2. Bacteria
PAOl, a clinical strain and well-characterised type strain of P.
aeruginosa, and CI705, a clinical strain of S. aureus, were available
in-house [20,24],
2.3. HNE activity assay
The HNE activity assay has been described in detail elsewhere [26],
Briefly, serial dilutions of test inhibitor were added to 300 ng of
purified HNE (Elastin Products, Owensville, MO, USA). All dilutions
were performed in Tris 50 mM, Triton 0.1%, sodium chloride 0.5 M,
pH 8.0. The samples were incubated for 15 min at 37°C before addi¬
tion of the chromogenic substrate A-methoxysuccinyl-Ala-Ala-Pro-
Val-p-nitroanilide (Sigma). In positive controls, buffer replaced test
inhibitor. The change in absorbance, measured spectrophotometri-
cally at 405 nm (MR5000 Plate Reader, Dynatech, Dynex, Billing-
hurst, UK), was expressed as a function of time. The inhibitory ca¬
pacity of test inhibitors was derived by extrapolation to the ordinate
of curves obtained by plotting the HNE activity against the concen¬
tration of inhibitor added, as described elsewhere [27],
2.4. Assay of microbial activity
Bacteria were grown initially as colonies on Columbia agar (Uni-
path, Basingstoke, UK) and, then, in 10 ml tryptone soya broth (TSB)
(Unipath) overnight at 37"C in an orbital shaker (Gallenkamp, Fisher
Scientific, Loughborough, UK) at 200 rev/min. 100 pi of the bacterial
culture was resuspended in 10 ml fresh TSB and incubated for 3 h at
37°C with rotation, corresponding to a point compatible with loga¬
rithmic growth for both PAOl and C1705. The resulting suspension
0014-5793/99/$20.00 © 1999 Federation of European Biochemical Societies. All rights reserved.
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was centrifuged at 4500 rpm for 20 min at room temperature (Bio-
fuge, Heraeus Instruments, Kendro, Bishops Stortford, UK), the
supernatant discarded and replaced with 10 ml phosphate buffer
and then resuspended. This process was repeated once. The quantity
of viable bacteria was calculated from pre-constructed growth curves
and dilutions made in phosphate buffer to give an estimated count of
5X 104 viable colonies per ml.
In experiments using purified elafin, HSA or SLPI, 30 pi aliquots of
the bacterial suspension were added to 90 pi aliquots of test sub¬
stance, each diluted in phosphate buffer to give final concentrations
of 1, 2.5, 10 or 25 pM of the test substance. In positive controls, 90 pi
of phosphate buffer replaced the test solution and in negative controls,
30 pi of phosphate buffer replaced the bacterial suspension.
The test bacterial suspension mix was incubated for 2 h at 37°C.
Appropriate dilutions were made in phosphate buffer and 100 pi
aliquots plated out on Columbia agar. Colonies were counted after
incubation of the plates for 16 h at 37°C.
2.5. Statistics
Data pertaining to S. aureus were normally distributed and com¬
parisons between test substances and controls were performed using
the paired t-test. Data pertaining to P. aeruginosa were not normally
distributed and comparisons between test substances and controls
were performed using the Wilcoxon signed rank test. Statistical sig¬
nificance was regarded as P < 0.05.
3. Results
3.1. Anti-elastase activity of elafin moieties
All three peptides (full-length elafin, the NH2-terminal do¬
main and the COOH-terminal domain) were tested for anti-
HNE activity (Fig. 1). No anti-HNE activity was detected in
the NHj-terminal domain. In contrast, the COOH-terminal
domain and the full-length molecule were found to have an
identical anti-HNE activity, indicating that elafin's anti-elas-
□ full-length elafin
0" NH2-terniinus
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concentration (uM)
Fig. 2. Anti-microbial effect of elafin moieties against P. aeruginosa
(PAOI) and S. aureus (C1705), expressed as a percentage of the col¬
ony count in phosphate buffer alone (control). In (a), results repre¬
sent medians (n = 8 for concentrations of 2.5-25 pM; n = 4 at l pM).
In (b), results represent means (n = 5). * = P<0.05, ** = P<0.0l,
*** = PC 0.001.
concentration of test peptide (uM)
Fig. 1. Anti-elastase activity of full-length elafin, NH2-terminal do¬
main elafin and COOH-terminal domain elafin. Known quantities
of test inhibitor were added to 300 ng HNE. All dilutions were per¬
formed in Tris 50 mM, Triton 0.1%, sodium chloride 0.5 M, pH
8.0. Chromogenic substrate (A-methoxysuccinyl-Ala-Ala-Pro-Val-p-
nitroanilide) was added and the change in absorbance at 405 nm
was measured as a function of time. The molecular weights of full-
length elafin, NH2-terminal domain elafin, COOH-terminal domain
elafin and HNE are 9.9, 5.2, 4.8 and 30 kDa, respectively. Results
are expressed as a percentage of the HNE activity when incubated
with buffer alone.
tase activity resides exclusively in the COOH-terminal do¬
main.
3.2. Anti-microbial activity of elafin
Full-length elafin resulted in a significant killing of PAOI at
all doses tested (1-25 pM) (Fig. 2). The maximum effect was
observed at 2.5 pM, at which 93% of PAOI was killed, rela¬
tive to PAOI grown in phosphate buffer alone. At 1 and
2.5 pM, the contributions of the NH2-terminus and COOH-
terminus were approximately additive, but at higher doses, the
predominant anti-microbial effect resided in the NH2-terminal




























Fig. 3. Anti-microbial effect of full-length elafin against P. aerugino¬
sa (PAOl) and 5. aureus (C1705), expressed as a percentage of the
colony count in HSA. In (a), results represent medians (n = 8 for
concentrations of 2.5-25 pM; n = 4 at 1 pM). In (b), results repre¬
sent means (n = 5). Comparisons were made between equimolar con¬
centrations of test peptide and HSA. * = P<0.05, ** = P<0.01,
*** = />< 0.001. For reasons of visual clarity, only data for full-
length elafin are shown, however, dose-response curves for NH2-ter-
minal domain elafin and COOH-terminal domain elafin also closely
paralleled those shown in Fig. 2.
S. aureus (CI705) was dose-dependent and was significant
over a dose range of 2.5-25 pM (Fig. 2). At 25 pM, 48%
killing of C1705 was achieved. The NH2-terminus showed a
significant anti-microbial activity only at 25 pM and the
COOH-terminus only at 10 pM. To ensure that the effects
observed were not attributable to a non-specific peptide effect,
the effects of full-length elafin, the NH2-terminal domain and
the COOH-terminal domain against PAOl and C1705 were
also compared with a control protein (HSA) (Fig. 3). For full-
length elafin, the maximal activity was described at 2.5 pM
against PAOl (81% killing) and at 25 pM against C1705 (63%
killing) (Fig. 3), closely in keeping with the findings when the
effect of full-length elafin was compared with that of phos¬
phate buffer alone (Fig. 2). The dose-response curves gener¬
ated for both NHj-terminal domain elafin and COOH-termi¬
nal domain elafin against PAOl and C1705 also closely
paralleled those obtained when survival was expressed relative
to P04 buffer instead of HSA (data not shown).
3.3. Anti-microbial activity of SLPI
In a separate set of experiments, the activity of SLPI
against PAOl and CI705 was tested over the dose range 1-
10 pM and compared with that of full-length elafin (Table 1).
The anti-microbial activity of elafin against PAOl conformed
to the characteristic pattern shown in Fig. 2, with a maximal
effect at 2.5 pM. The anti-microbial activity of elafin was
greater than that of SLPI at all doses tested. To test for
potential synergy, equimolar concentrations of SLPI and ela¬
fin (0.5 pM elafin added to 0.5 pM SLPI) were compared with
either 1 pM elafin or 1 pM SLPI alone. No evidence of a
synergistic effect was found (86% killing of PAOl using the
elafin/SLPI combination, 88% using elafin alone, 80% using
SLPI alone). The anti-microbial activity of elafin and SLPI
against C1705 was similar over the dose range tested.
4. Discussion
Elafin (ESI/SKALP) was originally characterised and se¬
quenced from human bronchial secretions and from human
psoriatic skin, on the basis of its anti-elastase activity [9,14].
The identification of anti-microbial activity against Gram-neg¬
ative and Gram-positive respiratory pathogens at concentra¬
tions potentially achievable in epithelial lining fluid [28] (espe¬
cially after genetic augmentation [26]) suggests more complex
functions for elafin in the context of inflammation. This ob¬
servation is in keeping with the identification of additional
functions for other major anti-elastases such as SLPI, which
has intrinsic anti-bacterial and anti-viral activity [5,16,29] and
which can influence the function of lipopolysaccharide (LPS)
[30] and prostaglandins [31].
Indeed, elafin can be added to the growing list of endoge¬
nous lung peptides which harbour an anti-microbial function,
including defensins, SLPI, lactoferrin and lysozyme [1-6].
These molecules share certain general characteristics, for ex¬
ample, a low molecular weight and net positive charge. How¬
ever, each has unique structural features, which may play a
role in determining the anti-microbial function. The gene se¬
quence and derived amino acid sequence of elafin have al¬
lowed identification of various structural determinants [13].
The NHj-terminal domain, as defined in this study, has a
net positive charge of +5, as well as repeated structural motifs
potentially acting as substrate for transglutaminase which
may allow elafin to bind to the interstitium covalently
[13,15,32]. The COOH-terminal domain, as defined in this
study, has a net positive charge of +2 and has four disulfide
bonds which confer structural stability [13,32], Previous stud¬
ies using elafin fragments of either 57 amino acids (H2N-
Table 1
Anti-microbial effect of full-length elafin and SLPI against P. aeru¬
ginosa (PAOl) and 5. aureus (C1705)
PAOl 1 pM 2.5 pM 10 pM
Full-length elafin 95.7 96.3 85.1
SLPI 93.8 94.7 73.1
CI 705
Full-length elafin -9.8 -7.9 13.6
SLPI -8.1 18.1 6.0
Results are expressed as percentage killing relative to that in PO4
buffer alone (taken as 0%) and represent medians from three sepa¬
rate experiments.
When expressed relative to HSA, the results obtained were similar
and followed the same trend (data not shown).
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39AQE 95Q-OH) or 48 amino acids (H2N-48STK 95Q-
OH) have demonstrated high affinity anti-elastase activity
(K-, in the nM range), but were unable to provide information
concerning the NH2-terminal end of the molecule [9,14,33].
These findings, in conjunction with crystallographic studies
[17], suggested that elafin's anti-elastase activity resides exclu¬
sively in the COOH-terminal domain. Using discrete function¬
al domains of elafin and studying full-length elafin for the first
time, we have been able to provide direct confirmatory evi¬
dence to support this hypothesis by demonstrating that the
COOH-terminal domain of elafin and the full-length molecule
bind HNE with an equal efficiency (Fig. 1).
Furthermore, the use of discrete functional domains of ela¬
fin has allowed us to infer which regions of the molecule may
be responsible for anti-microbial effects. In the case of P.
aeruginosa, our data suggest that inherent anti-microbial ac¬
tivity exists in both structural domains and imply that their
interaction may be necessary to augment anti-microbial activ¬
ity at low concentrations. The inverse dose-response relation¬
ship noted may reflect the ability of P. aeruginosa to use high¬
er concentrations of peptide as nutrients, promoting growth
and competing with the killing effect of elafin. Indeed, P.
aeruginosa is known to grow in increasing concentrations of
organic nitrogen [34]. This may explain why elafin's anti-mi¬
crobial effect was slightly less pronounced when albumin was
used as control (see Fig. 3).
The anti-microbial effects of several low molecular weight
peptides have been ascribed to their cationic nature. Cationic
peptides are capable of binding P. aeruginosa LPS, altering
the outer membrane stability and increasing susceptibility to
other bactericidal compounds [35]. While the charge may have
contributed to the killing observed here, it is unlikely to ex¬
plain the entire anti-microbial effect of elafin (especially at low
doses, where the less cationic COOH-terminal domain was
more effective).
The anti-microbial activity against P. aeruginosa was inde¬
pendent of the anti-elastase activity of elafin, as the majority
of anti-microbial activity resided in the NH2-terminal domain,
while anti-elastase activity resided exclusively in the COOH-
terminal domain. Interestingly, a quite different, dose-depend¬
ent pattern of anti-microbial activity was seen against S. au¬
reus. The NH2-terminal domain alone contributed only
slightly and at high concentrations. As with P. aeruginosa,
this suggests that a simple charge effect is unlikely to explain
elafin's anti-microbial effect. The observation that full-length
elafin was more effective than the additive effects of the two
structural domains may again imply a critical interaction
between these. In a similar study using structural domains
derived from SLPI, Hiemstra et al. [5] also found that the
full-length molecule was more active against Escherichia coli
and S. aureus than was either terminal fragment.
In our hands, SLPI was found to have anti-microbial ac¬
tivity against P. aeruginosa and S. aureus as has been de¬
scribed elsewhere [5,16]. The anti-microbial effects of SLPI
were less pronounced in our study, but this may reflect the
use of different clinical strains. Our data suggest that in equi-
molar concentrations, elafin is at least as effective as SLPI
against PAOl.
The anti-microbial activity of elafin adds to the emerging
picture of its primary role in the lung defence. Elafin is ideally
placed to promote the early eradication of invading pathogens
and to protect the host against proteolytic destruction in the
event of neutrophil recruitment. Indeed, the co-existence of
anti-microbial and anti-elastase activity in the elafin molecule
could have therapeutic implications. P. aeruginosa and S. au¬
reus can each cause severe pneumonia [18,21] and frequently
co-colonise patients with cystic fibrosis (CF) [19]. The signifi¬
cant morbidity and mortality associated with these organisms,
coupled with their propensity to develop resistance to conven¬
tional antibiotics [22,23], demands the development of novel
anti-microbial strategies. In CF, HNE is thought to contribute
to the airway pathology by degrading substrate in the inter-
stitium, enhancing inflammatory cell chemotaxis, stimulating
mucous hypersecretion and promoting the adherence of P.
aeruginosa [36-38]. Furthermore, PAOl is known to promote
significant release of elastase from hamster neutrophils in vivo
[39], Effective augmentation of anti-microbial anti-elastases
for patients known to be at risk of developing infection
with P. aeruginosa and/or S. aureus may thus be theoretically
desirable. Our findings suggest that elafin gene augmentation
could be particularly beneficial in CF. Elafin levels are known
to be reduced in CF [40], high levels of elafin can be effected
using adenoviral gene therapy in rats in vivo [26], elafin's
transglutamination sites may confer a longer biological half-
life in vivo [15,32] and elafin appears particularly active
against the non-mucoid clinical isolate PAOL Strategically,
eradication of P. aeruginosa whilst still in the non-mucoid
form may be especially important in preventing or delaying
progression to chronic infection with mucoid variants, which
are seldom eradicated and are associated with a significantly
worse prognosis in CF [20].
We recently showed that genetic augmentation of elafin
using adenoviral gene therapy protects human alveolar epithe¬
lial (A549) cells against HNE and activated neutrophils [41].
We have extended these findings to show that elafin's anti¬
microbial activity against PAOl can be augmented in super¬
natant derived from A549 cells transfected with adenovirus
encoding elafin (unpublished data). This suggests that genetic
augmentation of endogenous anti-microbials may be effective
against pulmonary pathogens, as has also been demonstrated
using y-interferon [42,43],
In summary, these findings demonstrate for the first time
that elafin has an intrinsic anti-microbial activity against im¬
portant Gram-negative and Gram-positive respiratory patho¬
gens and that this activity is independent of the molecule's
anti-elastase activity.
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